17 NULL NULL NULL NULL induced coronary angiogenesis is dependent 
3 NULL NULL bradycardia-induced coronary angiogenesis is dependent on vascular 
17 bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth 
0 dependent on vascular endothelial growth factor . NULL NULL 
3 NULL a marked coronary angiogenesis is known to occur 
0 hypothesis that vascular endothelial growth factor ( vegf ) 
0 cell mitogen and a major regulator of angiogenesis , 
0 mitogen and a major regulator of angiogenesis , is 
3 a major regulator of angiogenesis , is upregulated in 
17 of angiogenesis , is upregulated in response to low 
0 , is upregulated in response to low heart rate 
0 heart rate and consequential increased stroke volume . NULL 
0 NULL NULL bradycardia was induced in rats by administering 
19 induced in rats by administering the bradycardic drug alinidine 
0 NULL NULL heart rate decreased by 32 % for 
0 to 40 minutes after injection and was chronically reduced 
0 injection and was chronically reduced by 10 % , 
0 and 3 weeks of treatment , respectively . NULL 
0 NULL NULL NULL NULL arterial pressure and cardiac output 
17 ( 3 ) ) increased gradually with alinidine administration 
19 increased gradually with alinidine administration ; a 15 % 
17 ; a 15 % increase after 2 weeks and 
17 and a 40 % increase after 3 weeks of 
19 3 weeks of alinidine treatment were documented . NULL 
0 ratio were not significantly altered by alinidine treatment . 
19 significantly altered by alinidine treatment . NULL NULL NULL 
0 after 1 week of treatment , before an increase 
17 treatment , before an increase in capillary length density 
0 length density , vegf mrna increased greater than 2-fold 
17 density , vegf mrna increased greater than 2-fold and 
18 than 2-fold and then declined to control levels after 
0 and then declined to control levels after 3 weeks 
0 then declined to control levels after 3 weeks of 
0 after 3 weeks of treatment . NULL NULL NULL 
0 NULL NULL NULL vegf protein was higher in alinidine-treated 
19 protein was higher in treated rats than in controls 
0 alinidine-treated rats than in controls after 2 weeks and 
17 after 2 weeks and increased further after 3 weeks 
0 after 3 weeks of treatment . NULL NULL NULL 
19 NULL NULL NULL NULL injection of vegf-neutralizing antibodies over 
18 a 2-week period completely blocked alinidine-stimulated angiogenesis . NULL 
17 2-week period completely blocked stimulated angiogenesis . NULL NULL 
3 period completely blocked alinidine-stimulated angiogenesis . NULL NULL NULL 
0 in contrast , bfgf mrna was not altered by 
16 bfgf mrna was not altered by alinidine treatment . 
19 not altered by alinidine treatment . NULL NULL NULL 
16 data suggest that vegf plays a key role in 
16 that vegf plays a key role in the angiogenic 
16 vegf plays a key role in the angiogenic response 
3 key role in the angiogenic response that occurs with 
0 role in the angiogenic response that occurs with chronic 
0 NULL NULL NULL the mechanism underlying this vegf-associated angiogenesis 
16 the mechanism underlying this associated angiogenesis may be an 
3 mechanism underlying this vegf-associated angiogenesis may be an increase 
0 angiogenesis may be an increase in stretch due to 
0 in stretch due to enhanced diastolic filling . NULL 
18 uft and its metabolites inhibit the angiogenesis induced by 
3 its metabolites inhibit the angiogenesis induced by murine renal 
17 metabolites inhibit the angiogenesis induced by murine renal cell 
0 4 , is widely used in clinical practice in 
0 is widely used in clinical practice in japan to 
19 practice in japan to treat cancer patients requiring a 
0 to treat cancer patients requiring a long-term chemotherapy , 
19 patients requiring a long-term chemotherapy , and it is 
0 , and it is associated with few side effects 
0 associated with few side effects , if any . 
18 we have evaluated the inhibitory effect of uft against 
18 have evaluated the inhibitory effect of uft against renca 
17 of uft against renca induced angiogenesis by a dorsal 
3 uft against renca cell-induced angiogenesis by a dorsal air 
3 NULL NULL NULL marked angiogenesis is induced by implantation 
17 NULL marked angiogenesis is induced by implantation of a 
19 angiogenesis is induced by implantation of a chamber containing 
0 this model , uft showed a strong angiogenesis-inhibitory effect 
3 uft showed a strong angiogenesis effect , whereas 5-fluorouracil 
3 uft showed a strong inhibitory effect , whereas 5-fluorouracil 
18 showed a strong angiogenesis-inhibitory effect , whereas 5-fluorouracil ( 
18 and doxifluridine were less effective . NULL NULL NULL 
0 revealed ft to be effective component of uft ; 
16 uft ; uracil remained ineffective in the inhibition of 
18 remained ineffective in the inhibition of angiogenesis . NULL 
3 in the inhibition of angiogenesis . NULL NULL NULL 
3 , possess a potent angiogenesis inhibitory effect that is 
18 possess a potent angiogenesis inhibitory effect that is amplified 
18 a potent angiogenesis inhibitory effect that is amplified when 
17 inhibitory effect that is amplified when the compounds are 
19 when the compounds are administered by a continuous infusion 
0 administered by a continuous infusion . NULL NULL NULL 
0 NULL NULL this may reflect a transition in blood 
0 this may reflect a transition in blood concentration of 
0 concentration of each metabolite resulting from the administration of 
19 metabolite resulting from the administration of uft . NULL 
0 NULL NULL NULL similar results were also obtained with 
0 similar results were also obtained with respect to 5-fu 
3 uft has a stronger angiogenesis effect than did other 
3 uft has a stronger inhibitory effect than did other 
18 has a stronger angiogenesis-inhibitory effect than did other fluorinated 
0 due to its pharmacokinetic properties characterized by maintaining of 
0 pharmacokinetic properties characterized by maintaining of higher and long-lasting 
0 higher and long-lasting blood levels of 5-fu and partly 
0 and partly due the inhibitory effects derived from gamma-hydroxybutyric 
0 partly due the inhibitory effects derived from gamma-hydroxybutyric acid 
0 due the inhibitory effects derived from gamma-hydroxybutyric acid and 
0 NULL NULL external beam radiotherapy for subretinal neovascularization in 
3 beam radiotherapy for subretinal neovascularization in age-related macular degeneration 
6 neovascularization in age-related macular degeneration : is this treatment 
0 degeneration : is this treatment efficient ? NULL NULL 
16 NULL NULL purpose : control of the natural course 
3 natural course of subretinal neovascularization ( srnv ) in 
6 ) in age-related macular degeneration ( amd ) is 
0 aimed to determine the efficacy and individual benefit of 
0 benefit of external beam radiotherapy ( ebrt ) . 
3 287 patients with subfoveal neovascularization due to amd which 
0 was verified by fluorescein angiography . NULL NULL NULL 
19 NULL patients have been treated between january 1996 and 
19 NULL NULL all patients received a total dose of 
0 photons based on computerized treatment planning in individual head 
0 NULL NULL NULL NULL results : all patients completed 
19 : all patients completed therapy and tolerability was good 
0 NULL NULL NULL first clinical control with second angiography 
0 NULL NULL first clinical control with second angiography was 
0 clinical control with second angiography was performed 6 weeks 
18 eighteen patients with srnv refusing radiotherapy served as a 
19 patients with srnv refusing radiotherapy served as a control 
0 radiotherapy served as a control group and were matched 
19 were matched with 18 irradiated patients . NULL NULL 
19 was 20/160 for the irradiated and 20/400 for the 
19 and 20/400 for the untreated patients . NULL NULL 
0 NULL one year after radiotherapy final median va was 
0 NULL conclusion : these results suggest that 16 gy 
0 slows down the visual loss in exudative amd for 
17 NULL NULL NULL NULL increased serum levels of vascular 
0 NULL NULL increased serum levels of vascular endothelial growth 
0 levels of vascular endothelial growth factor in patients with 
3 NULL NULL NULL NULL neovascularization , an essential event 
17 NULL neovascularization , an essential event for the growth 
4 essential event for the growth of solid tumors , 
16 solid tumors , is regulated by a number of 
3 by a number of angiogenic factors . NULL NULL 
0 factor , vascular endothelial growth factor ( vegf ) 
3 to exert a potent angiogenic activity , as indicated 
0 exert a potent angiogenic activity , as indicated by 
0 , as indicated by immunohistochemical and molecular evidence . 
0 patients without cancer ( controls ) using a sandwich 
0 ) using a sandwich linked immunoassay . NULL NULL 
0 , serum samples were obtained separately from the bilateral 
0 NULL NULL there were significant differences in s-vegf between 
0 rcc patients and the controls ( 207.3+/-32.9 vs. 71.5+/-9.1 
0 the various parameters of tumor status such as tumor 
0 tumor status such as tumor extent ( p less 
0 than 0.001 ) and existence of metastasis ( p 
0 ) and existence of metastasis ( p less than 
0 significantly correlated with the tumor volume obtained by a 
0 with the tumor volume obtained by a three-dimensional measurement 
0 NULL NULL NULL the results indicate that tumor tissue 
0 the results indicate that tumor tissue of rcc liberates 
14 tumor tissue of rcc liberates vegf into the systemic 
17 NULL NULL NULL NULL induced vascular endothelial growth factor 
0 NULL insulin-induced vascular endothelial growth factor expression in retina 
9 vascular endothelial growth factor expression in retina . NULL 
0 NULL NULL purpose : clinical studies have demonstrated that 
19 demonstrated that intensive insulin therapy causes a transient worsening 
0 mechanisms underlying the initial induced deterioration of retinal status 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
0 be operative in the pathogenesis of diabetic retinopathy . 
16 conducted to characterize the effect of insulin on retinal 
9 on retinal vegf gene expression in vitro and in 
16 NULL methods : the effect of insulin on vegf 
9 of insulin on vegf expression in vivo was examined 
16 mechanisms by which insulin regulates vegf expression , human 
9 which insulin regulates vegf expression , human retinal pigment 
19 rpe ) cells were exposed to insulin , and 
0 insulin , and vegf mrna levels were quantified with 
0 , and vegf mrna levels were quantified with rnase 
0 were quantified with rnase protection assays ( rpas ) 
19 NULL conditioned media from treated rpe cells were assayed 
19 insulin-treated rpe cells were assayed for vegf protein and 
0 were assayed for vegf protein and capillary endothelial cell 
1 and capillary endothelial cell proliferation . NULL NULL NULL 
17 capacity of insulin to stimulate the vegf promoter linked 
19 stimulate the vegf promoter linked to a luciferase reporter 
0 was characterized in transient transfection assays . NULL NULL 
0 NULL NULL NULL NULL results : insulin increased vegf 
17 NULL results : insulin increased vegf mrna levels in 
0 : insulin increased vegf mrna levels in the ganglion 
0 insulin increased vegf mrna levels in the ganglion , 
17 in vitro , insulin increased vegf mrna levels in 
0 , insulin increased vegf mrna levels in human rpe 
0 insulin increased vegf mrna levels in human rpe cells 
17 human rpe cells and enhanced vegf promoter activity without 
0 and enhanced vegf promoter activity without affecting transcript stability 
0 vegf promoter activity without affecting transcript stability . NULL 
19 NULL NULL NULL insulin treatment also increased vegf protein 
17 NULL insulin treatment also increased vegf protein levels in 
0 treatment also increased vegf protein levels in conditioned rpe 
0 also increased vegf protein levels in conditioned rpe cell 
0 cell media in a dependent manner with a median 
0 manner with a median effective concentration of 5 nm 
17 insulin-conditioned rpe cell media stimulated capillary endothelial cell proliferation 
1 stimulated capillary endothelial cell proliferation , an effect that 
0 cell proliferation , an effect that was completely blocked 
18 effect that was completely blocked by anti-vegf neutralizing antibody 
17 NULL conclusions : insulin increases vegf mrna and secreted 
0 : insulin increases vegf mrna and secreted protein levels 
0 increases vegf mrna and secreted protein levels in rpe 
0 vegf mrna and secreted protein levels in rpe cells 
0 mrna and secreted protein levels in rpe cells through 
17 in rpe cells through enhanced transcription of the vegf 
10 rpe cells through enhanced transcription of the vegf gene 
19 NULL NULL intensive insulin therapy may cause a transient 
17 patients with diabetes through increased retinal vegf gene expression 
9 increased retinal vegf gene expression . NULL NULL NULL 
3 NULL NULL NULL the angiogenic agent linomide inhibits the 
18 the antiangiogenic agent linomide inhibits the growth rate of 
4 agent linomide inhibits the growth rate of von hippel-lindau 
0 was to ascertain the potential usefulness of the antiangiogenic 
3 potential usefulness of the angiogenic compound linomide for treatment 
19 antiangiogenic compound linomide for treatment of von hippel-lindau ( 
19 NULL paraganglioma tissue fragments obtained at surgery from a 
0 tissue fragments obtained at surgery from a vhl type 
19 type 2a patient were transplanted s.c . NULL NULL 
0 2-3-mm fragments for `` prevention '' experiments ; and 
0 2-3-mm fragments allowed to grow to 1 cm for 
19 NULL NULL both groups received either 0.5 mg/ml linomide 
0 and were followed until tumor diameter reached 3 cm 
0 NULL in both the prevention and intervention experiments , 
0 intervention experiments , a significant diminution of tumor size 
18 experiments , a significant diminution of tumor size and 
0 a significant diminution of tumor size and weight was 
0 size and weight was observed in the drug-treated animals 
0 was observed in the treated animals . NULL NULL 
0 magnetic resonance analysis of tumor blood flow in linomide-treated 
19 tumor blood flow in treated animals showed localization of 
0 flow in linomide-treated animals showed localization of blood vessels 
14 in linomide-treated animals showed localization of blood vessels almost 
0 periphery of the poorly vascularized tumors with a significant 
0 vascularized tumors with a significant reduction of both vascular 
0 tumors with a significant reduction of both vascular functionality 
19 examination of tumors from treated animals revealed marked avascularity 
0 NULL NULL NULL NULL treated animals also displayed a 
18 also displayed a 2.4-fold reduction of tumor vascular endothelial 
0 a 2.4-fold reduction of tumor vascular endothelial growth factor 
0 of tumor vascular endothelial growth factor mrna levels . 
0 vascular endothelial growth factor mrna levels . NULL NULL 
0 endothelial growth factor mrna levels . NULL NULL NULL 
0 in vhl disease , therapy directed at inhibition of 
18 , therapy directed at inhibition of constitutively expressed vegf 
9 at inhibition of constitutively expressed vegf induction of angiogenesis 
17 of constitutively expressed vegf induction of angiogenesis by vhl 
3 expressed vegf induction of angiogenesis by vhl tumors may 
0 tumors may constitute an effective medical treatment . NULL 
0 constitute an effective medical treatment . NULL NULL NULL 
2 NULL NULL NULL vascular proliferation and enhanced expression of 
17 NULL vascular proliferation and enhanced expression of endothelial nitric 
9 vascular proliferation and enhanced expression of endothelial nitric oxide 
0 synthase in human peritoneum exposed to long-term peritoneal dialysis 
0 ( pd ) is associated with alterations in peritoneal 
0 ) is associated with alterations in peritoneal permeability and 
0 in peritoneal permeability and loss of ultrafiltration . NULL 
0 NULL NULL NULL these changes originate from increased peritoneal 
0 NULL NULL these changes originate from increased peritoneal surface 
17 these changes originate from increased peritoneal surface area , 
0 morphologic and molecular mechanisms involved remain unknown . NULL 
0 hypothesis that modifications of activity and/or expression of nitric 
9 modifications of activity and/or expression of nitric oxide synthase 
16 nos ) isozymes might play a role in these 
16 isozymes might play a role in these modifications , 
17 these modifications , via enhanced local production of nitric 
8 , via enhanced local production of nitric oxide , 
0 NULL NULL NULL nos activities were measured by the 
0 peritoneal biopsies from seven control subjects , eight uremic 
0 NULL NULL peritoneal nos activity is increased fivefold in 
17 peritoneal nos activity is increased fivefold in long-term pd 
0 pd patients compared with control subjects . NULL NULL 
0 uremic patients , nos activity is positively correlated with 
17 NULL NULL NULL NULL increased nos activity is mediated 
0 NULL NULL increased nos activity is mediated solely by 
16 increased nos activity is mediated solely by ca ( 
0 ca ( 2+ ) dependent nos and , as 
17 by immunoblotting , an upregulation of endothelial nos . 
17 the biologic relevance of increased nos in long-term pd 
17 pd was demonstrated by enhanced nitrotyrosine immunoreactivity and a 
0 nitrotyrosine immunoreactivity and a significant increase in vascular density 
17 immunoreactivity and a significant increase in vascular density and 
17 immunostaining studies demonstrated an upregulation of vascular endothelial growth 
0 upregulation of vascular endothelial growth factor ( vegf ) 
14 the latter , vegf colocalized with the advanced glycation 
3 provide a morphologic ( angiogenesis and increased endothelial area 
17 morphologic ( angiogenesis and increased endothelial area ) and 
17 ) and molecular ( enhanced nos activity and endothelial 
0 molecular ( enhanced nos activity and endothelial nos upregulation 
17 activity and endothelial nos upregulation ) basis for explaining 
0 for explaining the permeability changes observed in long-term pd 
0 explaining the permeability changes observed in long-term pd . 
0 NULL NULL they also support the implication of local 
0 they also support the implication of local advanced glycation 
14 end product deposits and liberation of vegf in that 
0 NULL NULL NULL NULL active hair growth ( anagen 
4 NULL NULL active hair growth ( anagen ) is 
16 ( anagen ) is associated with angiogenesis . NULL 
3 ) is associated with angiogenesis . NULL NULL NULL 
2 the completion of skin development , angiogenesis , i.e. 
3 of skin development , angiogenesis , i.e. , the 
4 , i.e. , the growth of new capillaries from 
2 , that hair follicle cycling is associated with prominent 
16 hair follicle cycling is associated with prominent changes in 
0 is associated with prominent changes in skin perfusion , 
0 prominent changes in skin perfusion , that the epithelial 
3 of anagen follicles display angiogenic properties , and that 
0 anagen follicles display angiogenic properties , and that the 
0 follicular dermal papilla can produce angiogenic factors . NULL 
3 dermal papilla can produce angiogenic factors . NULL NULL 
3 for the concept that angiogenesis is a physiologic event 
4 hair follicles switch from resting ( telogen ) to 
0 ( telogen ) to active growth ( anagen ) 
4 telogen ) to active growth ( anagen ) . 
1 for the demarcation of proliferating endothelial cells , to 
2 that synchronized hair follicle cycling in adolescent c57bl/6 mice 
16 adolescent c57bl/6 mice is associated with substantial angiogenesis , 
3 is associated with substantial angiogenesis , and that inhibiting 
18 angiogenesis , and that inhibiting angiogenesis in vivo by 
3 , and that inhibiting angiogenesis in vivo by the 
0 vivo by the intraperitoneal application of a fumagillin derivative 
0 of a fumagillin derivative retards experimentally induced anagen development 
0 fumagillin derivative retards experimentally induced anagen development in these 
0 retards experimentally induced anagen development in these mice . 
3 NULL NULL thus , angiogenesis is a physiologic event 
0 and appears to be required for normal anagen development 
0 required for normal anagen development . NULL NULL NULL 
16 NULL NULL NULL NULL associated angiogenesis offers an attractive 
3 NULL NULL NULL anagen-associated angiogenesis offers an attractive model 
0 for identifying the physiologic controls of cutaneous angiogenesis , 
3 physiologic controls of cutaneous angiogenesis , and an interesting 
0 system for screening the effects of potential antiangiogenic drugs 
0 screening the effects of potential antiangiogenic drugs in vivo 
3 the effects of potential angiogenic drugs in vivo . 
0 NULL NULL NULL NULL stimulating hormone modulates activation of 
16 NULL NULL alpha-melanocyte-stimulating hormone modulates activation of nf-kappa b 
17 NULL alpha-melanocyte-stimulating hormone modulates activation of nf-kappa b and 
14 b and ap-1 and secretion of interleukin-8 in human 
0 NULL NULL NULL NULL stimulating hormone ( alpha-msh ) 
16 has evolved as a mediator of diverse biological activities 
0 mediator of diverse biological activities in an ever-growing number 
1 biological activities in an growing number of non-melanocytic cell 
0 NULL NULL NULL one mechanism by which alpha-msh exerts 
0 which alpha-msh exerts its effects is modulation of ap-1 
16 exerts its effects is modulation of ap-1 and nf-kappa 
0 NULL NULL these two transcription factors also play an 
16 two transcription factors also play an important role in 
16 factors also play an important role in fibroblasts , 
16 also play an important role in fibroblasts , in 
0 fibroblasts , in extracellular matrix composition , and in 
0 , and in cytokine expression . NULL NULL NULL 
0 NULL NULL NULL by use of electric mobility shift 
0 by use of electric mobility shift assays , we 
17 -14 ) m ) activates ap-1 in human dermal 
19 dermal fibroblasts , whereas coincubation with interleukin-1 beta ( 
0 ( il-1 beta ) results in suppression of its 
18 beta ) results in suppression of its activation . 
0 in suppression of its activation . NULL NULL NULL 
17 NULL NULL alpha-msh also induces activation of nf-kappa b 
17 NULL alpha-msh also induces activation of nf-kappa b but 
16 b but does not modulate dna binding on costimulation 
15 does not modulate dna binding on costimulation with il-1 
17 modulate dna binding on costimulation with il-1 beta . 
0 and nf-kappa b are key elements in controlling interleukin-8 
16 are key elements in controlling interleukin-8 ( il-8 ) 
10 interleukin-8 ( il-8 ) transcription , human fibroblasts were 
19 , human fibroblasts were treated with alpha-msh and il-1 
0 hours , and cytokine levels in the supernatants were 
0 alpha-msh alone had little effect , whereas coincubation with 
19 little effect , whereas coincubation with il-1 beta led 
17 coincubation with il-1 beta led to marked downregulation of 
18 beta led to marked downregulation of il-8 secretion ( 
14 marked downregulation of il-8 secretion ( at most 288 
19 ) when compared to treatment with il-1 beta alone 
0 NULL NULL NULL our results indicate that alpha-msh exerts 
16 that alpha-msh exerts modulatory effects on the activation of 
17 modulatory effects on the activation of nf-kappa b and 
0 and that it can regulate chemokine secretion in human 
0 it can regulate chemokine secretion in human dermal fibroblasts 
0 NULL NULL NULL these effects of alpha-msh may have 
16 of alpha-msh may have important regulatory functions in extracellular 
16 alpha-msh may have important regulatory functions in extracellular matrix 
16 may have important regulatory functions in extracellular matrix composition 
0 regulatory functions in extracellular matrix composition , wound healing 
3 wound healing , or angiogenesis . NULL NULL NULL 
0 NULL NULL NULL NULL stimulated phosphoprotein is involved in 
16 NULL vasodilator-stimulated phosphoprotein is involved in stress-fiber and membrane 
2 stress-fiber and membrane ruffle formation in endothelial cells . 
0 NULL NULL NULL NULL stimulated phosphoprotein ( vasp ) 
9 vasp ) is highly expressed in vascular endothelial cells 
0 where it has been implicated in cellular reorganization during 
0 been implicated in cellular reorganization during angiogenesis , as 
3 in cellular reorganization during angiogenesis , as well as 
16 in endothelial retraction and changes in vessel permeability . 
0 however , the cellular functions of vasp are not 
19 study , we have expressed wild-type and mutant forms 
0 in what aspects of cytoskeletal behavior this protein participates 
0 of cytoskeletal behavior this protein participates . NULL NULL 
9 NULL NULL NULL NULL expression of wild-type vasp induces 
17 expression of wild-type vasp induces marked membrane ruffling and 
16 vasp induces marked membrane ruffling and formation of prominent 
2 marked membrane ruffling and formation of prominent stress fibers 
0 NULL NULL NULL NULL deletion of the proline-rich domain 
18 proline-rich domain of vasp abolishes its ability to bind 
0 of vasp abolishes its ability to bind profilin but 
15 abolishes its ability to bind profilin but does not 
16 profilin but does not affect ruffling or stress fiber 
0 but does not affect ruffling or stress fiber formation 
2 ruffling or stress fiber formation . NULL NULL NULL 
0 carboxy-terminal domain that is responsible for in vivo bundle 
0 for in vivo bundle formation . NULL NULL NULL 
0 NULL NULL NULL NULL ruffling occurs only on the 
9 occurs only on the expression of forms of vasp 
0 vasp that possess bundling activity and the capacity to 
15 and the capacity to bind zyxin/vinculin-derived peptide . NULL 
0 the capacity to bind derived peptide . NULL NULL 
0 NULL NULL NULL the ability of distinct subdomains within 
15 subdomains within vasp to bind adhesion proteins and induce 
0 within vasp to bind adhesion proteins and induce f-actin 
17 bind adhesion proteins and induce f-actin bundling in vivo 
0 vivo suggests that this protein could function in the 
0 that this protein could function in the aggregation and 
0 could function in the aggregation and tethering of actin 
2 actin filaments during the formation of endothelial cell-substrate and 
0 of endothelial cell-substrate and cell-cell contacts . NULL NULL 
0 endothelial cell-substrate and cell-cell contacts . NULL NULL NULL 
0 these data provide a mechanism whereby vasp can influence 
18 mechanism whereby vasp can influence endothelial migration and organization 
14 vasp can influence endothelial migration and organization during capillary 
2 influence endothelial migration and organization during capillary formation and 
2 and organization during capillary formation and modulate vascular permeability 
16 during capillary formation and modulate vascular permeability via effects 
16 modulate vascular permeability via effects on endothelial cell contractility 
14 ( upar ) is colocalized pericellularly with components of 
0 components of the plasminogen activation system and endocytosis receptors 
9 NULL upar is also coexpressed with caveolin and members 
0 members of the integrin adhesion receptor superfamily . NULL 
0 NULL NULL NULL the formation of functional units with 
0 allows the upar to mediate the focused proteolysis required 
0 to mediate the focused proteolysis required for cell migration 
17 mediate the focused proteolysis required for cell migration and 
14 proteolysis required for cell migration and invasion and to 
14 for cell migration and invasion and to contribute both 
16 and invasion and to contribute both directly and indirectly 
15 and indirectly to cell adhesive processes in a non-proteolytic 
15 indirectly to cell adhesive processes in a non-proteolytic fashion 
0 NULL NULL this dual activity , together with the 
17 , together with the initiation of signal transduction pathways 
0 initiation of signal transduction pathways by upar , is 
18 , is believed to influence cellular behaviour in angiogenesis 
3 influence cellular behaviour in angiogenesis , inflammation , wound 
0 , inflammation , wound repair and tumor progression/metastasis and 
0 , wound repair and tumor progression/metastasis and open up 
2 wound repair and tumor progression and open up the 
14 wound repair and tumor metastasis and open up the 
18 NULL nitric oxide synthase inhibition results in synergistic anti-tumour 
17 nitric oxide synthase inhibition results in synergistic anti-tumour activity 
18 results in synergistic anti-tumour activity with melphalan and tumour 
0 with melphalan and tumour necrosis factor alpha-based isolated limb 
0 tumour necrosis factor alpha-based isolated limb perfusions . NULL 
0 no ) is an important molecule in regulating tumour 
0 an important molecule in regulating tumour blood flow and 
17 tumour blood flow and stimulating tumour angiogenesis . NULL 
3 flow and stimulating tumour angiogenesis . NULL NULL NULL 
18 NULL NULL NULL NULL inhibition of no synthase by 
17 synthase by l-name might induce an anti-tumour effect by 
18 might induce an anti-tumour effect by limiting nutrients and 
18 an anti-tumour effect by limiting nutrients and oxygen to 
14 nutrients and oxygen to reach tumour tissue or affecting 
16 reach tumour tissue or affecting vascular growth . NULL 
4 tissue or affecting vascular growth . NULL NULL NULL 
18 NULL NULL the anti-tumour effect of l-name after systemic 
19 of l-name after systemic administration was studied in a 
19 NULL moreover , regional administration of l-name , in 
0 was studied in an isolated limb perfusion ( ilp 
0 in an isolated limb perfusion ( ilp ) model 
19 NULL NULL NULL systemic treatment with l-name inhibited growth 
18 systemic treatment with l-name inhibited growth of adenocarcinoma significantly 
4 treatment with l-name inhibited growth of adenocarcinoma significantly but 
18 but was accompanied by impaired renal function . NULL 
0 accompanied by impaired renal function . NULL NULL NULL 
18 NULL in ilp , reduced tumour growth was observed 
4 ilp , reduced tumour growth was observed when l-name 
0 reduced tumour growth was observed when l-name was used 
0 observed when l-name was used alone . NULL NULL 
0 or melphalan , l-name increased response rates significantly compared 
0 melphalan , l-name increased response rates significantly compared to 
18 NULL an additional anti-tumour effect was demonstrated when l-name 
19 demonstrated when l-name was added to the synergistic combination 
0 and tnf ( responses increased from 70 to 100 
18 NULL NULL NULL NULL inhibition of no synthase reduces 
18 inhibition of no synthase reduces tumour growth both after 
4 no synthase reduces tumour growth both after systemic and 
0 regional ( ilp ) treatment . NULL NULL NULL 
18 NULL a synergistic anti-tumour effect of l-name is observed 
0 effect of l-name is observed in combination with melphalan 
0 NULL NULL NULL these results indicate a possible role 
16 results indicate a possible role of l-name for the 
19 of l-name for the treatment of solid tumours in 
0 NULL NULL NULL rna damage and inhibition of neoplastic 
18 NULL rna damage and inhibition of neoplastic endothelial cell 
1 of neoplastic endothelial cell growth : effects of human 
0 endothelial cell growth : effects of human and amphibian 
3 NULL NULL NULL NULL angiogenesis defines the many steps 
0 defines the many steps involved in the growth and 
4 steps involved in the growth and migration of endothelial 
14 in the growth and migration of endothelial cell-derived blood 
2 and migration of endothelial derived blood vessels . NULL 
4 is necessary for the growth and metastasis of tumors 
14 for the growth and metastasis of tumors , and 
0 to find inhibitors of tumor angiogenesis . NULL NULL 
3 find inhibitors of tumor angiogenesis . NULL NULL NULL 
0 NULL NULL this usually involves screening of potential anti-angiogenic 
0 usually involves screening of potential anti-angiogenic compounds on endothelial 
3 involves screening of potential angiogenic compounds on endothelial cells 
3 end , two candidate angiogenic rna-damaging agents , onconase 
16 were screened for their effects on endothelial cell proliferation 
1 effects on endothelial cell proliferation using three distinct types 
0 of endothelial cells in culture : hpv-16 e6/e7-immortalized human 
19 in culture : hpv-16 immortalized human umbilical vein endothelial 
19 huvecs ) , a transformed hpv-16 e6/e7 huvec ( 
0 rhim et al. , carcinogenesis 4 , 673-681 , 
18 NULL NULL onconase similarly inhibited proliferation in all three 
1 NULL onconase similarly inhibited proliferation in all three cell 
17 ) rhedn was more effective on immortalized huvec cell 
19 was more effective on immortalized huvec cell lines ( 
0 cell type must be used in proliferation assays to 
1 must be used in proliferation assays to screen for 
3 to screen for novel angiogenic compounds . NULL NULL 
18 NULL NULL NULL il-12 inhibition of endothelial cell functions 
0 inhibition of endothelial cell functions and angiogenesis depends on 
3 endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell 
0 cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk 
17 NULL NULL in vivo dependent tumor inhibition rests on 
0 NULL in vivo il-12-dependent tumor inhibition rests on the 
18 in vivo il-12-dependent tumor inhibition rests on the ability 
0 inhibition rests on the ability of il-12 to activate 
0 ability of il-12 to activate a cd8-mediated cytotoxicity , 
0 il-12 to activate a mediated cytotoxicity , inhibit angiogenesis 
18 a cd8-mediated cytotoxicity , inhibit angiogenesis , and cause 
3 cd8-mediated cytotoxicity , inhibit angiogenesis , and cause vascular 
0 have shown that such inhibition stems from complex interactions 
0 inhibition stems from complex interactions of immune cells and 
9 immune cells and the production of ifn-gamma and other 
0 of ifn-gamma and other downstream angiostatic chemokines , the 
0 chemokines , the mechanisms involved are still poorly defined 
17 we show that il-12 activates an anti-angiogenic program in 
3 that il-12 activates an angiogenic program in con a-activated 
18 il-12 activates an anti-angiogenic program in con a-activated mouse 
17 anti-angiogenic program in con activated mouse spleen cells ( 
17 mouse spleen cells ( activated spc ) or human 
17 or human pbmc ( activated pbmc ) . NULL 
0 the soluble factors they release in its presence arrest 
0 they release in its presence arrest the cycle of 
18 release in its presence arrest the cycle of endothelial 
18 ( ec ) , inhibit in vitro angiogenesis , 
3 , inhibit in vitro angiogenesis , negatively modulate the 
18 in vitro angiogenesis , negatively modulate the production of 
18 vitro angiogenesis , negatively modulate the production of matrix 
9 , negatively modulate the production of matrix metalloproteinase-9 , 
0 modulate the production of matrix metalloproteinase-9 , and the 
0 metalloproteinase-9 , and the ability of ec to adhere 
15 ability of ec to adhere to vitronectin and up-regulate 
17 adhere to vitronectin and up-regulate icam-1 and vcam-1 expression 
9 up-regulate icam-1 and vcam-1 expression . NULL NULL NULL 
0 NULL NULL NULL these effects do not require direct 
16 these effects do not require direct cell-cell contact , 
0 effects do not require direct cell-cell contact , yet 
0 do not require direct cell-cell contact , yet result 
15 not require direct cell-cell contact , yet result from 
15 yet result from continuous interaction between activated lymphoid cells 
17 from continuous interaction between activated lymphoid cells and ec 
0 NULL NULL NULL we used neutralizing abs to show 
0 to show that the inducible protein-10 and monokine-induced by 
0 show that the ifn-inducible protein and monokine-induced by ifn-gamma 
0 the ifn-inducible protein-10 and induced by ifn-gamma chemokines are 
0 by ifn-gamma chemokines are pivotal in inducing these effects 
0 pivotal in inducing these effects . NULL NULL NULL 
17 diabetic-scid mice , or activated spc enriched in specific 
16 are all needed to mediate the full anti-angiogenetic effect 
3 to mediate the full angiogenetic effect of il-12 . 
16 mediate the full anti-angiogenetic effect of il-12 . NULL 
0 NULL NULL vascular endothelial growth factor-b and vascular endothelial 
0 factor-b and vascular endothelial growth factor-c expression in renal 
9 vascular endothelial growth factor-c expression in renal cell carcinomas 
0 renal cell carcinomas : regulation by the von hippel-lindau 
3 NULL NULL NULL NULL angiogenesis is essential for tumor 
17 NULL NULL angiogenesis is essential for tumor growth and 
0 angiogenesis is essential for tumor growth and metastasis . 
4 is essential for tumor growth and metastasis . NULL 
14 for tumor growth and metastasis . NULL NULL NULL 
0 NULL NULL it is regulated by numerous angiogenic factors 
3 is regulated by numerous angiogenic factors , one of 
0 one of the most important being vascular endothelial growth 
0 important being vascular endothelial growth factor ( vegf ) 
15 have been identified that bind to the tyrosine kinase 
0 renal carcinomas , the contribution of these new ligands 
0 therefore , measured the mrna level of vegf-b and 
0 their receptors by rnase protection assay ( rpa ) 
0 NULL NULL NULL we observed a significant up-regulation of 
0 NULL we observed a significant up-regulation of vegf-b ( 
17 we observed a significant up-regulation of vegf-b ( p 
0 NULL NULL NULL in addition , although vegf receptors 
0 , there was a significant up-regulation of only flt-1 
17 there was a significant up-regulation of only flt-1 ( 
0 there was also a significant correlation between vegf-c and 
0 0.03 ) but no association between vegf-b and its 
0 NULL NULL NULL a significant increase was observed in 
17 NULL NULL a significant increase was observed in flt-1 
0 a significant increase was observed in flt-1 ( p 
9 p = 0.52 ) expression in clear cell compared 
0 NULL NULL NULL no significant association was demonstrated between 
0 NULL NULL no significant association was demonstrated between vegf-b 
0 patient age , or tumor size ( p greater 
16 NULL NULL NULL the effect of von hippel-lindau ( 
9 on vegf-b and vegf-c expression in the renal carcinoma 
19 carcinoma cell line 786-0 transfected with wild-type and mutant 
1 vhl was determined by growing cells under 21 % 
17 whereas vegf-a was significantly up-regulated under hypoxic compared with 
9 than 0.001 ) , expression of vegf-c was reduced 
18 expression of vegf-c was reduced ( p less than 
18 NULL nevertheless , the repression of vegf-c was lost 
16 contrast vegf-b was not regulated by vhl despite clear 
17 by vhl despite clear up-regulation in vivo . NULL 
0 NULL these findings strongly support an enhanced role for 
0 findings strongly support an enhanced role for this pathway 
0 strongly support an enhanced role for this pathway in 
16 clear cell carcinomas by regulating angiogenesis and/or lymphangiogenesis . 
3 cell carcinomas by regulating angiogenesis and/or lymphangiogenesis . NULL 
3 by regulating angiogenesis and/or angiogenesis . NULL NULL NULL 
0 tumors are able to up-regulate angiogenic growth factor receptors 
3 are able to up-regulate angiogenic growth factor receptors more 
0 able to up-regulate angiogenic growth factor receptors more efficiently 
0 clear cell tumors can use pathways independent of vhl 
0 cell tumors can use pathways independent of vhl to 
0 tumors can use pathways independent of vhl to regulate 
16 independent of vhl to regulate angiogenesis , and that 
3 of vhl to regulate angiogenesis , and that this 
0 and that this combined regulation may account for their 
0 , which suggests that targeting vegfr1 ( flt-l ) 
0 ) may be particularly effective in these tumor types 
0 particularly effective in these tumor types . NULL NULL 
16 NULL NULL NULL NULL effects of morphological patterning on 
0 NULL NULL effects of morphological patterning on endothelial cell 
14 patterning on endothelial cell migration . NULL NULL NULL 
14 NULL NULL NULL the migration of vascular endothelial cells 
16 cells ( ecs ) plays an important role in 
16 ecs ) plays an important role in vascular remodeling 
16 ) plays an important role in vascular remodeling . 
7 important role in vascular remodeling . NULL NULL NULL 
0 here we studied the effects of cell morphology on 
14 cell morphology on the migration of bovine aortic ecs 
19 bovine aortic ecs by culturing cells on micropatterned strips 
0 micropatterned strips of collagen matrix ( 60- , 30- 
0 NULL NULL NULL the spreading areas of the cells 
0 and had significantly lower shape index than those in 
14 , ecs tended to migrate in the direction of 
0 NULL NULL NULL vinculin staining showed that the leading 
0 NULL NULL vinculin staining showed that the leading edge 
0 staining showed that the leading edge of ecs on 
14 the direction of cell migration ; this arrangement of 
17 the focal adhesions may promote ec migration . NULL 
14 adhesions may promote ec migration . NULL NULL NULL 
0 NULL NULL NULL the present study provides direct evidence 
0 the present study provides direct evidence on the role 
16 direct evidence on the role of cell morphology in 
14 cell morphology in ec migration , and will help 
14 the mechanisms of ec migration during angiogenesis and wound 
3 of ec migration during angiogenesis and wound healing . 
0 NULL NULL NULL thrombospondin-2 plays a protective role in 
0 thrombospondin-2 plays a protective role in multistep carcinogenesis : 
0 protective role in multistep carcinogenesis : a novel host 
18 a novel host anti-tumor defense mechanism . NULL NULL 
0 novel host anti-tumor defense mechanism . NULL NULL NULL 
3 NULL NULL NULL the angiogenic switch during tumorigenesis is 
17 is thought to be induced by a change in 
0 be induced by a change in the balance of 
3 the balance of pro- angiogenic and anti-angiogenic factors . 
3 of pro- angiogenic and angiogenic factors . NULL NULL 
0 to elucidate the biological role of the endogenous angiogenesis 
3 role of the endogenous angiogenesis inhibitor thrombospondin-2 ( tsp-2 
18 of the endogenous angiogenesis inhibitor thrombospondin-2 ( tsp-2 ) 
0 tsp-2 ) during multistep carcinogenesis , we subjected tsp-2-deficient 
19 multistep carcinogenesis , we subjected tsp-2-deficient and wild-type mice 
9 carcinogenesis , we subjected deficient and wild-type mice to 
0 to a chemical skin carcinogenesis regimen . NULL NULL 
9 NULL surprisingly , tsp-2 expression was strongly upregulated in 
17 tsp-2 expression was strongly upregulated in the mesenchymal stroma 
3 of tumorigenesis whereas the angiogenesis factor , vascular endothelial 
0 factor , vascular endothelial growth factor , was induced 
17 growth factor , was induced predominantly in tumor cells 
0 was induced predominantly in tumor cells . NULL NULL 
9 NULL NULL NULL tsp-2 deficiency dramatically enhanced susceptibility to 
0 NULL tsp-2 deficiency dramatically enhanced susceptibility to skin carcinogenesis 
0 enhanced susceptibility to skin carcinogenesis and resulted in accelerated 
0 to skin carcinogenesis and resulted in accelerated and increased 
0 carcinogenesis and resulted in accelerated and increased tumor formation 
17 resulted in accelerated and increased tumor formation . NULL 
0 in accelerated and increased tumor formation . NULL NULL 
2 accelerated and increased tumor formation . NULL NULL NULL 
3 NULL NULL NULL the angiogenic switch occurred in early 
0 in early stages of malignant tumor formation , and 
0 early stages of pre-malignant tumor formation , and tumor 
2 stages of pre-malignant tumor formation , and tumor angiogenesis 
0 tumor formation , and tumor angiogenesis was significantly enhanced 
3 formation , and tumor angiogenesis was significantly enhanced in 
17 tumor angiogenesis was significantly enhanced in tsp-2-deficient mice . 
9 was significantly enhanced in deficient mice . NULL NULL 
9 NULL NULL while tsp-2 deficiency did not affect tumor 
16 tsp-2 deficiency did not affect tumor differentiation or proliferation 
0 deficiency did not affect tumor differentiation or proliferation , 
2 did not affect tumor differentiation or proliferation , tumor 
4 affect tumor differentiation or proliferation , tumor cell apoptosis 
0 differentiation or proliferation , tumor cell apoptosis was significantly 
5 proliferation , tumor cell apoptosis was significantly reduced . 
18 cell apoptosis was significantly reduced . NULL NULL NULL 
0 NULL NULL NULL these results reveal upregulation of an 
0 NULL these results reveal upregulation of an endogenous angiogenesis 
3 upregulation of an endogenous angiogenesis inhibitor during multi step 
0 of an endogenous angiogenesis inhibitor during multi step tumorigenesis 
17 step tumorigenesis and identify enhanced stromal tsp-2 expression as 
9 identify enhanced stromal tsp-2 expression as a novel host 
18 a novel host anti-tumor defense mechanism . NULL NULL 
0 novel host anti-tumor defense mechanism . NULL NULL NULL 
16 NULL current prospects for controlling cancer growth with non-cytotoxic 
4 prospects for controlling cancer growth with non-cytotoxic agents -- 
19 in animal or cell culture studies , the growth 
4 culture studies , the growth and spread of cancer 
14 , the growth and spread of cancer can be 
18 of cancer can be slowed by many nutrients , 
0 that are still rarely used in the clinical management 
0 rarely used in the clinical management of cancer , 
0 unlikely to constitute definitive therapies in themselves . NULL 
0 to expect that mechanistically complementary combinations of these measures 
0 could have a worthwhile impact on survival times and 
0 a worthwhile impact on survival times and , when 
0 times and , when used as adjuvants , could 
0 as adjuvants , could improve the cure rates achievable 
0 rates achievable with standard therapies . NULL NULL NULL 
18 include measures that : down-regulate serum free igf-i ; 
0 that : down-regulate serum free igf-i ; suppress the 
18 serum free igf-i ; suppress the synthesis of mevalonic 
8 igf-i ; suppress the synthesis of mevalonic acid and/or 
16 certain derivatives thereof ; modulate arachidonate metabolism by inhibiting 
18 modulate arachidonate metabolism by inhibiting 5-lipoxygenase , 12-lipoxygenase , 
18 , or cox-2 ; antagonize the activation of ap-1 
17 cox-2 ; antagonize the activation of ap-1 transcription factors 
0 the activation of ap-1 transcription factors ; promote the 
17 ap-1 transcription factors ; promote the activation of ppar-gamma 
17 factors ; promote the activation of ppar-gamma transcription factors 
0 the activation of ppar-gamma transcription factors ; and that 
18 factors ; and that suppress angiogenesis by additional mechanisms 
3 ; and that suppress angiogenesis by additional mechanisms . 
0 measures appear suitable for use in cancer prevention . 
18 for use in cancer prevention . NULL NULL NULL 
18 NULL NULL NULL NULL inhibition of pdgf-stimulated and matrix-mediated 
17 NULL NULL inhibition of stimulated and matrix-mediated proliferation of 
17 inhibition of pdgf-stimulated and mediated proliferation of human vascular 
1 of pdgf-stimulated and matrix-mediated proliferation of human vascular smooth 
16 cells by sparc is independent of changes in cell 
2 sparc is independent of changes in cell shape or 
0 of changes in cell shape or cyclin-dependent kinase inhibitors 
0 in cell shape or dependent kinase inhibitors . NULL 
15 NULL NULL NULL NULL interactions among growth factors , 
0 NULL NULL interactions among growth factors , cells , 
0 cells , and extracellular matrix regulate proliferation during normal 
16 , and extracellular matrix regulate proliferation during normal development 
1 and extracellular matrix regulate proliferation during normal development and 
0 regulate proliferation during normal development and in pathologies such 
0 NULL NULL sparc ( secreted protein , acidic , 
0 NULL sparc ( secreted protein , acidic , and 
15 cysteine ) is a associated glycoprotein that modulates the 
16 a matrix-associated glycoprotein that modulates the adhesion and proliferation 
15 glycoprotein that modulates the adhesion and proliferation of vascular 
1 modulates the adhesion and proliferation of vascular cells . 
18 we demonstrate that sparc inhibits human arterial smooth muscle 
0 that sparc inhibits human arterial smooth muscle cell proliferation 
1 arterial smooth muscle cell proliferation stimulated by platelet-derived growth 
17 smooth muscle cell proliferation stimulated by platelet-derived growth factor 
0 cell proliferation stimulated by derived growth factor or by 
0 proliferation stimulated by platelet-derived growth factor or by adhesion 
15 growth factor or by adhesion to monomeric type i 
15 NULL NULL NULL NULL binding studies with sparc and 
15 indicate specific and saturable interaction with smooth muscle cells 
0 smooth muscle cells that involves the c-terminal ca2+-binding region 
0 that involves the c-terminal binding region of the protein 
0 ca2+-binding region of the protein . NULL NULL NULL 
18 also report that sparc arrests monomeric collagen-supported smooth muscle 
17 that sparc arrests monomeric supported smooth muscle cell proliferation 
1 collagen-supported smooth muscle cell proliferation in the late g1-phase 
16 the absence of an effect on cell shape or 
0 an effect on cell shape or on levels of 
0 cell shape or on levels of cyclin-dependent kinase inhibitors 
0 or on levels of dependent kinase inhibitors . NULL 
0 NULL NULL NULL NULL dependent kinase-2 activity , p107 
0 NULL NULL cyclin-dependent kinase-2 activity , p107 and cyclin 
0 p107 and cyclin a levels , and retinoblastoma protein 
0 levels , and retinoblastoma protein phosphorylation are markedly reduced 
12 , and retinoblastoma protein phosphorylation are markedly reduced in 
18 protein phosphorylation are markedly reduced in response to the 
17 are markedly reduced in response to the addition of 
19 in response to the addition of exogenous sparc and/or 
0 exogenous sparc and/or peptides derived from specific domains of 
0 previously characterized as an inhibitor of platelet-derived growth factor 
0 as an inhibitor of derived growth factor binding to 
0 an inhibitor of platelet-derived growth factor binding to its 
15 of platelet-derived growth factor binding to its receptor , 
18 its receptor , also antagonizes smooth muscle cell proliferation 
1 antagonizes smooth muscle cell proliferation mediated by monomeric collagen 
16 smooth muscle cell proliferation mediated by monomeric collagen at 
0 at the level of dependent kinase-2 activity . NULL 
0 level of cyclin-dependent kinase-2 activity . NULL NULL NULL 
17 NULL NULL NULL NULL upregulation of vascular endothelial growth 
0 upregulation of vascular endothelial growth factor receptors is associated 
0 growth factor receptors is associated with advanced neuroblastoma . 
3 NULL NULL background : angiogenesis is essential for tumor 
17 background : angiogenesis is essential for tumor growth and 
0 angiogenesis is essential for tumor growth and relies on 
4 is essential for tumor growth and relies on the 
0 and relies on the production of angiogenic factors . 
3 on the production of angiogenic factors . NULL NULL 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
0 vegf ) is a major regulator of angiogenesis that 
0 ) is a major regulator of angiogenesis that binds 
3 a major regulator of angiogenesis that binds to tyrosine 
15 regulator of angiogenesis that binds to tyrosine kinase receptors 
15 NULL NULL NULL the interaction of vegf and its 
0 receptors at gene and protein levels in neuroblastoma remains 
0 at gene and protein levels in neuroblastoma remains widely 
0 NULL NULL methods : tumor biopsy specimens and serum 
0 specimens and serum were obtained from 37 neuroblastoma patients 
0 normal children served as controls . NULL NULL NULL 
0 examined by real-time reverse transcription polymerase chain reaction ( 
0 serum was analyzed by linked immunosorbent assay ( elisa 
0 NULL NULL NULL NULL results : vegf isoforms and 
0 and its receptors ' mrna were expressed in neuroblastoma 
10 receptors ' mrna were expressed in neuroblastoma and control 
0 expressed in neuroblastoma and control tissues . NULL NULL 
0 whereas the ligands were increased in stages iii and 
0 , the receptors were upregulated in stage iii only 
0 NULL NULL NULL at protein level , vegf-b and 
9 and kdr were not detectable in tissue lysates , 
17 , whereas vegf-a was increased in stages iii and 
9 NULL NULL serum vegf protein levels were upregulated in 
9 NULL serum vegf protein levels were upregulated in stage 
17 vegf protein levels were upregulated in stage iii . 
0 is one of the major angiogenesis regulators among the 
3 one of the major angiogenesis regulators among the ligands 
0 probably flt-1 , may contribute to a poor prognosis 
3 a poor prognosis ( angiogenic ) phenotype , as 
0 as indicated by their upregulated mrna levels in stage 
0 indicated by their upregulated mrna levels in stage iii 
0 by their upregulated mrna levels in stage iii neuroblastoma 
16 ( 165 ) mainly contributes to increased serum vegf 
17 ) mainly contributes to increased serum vegf levels and 
0 to increased serum vegf levels and may serve as 
19 NULL NULL NULL optimizing treatment of choroidal neovascularization feeder 
3 optimizing treatment of choroidal neovascularization feeder vessels associated with 
16 choroidal neovascularization feeder vessels associated with age-related macular degeneration 
6 associated with age-related macular degeneration . NULL NULL NULL 
19 optimize the method of treating choroidal neovascularization ( cnv 
3 method of treating choroidal neovascularization ( cnv ) associated 
3 treating choroidal neovascularization ( cnv ) associated with age-related 
16 neovascularization ( cnv ) associated with age-related macular degeneration 
6 associated with age-related macular degeneration ( amd ) . 
0 methods : the parameters associated with locating and then 
19 with locating and then photocoagulating cnv feeder vessels were 
3 locating and then photocoagulating cnv feeder vessels were identified 
0 published data and data derived from modeling the choroidal 
0 and data derived from modeling the choroidal vasculature . 
0 parameters , a prototype treatment system was designed that 
0 ) angiogram images and facilitates analysis of the images 
0 of the images by enhancing visualization of dye movement 
3 of dye movement through cnv feeder vessels ( fvs 
0 permits precise aiming and delivery of 810- nm wavelength 
0 of 810- nm wavelength photocoagulation laser energy to target 
0 photocoagulation laser energy to target fvs on a real-time 
0 NULL NULL NULL NULL target fvs are tracked by 
0 tracked by a joy-stick controlled laser aiming beam until 
19 aiming beam until an intravenously-injected high-concentration icg dye bolus 
14 icg dye bolus is observed to enter the target 
0 bolus is observed to enter the target vessel , 
0 observed to enter the target vessel , at which 
0 principle of the combined treatment system design for performing 
0 system design for performing enhanced photocoagulation ( dep ) 
0 design for performing dye-enhanced photocoagulation ( dep ) in 
0 dep ) in the clinical setting and determination of 
3 energy needed to close cnv fvs was made in 
17 in 11 amd patients requiring treatment of cnv , 
19 11 amd patients requiring treatment of cnv , but 
3 patients requiring treatment of cnv , but for whom 
0 but for whom other treatment was not appropriate . 
0 NULL NULL NULL NULL results : using icg-dep , 
3 : using icg-dep , cnv feeder vessels were closed 
19 cnv feeder vessels were closed with single pulse laser 
0 , producing no visible change in the fundus . 
19 NULL NULL successful fv closure was usually indicated immediately 
0 usually indicated immediately by presence of incarcerated icg dye 
0 feeder vessel dep and treatment evaluation required 15 to 
0 dep and treatment evaluation required 15 to 20 minutes 
17 conclusions : indocyanine green enhanced photocoagulation of cnv feeder 
19 : indocyanine green dye-enhanced photocoagulation of cnv feeder vessels 
3 green dye-enhanced photocoagulation of cnv feeder vessels , facilitated 
0 vessels , facilitated by use of a device that 
0 circulation while aiming the treatment laser beam , appears 
0 volume of fundus tissue affected by treatment , compared 
0 fundus tissue affected by treatment , compared with other 
0 , compared with other treatment modalities . NULL NULL 
0 NULL NULL the combination treatment device should be useful 
19 useful in optimizing fv treatment and in refining and 
0 refining and evaluating the efficacy of dep in future 
0 of dep in future clinical trials . NULL NULL 
0 dep in future clinical trials . NULL NULL NULL 
18 NULL NULL NULL NULL inhibition of angiogenesis by the 
3 NULL NULL inhibition of angiogenesis by the cancer chemopreventive 
0 been shown previously to inhibit rat mammary carcinogenesis . 
0 to inhibit rat mammary carcinogenesis . NULL NULL NULL 
0 NULL NULL NULL in addition to direct effects on 
0 NULL in addition to direct effects on mammary epithelial 
16 in addition to direct effects on mammary epithelial cells 
18 epithelial cells , including decreased proliferation and induction of 
1 cells , including decreased proliferation and induction of apoptosis 
17 including decreased proliferation and induction of apoptosis , cla 
5 proliferation and induction of apoptosis , cla may exert 
16 cla may exert its effects indirectly by inhibiting the 
18 its effects indirectly by inhibiting the differentiation of mammary 
2 indirectly by inhibiting the differentiation of mammary stromal cells 
18 cla was found to decrease the ability of mammary 
0 found to decrease the ability of mammary stromal cells 
2 mammary stromal cells to form complex anastomosing microcapillary networks 
0 networks in vitro on derived reconstituted basement membrane . 
0 in vitro on engelbreth-holm-swarm-derived reconstituted basement membrane . NULL 
18 suggested that cla might inhibit angiogenesis in vivo . 
3 that cla might inhibit angiogenesis in vivo . NULL 
19 1 ) mice were placed on synthetic diets containing 
3 6 weeks , before angiogenic challenge by s.c . 
19 NULL NULL NULL NULL injection with an angiogenic gel 
3 NULL injection with an angiogenic gel substrate ( matrigel 
0 the pellets from animals fed the control diet were 
0 from animals fed the control diet were infiltrated by 
17 diet were infiltrated by abundant branching networks of blood 
2 were infiltrated by abundant branching networks of blood vessels 
19 , pellets from the fed animals contained fewer infiltrating 
14 cla-fed animals contained fewer infiltrating cells , which formed 
2 infiltrating cells , which formed limited branching cellular networks 
0 cells , which formed limited branching cellular networks , 
0 , which formed limited branching cellular networks , the 
6 majority of which had collapsed lumen and no rbcs 
0 NULL NULL NULL both levels of dietary cla showed 
0 levels of dietary cla showed similar effects , with 
0 dietary cla showed similar effects , with the number 
0 vessels per 20x field decreased to a third of 
0 of that seen in control . NULL NULL NULL 
18 NULL NULL dietary cla decreased serum levels of vascular 
0 dietary cla decreased serum levels of vascular endothelial growth 
0 levels of vascular endothelial growth factor ( vegf ) 
0 and whole mammary gland levels of vegf and its 
16 cis-12 cla isomers were effective in inhibiting angiogenesis in 
18 isomers were effective in inhibiting angiogenesis in vitro in 
3 were effective in inhibiting angiogenesis in vitro in a 
0 in vitro in a dependent fashion . NULL NULL 
0 NULL NULL NULL the ability of cla to inhibit 
18 ability of cla to inhibit angiogenesis may contribute to 
3 of cla to inhibit angiogenesis may contribute to its 
0 to inhibit angiogenesis may contribute to its efficacy as 
0 may contribute to its efficacy as a chemopreventive agent 
3 NULL molecular characterization of angiogenic properties of human oral 
0 molecular characterization of angiogenic properties of human oral squamous 
3 about the specificity of angiogenic properties of oral cancer 
0 the specificity of angiogenic properties of oral cancer cells 
17 NULL NULL NULL NULL stimulatory effects on proliferation and 
17 NULL NULL NULL stimulatory effects on proliferation and migration 
1 NULL stimulatory effects on proliferation and migration of human 
14 effects on proliferation and migration of human umbilical vein 
3 huvec ) characterized the angiogenic properties of oral cancer 
0 ) characterized the angiogenic properties of oral cancer cells 
0 NULL elisa found the presence of vascular endothelial growth 
0 presence of vascular endothelial growth factors ( vegf ) 
18 NULL NULL NULL NULL attenuation of the proangiogenic effects 
3 NULL attenuation of the angiogenic effects by neutralizing vegf 
0 attenuation of the proangiogenic effects by neutralizing vegf antibodies 
16 vegf antibodies suggests vegf play a key role in 
16 suggests vegf play a key role in the acquisition 
16 vegf play a key role in the acquisition of 
3 the acquisition of the angiogenic phenotype in oral cancer 
18 analysis indicate that p53 function loss by mutation or 
18 indicate that p53 function loss by mutation or overexpression 
9 loss by mutation or overexpression of mdm2 occurred in 
3 in summary , the angiogenic property of oral cancer 
0 summary , the angiogenic property of oral cancer cells 
16 oral cancer cells is mediated by many factors in 
0 by many factors in addition to vegf and the 
6 microangiopathies overlying pigment epithelial detachment in age-related macular degeneration 
6 detachment in age-related macular degeneration . NULL NULL NULL 
7 purpose : to evaluate alterations in the retinal vasculature 
6 vasculature overlying pigment epithelial detachments ( ped ) in 
6 in exudative age-related macular degeneration ( armd ) using 
0 indocyanine green and fluorescein angiography . NULL NULL NULL 
0 eyes ) with a clinical diagnosis of exudative armd 
0 exudative armd with ped underwent simultaneous fluorescein and indocyanine 
19 fluorescein and indocyanine green angiography , also under high 
0 compared between patients with vascularized ( n = 34 
0 ped on indocyanine green angiography and correlated with the 
0 the ped and the presence of serous retinal detachment 
6 presence of serous retinal detachment . NULL NULL NULL 
0 NULL NULL NULL NULL results : in all , 
0 found by indocyanine green angiography and only 22 by 
0 only 22 by fluorescein angiography ; this finding was 
0 this finding was statistically significant ( p less than 
0 directly correlated with the presence of choroidal neovascularizations ( 
3 the presence of choroidal neovascularizations ( p = 0.002 
0 there was also a direct correlation between the presence 
0 direct correlation between the presence of choroidal neovascularization and 
3 the presence of choroidal neovascularization and size of the 
17 significantly correlated with serous elevation of the retina . 
0 retinal vasculopathies may be observed in eyes with ped 
0 with ped and are detectable by indocyanine green and 
19 indocyanine green and fluorescein angiography . NULL NULL NULL 
17 NULL NULL NULL NULL enforced expression of tissue inhibitor 
9 NULL NULL NULL enforced expression of tissue inhibitor of 
0 enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects 
0 of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary 
16 inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and 
2 metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth 
18 functional capillary morphogenesis and inhibits tumor growth in a 
0 capillary morphogenesis and inhibits tumor growth in a murine 
4 morphogenesis and inhibits tumor growth in a murine tumor 
0 growth in a murine tumor model . NULL NULL 
0 homeostasis of the extracellular matrix is a delicate balance 
6 a delicate balance between degradation and remodeling , the 
7 balance between degradation and remodeling , the balance being 
16 , the balance being maintained by the interaction of 
15 being maintained by the interaction of activated matrix metalloproteinases 
17 by the interaction of activated matrix metalloproteinases ( mmps 
0 the interaction of activated matrix metalloproteinases ( mmps ) 
0 specific tissue inhibitors of matrix metalloproteinases ( timps ) 
17 NULL NULL NULL NULL up-regulation of mmp activity , 
0 NULL up-regulation of mmp activity , favoring proteolytic degradation 
6 activity , favoring proteolytic degradation of the basement membrane 
0 basement membrane and extracellular matrix , has been linked 
0 matrix , has been linked to tumor growth and 
0 has been linked to tumor growth and metastasis , 
4 been linked to tumor growth and metastasis , as 
14 to tumor growth and metastasis , as well as 
0 , as well as tumor angiogenesis , whereas inhibition 
0 , as well as associated angiogenesis , whereas inhibition 
3 as well as tumor-associated angiogenesis , whereas inhibition of 
18 tumor-associated angiogenesis , whereas inhibition of mmp activity appears 
0 whereas inhibition of mmp activity appears to restrict these 
18 mmp activity appears to restrict these processes . NULL 
0 appears to restrict these processes . NULL NULL NULL 
0 NULL NULL we have used retroviral-mediated gene delivery to 
0 NULL we have used mediated gene delivery to effect 
0 have used retroviral-mediated gene delivery to effect sustained autocrine 
17 retroviral-mediated gene delivery to effect sustained autocrine expression of 
9 to effect sustained autocrine expression of timp-3 in murine 
0 murine neuroblastoma and melanoma tumor cells in order to 
0 to further examine the ability of timps to inhibit 
18 ability of timps to inhibit angiogenesis in vivo . 
3 of timps to inhibit angiogenesis in vivo . NULL 
4 NULL NULL NULL NULL growth of both histologic types 
0 histologic types of gene-modified tumor cells in severe combined 
18 ) mice was significantly restricted when compared with controls 
0 restricted when compared with controls . NULL NULL NULL 
9 revealed that although tumors overexpressing timp-3 had an increased 
0 overexpressing timp-3 had an increased number of cd31 ( 
2 endothelial cells had not formed functional tubules , as 
18 , as evidenced by decreased vessel continuity and minimal 
14 continuity and minimal pericyte recruitment . NULL NULL NULL 
0 NULL NULL NULL this effect appears to be mediated 
0 effect appears to be mediated , in part , 
18 in part , by decreased expression of vascular endothelial 
9 part , by decreased expression of vascular endothelial ( 
0 endothelial cells in the presence of timp-3 as seen 
9 vitro assay and in overexpressing tumors . NULL NULL 
0 taken together , these results demonstrate that overexpression of 
9 these results demonstrate that overexpression of timp-3 can inhibit 
18 overexpression of timp-3 can inhibit angiogenesis and associated tumor 
3 of timp-3 can inhibit angiogenesis and associated tumor growth 
0 can inhibit angiogenesis and associated tumor growth , and 
0 inhibit angiogenesis and associated tumor growth , and that 
4 angiogenesis and associated tumor growth , and that the 
3 , and that the angiogenic effects of timp-3 appear 
18 and that the antiangiogenic effects of timp-3 appear to 
16 timp-3 appear to be mediated through the inhibition of 
18 be mediated through the inhibition of functional capillary morphogenesis 
2 inhibition of functional capillary morphogenesis . NULL NULL NULL 
0 brn-3a , a neuronal transcription factor of the pou 
0 : indications for its involvement in cancer and angiogenesis 
3 involvement in cancer and angiogenesis . NULL NULL NULL 
0 with the group of transcription factors pit , oct 
16 found in neuronal cells engaged in the transcription activity 
10 cells engaged in the transcription activity of the p1 
0 engaged in the transcription activity of the p1 and 
0 alternative splicing of brn-3a mrna produces two molecular forms 
9 splicing of brn-3a mrna produces two molecular forms : 
0 longer , bcl-2 transactivating form , and a shorter 
0 and a shorter inactive form , lacking 84 aa 
19 , following brn-3a gene transfection and superexpression , an 
9 brn-3a gene transfection and superexpression , an increase of 
17 and superexpression , an increase of 30 fold of 
0 fold of the bcl-2 protein occurs , leading to 
17 bcl-2 protein occurs , leading to apoptosis protection . 
5 occurs , leading to apoptosis protection . NULL NULL 
18 , leading to apoptosis protection . NULL NULL NULL 
9 works demonstrate that brn-3a expression is not restricted to 
18 brn-3a expression is not restricted to neuronal cells , 
0 cells , as its activity was detected also in 
0 as its activity was detected also in cancer cells 
0 mechanisms linking brn-3a to carcinogenesis , we discuss the 
16 , we discuss the role of this transcription factor 
0 the role of this transcription factor in influencing bcl-2/p53 
18 this transcription factor in influencing bcl-2/p53 antagonism and bcl-2/vegf 
18 factor in influencing bcl-2/p53 antagonism and bcl-2/vegf induction of 
17 bcl-2/p53 antagonism and bcl-2/vegf induction of tumor angiogenesis , 
0 and bcl-2/vegf induction of tumor angiogenesis , concluding this 
3 bcl-2/vegf induction of tumor angiogenesis , concluding this review 
0 NULL NULL NULL NULL roles of cell adhesion molecules 
0 NULL roles of cell adhesion molecules in tumor angiogenesis 
0 cell adhesion molecules in tumor angiogenesis induced by cotransplantation 
3 adhesion molecules in tumor angiogenesis induced by cotransplantation of 
17 molecules in tumor angiogenesis induced by cotransplantation of cancer 
19 tumor angiogenesis induced by cotransplantation of cancer and endothelial 
0 NULL NULL NULL NULL roles of cell adhesion molecules 
0 NULL roles of cell adhesion molecules mediating the interaction 
17 of cell adhesion molecules mediating the interaction of cancer 
15 adhesion molecules mediating the interaction of cancer and endothelial 
0 and endothelial cells in tumor angiogenesis were investigated using 
3 endothelial cells in tumor angiogenesis were investigated using new 
19 model systems with a cultured murine endothelial cell line 
19 f-2 ) and human cultured epidermoid cancer cells ( 
0 NULL the a431 cells exhibited typical in vitro cell 
15 typical in vitro cell adhesion to the endothelial f-2 
15 the initial step of adhesion was mediated by sialyl 
17 step of adhesion was mediated by sialyl lewis ( 
0 , the carbohydrate determinants expressed on the cancer cells 
9 cells , and e-selectin expressed constitutively on f-2 cells 
0 NULL NULL NULL NULL prolonged culture led to the 
0 NULL NULL NULL prolonged culture led to the implantation 
0 NULL NULL prolonged culture led to the implantation of 
19 culture led to the implantation of cancer cells into 
16 cells , which was mediated mainly by alpha ( 
19 NULL NULL f-2 cells cultured on matrigel showed evident 
0 cells cultured on matrigel showed evident tube formation , 
2 matrigel showed evident tube formation , and coculture of 
19 tube formation , and coculture of f-2 cells with 
0 cells with a431 cells led to the formation of 
0 cells led to the formation of a431 cell nests 
0 NULL this in vitro morphogenesis was inhibited by the 
0 in vitro morphogenesis was inhibited by the addition of 
0 was inhibited by the addition of anti-sialyl le ( 
0 -integrin antibodies , which led to the formation of 
17 which led to the formation of cancer cell aggregates 
15 formation of cancer cell aggregates that were independent from 
16 cell aggregates that were independent from the f-2 cell 
0 NULL this in vitro morphological appearance was exactly reproduced 
0 this in vitro morphological appearance was exactly reproduced in 
0 morphological appearance was exactly reproduced in the in vivo 
2 tumors , which were formed when the mixture of 
19 10 : 1 were cotransplanted s.c . NULL NULL 
19 the tumors of a431 supplemented with f-2 cells were 
0 f-2 cells were profoundly vascularized throughout by the tubular 
2 by the tubular structures formed by f-2 cells , 
0 NULL NULL NULL the tumor mass thus formed was 
2 the tumor mass thus formed was an average 5.8-fold 
0 5.8-fold as large as control a431 tumors that were 
4 a431 tumors that were grown without f-2 cells . 
19 NULL NULL NULL the co-injection of anti-le ( x 
17 1 ) -integrin antibodies produced a marked reduction in 
18 antibodies produced a marked reduction in the size of 
0 , which were not vascularized and accompanied an independent 
0 vascularized and accompanied an independent tiny remnant clump of 
0 significantly from those of control a431 tumors raised without 
4 of control a431 tumors raised without f-2 cells . 
0 NULL NULL NULL these results indicate that the interaction 
15 results indicate that the interaction of tumor cells and 
0 that the interaction of tumor cells and endothelial cells 
0 endothelial cells in orderly tumor angiomorphogenesis is highly dependent 
3 cells in orderly tumor angiomorphogenesis is highly dependent on 
17 tumor angiomorphogenesis is highly dependent on the action of 
0 highly dependent on the action of cell adhesion molecules 
0 the action of cell adhesion molecules mediating the adhesion 
16 of cell adhesion molecules mediating the adhesion of cancer 
15 adhesion molecules mediating the adhesion of cancer cells to 
18 to endothelial cells , inhibition of which remarkably retards 
18 inhibition of which remarkably retards tumor growth and angiogenesis 
0 of which remarkably retards tumor growth and angiogenesis . 
4 which remarkably retards tumor growth and angiogenesis . NULL 
3 retards tumor growth and angiogenesis . NULL NULL NULL 
0 NULL NULL NULL adaptor protein crk is required for 
17 adaptor protein crk is required for ephrin-b1-induced membrane ruffling 
17 crk is required for induced membrane ruffling and focal 
14 required for ephrin-b1-induced membrane ruffling and focal complex assembly 
15 ruffling and focal complex assembly of human aortic endothelial 
14 NULL NULL endothelial cell migration is an essential step 
17 cell migration is an essential step in vasculogenesis and 
3 an essential step in vasculogenesis and angiogenesis , in 
3 step in vasculogenesis and angiogenesis , in which receptor 
16 which receptor tyrosine kinases play a pivotal role . 
16 tyrosine kinases play a pivotal role . NULL NULL 
16 kinases play a pivotal role . NULL NULL NULL 
0 NULL we investigated the mechanism by which ephrin-b1 promotes 
17 mechanism by which ephrin-b1 promotes membrane ruffling in human 
14 which ephrin-b1 promotes membrane ruffling in human aortic endothelial 
14 cells , because membrane ruffling heralds cell body migration 
14 ruffling heralds cell body migration . NULL NULL NULL 
16 especially focused on the role of crk adaptor protein 
0 role of crk adaptor protein in ephb-mediated signaling . 
17 crk adaptor protein in mediated signaling . NULL NULL 
19 NULL NULL NULL using tagged crk and a fluorescent 
0 time-lapse microscope , we showed that crk was recruited 
14 showed that crk was recruited to the nascent focal 
17 focal complex after ephrin-b1 stimulation . NULL NULL NULL 
14 but not paxillin , recruited crk to the nascent 
17 but not paxillin , recruited crk to the nascent 
17 NULL NULL NULL the necessity of crk in ephrin-b1-induced 
17 necessity of crk in induced membrane ruffling was shown 
14 crk in ephrin-b1-induced membrane ruffling was shown both by 
0 shown both by the overexpression of dominant negative crk 
0 the overexpression of dominant negative crk mutants and by 
18 mutants and by the depletion of crk by using 
0 crk by using rna interference . NULL NULL NULL 
0 , we examined the role of two major downstream 
0 the role of two major downstream molecules of crk 
0 role of two major downstream molecules of crk , 
0 NULL NULL the dominant negative mutant of rac1 completely 
18 mutant of rac1 completely inhibited ephrin-b1-induced membrane ruffling and 
17 of rac1 completely inhibited induced membrane ruffling and focal 
14 completely inhibited ephrin-b1-induced membrane ruffling and focal complex assembly 
15 ruffling and focal complex assembly . NULL NULL NULL 
0 , rap1gapii , a negative regulator of rap1 , 
0 rap1gapii , a negative regulator of rap1 , did 
18 rap1 , did not inhibit ephrin-b1-induced membrane ruffling . 
17 , did not inhibit induced membrane ruffling . NULL 
14 not inhibit ephrin-b1-induced membrane ruffling . NULL NULL NULL 
9 NULL however , in expressing cells , ephrin-b1 did 
17 , ephrin-b1 did not induce membrane spreading , probably 
14 did not induce membrane spreading , probably due to 
0 NULL NULL NULL these results indicated that crk plays 
16 results indicated that crk plays a critical role in 
16 that crk plays a critical role in rac1-induced membrane 
16 crk plays a critical role in rac1-induced membrane ruffling 
17 a critical role in induced membrane ruffling and rap1-mediated 
14 role in rac1-induced membrane ruffling and rap1-mediated nascent focal 
16 rac1-induced membrane ruffling and mediated nascent focal complex stabilization 
19 rap1-mediated nascent focal complex stabilization contributing to ephrin-b1-induced human 
16 nascent focal complex stabilization contributing to ephrin-b1-induced human aortic 
17 complex stabilization contributing to induced human aortic endothelial cells 
14 human aortic endothelial cells migration . NULL NULL NULL 
16 NULL NULL NULL NULL regulation of transforming growth factor-beta 
0 NULL regulation of transforming growth factor-beta signaling and vascular 
0 members of the transforming growth factor ( tgf ) 
0 tgf ) -beta superfamily play critical roles in regulation 
0 ) -beta superfamily play critical roles in regulation of 
0 -beta superfamily play critical roles in regulation of various 
0 play critical roles in regulation of various cellular functions 
0 regulation of various cellular functions . NULL NULL NULL 
16 NULL NULL NULL NULL dysregulation of the signaling mechanisms 
0 tgf-beta superfamily proteins is associated with clinical diseases such 
0 proteins is associated with clinical diseases such as cancer 
0 to develop strategies for treating clinical diseases induced by 
0 develop strategies for treating clinical diseases induced by these 
0 for treating clinical diseases induced by these cytokines . 
16 , focusing on the roles of tgf-beta in regulation 
16 roles of tgf-beta in regulation of vascular wall cells 
16 cells and on the regulation of tgf-beta superfamily signals 
0 regulation of tgf-beta superfamily signals by inhibitory smads . 
18 tgf-beta superfamily signals by inhibitory smads . NULL NULL 
17 NULL NULL NULL postoperative progression of pulmonary metastasis in 
14 postoperative progression of pulmonary metastasis in osteosarcoma . NULL 
14 early relapse with distant metastasis often is observed in 
0 distant metastasis often is observed in patients with cancer 
19 patients with cancer after resection of the primary tumor 
0 resection of the primary tumor . NULL NULL NULL 
19 it is considered that resection of the primary tumor 
0 resection of the primary tumor induces activation of systemic 
17 of the primary tumor induces activation of systemic angiogenesis 
17 the primary tumor induces activation of systemic angiogenesis and 
3 induces activation of systemic angiogenesis and enhances progression of 
17 of systemic angiogenesis and enhances progression of remote metastasis 
17 systemic angiogenesis and enhances progression of remote metastasis . 
14 enhances progression of remote metastasis . NULL NULL NULL 
19 the authors show that resection of the primary osteosarcoma 
0 of the primary osteosarcoma tumor enhances progression of pulmonary 
17 the primary osteosarcoma tumor enhances progression of pulmonary metastasis 
17 primary osteosarcoma tumor enhances progression of pulmonary metastasis in 
14 enhances progression of pulmonary metastasis in animal osteosarcoma models 
3 NULL NULL matrigel plug neovascularization assay revealed that systemic 
3 assay revealed that systemic angiogenic activity was elevated after 
0 revealed that systemic angiogenic activity was elevated after primary 
17 systemic angiogenic activity was elevated after primary tumor removal 
0 was elevated after primary tumor removal ( tumor intact 
19 elevated after primary tumor removal ( tumor intact group 
0 primary tumor removal ( tumor intact group , 1.61 
0 +/- 0.21 g/dl ; tumor removed group , 4.92 
0 0.21 g/dl ; tumor removed group , 4.92 +/- 
0 NULL NULL NULL in addition , serum concentration of 
3 serum concentration of the angiogenesis inhibitor , endostatin , 
0 concentration of the angiogenesis inhibitor , endostatin , decreased 
18 inhibitor , endostatin , decreased significantly after primary tumor 
0 decreased significantly after primary tumor removal . NULL NULL 
19 significantly after primary tumor removal . NULL NULL NULL 
19 NULL NULL NULL NULL treatment with the antiangiogenic reagent 
3 NULL treatment with the angiogenic reagent tnp-470 suppressed postoperative 
18 the antiangiogenic reagent tnp-470 suppressed postoperative progression of pulmonary 
17 reagent tnp-470 suppressed postoperative progression of pulmonary metastasis . 
14 postoperative progression of pulmonary metastasis . NULL NULL NULL 
0 NULL NULL NULL these results indicate the possibility that 
17 indicate the possibility that activation of angiogenic activity after 
3 possibility that activation of angiogenic activity after resection of 
0 that activation of angiogenic activity after resection of osteosarcoma 
19 of angiogenic activity after resection of osteosarcoma tumors enhances 
17 resection of osteosarcoma tumors enhances progression of pulmonary metastasis 
17 of osteosarcoma tumors enhances progression of pulmonary metastasis . 
14 enhances progression of pulmonary metastasis . NULL NULL NULL 
19 data also suggest that administration of antiangiogenic reagents can 
3 suggest that administration of angiogenic reagents can prevent progression 
18 of antiangiogenic reagents can prevent progression of pulmonary metastasis 
17 antiangiogenic reagents can prevent progression of pulmonary metastasis in 
14 prevent progression of pulmonary metastasis in osteosarcoma postoperatively . 
3 NULL NULL NULL NULL arteriogenesis : the development and 
2 NULL arteriogenesis : the development and growth of collateral 
4 : the development and growth of collateral arteries . 
0 , collateral vessels bypassing major arterial obstructions have frequently 
0 collateral vessels bypassing major arterial obstructions have frequently been 
0 obstructions have frequently been observed . NULL NULL NULL 
3 NULL the term `` arteriogenesis '' was introduced to 
0 '' was introduced to differentiate the formation of collateral 
2 introduced to differentiate the formation of collateral arteries from 
3 of collateral arteries from angiogenesis , which mainly occurs 
17 the ischemic , collateral dependent tissue . NULL NULL 
0 animal models and humans support that the remodeling of 
7 humans support that the remodeling of preexisting collateral vessels 
0 collateral vessels is the mechanism of collateral artery formation 
2 mechanism of collateral artery formation . NULL NULL NULL 
7 NULL NULL NULL this remodeling process seems to be 
0 seems to be mainly mediated . NULL NULL NULL 
16 NULL NULL NULL it involves endothelial cell activation , 
17 it involves endothelial cell activation , basal membrane degradation 
6 activation , basal membrane degradation , leukocyte invasion , 
14 membrane degradation , leukocyte invasion , proliferation of vascular 
1 , leukocyte invasion , proliferation of vascular cells , 
2 vascular cells , neointima formation ( in most species 
16 studied ) , and changes of the extracellular matrix 
0 changes of the extracellular matrix . NULL NULL NULL 
0 NULL NULL NULL the contribution of ischemia to arteriogenesis 
3 contribution of ischemia to arteriogenesis is still unclear , 
3 still unclear , but arteriogenesis clearly can occur in 
0 the absence of any significant ischemia . NULL NULL 
2 whether collateral arteries also form de novo in ischemic 
3 of the mechanisms of arteriogenesis will be important for 
0 of arteriogenesis will be important for the design of 
0 the design of more effective strategies for the treatment 
0 effective strategies for the treatment of patients with ischemic 
0 NULL NULL NULL possible role of cyclooxygenase ii in 
0 acquisition of ovarian luteal function in rodents . NULL 
2 NULL NULL NULL the development of the corpus luteum 
0 cl ) , which involves angiogenesis , is essential 
3 ) , which involves angiogenesis , is essential for 
0 involves angiogenesis , is essential for the establishment of 
0 is essential for the establishment of early pregnancy . 
16 NULL we investigated the roles of the prostaglandin synthases 
3 i and cox-ii in angiogenesis and progesterone production in 
8 in angiogenesis and progesterone production in the newly formed 
2 production in the newly formed cl , using inhibitors 
17 cox enzymes and the induced pseudopregnant rat as a 
19 enzymes and the gonadotropin-induced pseudopregnant rat as a model 
19 NULL NULL NULL NULL injection of indomethacin , a 
0 , a nonselective cox inhibitor , on the day 
18 and the following day decreased serum levels of progesterone 
0 following day decreased serum levels of progesterone , as 
19 progesterone , as did injection of the selective cox-ii 
0 of the selective cox-ii inhibitor ns-398 . NULL NULL 
0 , a selective cox-i inhibitor , sc-560 , had 
16 sc-560 , had no effect on serum progesterone concentrations 
16 the inhibitors had any effect on the weight of 
8 ovaries or on the synthesis of progesterone by cultured 
0 synthesis of progesterone by cultured luteal cells . NULL 
16 NULL to determine whether changes in angiogenesis are responsible 
3 determine whether changes in angiogenesis are responsible for the 
16 changes in angiogenesis are responsible for the decrease in 
18 are responsible for the decrease in progesterone synthesis , 
8 the decrease in progesterone synthesis , we measured hemoglobin 
0 measured hemoglobin and cd34 levels in luteinized ovaries following 
2 and cd34 levels in luteinized ovaries following injection of 
0 in luteinized ovaries following injection of cox inhibitors and 
0 relative frequency of cells positive for platelet-endothelial cell adhesion 
0 positive for platelet-endothelial cell adhesion molecule as a specific 
0 of these parameters were reduced by the cox-ii inhibitors 
16 inhibitors , suggesting that changes in the vasculature are 
16 in the vasculature are responsible for the decrease in 
18 are responsible for the decrease in serum progesterone . 
18 casts indicated that ns-398 inhibited the establishment of luteal 
2 that ns-398 inhibited the establishment of luteal capillary vessels 
19 capillary vessels following the injection of hcg . NULL 
0 NULL NULL NULL the results are consistent with the 
0 the hypothesis that the activity of cox-ii is associated 
16 activity of cox-ii is associated with the formation of 
2 is associated with the formation of functional cl via 
17 functional cl via its stimulation of angiogenesis . NULL 
3 via its stimulation of angiogenesis . NULL NULL NULL 
0 NULL NULL NULL NULL tumor angiogenesis modulates leukocyte-vessel wall 
3 NULL NULL NULL tumor angiogenesis modulates leukocyte-vessel wall interactions 
16 NULL NULL tumor angiogenesis modulates leukocyte-vessel wall interactions in 
15 angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing 
18 interactions in vivo by reducing endothelial adhesion molecule expression 
0 vivo by reducing endothelial adhesion molecule expression . NULL 
9 reducing endothelial adhesion molecule expression . NULL NULL NULL 
9 NULL NULL NULL the expression of endothelial cell ( 
0 cell ( ec ) adhesion molecules involved in leukocyte-vessel 
16 ec ) adhesion molecules involved in leukocyte-vessel wall interactions 
15 involved in leukocyte-vessel wall interactions is suppressed in malignancies 
0 leukocyte-vessel wall interactions is suppressed in malignancies . NULL 
0 NULL NULL in the present study , we investigated 
16 investigated in vivo the regulation of leukocyte-vessel wall interactions 
15 regulation of leukocyte-vessel wall interactions by the presence of 
0 wall interactions by the presence of a tumor . 
0 the presence of a tumor . NULL NULL NULL 
0 of intravital microscopy , tumor necrosis factor alpha-stimulated leukocyte-vessel 
0 intravital microscopy , tumor necrosis factor alpha-stimulated leukocyte-vessel wall 
17 , tumor necrosis factor stimulated leukocyte-vessel wall interactions were 
15 factor alpha-stimulated leukocyte-vessel wall interactions were studied in ear 
15 NULL NULL leukocyte-vessel wall interactions were studied both within 
4 and outside small tumors growing in the ear , 
0 mice with a large tumor growing on their flank 
4 with a large tumor growing on their flank . 
0 NULL NULL NULL NULL free mice were used as 
0 NULL tumor-free mice were used as controls . NULL 
0 mice were used as controls . NULL NULL NULL 
15 contralateral ear , leukocyte adhesion was found to be 
18 was found to be diminished significantly in vessels inside 
0 vessels inside the ear tumor in both mouse models 
18 NULL NULL NULL this reduction disappeared with increasing distance 
0 this reduction disappeared with increasing distance from the tumor 
0 increasing distance from the tumor . NULL NULL NULL 
15 the level of leukocyte adhesion in ear venules of 
0 with a large flank tumor was also reduced significantly 
18 flank tumor was also reduced significantly . NULL NULL 
0 , the step preceding adhesion , was not influenced 
0 not influenced by the presence of a tumor in 
0 the presence of a tumor in nude mice , 
0 mice , but was down-regulated in immune-competent c57bl/6 mice 
19 NULL NULL NULL NULL treatment of mice bearing a 
0 bearing a small ear tumor with a humanized antivascular 
0 a humanized antivascular endothelial growth factor antibody prevented the 
18 endothelial growth factor antibody prevented the down-regulation of leukocyte-vessel 
18 factor antibody prevented the down-regulation of leukocyte-vessel wall interactions 
15 down-regulation of leukocyte-vessel wall interactions inside the tumor vessels 
0 wall interactions inside the tumor vessels compared with the 
19 vessels compared with the nontreated group . NULL NULL 
17 NULL NULL NULL NULL activated cell sorter analysis showed 
0 fluorescence-activated cell sorter analysis showed that isolated tumor ecs 
0 sorter analysis showed that isolated tumor ecs have suppressed 
0 analysis showed that isolated tumor ecs have suppressed levels 
18 isolated tumor ecs have suppressed levels of intercellular adhesion 
0 tumor ecs have suppressed levels of intercellular adhesion molecule 
0 suppressed levels of intercellular adhesion molecule 1 as compared 
0 NULL NULL NULL in cultured b.end5 cells the tumor 
0 cultured b.end5 cells the tumor necrosis factor alpha-induced up-regulation 
0 b.end5 cells the tumor necrosis factor alpha-induced up-regulation of 
17 the tumor necrosis factor induced up-regulation of intercellular adhesion 
17 tumor necrosis factor alpha-induced up-regulation of intercellular adhesion molecule 
0 alpha-induced up-regulation of intercellular adhesion molecule 1 and vascular 
0 1 and vascular cell adhesion molecule 1 was reduced 
18 adhesion molecule 1 was reduced in ecs that were 
19 in ecs that were preincubated with basic fibroblast growth 
0 preincubated with basic fibroblast growth factor or vascular endothelial 
0 factor or vascular endothelial growth factor . NULL NULL 
0 NULL NULL the current results may have an impact 
0 results may have an impact on the effectiveness of 
0 an impact on the effectiveness of clinical immunotherapeutic treatment 
0 on the effectiveness of clinical immunotherapeutic treatment protocols , 
0 effectiveness of clinical immunotherapeutic treatment protocols , because immune 
14 not be able to enter tumor tissue . NULL 
0 be able to enter tumor tissue . NULL NULL 
0 NULL NULL NULL antiapoptotic effect of coagulation factor viia 
15 NULL NULL NULL NULL binding of factor viia ( 
17 was previously shown to induce various intracellular signaling events 
0 were thought to be responsible for tf-mediated biologic effects 
17 to be responsible for mediated biologic effects , including 
0 responsible for tf-mediated biologic effects , including angiogenesis , 
3 biologic effects , including angiogenesis , tumor metastasis , 
0 , including angiogenesis , tumor metastasis , and restenosis 
14 including angiogenesis , tumor metastasis , and restenosis . 
0 the mechanisms behind these processes , we have examined 
0 we have examined the effect of fviia on apoptosis 
0 effect of fviia on apoptosis . NULL NULL NULL 
17 NULL NULL NULL serum induced apoptosis of bhk ( 
5 NULL NULL serum deprivation-induced apoptosis of bhk ( +tf 
0 chromatin-condensed bodies , dna degradation , and activation of 
17 dna degradation , and activation of caspase 3 . 
0 NULL NULL fviia markedly decreased the number of cells 
0 with apoptotic morphology and prevented the dna degradation as 
0 and prevented the dna degradation as measured by means 
0 measured by means of mediated dutp nick end labeling 
0 NULL NULL the antiapoptotic effect of fviia was confirmed 
18 the observation that fviia attenuated caspase 3 activation . 
17 fviia attenuated caspase 3 activation . NULL NULL NULL 
0 NULL NULL NULL NULL induced antiapoptotic effect was dependent 
0 NULL NULL fviia-induced antiapoptotic effect was dependent on its 
0 fviia-induced antiapoptotic effect was dependent on its proteolytic activity 
0 dependent on its proteolytic activity and tf but independent 
0 activity and tf but independent of factor xa and 
17 NULL NULL NULL NULL induced cell survival correlated with 
5 NULL NULL fviia-induced cell survival correlated with the activation 
17 survival correlated with the activation of akt and was 
0 of akt and was inhibited markedly by the specific 
0 by the specific pi3-kinase inhibitor , ly294002 . NULL 
18 NULL NULL NULL NULL blocking the activation of p44/42 
17 NULL NULL blocking the activation of p44/42 mitogen-activated protein 
0 the activation of p44/42 activated protein kinase ( mapk 
0 activation of p44/42 mitogen-activated protein kinase ( mapk ) 
0 ) by the specific induced extracellular kinase ( mek 
0 kinase ( mek ) inhibitor , u0126 , impaired 
18 inhibitor , u0126 , impaired modestly the ability of 
0 , impaired modestly the ability of fviia to promote 
17 ability of fviia to promote cell survival . NULL 
5 fviia to promote cell survival . NULL NULL NULL 
15 in conclusion , fviia binding to tf provided protection 
0 binding to tf provided protection against apoptosis induced by 
0 tf provided protection against apoptosis induced by growth factor 
0 provided protection against apoptosis induced by growth factor deprivation 
0 against apoptosis induced by growth factor deprivation , primarily 
17 deprivation , primarily through activation of pi3-kinase/akt pathway , 
0 prognostic value of p53 protein expression and vascular endothelial 
9 value of p53 protein expression and vascular endothelial growth 
0 expression and vascular endothelial growth factor expression in resected 
9 vascular endothelial growth factor expression in resected squamous cell 
19 growth factor expression in resected squamous cell carcinoma of 
0 the most common genetic alterations found in a wide 
0 of cancers are p53 tumor suppressor gene mutations . 
0 cancers are p53 tumor suppressor gene mutations . NULL 
0 to be a nuclear transcription factor that plays a 
0 nuclear transcription factor that plays a role in the 
0 factor that plays a role in the control of 
16 a role in the control of cell proliferation , 
1 the control of cell proliferation , apoptosis , and 
5 of cell proliferation , apoptosis , and the maintenance 
0 apoptosis , and the maintenance of genetic stability . 
3 NULL NULL NULL NULL angiogenesis is a critical process 
16 NULL angiogenesis is a critical process in solid tumor 
0 critical process in solid tumor growth and metastasis . 
4 process in solid tumor growth and metastasis . NULL 
14 solid tumor growth and metastasis . NULL NULL NULL 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
0 , a recently identified growth factor with significant angiogenic 
0 identified growth factor with significant angiogenic properties , may 
3 growth factor with significant angiogenic properties , may be 
0 factor with significant angiogenic properties , may be a 
0 , may be a major tumor angiogenesis regulator . 
0 may be a major tumor angiogenesis regulator . NULL 
3 be a major tumor angiogenesis regulator . NULL NULL 
16 a major tumor angiogenesis regulator . NULL NULL NULL 
0 studies have investigated the association between p53 and vegf 
9 between p53 and vegf expressions and prognosis in esophageal 
19 NULL NULL forty-seven specimens resected from patients with stage 
0 esophagus were studied using immunohistochemical staining . NULL NULL 
0 were studied using immunohistochemical staining . NULL NULL NULL 
9 NULL vegf and p53 expressions were observed in 40 
0 and p53 expressions were observed in 40 % and 
0 the p53 and vegf staining statuses were coincident in 
0 tumors , and no significant correlation was found between 
9 with p53 or vegf expression . NULL NULL NULL 
0 NULL NULL NULL no significant association between p53 and 
0 NULL NULL no significant association between p53 and vegf 
9 between p53 and vegf expressions and poor prognosis was 
0 NULL NULL NULL the role of organ vascularization and 
3 the role of organ vascularization and lipoplex-serum initial contact 
0 vascularization and lipoplex-serum initial contact in intravenous murine lipofection 
19 contact in intravenous murine lipofection . NULL NULL NULL 
19 NULL NULL following intravenous administration of cationic lipid-dna complexes 
0 ) into mice , transfection ( lipofection ) occurs 
0 mice , transfection ( lipofection ) occurs predominantly in 
14 was attributed to high entrapment of lipoplexes in the 
0 of lipoplexes in the extended lung vascular tree . 
19 NULL to determine whether lipofection in other organs could 
17 other organs could be enhanced by increasing the degree 
17 could be enhanced by increasing the degree of vascularization 
3 increasing the degree of vascularization , we used a 
0 of vascularization , we used a transgenic mouse model 
0 , we used a transgenic mouse model with tissue-specific 
3 mouse model with tissue-specific angiogenesis in liver . NULL 
19 NULL NULL tail vein injection of n- ( 1- 
17 dotap ) /cholesterol lipoplexes resulted in increased lipoplex entrapment 
17 /cholesterol lipoplexes resulted in increased lipoplex entrapment in hypervascularized 
14 resulted in increased lipoplex entrapment in hypervascularized liver but 
17 liver but did not boost luciferase expression , suggesting 
9 did not boost luciferase expression , suggesting that lipoplex 
14 , suggesting that lipoplex delivery is not a sufficient 
17 delivery is not a sufficient condition for efficient organ 
19 condition for efficient organ lipofection . NULL NULL NULL 
19 NULL because the intravenously injected lipoplexes migrated within seconds 
14 the intravenously injected lipoplexes migrated within seconds to lungs 
0 we checked whether the effects of immediate contact with 
0 the effects of immediate contact with serum correlate with 
19 serum correlate with lung lipofection efficiency of different dotap-based 
0 under conditions mimicking the injection environment , the lipoplex-serum 
0 environment , the lipoplex-serum interaction was strongly dependent on 
0 lipoplex-serum interaction was strongly dependent on helper lipid and 
15 cholesterol were found to aggregate immediately . NULL NULL 
15 NULL NULL NULL this aggregation process was irreversible and 
19 with the efficiency of lipofection . NULL NULL NULL 
0 NULL NULL no other structural changes in serum were 
0 NULL no other structural changes in serum were observed 
0 changes in serum were observed for cholesterol-based lipoplexes . 
0 found to give low expression , apparently because of 
0 because of an immediate loss of integrity in serum 
0 that efficient in vivo lipofection is the result of 
0 between lipoplex composition , interaction with serum , hemodynamics 
0 , hemodynamics , and target tissue `` susceptibility '' 
0 `` susceptibility '' to transfection . NULL NULL NULL 
0 NULL NULL NULL NULL proliferative diabetic retinopathy is associated 
0 proliferative diabetic retinopathy is associated with a low level 
3 of the natural ocular angiogenic agent pigment epithelium-derived factor 
0 ocular anti-angiogenic agent pigment derived factor ( pedf ) 
0 complication and represents a major threat to the eyesight 
0 was to address the role of pro- and anti-angiogenic 
3 role of pro- and angiogenic molecules in diabetic retinopathy 
19 NULL aqueous humor was collected at cataract surgery from 
0 was collected at cataract surgery from 19 diabetic patients 
0 age- and sex-matched normoglycemic controls . NULL NULL NULL 
0 NULL NULL NULL NULL levels of pro-angiogenic vascular endothelial 
3 NULL NULL levels of angiogenic vascular endothelial growth factor 
0 of pro-angiogenic vascular endothelial growth factor ( vegf ) 
3 ( vegf ) and angiogenic inhibitor pigment epithelium-derived factor 
0 vegf ) and angiogenic inhibitor pigment epithelium-derived factor ( 
0 and angiogenic inhibitor pigment derived factor ( pedf ) 
3 NULL NULL NULL NULL angiogenic activity of the aqueous 
0 NULL NULL NULL angiogenic activity of the aqueous humor 
16 quantified by measuring its effect on the migration of 
14 its effect on the migration of capillary endothelial cells 
0 aqueous fluid , vegf levels were increased in diabetics 
17 , vegf levels were increased in diabetics ( mean 
0 ) , compared to controls . NULL NULL NULL 
18 was found to be decreased in diabetics ( mean 
0 0.04 ) compared to controls . NULL NULL NULL 
0 seven diabetic patients with proliferative retinopathy , the most 
0 profound finding was a significant decrease of the pedf 
18 finding was a significant decrease of the pedf level 
0 ) , whereas vegf levels were comparable to diabetic 
0 to diabetic patients without proliferation ( mean value : 
3 NULL NULL NULL NULL angiogenic activity in samples of 
0 NULL NULL NULL angiogenic activity in samples of patients 
0 of patients from the control group was generally inhibitory 
18 control group was generally inhibitory due to pedf , 
18 to pedf , and inhibition was blocked by neutralizing 
18 , and inhibition was blocked by neutralizing antibodies to 
0 , in diabetics without proliferation , angiogenic activity was 
3 diabetics without proliferation , angiogenic activity was also blocked 
0 without proliferation , angiogenic activity was also blocked by 
18 angiogenic activity was also blocked by antibodies to pedf 
3 of the natural ocular angiogenic agent pedf is inversely 
0 agent pedf is inversely associated with proliferative retinopathy . 
0 is inversely associated with proliferative retinopathy . NULL NULL 
0 NULL pedf is an important negative regulator of angiogenic 
18 pedf is an important negative regulator of angiogenic activity 
18 is an important negative regulator of angiogenic activity of 
3 important negative regulator of angiogenic activity of aqueous humor 
0 negative regulator of angiogenic activity of aqueous humor . 
0 have implications for the development of novel regimens for 
3 NULL NULL NULL NULL angiogenesis -- biomedical technology . 
3 these studies show that angiogenesis research can benefit from 
0 technology tools currently being developed , as well as 
0 , as well as contribute by providing new technologies 
0 technologies that can be used in other areas of 
18 NULL interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal 
6 ischaemic and excitotoxic neuronal damage in the rat . 
9 interleukin-1 ( il-1 ) synthesis in the brain is 
17 in the brain is stimulated by mechanical injury and 
0 and il-1 mimics some effects of injury , such 
3 such as gliosis and neovascularization . NULL NULL NULL 
5 we report that neuronal death resulting from focal cerebral 
0 report that neuronal death resulting from focal cerebral ischaemia 
18 h ) is significantly inhibited ( by 50 % 
19 % ) in rats injected with a recombinant il-1 
0 NULL NULL NULL excitotoxic damage due to striatal infusion 
19 damage due to striatal infusion of an nmda-receptor agonist 
0 ) was also markedly inhibited ( 71 % ) 
19 71 % ) by injection of the il-1ra . 
17 endogenous il-1 is a mediator of ischaemic and excitotoxic 
6 ischaemic and excitotoxic brain damage , and that inhibitors 
0 that inhibitors of il-1 action may be of therapeutic 
0 therapeutic value in the treatment of acute or chronic 
5 acute or chronic neuronal death . NULL NULL NULL 
0 NULL NULL NULL laser treatment of eccentric leaks in 
0 of eccentric leaks in central serous chorioretinopathy resulting in 
0 in central serous chorioretinopathy resulting in disappearance of untreated 
0 resulting in disappearance of untreated juxtafoveal leaks . NULL 
0 NULL NULL NULL in central serous chorioretinopathy ( cscr 
0 ( cscr ) laser treatment of leaking points close 
17 producing juxtafoveal scotoma and stimulating choroidal neovascularization . NULL 
3 scotoma and stimulating choroidal neovascularization . NULL NULL NULL 
6 points within a macular detachment , one of which 
0 NULL NULL NULL NULL photocoagulation with green argon laser 
0 in all eyes , treating all the leaking points 
0 points except for the central one . NULL NULL 
0 NULL NULL visual symptoms regressed after treatment , and 
0 visual symptoms regressed after treatment , and the serous 
0 , and the serous detachment was resolved 10 days 
0 to 4 weeks after photocoagulation in all cases . 
0 NULL NULL NULL fluorescein angiography showed no leakage at 
0 NULL NULL fluorescein angiography showed no leakage at either 
0 fluorescein angiography showed no leakage at either the central 
0 leakage at either the central leakage point or the 
0 at either the central leakage point or the leakage 
0 leakage point or the leakage point that had been 
0 point that had been treated . NULL NULL NULL 
0 NULL NULL NULL these results led us to believe 
0 NULL NULL these results led us to believe that 
0 to believe that the central or dependent leak in 
0 that the central or dependent leak in our cases 
0 our cases was not sufficient to maintain the serous 
0 to maintain the serous detachment by itself . NULL 
0 hypothesis is that the untreated leak did not represent 
6 within a single macular detachment , we believe that 
0 leak may be a dependent or false leak and 
0 false leak and that direct treatment is not necessary 
0 leak and that direct treatment is not necessary . 
10 NULL NULL NULL NULL transcriptional and post-translation regulation of 
16 NULL transcriptional and post-translation regulation of the tie1 receptor 
0 by fluid shear stress changes in vascular endothelial cells 
0 NULL NULL NULL the interaction between the vascular endothelium 
0 shear stress ) , induced by the flow of 
16 flow of blood , plays a major role in 
16 blood , plays a major role in vascular remodeling 
16 , plays a major role in vascular remodeling and 
7 major role in vascular remodeling and in new blood 
2 in new blood vessels formation via a process termed 
3 via a process termed arteriogenesis . NULL NULL NULL 
9 orphan tyrosine kinase receptor expressed almost exclusively in endothelial 
17 endothelial cells and is required for normal vascular development 
2 required for normal vascular development and maintenance . NULL 
16 normal vascular development and maintenance . NULL NULL NULL 
0 NULL NULL NULL the present study demonstrates that tie1 
9 study demonstrates that tie1 expression is rapidly down-regulated in 
18 tie1 expression is rapidly down-regulated in endothelial cells exposed 
19 down-regulated in endothelial cells exposed to shear stress , 
0 so to shear stress changes . NULL NULL NULL 
18 NULL NULL NULL this down-regulation is accompanied by a 
11 accompanied by a rapid cleavage of tie1 and binding 
15 cleavage of tie1 and binding of the cleaved tie1 
11 and binding of the cleaved tie1 45 kda endodomain 
11 NULL NULL the rapid cleavage of tie1 is followed 
10 is followed by a transcriptional down-regulation in response to 
18 followed by a transcriptional down-regulation in response to shear 
0 a transcriptional down-regulation in response to shear stress . 
0 NULL NULL NULL the activity of the tie1 promoter 
18 the tie1 promoter is suppressed by shear stress and 
0 shear stress and by tumor necrosis factor alpha . 
0 stress and by tumor necrosis factor alpha . NULL 
17 NULL NULL NULL shear induced transcriptional suppression of tie1 
10 NULL NULL shear stress-induced transcriptional suppression of tie1 is 
18 NULL shear stress-induced transcriptional suppression of tie1 is mediated 
16 suppression of tie1 is mediated by a negative shear 
0 is mediated by a negative shear stress response element 
0 a negative shear stress response element , localized in 
0 stress response element , localized in a region of 
18 NULL NULL the rapid down-regulation of tie1 by shear 
0 tie1 by shear stress changes and its rapid binding 
15 changes and its rapid binding to tie2 may be 
17 to tie2 may be required for destabilization of endothelial 
18 may be required for destabilization of endothelial cells in 
17 cells in order to initiate the process of vascular 
7 the process of vascular restructuring . NULL NULL NULL 
3 NULL NULL NULL therapeutic angiogenesis : a complex problem 
0 : a complex problem requiring a sophisticated approach . 
0 NULL NULL ischemia , involving restricted blood flow to 
0 NULL ischemia , involving restricted blood flow to tissues 
6 common consequence of vessel dysfunction resulting in the disruption 
0 consequence of vessel dysfunction resulting in the disruption of 
11 dysfunction resulting in the disruption of oxygen and nutrient 
0 of oxygen and nutrient delivery and the accumulation of 
0 nutrient delivery and the accumulation of waste metabolites . 
5 NULL cells can not survive extended severe ischemia but 
0 cells can not survive extended severe ischemia but may 
0 nonischemic regions sustains vital functions . NULL NULL NULL 
0 condition , the secondary functions of effected cells are 
16 the secondary functions of effected cells are likely to 
0 are likely to be impaired , and a new 
0 new metabolic equilibrium is established , determined by the 
0 a normally high metabolic turnover such as skeletal and 
0 acidosis , and depressed function ( contractility ) and 
0 myocyte viability and organ function . NULL NULL NULL 
0 vulnerable because reperfusion is essential for survival but reperfusion 
0 reperfusion is essential for survival but reperfusion itself poses 
0 additional stress principally from increased production of free radicals 
0 stress principally from increased production of free radicals during 
0 from increased production of free radicals during reoxygenation . 
0 NULL NULL the latter effect is called reperfusion injury 
0 can cause as much damage as the ischemia . 
0 NULL NULL NULL the treatment possibilities for ischemia-related vascular 
0 ischemia-related vascular disease are limited . NULL NULL NULL 
19 adherence ( aspirin ) therapy may help slow the 
0 ) therapy may help slow the progression of vessel 
0 may help slow the progression of vessel disease in 
0 some instances ; but surgical reconstruction may be the 
0 rather obvious strategy to treat ischemia is to activate 
17 treat ischemia is to activate endogenous angiogenic or arteriogenic 
3 is to activate endogenous angiogenic or arteriogenic pathways to 
3 activate endogenous angiogenic or arteriogenic pathways to stimulate revascularization 
3 endogenous angiogenic or arteriogenic pathways to stimulate revascularization of 
17 or arteriogenic pathways to stimulate revascularization of the tissue 
3 arteriogenic pathways to stimulate revascularization of the tissue . 
0 strategy has now been established through the results of 
0 been established through the results of studies over the 
3 new discipline called therapeutic angiogenesis has emerged . NULL 
0 review focuses on the application of therapeutic angiogenesis for 
3 the application of therapeutic angiogenesis for treating ischemic muscle 
0 of therapeutic angiogenesis for treating ischemic muscle disease and 
0 disease and includes a critical evaluation of the parameters 
0 NULL NULL NULL the development of this technology has 
0 has benefited from its application to both peripheral and 
0 coronary artery disease and results from both are reviewed 
9 NULL NULL NULL NULL expression , regulation , and 
16 NULL NULL expression , regulation , and function of 
0 , regulation , and function of igf-1 , igf-1r 
0 igf-1r , and igf-1 binding proteins in blood vessels 
0 NULL the vascular insulin-like growth factor ( igf ) 
0 ) , and multiple binding proteins . NULL NULL 
0 NULL NULL NULL this growth factor system exerts multiple 
0 system exerts multiple physiologic effects on the vasculature through 
0 NULL NULL NULL the effects of igf-1 are mediated 
16 effects of igf-1 are mediated principally through the igf-1r 
0 the igf-1r but are modulated by complex interactions with 
15 are modulated by complex interactions with multiple igf binding 
0 interactions with multiple igf binding proteins that themselves are 
16 proteins that themselves are regulated by phosphorylation , proteolysis 
12 themselves are regulated by phosphorylation , proteolysis , polymerization 
11 regulated by phosphorylation , proteolysis , polymerization , and 
15 phosphorylation , proteolysis , polymerization , and cell or 
0 , and cell or matrix association . NULL NULL 
15 and cell or matrix association . NULL NULL NULL 
0 last decade , a significant body of evidence has 
0 body of evidence has accumulated , indicating that expression 
0 accumulated , indicating that expression of the components of 
0 the igf system are regulated by multiple factors , 
0 multiple factors , including growth factors , cytokines , 
0 NULL NULL NULL in addition , cross-talk between the 
0 igf system and other growth factors and integrin receptors 
16 accumulating evidence of a role for igf-1 in multiple 
3 hypertension , restenosis , angiogenesis , and diabetic vascular 
16 review will discuss the regulation of expression of igf-1 
9 discuss the regulation of expression of igf-1 , igf-1r 
0 igf-1r , and igf binding proteins in the vasculature 
0 and summarize evidence implicating involvement of this system in 
3 angiopoietin/tie-2 as mediators of angiogenesis : a role in 
0 of angiogenesis : a role in congestive heart failure 
3 NULL NULL NULL NULL angiogenic factors , in particular 
0 in particular vascular endothelial growth factor ( vegf ) 
0 , have recently generated significant interest , especially in 
3 NULL the process of angiogenesis is also thought to 
0 thought to occur in response to ischaemic conditions , 
3 conclusively show evidence of angiogenesis per se in these 
14 for example ) the presence of high levels of 
0 the presence of high levels of vegf and ang-2 
0 NULL NULL NULL high levels of these angiogenic factors 
3 high levels of these angiogenic factors in heart disease 
0 not translated into clinically significant new vessel formation , 
2 clinically significant new vessel formation , as in accelerated 
17 formation , as in accelerated cancer growth or proliferative 
4 as in accelerated cancer growth or proliferative retinopathy . 
0 accelerated cancer growth or proliferative retinopathy . NULL NULL 
3 would hypothesize that these angiogenic markers -- especially the 
16 -- do not necessarily translate into new vessel formation 
2 translate into new vessel formation in congestive heart failure 
16 , but may well reflect disturbances of endothelial integrity 
6 but may well reflect disturbances of endothelial integrity in 
2 NULL NULL NULL NULL morphogenesis of embryonic cns vessels 
2 morphology of blood vessel formation in and around the 
0 and around the early central nervous system ( cns 
1 discuss cell lineages , proliferation and interactions of endothelial 
15 lineages , proliferation and interactions of endothelial cells , 
16 not review the molecular control of cns angiogenesis , 
3 molecular control of cns angiogenesis , but refer the 
2 recent publications on the assembly of the vasculature ( 
18 NULL the candidate tumour suppressor protein ing4 regulates brain 
0 the candidate tumour suppressor protein ing4 regulates brain tumour 
16 tumour suppressor protein ing4 regulates brain tumour growth and 
4 ing4 regulates brain tumour growth and angiogenesis . NULL 
3 brain tumour growth and angiogenesis . NULL NULL NULL 
0 primary tumours of the central nervous system , with 
17 NULL NULL the marked induction of angiogenesis in glioblastomas 
3 the marked induction of angiogenesis in glioblastomas suggests that 
2 a necessary part of malignant progression ; however , 
2 necessary part of malignant progression ; however , the 
16 molecular mechanisms underlying the regulation of brain tumour growth 
4 regulation of brain tumour growth and angiogenesis remain unresolved 
3 brain tumour growth and angiogenesis remain unresolved . NULL 
0 that a candidate tumour suppressor gene , ing4 , 
0 , ing4 , is involved in regulating brain tumour 
16 , is involved in regulating brain tumour growth and 
4 in regulating brain tumour growth and angiogenesis . NULL 
3 brain tumour growth and angiogenesis . NULL NULL NULL 
9 NULL NULL NULL NULL expression of ing4 is significantly 
18 of ing4 is significantly reduced in gliomas as compared 
18 and the extent of reduction correlates with the progression 
2 reduction correlates with the progression from lower to higher 
18 u87mg , which has decreased expression of ing4 , 
9 , which has decreased expression of ing4 , grow 
4 expression of ing4 , grow significantly faster and have 
0 vascular volume fractions than control tumours . NULL NULL 
15 show that ing4 physically interacts with p65 ( rela 
16 , and that ing4 regulates brain tumour angiogenesis through 
3 ing4 regulates brain tumour angiogenesis through transcriptional repression of 
0 brain tumour angiogenesis through transcriptional repression of nf-kappab-responsive genes 
0 tumour angiogenesis through transcriptional repression of nf-kappab-responsive genes . 
0 NULL NULL NULL these results indicate that ing4 has 
16 that ing4 has an important role in brain tumour 
16 ing4 has an important role in brain tumour pathogenesis 
2 role in brain tumour pathogenesis . NULL NULL NULL 
0 future : revisiting its role as a transforming growth 
0 role as a transforming growth factor . NULL NULL 
0 was initially identified in culture media from transformed cells 
0 in culture media from transformed cells as part of 
0 a factor that could produce a transformed phenotype in 
0 that could produce a transformed phenotype in a nontransformed 
0 NULL NULL subsequently this activity was separated into tgfbeta 
4 tgfbeta1 was a potent growth inhibitor of epithelial cells 
0 was a potent growth inhibitor of epithelial cells , 
18 and the identification of inactivating mutations within the tgfbeta1 
0 tgfbeta1 signaling is a tumor suppressor pathway for early 
0 signaling is a tumor suppressor pathway for early stages 
9 however many human carcinomas overexpress tgfbeta1 and this is 
0 tgfbeta1 and this is associated with poor patient prognosis 
17 poor patient prognosis and increased frequency of metastasis . 
14 and increased frequency of metastasis . NULL NULL NULL 
0 NULL NULL NULL similar results have been obtained with 
0 similar results have been obtained with tumor cell lines 
0 have been obtained with tumor cell lines and experimental 
0 stage specific duality of function is the emerging paradigm 
16 emerging paradigm for the role of tgfbeta1 in cancer 
0 for tgfbeta1 as a tumor promoting and metastasis factor 
17 tgfbeta1 as a tumor promoting and metastasis factor and 
14 a tumor promoting and metastasis factor and examine the 
0 molecular basis for these effects . NULL NULL NULL 
0 that the switch from tumor suppressor to oncogene reflects 
0 the switch from tumor suppressor to oncogene reflects genetic 
0 reflects genetic or epigenetic alterations in signaling pathways in 
0 epigenetic alterations in signaling pathways in tumor cells that 
0 in signaling pathways in tumor cells that alter the 
16 in tumor cells that alter the readout from the 
16 NULL NULL NULL NULL role of thrombin in angiogenesis 
3 role of thrombin in angiogenesis and tumor progression . 
0 thrombin in angiogenesis and tumor progression . NULL NULL 
2 in angiogenesis and tumor progression . NULL NULL NULL 
0 NULL NULL NULL NULL clinical , laboratory , histopathological 
0 , and pharmacological evidence support the notion that the 
17 system , which is activated in most cancer patients 
16 most cancer patients , plays an important role in 
16 patients , plays an important role in tumor biology 
16 , plays an important role in tumor biology . 
0 an important role in tumor biology . NULL NULL 
17 provided evidence that thrombin activates angiogenesis , a process 
3 evidence that thrombin activates angiogenesis , a process which 
17 a process which is essential in tumor growth and 
0 which is essential in tumor growth and metastasis . 
4 is essential in tumor growth and metastasis . NULL 
14 in tumor growth and metastasis . NULL NULL NULL 
0 NULL this event is independent of fibrin formation . 
0 is independent of fibrin formation . NULL NULL NULL 
0 actions of thrombin can contribute to activation of angiogenesis 
17 thrombin can contribute to activation of angiogenesis : ( 
3 contribute to activation of angiogenesis : ( 1 ) 
18 NULL NULL NULL thrombin decreases the ability of endothelial 
0 NULL thrombin decreases the ability of endothelial cells to 
15 of endothelial cells to attach to basement membrane proteins 
16 NULL NULL thrombin greatly potentiates vascular endothelial growth factor- 
0 greatly potentiates vascular endothelial growth factor- ( vegf- ) 
17 factor- ( vegf- ) induced endothelial cell proliferation . 
1 ) induced endothelial cell proliferation . NULL NULL NULL 
17 potentiation is accompanied by up-regulation of the expression of 
9 by up-regulation of the expression of vegf receptors ( 
17 NULL NULL NULL thrombin increases the mrna and protein 
10 NULL thrombin increases the mrna and protein levels of 
9 increases the mrna and protein levels of alpha ( 
9 the mrna and protein levels of alpha ( v 
17 NULL furthermore , thrombin increases the secretion of vegf 
14 , thrombin increases the secretion of vegf and enhances 
17 secretion of vegf and enhances the expression and protein 
9 vegf and enhances the expression and protein synthesis of 
0 enhances the expression and protein synthesis of matrix metalloprotease-9 
0 the expression and protein synthesis of matrix metalloprotease-9 and 
0 and protein synthesis of matrix metalloprotease-9 and alpha ( 
0 NULL NULL NULL these results could explain the angiogenic 
3 results could explain the angiogenic and tumor-promoting effect of 
17 explain the angiogenic and tumor effect of thrombin and 
17 explain the angiogenic and promoting effect of thrombin and 
0 the angiogenic and tumor-promoting effect of thrombin and provide 
0 provide the basis for development of thrombin receptor mimetics 
0 or antagonists for therapeutic application . NULL NULL NULL 
17 NULL NULL hypothesis : induced angiogenesis after surgery in 
3 NULL hypothesis : induced angiogenesis after surgery in premenopausal 
19 : induced angiogenesis after surgery in premenopausal node-positive breast 
0 after surgery in premenopausal positive breast cancer patients is 
0 cancer patients is a major underlying reason why adjuvant 
19 underlying reason why adjuvant chemotherapy works particularly well for 
19 : we suggest that surgical extirpation of primary breast 
19 we suggest that surgical extirpation of primary breast cancer 
0 breast cancer among other effects accelerates relapse for some 
0 relapse for some premenopausal positive patients . NULL NULL 
0 NULL NULL NULL these accelerated relapses occur within 10 
19 within 10 months of surgery for untreated patients . 
19 months of surgery for untreated patients . NULL NULL 
0 NULL NULL NULL the mechanism proposed is a stimulation 
17 mechanism proposed is a stimulation of angiogenesis for distant 
3 is a stimulation of angiogenesis for distant dormant micrometastases 
0 imagine that it also plays a role in adjuvant 
0 it also plays a role in adjuvant chemotherapy effectiveness 
19 a role in adjuvant chemotherapy effectiveness since , perhaps 
0 role in adjuvant chemotherapy effectiveness since , perhaps not 
0 , this is most beneficial for premenopausal node-positive patients 
0 most beneficial for premenopausal positive patients . NULL NULL 
17 that there is a burst of angiogenesis of distant 
3 is a burst of angiogenesis of distant dormant micrometastases 
19 distant dormant micrometastases after surgery in approximately 20 % 
0 20 % of premenopausal positive patients . NULL NULL 
19 underlying reason why adjuvant chemotherapy works particularly well for 
17 testing the hypothesis : stimulation of dormant micrometastases by 
0 dormant micrometastases by primary tumor removal is known to 
19 micrometastases by primary tumor removal is known to occur 
0 NULL NULL NULL transient circulating levels of angioactive molecules 
0 NULL NULL transient circulating levels of angioactive molecules and 
3 transient circulating levels of angioactive molecules and serial high-resolution 
3 imaging studies of focal angiogenesis might help . NULL 
0 implications : short-course cytotoxic chemotherapy after surgery has probably 
0 short-course cytotoxic chemotherapy after surgery has probably reached its 
3 other strategies , perhaps angiogenic methods , are needed 
19 are needed to successfully treat more patients . NULL 
0 NULL NULL NULL in addition , the hypothesis predicts 
0 find more patients without involved lymph nodes , may 
19 synergistic strategy with adjuvant chemotherapy , which works best 
0 which works best with positive lymph node patients . 
0 NULL NULL NULL NULL matrix metalloproteinase activity and immunohistochemical 
0 NULL NULL matrix metalloproteinase activity and immunohistochemical profile of 
0 matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase-2 
0 and immunohistochemical profile of matrix metalloproteinase-2 and -9 and 
0 and -9 and tissue inhibitor of metalloproteinase-1 during human 
0 NULL NULL NULL proteolytic activity is required for the 
0 NULL proteolytic activity is required for the turnover of 
7 is required for the turnover of the extracellular matrix 
0 turnover of the extracellular matrix during wound healing . 
0 NULL NULL NULL NULL matrix metalloproteinases can collectively cleave 
6 matrix metalloproteinases can collectively cleave all components of the 
17 matrix metalloproteinases can collectively cleave all components of the 
0 components of the extracellular matrix , with the endogenous 
0 with the endogenous tissue inhibitor of metalloproteinase-1 regulating their 
16 tissue inhibitor of metalloproteinase-1 regulating their activity . NULL 
0 of metalloproteinase-1 regulating their activity . NULL NULL NULL 
0 92 ) or during surgery ( controls , n= 
0 or during surgery ( controls , n= 17 ) 
0 17 ) , was used to investigate the temporal 
0 the temporal and spatial activity of matrix metalloproteinase-2 and 
0 and spatial activity of matrix metalloproteinase-2 and -9 and 
0 and -9 and tissue inhibitor of metalloproteinase-1 during human 
0 NULL NULL NULL NULL matrix metalloproteinase activity , determined 
0 NULL NULL matrix metalloproteinase activity , determined using a 
17 fluorescence substrate assay , increased during early healing ( 
0 weeks ) compared to controls , and then decreased 
18 controls , and then decreased between 24 and 36 
0 and 36 weeks after surgery ( p less than 
0 NULL immunohistochemistry scores for matrix metalloproteinase-9 expression were significantly 
9 scores for matrix metalloproteinase-9 expression were significantly elevated compared 
17 metalloproteinase-9 expression were significantly elevated compared to controls in 
0 significantly elevated compared to controls in scar endothelial cells 
0 NULL NULL NULL NULL matrix metalloproteinase-2 staining was observed 
0 NULL NULL matrix metalloproteinase-2 staining was observed exclusively in 
0 matrix metalloproteinase-2 staining was observed exclusively in fibroblasts , 
0 fibroblasts , reaching maximum levels 8-12 weeks after surgery 
0 levels 8-12 weeks after surgery , decreasing by 1.5 
18 weeks after surgery , decreasing by 1.5 years but 
17 years but remaining significantly increased . NULL NULL NULL 
0 NULL NULL NULL tissue inhibitor of metalloproteinase-1 staining was 
0 tissue inhibitor of metalloproteinase-1 staining was relatively sparse but 
17 sparse but was significantly increased until 8 weeks after 
0 until 8 weeks after surgery . NULL NULL NULL 
0 NULL NULL NULL these results show that matrix metalloproteinases 
0 these results show that matrix metalloproteinases are present at 
9 that matrix metalloproteinases are present at elevated levels during 
17 metalloproteinases are present at elevated levels during early wound 
0 are present at elevated levels during early wound healing 
3 wound healing , when angiogenesis occurs , and suggest 
0 , and suggest that matrix metalloproteinase-9 may play a 
16 that matrix metalloproteinase-9 may play a significant role . 
16 metalloproteinase-9 may play a significant role . NULL NULL 
16 may play a significant role . NULL NULL NULL 
9 NULL NULL the later expression of matrix metalloproteinase-2 and 
0 the later expression of matrix metalloproteinase-2 and -9 in 
16 in fibroblasts suggests a role in extracellular matrix remodeling 
0 a role in extracellular matrix remodeling . NULL NULL 
7 role in extracellular matrix remodeling . NULL NULL NULL 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
0 ) is a vascular growth factor which induces angiogenesis 
17 vascular growth factor which induces angiogenesis ( the development 
3 growth factor which induces angiogenesis ( the development of 
2 induces angiogenesis ( the development of new blood vessels 
0 for vegf have been localized to vascular endothelium , 
17 NULL NULL vegf is upregulated after hypoxic injury to 
0 , and has been implicated in the blood-brain barrier 
6 in the blood-brain barrier breakdown associated with these conditions 
0 the blood-brain barrier breakdown associated with these conditions . 
0 NULL NULL NULL NULL given its recently-described role as 
0 NULL given its recently-described role as an inflammatory mediator 
0 role as an inflammatory mediator , vegf could also 
0 , vegf could also contribute to the inflammatory responses 
0 to the inflammatory responses observed in cerebral ischemia . 
6 seizures , blood-brain barrier breakdown and inflammation is also 
0 and inflammation is also observed in brain , albeit 
0 lower scale than that observed after stroke . NULL 
0 evidence has suggested a role for inflammation in seizure 
17 we have described striking increases in vegf protein in 
0 striking increases in vegf protein in both neurons and 
0 neurons and glia after induced status epilepticus in the 
17 NULL NULL NULL NULL increases in vegf could contribute 
17 increases in vegf could contribute to the blood-brain barrier 
6 to the blood-brain barrier breakdown and inflammation observed after 
0 barrier breakdown and inflammation observed after seizures . NULL 
18 and hence could potentially protect vulnerable cells from damage 
6 protect vulnerable cells from damage associated with seizures . 
0 vulnerable cells from damage associated with seizures . NULL 
0 NULL therefore , the role of vegf after seizures 
0 nature of vegf 's role after seizures , preliminary 
0 data indicate that vegf plays a protective role after 
0 vegf plays a protective role after seizures . NULL 
19 safety of verteporfin for treatment of subfoveal choroidal neovascular 
0 treatment of subfoveal choroidal neovascular membranes associated with age-related 
0 subfoveal choroidal neovascular membranes associated with age-related macular degeneration 
6 associated with age-related macular degeneration . NULL NULL NULL 
0 NULL NULL NULL NULL photodynamic therapy ( pdt ) 
0 NULL NULL NULL photodynamic therapy ( pdt ) is 
0 NULL photodynamic therapy ( pdt ) is a novel 
0 ) is a novel treatment entity that exploits the 
0 that exploits the photophysical properties of various photosensitive chemical 
0 which , upon light activation , results in targeted 
0 upon light activation , results in targeted photooxidation and 
0 activation , results in targeted photooxidation and subsequent tissue 
6 photooxidation and subsequent tissue destruction . NULL NULL NULL 
3 NULL NULL NULL the angiogenic properties of pdt have 
18 NULL NULL the antiangiogenic properties of pdt have been 
0 the antiangiogenic properties of pdt have been adapted for 
19 have been adapted for treatment of subfoveal choroidal neovascular 
0 treatment of subfoveal choroidal neovascular membranes due to disease 
6 such as age-related macular degeneration ( amd ) . 
0 NULL NULL historically , pdt has been limited by 
0 , pdt has been limited by a lack of 
0 as verteporfin , a generation benzoporphyrin derivative , appear 
0 , appear to be free from the extensive phototoxicity 
0 the extensive phototoxicity that limited the success of previous 
15 verteporfin has a high affinity for choroidal neovascular membranes 
0 high affinity for choroidal neovascular membranes , typically found 
17 , and upon photoactivation results in targeted microvascular damage 
0 upon photoactivation results in targeted microvascular damage and thrombus 
6 results in targeted microvascular damage and thrombus formation with 
2 microvascular damage and thrombus formation with resultant vessel occlusion 
19 diagnostic indicators for verteporfin administration , including critical angiographic 
0 verteporfin administration , including critical angiographic evaluation of lesion 
0 visual acuity , is essential to treatment success . 
0 , is essential to treatment success . NULL NULL 
0 risk for marked vision loss following verteporfin administration . 
19 vision loss following verteporfin administration . NULL NULL NULL 
0 composition also appears to influence visual outcome with verteporfin 
19 visual outcome with verteporfin use . NULL NULL NULL 
0 of verteporfin is directly dependent upon the appropriate integration 
0 integration of dosage , infusion and light activation required 
0 , infusion and light activation required for a suitable 
0 infusion and light activation required for a suitable pharmacotherapeutic 
0 NULL NULL NULL when used appropriately , and with 
19 verteporfin for the medical treatment of neovascular amd is 
0 the medical treatment of neovascular amd is favourable . 
3 series of juxtafoveal choroidal neovascularization treated with photodynamic therapy 
19 of juxtafoveal choroidal neovascularization treated with photodynamic therapy with 
0 choroidal neovascularization treated with photodynamic therapy with verteporfin . 
0 neovascularization treated with photodynamic therapy with verteporfin . NULL 
3 outcomes of juxtafoveal choroidal neovascularization ( cnv ) treated 
3 juxtafoveal choroidal neovascularization ( cnv ) treated with photodynamic 
19 neovascularization ( cnv ) treated with photodynamic therapy and 
0 cnv ) treated with photodynamic therapy and verteporfin ( 
0 ) treated with photodynamic therapy and verteporfin ( pdt 
0 therapy and verteporfin ( pdt ) . NULL NULL 
19 eyes of 446 patients treated with pdt from january 
0 446 patients treated with pdt from january 1 , 
3 retrospectively to identify juxtafoveal cnv . NULL NULL NULL 
3 NULL eligible patients had cnv in which the central 
0 cnv in which the central boundary of the lesion 
19 visual acuity of the treated eye before pdt and 
0 the treated eye before pdt and at 6- and 
0 NULL NULL NULL NULL presence of subfoveal cnv at 
3 NULL presence of subfoveal cnv at 6 and 12 
0 considered subfoveal if it extended underneath the geometric center 
0 NULL NULL NULL NULL results : twenty-one eyes had 
3 twenty-one eyes had juxtafoveal cnv . NULL NULL NULL 
0 NULL NULL NULL median change in visual acuity both 
0 months after the initial pdt was 0 lines ( 
2 NULL NULL eleven lesions progressed to a subfoveal location 
0 eyes with progressive lesions decreased a median of 4 
0 small sample size and limited length of follow-up , 
0 least 12 months after pdt of juxtafoveal lesions . 
0 NULL NULL NULL NULL growth through the foveal center 
0 and this can be associated with substantial visual loss 
0 associated with substantial visual loss . NULL NULL NULL 
17 NULL NULL NULL NULL enhanced igf-1 expression improves smooth 
9 NULL NULL enhanced igf-1 expression improves smooth muscle cell 
17 NULL enhanced igf-1 expression improves smooth muscle cell engraftment 
2 improves smooth muscle cell engraftment after cell transplantation . 
19 cell engraftment after cell transplantation . NULL NULL NULL 
19 functional benefit of cell transplantation after a myocardial infarction 
0 a myocardial infarction is diminished by early cell losses 
5 diminished by early cell losses . NULL NULL NULL 
17 NULL NULL NULL igf-1 enhances cell proliferation and survival 
1 NULL igf-1 enhances cell proliferation and survival . NULL 
5 enhances cell proliferation and survival . NULL NULL NULL 
19 NULL we hypothesized that transfected smooth muscle cells ( 
17 ( smcs ) would enhance cell survival and improve 
5 ) would enhance cell survival and improve engraftment after 
17 enhance cell survival and improve engraftment after cell transplantation 
2 cell survival and improve engraftment after cell transplantation . 
19 improve engraftment after cell transplantation . NULL NULL NULL 
19 the igf-1 gene was transfected into male smcs and 
19 and compared with smcs transfected with a plasmid vector 
0 plasmid vector ( vector control ) and nontransfected smcs 
19 vector control ) and nontransfected smcs ( cell control 
0 nontransfected smcs ( cell control ) . NULL NULL 
0 NULL NULL NULL igf-1 mrna ( n=10/group ) and 
0 ( n=10/group ) and protein levels ( n=6/group ) 
0 n=10/group ) and protein levels ( n=6/group ) were 
0 14 days compared with controls . NULL NULL NULL 
17 NULL vegf was also increased in parallel to enhanced 
17 increased in parallel to enhanced igf-1 expression . NULL 
9 parallel to enhanced igf-1 expression . NULL NULL NULL 
19 NULL NULL NULL NULL transfected cells demonstrated greater cell 
1 cells demonstrated greater cell proliferation , stimulated angiogenesis , 
17 greater cell proliferation , stimulated angiogenesis , and decreased 
3 cell proliferation , stimulated angiogenesis , and decreased caspase-3 
18 stimulated angiogenesis , and decreased caspase-3 activity after simulated 
0 , and decreased caspase-3 activity after simulated ischemia and 
0 with vector or cell controls ) . NULL NULL 
0 left ventricular injury was produced in female rats using 
19 from three groups were implanted into the scar . 
19 one week later , transfected smcs had increased myocardial 
17 , igf-1-transfected smcs had increased myocardial igf-1 and vegf 
0 myocardial igf-1 and vegf levels , increased bcl2 expression 
17 and vegf levels , increased bcl2 expression , limited 
9 levels , increased bcl2 expression , limited cell apoptosis 
18 increased bcl2 expression , limited cell apoptosis , and 
5 expression , limited cell apoptosis , and enhanced vessel 
17 cell apoptosis , and enhanced vessel formation in the 
2 , and enhanced vessel formation in the myocardial scar 
0 compared with the two control groups ( p less 
5 the proportion of smcs surviving in the implanted region 
19 smcs surviving in the implanted region was greater ( 
19 0.05 ) in the transfected group than in the 
0 the vector or cell controls . NULL NULL NULL 
17 NULL NULL NULL gene enhancement with igf-1 improved donor 
17 gene enhancement with igf-1 improved donor cell proliferation , 
1 igf-1 improved donor cell proliferation , survival , and 
5 donor cell proliferation , survival , and engraftment after 
2 , survival , and engraftment after cell transplantation , 
19 and engraftment after cell transplantation , perhaps mediated by 
0 cell transplantation , perhaps mediated by enhanced angiogenesis and 
17 , perhaps mediated by enhanced angiogenesis and reduced apoptosis 
3 perhaps mediated by enhanced angiogenesis and reduced apoptosis . 
0 by enhanced angiogenesis and reduced apoptosis . NULL NULL 
0 enhanced angiogenesis and reduced apoptosis . NULL NULL NULL 
0 often poorly diagnosed and treated as primary open angle 
0 later on , as neovascular glaucoma . NULL NULL 
0 NULL NULL NULL we present a 54 year old 
19 year old male , treated topical since 23 years 
0 NULL NULL NULL NULL results : because of typical 
3 of ios ( iris neovascularization , mid-peripheral dot and 
0 arteries , digital subtractional angiography of the carotid vessels 
0 vessels and magnetic resonance angiography . NULL NULL NULL 
0 NULL NULL the examinations showed occlusion of the right 
19 NULL after phacoemulsification with implantation of intraocular lens because 
3 carotid artery , the neovascularization of the iris regressed 
18 neovascularization of the iris regressed in both eyes . 
3 in case of iris neovascularization or mid-peripheral hemorrhages the 
0 seems to stop progressing changes of ocular ischemic syndrome 
16 NULL NULL NULL hypoxia-responsive mediated soluble tie2 vector exhibits 
3 tie2 vector exhibits an angiogenic activity in vitro under 
18 vector exhibits an anti-angiogenic activity in vitro under hypoxic 
0 NULL NULL NULL NULL inducible factor-1 ( hif-1 ) 
0 is one of the key mammalian transcription factors and 
0 of the key mammalian transcription factors and shows increased 
0 transcription factors and shows increased levels in both protein 
0 factors and shows increased levels in both protein stability 
0 increased levels in both protein stability and intrinsic transcriptional 
0 protein stability and intrinsic transcriptional activity during low oxygen 
0 stability and intrinsic transcriptional activity during low oxygen tension 
0 NULL NULL NULL NULL activated functional hif-1 protein binds 
0 NULL hypoxia-activated functional hif-1 protein binds to hypoxia-responsive elements 
15 hypoxia-activated functional hif-1 protein binds to hypoxia-responsive elements ( 
0 including vegf , the major player in angiogenesis , 
3 the major player in angiogenesis , and initiates their 
17 in angiogenesis , and initiates their mrna expression . 
0 , and initiates their mrna expression . NULL NULL 
10 and initiates their mrna expression . NULL NULL NULL 
0 NULL the molecular mechanisms regulating the gene expression under 
0 mechanisms regulating the gene expression under hypoxic conditions could 
0 under hypoxic conditions could increase the therapeutic window of 
0 therapeutic window of tumor-specific delivery systems . NULL NULL 
0 , to examine hypoxia-specific production of anti-angiogenic therapeutic gene 
3 examine hypoxia-specific production of angiogenic therapeutic gene , we 
19 therapeutic gene , we constructed 5 copies of hre 
19 ) of human vegf linked to soluble tie2 ( 
0 NULL NULL our data showed that under hypoxia the 
14 that under hypoxia the secreted stie2 selectively inhibited tube 
18 the secreted stie2 selectively inhibited tube formation and migration 
2 stie2 selectively inhibited tube formation and migration capacities of 
14 inhibited tube formation and migration capacities of endothelial cells 
18 a useful tool for down-regulating tumor angiogenesis under hypoxic 
0 useful tool for down-regulating tumor angiogenesis under hypoxic condition 
3 tool for down-regulating tumor angiogenesis under hypoxic condition . 
18 NULL NULL NULL 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha , 
0 NULL NULL 2-methoxyestradiol inhibits inducible factor 1alpha , tumor 
0 hypoxia-inducible factor 1alpha , tumor growth , and angiogenesis 
4 factor 1alpha , tumor growth , and angiogenesis and 
3 tumor growth , and angiogenesis and augments paclitaxel efficacy 
0 angiogenesis and augments paclitaxel efficacy in head and neck 
9 have been reported to overexpress hypoxia-inducible factor ( hif 
0 been reported to overexpress inducible factor ( hif ) 
0 ) -1alpha , a transcription factor that promotes expression 
0 a transcription factor that promotes expression of angiogenesis factors 
0 transcription factor that promotes expression of angiogenesis factors and 
3 that promotes expression of angiogenesis factors and resistance to 
17 resistance to programmed and therapy cell death . NULL 
17 resistance to programmed and induced cell death . NULL 
5 programmed and therapy-induced cell death . NULL NULL NULL 
18 natural compound with hif-1alpha inhibitory activity that is currently 
0 compound with hif-1alpha inhibitory activity that is currently being 
19 phase 1 and 2 clinical trials for advanced solid 
19 1 and 2 clinical trials for advanced solid tumors 
16 study to evaluate the effects of 2me2 in head 
0 design : in the present study , we investigated 
16 , we investigated the effects of 2me2 alone and 
0 with paclitaxel , an active agent in recurrent or 
0 NULL NULL NULL NULL results : 2me2 exhibited antiproliferative 
16 NULL results : 2me2 exhibited antiproliferative and cytotoxic effects 
0 exhibited antiproliferative and cytotoxic effects in a panel of 
17 micromol/l range , including induction of g2-m blockade , 
0 including induction of g2-m blockade , caspase-3/7 activation , 
17 g2-m blockade , caspase-3/7 activation , and apoptosis at 
5 caspase-3/7 activation , and apoptosis at 48 hours . 
0 NULL NULL NULL 2me2 resulted in decreased nuclear hif-1alpha-binding 
18 NULL 2me2 resulted in decreased nuclear hif-1alpha-binding activity and 
15 resulted in decreased nuclear binding activity and affected the 
0 in decreased nuclear hif-1alpha-binding activity and affected the expression 
16 nuclear hif-1alpha-binding activity and affected the expression of downstream 
9 activity and affected the expression of downstream genes , 
0 affected the expression of downstream genes , such as 
0 , and vascular endothelial growth factor , a proangiogenic 
3 growth factor , a angiogenic cytokine . NULL NULL 
17 NULL NULL NULL the up-regulation of bid ( 57.5 
18 than 0.0006 ) and inhibition of vascular endothelial growth 
0 inhibition of vascular endothelial growth factor secretion ( 57.7 
14 vascular endothelial growth factor secretion ( 57.7 % at 
16 partially attributed to the effects on hif-1alpha , because 
0 hif-1alpha small interfering rnas produced similar effects . NULL 
0 interfering rnas produced similar effects . NULL NULL NULL 
0 um-scc-11a cells , 2me2 exhibited antitumor and antiangiogenic activity 
3 2me2 exhibited antitumor and angiogenic activity , as measured 
18 exhibited antitumor and antiangiogenic activity , as measured by 
0 NULL conclusions : these results provide support for the 
0 : these results provide support for the use of 
0 provide support for the use of 2me2 in combination 
19 with paclitaxel for the treatment of recurrent or advanced 
9 NULL NULL NULL NULL expression and purification of the 
0 of human vascular endothelial growth factor receptor 2 for 
0 factor receptor 2 for inhibitor screening . NULL NULL 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
16 cell-specific mitogen , can act in tumor-induced angiogenesis by 
17 , can act in induced angiogenesis by binding to 
3 can act in tumor-induced angiogenesis by binding to specific 
15 in tumor-induced angiogenesis by binding to specific receptors on 
16 receptor , vegfr-2/kdr , plays a key role in 
16 vegfr-2/kdr , plays a key role in vegf-induced angiogenesis 
16 , plays a key role in vegf-induced angiogenesis . 
17 a key role in induced angiogenesis . NULL NULL 
3 key role in vegf-induced angiogenesis . NULL NULL NULL 
9 NULL here , we expressed the catalytic domain of 
0 vegfr-2 as a soluble active kinase using bac-to-bac expression 
0 active kinase using bac-to-bac expression system , and investigated 
0 investigated correlations between vegfr-2 activity and enzyme concentration , 
0 NULL NULL NULL we used these data to establish 
0 establish a convenient , effective and non-radioactive elisa screening 
0 identification and evaluation of potential inhibitors for vegfr-2 kinase 
0 we screened 200 rtk target compounds and identified one 
18 tki-31 ) that potently inhibited vegfr-2 kinase activity ( 
0 potently inhibited vegfr-2 kinase activity ( ic50=0.596 microm ) 
19 NULL NULL NULL NULL treatment of nih3t3/kdr cells with 
18 nih3t3/kdr cells with tki-31 blocked vegf-induced phosphorylation of kdr 
17 cells with tki-31 blocked induced phosphorylation of kdr in 
12 with tki-31 blocked vegf-induced phosphorylation of kdr in a 
0 of kdr in a dependent manner . NULL NULL 
18 moreover , tki-31 dose-dependently suppressed huvec tube formation . 
2 dose-dependently suppressed huvec tube formation . NULL NULL NULL 
3 be a useful new angiogenesis inhibitor . NULL NULL 
0 a useful new angiogenesis inhibitor . NULL NULL NULL 
19 heparin and hyperbaric oxygen treatment in the prevention of 
0 oxygen treatment in the prevention of intra-abdominal adhesions and 
0 NULL background : abdominal surgery can lead to intra-abdominal 
0 : abdominal surgery can lead to intra-abdominal adhesions with 
0 to intra-abdominal adhesions with significant morbidity and mortality . 
0 NULL NULL NULL to prevent adhesions , an experimental 
0 planned to designate the effects of low molecular weight 
19 oxygen ( hbo ) therapy both on the formation 
0 therapy both on the formation of adhesions and wound 
19 thirty-eight wistar albino rats underwent laparotomy to cause intra-abdominal 
19 intra-abdominal adhesions by mechanical abrasion of the cecum and 
19 the cecum and ethanol application . NULL NULL NULL 
0 NULL NULL in the control group ( group 1 
19 NULL group 2 was treated by enoxaparine na , 
0 na , group 3 received hbo therapy , and 
19 group 3 received hbo therapy , and group 4 
0 and group 4 was given both enoxaparine na and 
19 enoxaparine na and hbo treatment . NULL NULL NULL 
0 NULL NULL NULL NULL results : there was a 
0 there was a statistically significant difference between the control 
0 significant difference between the control and enoxaparine na groups 
0 NULL NULL NULL statistically significant differences were observed between 
0 statistically significant differences were observed between groups 1 and 
0 there was no statistically significant difference between any of 
0 groups , including the control group , regarding inflammation 
0 NULL NULL NULL statistically significant differences were observed regarding 
0 statistically significant differences were observed regarding angiogenesis between the 
3 differences were observed regarding angiogenesis between the control group 
0 regarding angiogenesis between the control group and groups 3 
0 was also a statistically significant difference regarding fibrosis between 
0 conclusions : enoxaparine na decreased intra-abdominal adhesions , and 
19 adhesions , and hbo therapy had no beneficial effect 
0 hbo therapy had no beneficial effect on adhesions . 
0 therapy had no beneficial effect on adhesions . NULL 
0 na had no harmful effects on wound healing , 
19 healing , and hbo therapy increased the process of 
0 , and hbo therapy increased the process of wound 
19 biological agents for the treatment of hormone-refractory prostate cancer 
2 inevitable evolution of prostate carcinogenesis , through which the 
0 dependence on hormones for growth and survival is bypassed 
0 hormones for growth and survival is bypassed . NULL 
0 been addressed with current treatment options , innovative approaches 
0 approaches are needed to improve survival rates . NULL 
0 are needed to improve survival rates . NULL NULL 
0 a thorough understanding of associated molecular pathways and mechanisms 
0 understanding of hrpc-associated molecular pathways and mechanisms of resistance 
0 a prerequisite for novel potential therapeutic interventions . NULL 
0 for novel potential therapeutic interventions . NULL NULL NULL 
0 NULL preclinical and early clinical studies are ongoing to 
0 ongoing to evaluate new therapies that target specific molecular 
0 evaluate new therapies that target specific molecular entities . 
0 NULL NULL agents under development include growth factor receptor 
0 agents under development include growth factor receptor inhibitors , 
0 inhibitors , small molecules targeting signal transduction pathways , 
0 molecules targeting signal transduction pathways , apoptosis and cell-cycle 
0 signal transduction pathways , apoptosis and cell-cycle regulators , 
3 and cell-cycle regulators , angiogenesis and metastasis inhibitors , 
0 regulators , angiogenesis and metastasis inhibitors , differentiation agents 
0 and metastasis inhibitors , differentiation agents , telomerase inactivators 
0 NULL NULL NULL NULL incorporation of these agents into 
0 these agents into existing treatment regimens will guide us 
0 guide us in the development of a multidisciplinary treatment 
0 development of a multidisciplinary treatment strategy of hrpc . 
0 being tested in hrpc clinical trials , highlights ongoing 
0 tested in hrpc clinical trials , highlights ongoing research 
0 NULL NULL NULL NULL role of thrombogenic factors in 
0 thrombogenic factors in the development of atherosclerosis . NULL 
17 NULL NULL hemostatic factors play a crucial role in 
17 hemostatic factors play a crucial role in generating thrombotic 
17 factors play a crucial role in generating thrombotic plugs 
2 a crucial role in generating thrombotic plugs at sites 
6 at sites of vascular damage ( atherothrombosis ) . 
0 , whether hemostatic factors contribute directly or indirectly to 
0 or indirectly to the pathogenesis of atherosclerosis remains uncertain 
4 have revealed that intimal thickening represents the first stage 
17 NULL NULL several factors contribute to the start of 
4 the start of intimal thickening . NULL NULL NULL 
0 NULL NULL NULL platelets release several growth factors and 
0 NULL platelets release several growth factors and bioactive agents 
17 and bioactive agents that play a central role in 
17 agents that play a central role in development of 
17 that play a central role in development of not 
2 a central role in development of not only thrombus 
4 but also of intimal thickening . NULL NULL NULL 
15 or subsequently with platelet aggregation , participate in thrombus 
17 with platelet aggregation , participate in thrombus formation . 
2 , participate in thrombus formation . NULL NULL NULL 
0 tf ) is an essential initiator of blood coagulation 
9 blood coagulation that is expressed in various stages of 
16 fibrin , which are downstream of the coagulation cascade 
17 of the coagulation cascade activated by tf , also 
0 by tf , also contribute to atherosclerosis . NULL 
17 NULL NULL tf is involved in cell migration , 
14 is involved in cell migration , embryogenesis and angiogenesis 
3 migration , embryogenesis and angiogenesis . NULL NULL NULL 
0 thus tf , in addition to factors downstream of 
0 in addition to factors downstream of the coagulation cascade 
0 coagulation cascade and the activated receptor 2 activation system 
0 the protease-activated receptor 2 activation system , would be 
0 would be a multifactorial regulator of atherogenesis . NULL 
0 NULL rofecoxib as adjunctive therapy for haemophilic arthropathy . 
0 subsequent haemophilic arthropathy are significant complications in haemophilia . 
0 NULL NULL the pathophysiology involves inflammation and angiogenesis . 
3 pathophysiology involves inflammation and angiogenesis . NULL NULL NULL 
3 have potent anti-inflammatory , angiogenic and analgesic properties yet 
18 , anti-angiogenic and analgesic properties yet do not affect 
16 properties yet do not affect platelet function in the 
0 do not affect platelet function in the manner of 
0 NULL NULL NULL these properties make such agents potentially 
0 potentially useful as adjunctive therapy in haemophilia . NULL 
19 prior report describing rofecoxib treatment in a single haemophilia 
0 determine the safety and efficacy of rofecoxib in treating 
19 efficacy of rofecoxib in treating acute haemarthrosis , chronic 
0 , chronic synovitis , target joints and pain . 
19 record review of patients treated with rofecoxib for acute 
0 , chronic synovitis , target joint or pain . 
0 NULL the safety and efficacy of rofecoxib treatment were 
19 and efficacy of rofecoxib treatment were determined based on 
19 years of age were treated for a total of 
19 42 courses of rofecoxib treatment . NULL NULL NULL 
0 safety and 31 for efficacy . NULL NULL NULL 
19 NULL NULL rofecoxib was used for eight acute haemarthrosis 
0 acute haemarthrosis , four target joints , seven cases 
0 NULL NULL NULL NULL efficacy was demonstrated particularly for 
0 cox-2 inhibitors as adjunctive therapy in haemophilia and suggests 
0 agents may be an important adjunctive therapy in the 
0 be an important adjunctive therapy in the management of 
0 NULL NULL NULL NULL targeted therapy : therapeutic potential 
0 NULL NULL NULL vegf-targeted therapy : therapeutic potential and 
0 vegf-targeted therapy : therapeutic potential and recent advances . 
0 of theorizing , the use of angiogenesis inhibitors as 
3 , the use of angiogenesis inhibitors as anticancer therapy 
0 angiogenesis inhibitors as anticancer therapy has finally moved from 
4 in contrast , the growth of tumors requires constant 
17 the growth of tumors requires constant vascular growth and 
4 tumors requires constant vascular growth and remodeling in order 
7 constant vascular growth and remodeling in order for solid 
4 for solid tumors to grow beyond 1-2 mm ( 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
0 and its receptors are key regulators of the process 
3 of the process of angiogenesis , which makes them 
0 makes them attractive therapeutic targets . NULL NULL NULL 
0 NULL a multitude of targeted inhibitory agents are currently 
0 a multitude of vegf-targeted inhibitory agents are currently being 
0 being investigated for the treatment of cancer . NULL 
0 recent developments in the use of angiogenesis inhibitors for 
3 in the use of angiogenesis inhibitors for the treatment 
19 angiogenesis inhibitors for the treatment of breast , lung 
18 NULL thalidomide and angiostatin inhibit tumor growth in a 
0 thalidomide and angiostatin inhibit tumor growth in a murine 
4 and angiostatin inhibit tumor growth in a murine xenograft 
0 : to determine the impact of thalidomide and angiostatin 
0 thalidomide and angiostatin on tumor growth , angiogenesis , 
4 and angiostatin on tumor growth , angiogenesis , and 
3 on tumor growth , angiogenesis , and apoptosis in 
5 , angiogenesis , and apoptosis in a xenograft model 
19 umbilical endothelial cells were treated with angiostatin or thalidomide 
0 angiostatin or thalidomide and induced proliferation was assessed with 
0 or thalidomide and bfgf-induced proliferation was assessed with the 
19 and siha ) were injected into the flanks of 
2 NULL NULL after tumors developed , mice were treated 
19 developed , mice were treated with angiostatin 20 mg/kg/day 
0 NULL NULL NULL fractional tumor growth was determined and 
4 NULL NULL fractional tumor growth was determined and immunohistochemical 
0 growth was determined and immunohistochemical analysis of tumors was 
0 analysis of tumors was used to determine degree of 
3 to determine degree of angiogenesis . NULL NULL NULL 
0 NULL tunel assay was used to assess apoptosis . 
0 was used to assess apoptosis . NULL NULL NULL 
0 NULL NULL NULL NULL results : angiostatin inhibited endothelial 
18 NULL results : angiostatin inhibited endothelial cell proliferation by 
1 angiostatin inhibited endothelial cell proliferation by 50-60 % . 
16 NULL thalidomide had no direct effect on endothelial cells 
16 thalidomide had no direct effect on endothelial cells . 
18 angiostatin and thalidomide both inhibited tumor growth by about 
0 and thalidomide both inhibited tumor growth by about 55 
4 thalidomide both inhibited tumor growth by about 55 % 
0 no additive or synergistic effect when the two agents 
18 NULL NULL both agents inhibited angiogenesis and induced apoptosis 
3 NULL both agents inhibited angiogenesis and induced apoptosis when 
0 agents inhibited angiogenesis and induced apoptosis when compared to 
0 inhibited angiogenesis and induced apoptosis when compared to tumors 
0 compared to tumors from control animals . NULL NULL 
18 : angiostatin and thalidomide inhibit tumor growth , angiogenesis 
0 angiostatin and thalidomide inhibit tumor growth , angiogenesis , 
4 and thalidomide inhibit tumor growth , angiogenesis , and 
3 inhibit tumor growth , angiogenesis , and induce apoptosis 
17 , angiogenesis , and induce apoptosis in this xenograft 
5 angiogenesis , and induce apoptosis in this xenograft model 
4 human breast cancer xenograft growth , angiogenesis and metastasis 
3 cancer xenograft growth , angiogenesis and metastasis . NULL 
0 growth , angiogenesis and metastasis . NULL NULL NULL 
0 NULL background : the effects of a rectified semi-sinewave 
0 irradiation ( ir ) therapy in nude mice bearing 
0 NULL NULL green fluorescence protein transfected cancer cells were 
19 NULL green fluorescence protein transfected cancer cells were injected 
19 transfected cancer cells were injected into the mammary fat 
0 randomly divided into four treatment groups : untreated controls 
0 four treatment groups : untreated controls ; 10 minute 
0 treatment groups : untreated controls ; 10 minute daily 
19 in each group were euthanized 24 hours after the 
0 NULL NULL NULL temf treatment continued for 3 additional 
0 NULL NULL NULL NULL tumor sections were stained for 
0 and pas or hypoxia inducible factor 1alpha ( hif 
0 NULL NULL NULL NULL results : most tumors less 
0 pink and had a vascularized capsule . NULL NULL 
3 the capsule had little vascularization . NULL NULL NULL 
19 greater than 35 mm3 treated with ir 24 hours 
18 or with temf had decreased blood vessels in the 
0 into hypoxic , hif positive areas than tumors from 
0 than tumors from the control group . NULL NULL 
19 NULL NULL mice that received either ir or temf 
0 had significantly fewer lung metastatic sites and slower tumor 
0 metastatic sites and slower tumor growth than did untreated 
4 sites and slower tumor growth than did untreated mice 
19 tumor growth than did untreated mice . NULL NULL 
0 NULL no harmful side effects were attributed to temf 
0 NULL conclusion : temf therapy provided a safe means 
18 a safe means for retarding tumor vascularization , growth 
0 safe means for retarding tumor vascularization , growth and 
3 means for retarding tumor vascularization , growth and metastasis 
4 retarding tumor vascularization , growth and metastasis . NULL 
14 vascularization , growth and metastasis . NULL NULL NULL 
0 receptors messenger rna and protein expression in different tumour 
9 messenger rna and protein expression in different tumour sublines 
10 messenger rna and protein expression in different tumour sublines 
0 thrombospondin is a potent inhibitor of angiogenesis and might 
3 a potent inhibitor of angiogenesis and might therefore be 
0 and might therefore be important in controlling tumour growth 
16 therefore be important in controlling tumour growth . NULL 
4 important in controlling tumour growth . NULL NULL NULL 
15 NULL NULL NULL tsp interacts with a number of 
18 and in this way inhibits stimulation of angiogenesis . 
17 in this way inhibits stimulation of angiogenesis . NULL 
3 way inhibits stimulation of angiogenesis . NULL NULL NULL 
0 NULL an earlier study showed that thrombospondin is expressed 
9 showed that thrombospondin is expressed in benign prostatic hyperplasia 
9 pin ) but is absent in prostate cancer . 
0 NULL NULL NULL the present study was therefore designed 
9 designed to evaluate the expression of thrombospondin 1 and 
0 and cd47 , and matrix 2 and 9 ( 
9 and real-time pcr the expression patterns of tsp-1 , 
0 prostate tissue and five malignant dunning sublines tissue . 
0 NULL NULL NULL tsp-1 mrna levels were decreased in 
0 NULL NULL tsp-1 mrna levels were decreased in all 
18 tsp-1 mrna levels were decreased in all tumours compared 
10 was no difference in expression of tsp-2 and cd36 
0 of tsp-2 and cd36 mrna in these samples . 
17 NULL NULL mmp-2 was increased with malignancy , but 
9 malignancy , but no expression of mmp-9 was seen 
17 cd47 receptor did slightly increase with malignancy except for 
0 NULL NULL NULL the results showed that thrombospondin is 
0 NULL NULL the results showed that thrombospondin is expressed 
9 showed that thrombospondin is expressed in normal prostate but 
9 NULL simultaneously , mmp-2 expression increases with malignancy . 
17 simultaneously , mmp-2 expression increases with malignancy . NULL 
16 NULL NULL NULL minimal contribution of marrow-derived endothelial precursors 
0 NULL minimal contribution of derived endothelial precursors to tumor 
0 marrow-derived endothelial precursors to tumor vasculature . NULL NULL 
2 vascular and hemopoietic cells originate from a common precursor 
14 recent evidence suggests the existence of endothelial precursors in 
16 those precursors have a role in tumor neovascularization . 
0 have a role in tumor neovascularization . NULL NULL 
3 a role in tumor neovascularization . NULL NULL NULL 
0 and can integrate into tumor microvasculature , albeit at 
0 NULL NULL NULL a transgenic double-reporter strategy allowed us 
0 to demonstrate definitively that tumor bone marrow-derived endothelial cells 
0 definitively that tumor bone derived endothelial cells arise by 
2 endothelial cells arise by transdifferentiation of marrow progenitors rather 
2 rather than by cell fusion . NULL NULL NULL 
19 NULL NULL single cell transplants showed that a common 
0 NULL single cell transplants showed that a common precursor 
16 that a common precursor contributes to both the hemopoietic 
0 , thus demonstrating the presence of an adult hemangioblast 
17 , we demonstrate that increased vascular endothelial growth factor 
0 that increased vascular endothelial growth factor ( vegf ) 
14 ( vegf ) -a secretion by tumor cells , 
0 ) -a secretion by tumor cells , as well 
17 , as well as activation of vegf receptor-2 in 
0 marrow cells does not alter the mobilization and incorporation 
0 does not alter the mobilization and incorporation of marrow-derived 
14 alter the mobilization and incorporation of marrow-derived endothelial progenitors 
0 mobilization and incorporation of derived endothelial progenitors into tumor 
0 marrow-derived endothelial progenitors into tumor vasculature . NULL NULL 
2 by ruling out cell fusion , we clearly demonstrate 
14 we clearly demonstrate the existence of an adult hemangioblast 
2 hemangioblast , but the differentiation of marrow stem cells 
17 we show that vegf-a stimulation of hemopoietic cells does 
0 cells does not significantly alter this process . NULL 
0 the merits of vascular targeting for gynecologic malignancies . 
3 NULL NULL NULL NULL neovascularization is an early and 
0 is an early and critical step in tumor development 
0 and critical step in tumor development and progression . 
2 critical step in tumor development and progression . NULL 
2 in tumor development and progression . NULL NULL NULL 
0 NULL NULL NULL NULL tumor vessels are distinct from 
0 recent studies on factors involved in tumor vascular development 
0 on factors involved in tumor vascular development have identified 
2 involved in tumor vascular development have identified new therapeutic 
0 have identified new therapeutic targets for inhibiting tumor neovascularization 
18 new therapeutic targets for inhibiting tumor neovascularization and thus 
0 therapeutic targets for inhibiting tumor neovascularization and thus tumor 
3 targets for inhibiting tumor neovascularization and thus tumor progression 
0 tumor neovascularization and thus tumor progression . NULL NULL 
2 neovascularization and thus tumor progression . NULL NULL NULL 
0 , the process of tumor blood vessel formation is 
2 of tumor blood vessel formation is complex , and 
0 complex , and each tumor exhibits unique features in 
0 understanding of the relative contribution of various pathways in 
0 relative contribution of various pathways in the development of 
2 various pathways in the development of tumor vasculature is 
0 in the development of tumor vasculature is critical for 
0 of tumor vasculature is critical for developing effective and 
0 vasculature is critical for developing effective and selective therapeutic 
0 is critical for developing effective and selective therapeutic approaches 
0 agents are currently in clinical trials , and many 
0 are currently in clinical trials , and many others 
0 many others are under development . NULL NULL NULL 
0 the mechanisms and factors involved in tumor blood vessel 
0 and factors involved in tumor blood vessel formation are 
2 in tumor blood vessel formation are discussed . NULL 
0 NULL NULL NULL in addition , selected novel classes 
0 novel classes of antivascular therapies , including those targeting 
19 therapies , including those targeting tumor endothelial cells and 
0 , including those targeting tumor endothelial cells and other 
0 other components of the tumor vasculature , are summarized 
0 NULL domain 5 of cleaved high molecular weight kininogen 
18 high molecular weight kininogen inhibits endothelial cell migration through 
16 high molecular weight kininogen inhibits endothelial cell migration through 
14 kininogen inhibits endothelial cell migration through akt . NULL 
0 ( d5 ) of cleaved high molecular weight kininogen 
18 kininogen ( hka ) inhibits angiogenesis in vivo and 
3 ( hka ) inhibits angiogenesis in vivo and endothelial 
14 vivo and endothelial cell migration in vitro , but 
0 but the cell signaling pathways involved in hka and 
16 the cell signaling pathways involved in hka and d5 
18 in hka and d5 inhibition of endothelial cell migration 
14 inhibition of endothelial cell migration are incompletely delineated . 
0 this study examines the mechanism of hka and d5 
18 of hka and d5 inhibition of two potent stimulators 
14 stimulators of endothelial cell migration , sphingosine 1-phosphate ( 
0 ) and vascular endothelial growth factor ( vegf ) 
16 vegf ) , that act through the p13-kinase-akt signaling 
18 NULL hka and d5 inhibit bovine pulmonary artery endothelial 
14 umbilical vein endothelial cell chemotaxis in the modified-boyden chamber 
17 the modified-boyden chamber in response tovegf or s1p . 
18 NULL NULL NULL the inhibition of migration by hka 
14 NULL the inhibition of migration by hka is reversed 
18 migration by hka is reversed by antibodies to urokinase-type 
0 antibodies to urokinase-type plasminogen activator receptor . NULL NULL 
18 both hka and d5 decrease the speed of bpae 
14 speed of bpae cell migration and alter the morphology 
0 bpae cell migration and alter the morphology in live 
17 , time-lapse microscopy after stimulation with s1p or vegf 
18 NULL hka and d5 reduce the localization of paxillin 
14 and d5 reduce the localization of paxillin to the 
17 after s1p and vegf stimulation . NULL NULL NULL 
0 understand the intracellular signaling pathways , we examined the 
16 , we examined the effect of hka on the 
12 of hka on the phosphorylation of akt and its 
0 of akt and its downstream effector , gsk-3alpha hka 
18 gsk-3alpha hka and d5 inhibit phosphorylation of akt and 
12 hka and d5 inhibit phosphorylation of akt and gsk-3alpha 
17 akt and gsk-3alpha after stimulation withvegf and s1p . 
0 p13-kinase , the upstream activator of akt , block 
18 activator of akt , block endothelial cell migration and 
14 , block endothelial cell migration and disrupt paxillin localization 
18 endothelial cell migration and disrupt paxillin localization to the 
14 migration and disrupt paxillin localization to the focal adhesions 
17 the focal adhesions after stimulation with vegf and s1p 
16 through its d5 domain alters p13-kinase-akt signaling to inhibit 
18 alters p13-kinase-akt signaling to inhibit endothelial cell migration through 
14 to inhibit endothelial cell migration through alterations in the 
16 endothelial cell migration through alterations in the focal adhesions 
0 NULL NULL NULL NULL effect of thalidomide affecting vegf 
16 NULL effect of thalidomide affecting vegf secretion , cell 
14 of thalidomide affecting vegf secretion , cell migration , 
14 vegf secretion , cell migration , adhesion and capillary 
15 , cell migration , adhesion and capillary tube formation 
2 adhesion and capillary tube formation of human endothelial ea.hy 
3 NULL NULL NULL NULL angiogenesis , new blood vessel 
2 , new blood vessel formation , is a multistep 
16 multistep process , precisely regulated by pro-angiogenic cytokines , 
3 , precisely regulated by angiogenic cytokines , which stimulate 
17 pro-angiogenic cytokines , which stimulate endothelial cells to migrate 
14 stimulate endothelial cells to migrate , proliferate and differentiate 
1 cells to migrate , proliferate and differentiate to form 
2 migrate , proliferate and differentiate to form new capillary 
2 proliferate and differentiate to form new capillary microvessels . 
2 NULL NULL excessive vascular development and blood vessel remodeling 
7 development and blood vessel remodeling appears in psoriasis , 
2 retinopathy and solid tumors formation . NULL NULL NULL 
0 to be a potent inhibitor of angiogenesis , but 
3 a potent inhibitor of angiogenesis , but the mechanism 
0 angiogenesis , but the mechanism of its inhibitory action 
18 the mechanism of its inhibitory action remains unclear . 
18 mechanism of its inhibitory action remains unclear . NULL 
0 was to investigate the potential influence of thalidomide on 
16 to investigate the potential influence of thalidomide on the 
3 the several steps of angiogenesis , using in vitro 
16 we have evaluated the effect of thalidomide on vegf 
14 of thalidomide on vegf secretion , cell migration , 
14 vegf secretion , cell migration , adhesion as well 
15 , cell migration , adhesion as well as in 
2 well as in capillary formation of human endothelial cell 
18 microm and 10 microm inhibited vegf secretion into supernatants 
14 10 microm inhibited vegf secretion into supernatants , decreased 
18 secretion into supernatants , decreased the number of formed 
2 decreased the number of formed capillary tubes and increased 
17 formed capillary tubes and increased cell adhesion to collagen 
15 tubes and increased cell adhesion to collagen . NULL 
19 NULL NULL NULL NULL administration of thalidomide at the 
17 concentration of 0.01 microm increased cell migration , while 
14 0.01 microm increased cell migration , while at 10 
18 10 microm , it decreased cell migration . NULL 
14 , it decreased cell migration . NULL NULL NULL 
16 10 microm did not change cell proliferation of 72-h 
1 did not change cell proliferation of 72-h cell cultures 
3 NULL we conclude that angiogenic action of thalidomide is 
18 we conclude that anti-angiogenic action of thalidomide is due 
0 thalidomide is due to direct inhibitory action on vegf 
18 is due to direct inhibitory action on vegf secretion 
18 due to direct inhibitory action on vegf secretion and 
14 inhibitory action on vegf secretion and capillary microvessel formation 
2 secretion and capillary microvessel formation as well as immunomodulatory 
16 as well as immunomodulatory influence on ea.hy 926 cells 
14 on ea.hy 926 cells migration and adhesion . NULL 
15 926 cells migration and adhesion . NULL NULL NULL 
16 NULL NULL NULL NULL regulation of skin microvasculature angiogenesis 
3 regulation of skin microvasculature angiogenesis , cell migration , 
14 microvasculature angiogenesis , cell migration , and permeability by 
0 permeability by a specific inhibitor of pkcalpha . NULL 
17 NULL NULL NULL NULL activation of protein kinase c 
0 NULL NULL activation of protein kinase c ( pkc 
17 c ( pkc ) induces phenotypic changes in the 
0 ( pkc ) induces phenotypic changes in the morphology 
16 pkc ) induces phenotypic changes in the morphology of 
16 microvascular endothelial cells that affect major functions of the 
0 endothelial cells that affect major functions of the microvasculature 
0 cells that affect major functions of the microvasculature . 
0 NULL NULL NULL these functions include the first stages 
0 the first stages of sprouting in angiogenesis , cell 
3 stages of sprouting in angiogenesis , cell migration following 
14 in angiogenesis , cell migration following wounding , and 
16 s ) of pkc responsible for each of these 
0 for each of these changes has not been previously 
0 this study , we used two inflammatory agents , 
17 myristic acetate , to activate pkc isozymes and specific 
16 isoform ( s ) controls angiogenesis , wound healing 
3 ( s ) controls angiogenesis , wound healing , 
18 all cases , only inhibition of pkcalpha inhibited each 
0 only inhibition of pkcalpha inhibited each of these functions 
0 inhibited each of these functions when compared to the 
18 when compared to the inhibition of pkcbeta . NULL 
0 additional analysis of the mechanism of action of go6976 
0 of the mechanism of action of go6976 ( rt-pcr 
16 immunohistochemistry ) of the changes in the phosphorylated and 
12 the changes in the phosphorylated and nonphosphorylated forms of 
12 in the phosphorylated and nonphosphorylated forms of pkcalpha in 
18 the specificity of pkcalpha inhibition by go6976 . NULL 
0 a specific and a regulatory role of the pkcalpha 
0 specific and a regulatory role of the pkcalpha isoform 
0 pkcalpha isoform in three major endothelial cell functions that 
0 three major endothelial cell functions that are important in 
0 cell functions that are important in the maintenance of 
0 are important in the maintenance of microvascular homeostasis . 
16 NULL NULL the differential regulation of human telomerase reverse 
0 transcriptase and vascular endothelial growth factor may contribute to 
0 endothelial growth factor may contribute to the clinically more 
0 more aggressive behavior of positive breast carcinomas . NULL 
0 normal mammary gland but positive neoplastic cells may be 
9 the relationship between p63 expression and several clinicopathological features 
0 several clinicopathological features and tumor markers of clinical significance 
0 and tumor markers of clinical significance in breast pathology 
0 in breast pathology including key regulators of the cell 
0 cycle , oncogenes , apoptosis proteins , metalloproteinases and 
0 performed in 100 formalin-fixed embedded samples of invasive ductal 
0 NULL NULL NULL NULL positive cells were found in 
0 NULL NULL NULL NULL positive carcinomas were poorly differentiated 
2 p63-positive carcinomas were poorly differentiated , hormone receptor-negative neoplasms 
0 poorly differentiated , hormone negative neoplasms with a high 
4 neoplasms with a high proliferation rate . NULL NULL 
0 advanced pathological stage , tumor size , and the 
9 size , and the expression of human telomerase reverse 
0 htert ) , tissue inhibitor of matrix metalloproteinase 1 
0 , tissue inhibitor of matrix metalloproteinase 1 ( timp1 
0 ) and vascular endothelial growth factor ( vegf ) 
9 NULL NULL NULL the expression of timp1 suggests that 
0 may be preponderant in positive carcinomas . NULL NULL 
0 NULL NULL NULL htert activity is associated with nodal 
0 NULL htert activity is associated with nodal metastases and 
0 is associated with nodal metastases and cellular proliferation . 
0 nodal metastases and cellular proliferation . NULL NULL NULL 
16 NULL NULL NULL vegf regulates angiogenesis , which is 
3 NULL NULL vegf regulates angiogenesis , which is also 
0 in the process of tumor growth and metastatic dissemination 
4 the process of tumor growth and metastatic dissemination . 
14 of tumor growth and metastatic dissemination . NULL NULL 
14 tumor growth and metastatic dissemination . NULL NULL NULL 
16 thus , the differential regulation of htert and vegf 
0 htert and vegf in positive breast carcinomas may contribute 
0 p63-positive breast carcinomas may contribute to the clinically more 
16 NULL NULL NULL NULL regulation of tumor angiogenesis by 
0 NULL NULL regulation of tumor angiogenesis by thrombospondin-1 . 
3 NULL regulation of tumor angiogenesis by thrombospondin-1 . NULL 
3 NULL NULL NULL NULL angiogenesis plays a critical role 
16 NULL NULL NULL angiogenesis plays a critical role in 
16 NULL angiogenesis plays a critical role in the growth 
16 angiogenesis plays a critical role in the growth and 
4 critical role in the growth and metastasis of tumors 
14 in the growth and metastasis of tumors . NULL 
3 ) is a potent angiogenesis inhibitor , and down-regulation 
0 is a potent angiogenesis inhibitor , and down-regulation of 
18 angiogenesis inhibitor , and down-regulation of tsp-1 has been 
16 has been suggested to alter tumor growth by modulating 
0 been suggested to alter tumor growth by modulating angiogenesis 
4 suggested to alter tumor growth by modulating angiogenesis in 
16 alter tumor growth by modulating angiogenesis in a variety 
3 tumor growth by modulating angiogenesis in a variety of 
0 in a variety of tumor types . NULL NULL 
9 NULL NULL NULL NULL expression of tsp-1 is up-regulated 
17 expression of tsp-1 is up-regulated by the tumor suppressor 
0 is up-regulated by the tumor suppressor gene , p53 
0 up-regulated by the tumor suppressor gene , p53 , 
18 , p53 , and down-regulated by oncogenes such as 
18 NULL NULL NULL tsp-1 inhibits angiogenesis by inhibiting endothelial 
3 NULL NULL tsp-1 inhibits angiogenesis by inhibiting endothelial cell 
18 tsp-1 inhibits angiogenesis by inhibiting endothelial cell migration and 
14 by inhibiting endothelial cell migration and proliferation and by 
1 endothelial cell migration and proliferation and by inducing apoptosis 
0 proliferation and by inducing apoptosis . NULL NULL NULL 
0 NULL NULL NULL in addition , activation of transforming 
17 NULL in addition , activation of transforming growth factor 
0 , activation of transforming growth factor beta ( tgf-beta 
16 tgf-beta ) by tsp-1 plays a crucial role in 
16 by tsp-1 plays a crucial role in the regulation 
16 tsp-1 plays a crucial role in the regulation of 
16 crucial role in the regulation of tumor progression . 
0 in the regulation of tumor progression . NULL NULL 
2 the regulation of tumor progression . NULL NULL NULL 
0 the molecular basis of mediated inhibition of angiogenesis and 
18 molecular basis of tsp-1-mediated inhibition of angiogenesis and tumor 
3 of tsp-1-mediated inhibition of angiogenesis and tumor progression will 
0 inhibition of angiogenesis and tumor progression will aid in 
2 of angiogenesis and tumor progression will aid in the 
0 will aid in the development of novel therapeutics for 
0 novel therapeutics for the treatment of cancer . NULL 
16 NULL NULL NULL NULL regulation of the composition of 
0 composition of the extracellular matrix by low density lipoprotein 
0 low density lipoprotein receptor-related protein : activities based on 
0 lipoprotein receptor-related protein-1 : activities based on regulation of 
0 : activities based on regulation of mrna expression . 
0 based on regulation of mrna expression . NULL NULL 
0 on regulation of mrna expression . NULL NULL NULL 
0 low density lipoprotein receptor-related protein ( lrp-1 ) is 
0 catabolic receptor for extracellular matrix ( ecm ) structural 
0 matrix ( ecm ) structural proteins and for proteins 
15 and for proteins that bind to ecm . NULL 
16 NULL lrp-1 also is implicated in integrin maturation . 
0 is implicated in integrin maturation . NULL NULL NULL 
0 to identify novel proteins involved in ecm modeling that 
2 proteins involved in ecm modeling that are regulated by 
16 ecm modeling that are regulated by lrp-1 . NULL 
9 we show that lrp-1 deficiency in murine embryonic fibroblasts 
0 ( mefs ) is associated with increased levels of 
17 ) is associated with increased levels of type iii 
0 is associated with increased levels of type iii collagen 
0 iii collagen and pigment derived factor , which accumulate 
17 upar-ap/endo-180 , is also increased in lrp-1-deficient mefs . 
9 is also increased in deficient mefs . NULL NULL 
0 NULL NULL human lrp-1 reversed the changes in protein 
0 human lrp-1 reversed the changes in protein expression associated 
0 reversed the changes in protein expression associated with lrp-1 
0 the changes in protein expression associated with lrp-1 deficiency 
0 changes in protein expression associated with lrp-1 deficiency ; 
9 expression associated with lrp-1 deficiency ; however , the 
0 however , the endocytic activity of lrp-1 was not 
0 of lrp-1 was not involved . NULL NULL NULL 
0 NULL NULL instead , regulation occurred at the mrna 
0 regulation occurred at the mrna level . NULL NULL 
18 NULL NULL NULL NULL inhibition of c-jun amino-terminal kinase 
18 kinase ( jnk ) blocked type iii collagen expression 
9 blocked type iii collagen expression in lrp-1-deficient mefs , 
9 iii collagen expression in deficient mefs , suggesting regulation 
16 lrp-1-deficient mefs , suggesting regulation of jnk activity as 
0 suggesting regulation of jnk activity as a mechanism by 
0 jnk activity as a mechanism by which lrp-1 controls 
0 mechanism by which lrp-1 controls mrna expression . NULL 
0 by which lrp-1 controls mrna expression . NULL NULL 
0 which lrp-1 controls mrna expression . NULL NULL NULL 
0 NULL NULL NULL the ability of lrp-1 to regulate 
0 ability of lrp-1 to regulate expression of the factors 
0 of lrp-1 to regulate expression of the factors identified 
16 identified here suggests a role for lrp-1 in determining 
3 vessel structure and in angiogenesis . NULL NULL NULL 
18 NULL NULL NULL pericytes limit tumor cell metastasis . 
0 NULL NULL pericytes limit tumor cell metastasis . NULL 
14 pericytes limit tumor cell metastasis . NULL NULL NULL 
0 NULL NULL previously we observed that neural cell adhesion 
0 observed that neural cell adhesion molecule ( ncam ) 
9 molecule ( ncam ) deficiency in beta tumor cells 
0 ) deficiency in beta tumor cells facilitates metastasis into 
17 in beta tumor cells facilitates metastasis into distant organs 
14 beta tumor cells facilitates metastasis into distant organs and 
0 , we show that deficient beta cell tumors grew 
2 ncam-deficient beta cell tumors grew leaky blood vessels with 
15 vessels with perturbed pericyte-endothelial cell-cell interactions and deficient perivascular 
15 with perturbed pericyte-endothelial cell-cell interactions and deficient perivascular deposition 
0 pericyte-endothelial cell-cell interactions and deficient perivascular deposition of ecm 
14 interactions and deficient perivascular deposition of ecm components . 
0 NULL NULL conversely , tumor cell expression of ncam 
9 conversely , tumor cell expression of ncam in a 
17 model ( t241 ) improved pericyte recruitment and increased 
14 t241 ) improved pericyte recruitment and increased perivascular deposition 
17 improved pericyte recruitment and increased perivascular deposition of ecm 
14 recruitment and increased perivascular deposition of ecm molecules . 
18 suggest that ncam may limit tumor cell metastasis by 
0 that ncam may limit tumor cell metastasis by stabilizing 
14 may limit tumor cell metastasis by stabilizing the microvessel 
17 tumor cell metastasis by stabilizing the microvessel wall . 
5 directly address whether pericyte dysfunction increases the metastatic potential 
17 address whether pericyte dysfunction increases the metastatic potential of 
14 pericyte dysfunction increases the metastatic potential of solid tumors 
0 dysfunction increases the metastatic potential of solid tumors , 
0 cell tumorigenesis in primary deficient pdgfb ( ret/ret ) 
0 NULL NULL NULL this resulted in beta tumor cell 
0 this resulted in beta tumor cell metastases in distant 
14 in beta tumor cell metastases in distant organs and 
16 nodes , demonstrating a role for pericytes in limiting 
18 role for pericytes in limiting tumor cell metastasis . 
0 for pericytes in limiting tumor cell metastasis . NULL 
14 in limiting tumor cell metastasis . NULL NULL NULL 
0 NULL NULL these data support a new model for 
0 new model for how tumor cells trigger metastasis by 
17 for how tumor cells trigger metastasis by perturbing pericyte-endothelial 
14 how tumor cells trigger metastasis by perturbing pericyte-endothelial cell-cell 
16 cells trigger metastasis by perturbing pericyte-endothelial cell-cell interactions . 
15 metastasis by perturbing pericyte-endothelial cell-cell interactions . NULL NULL 
15 by perturbing pericyte-endothelial cell-cell interactions . NULL NULL NULL 
0 and ikk as therapeutic targets in cancer . NULL 
0 NULL NULL NULL the transcription factor nf-kappab and associated 
15 transcription factor nf-kappab and associated regulatory factors ( including 
0 factor nf-kappab and associated regulatory factors ( including ikappab 
0 bcl-3 ) are strongly implicated in a variety of 
0 of hematologic and solid tumor malignancies . NULL NULL 
0 NULL NULL NULL a role for nf-kappab in cancer 
0 cancer cells appears to involve regulation of cell proliferation 
16 cells appears to involve regulation of cell proliferation , 
1 involve regulation of cell proliferation , control of apoptosis 
16 of cell proliferation , control of apoptosis , promotion 
5 proliferation , control of apoptosis , promotion of angiogenesis 
17 control of apoptosis , promotion of angiogenesis , and 
3 apoptosis , promotion of angiogenesis , and stimulation of 
17 of angiogenesis , and stimulation of invasion/metastasis . NULL 
14 , and stimulation of invasion . NULL NULL NULL 
14 , and stimulation of metastasis . NULL NULL NULL 
0 NULL consistent with a role for nf-kappab in oncogenesis 
18 oncogenesis are observations that inhibition of nf-kappab alone or 
19 in combination with cancer therapies leads to tumor cell 
17 combination with cancer therapies leads to tumor cell death 
0 cancer therapies leads to tumor cell death or growth 
5 leads to tumor cell death or growth inhibition . 
4 tumor cell death or growth inhibition . NULL NULL 
18 cell death or growth inhibition . NULL NULL NULL 
18 indicate that nf-kappab can play a tumor suppressor role 
0 nf-kappab can play a tumor suppressor role in certain 
0 can play a tumor suppressor role in certain settings 
0 play a tumor suppressor role in certain settings and 
0 that it can be important in promoting an apoptotic 
0 can be important in promoting an apoptotic signal downstream 
0 promoting an apoptotic signal downstream of certain cancer therapy 
0 downstream of certain cancer therapy regimens . NULL NULL 
0 thorough approaches must be initiated to determine the molecular 
0 therapeutic outcomes that are controlled by nf-kappab . NULL 
0 NULL NULL NULL NULL circulating endothelial cells in malignant 
0 circulating endothelial cells in malignant disease . NULL NULL 
17 is a disease largely dependent on neoangiogenesis . NULL 
3 disease largely dependent on angiogenesis . NULL NULL NULL 
3 NULL NULL NULL cancer angiogenesis is often disordered and 
6 of coexisting vascular endothelial dysfunction . NULL NULL NULL 
0 of assessing vascular endothelial function in cancer is via 
0 via the quantification of circulating endothelial cells ( cec 
0 healthy individuals , their presence in elevated numbers often 
0 , their presence in elevated numbers often indicates substantial 
17 ) , whose numbers increase in the presence of 
0 numbers increase in the presence of vascular damage . 
6 the presence of vascular damage . NULL NULL NULL 
16 that epcs have an important role in tumor vasculogenesis 
16 epcs have an important role in tumor vasculogenesis . 
0 an important role in tumor vasculogenesis . NULL NULL 
3 important role in tumor vasculogenesis . NULL NULL NULL 
6 the context of vascular dysfunction and coagulopathy is the 
0 on their relationship to malignant disease . NULL NULL 
6 : mechanisms of peritoneal damage . NULL NULL NULL 
0 ( pd ) is limited by morphological changes of 
7 ) is limited by morphological changes of the peritoneal 
7 is limited by morphological changes of the peritoneal membrane 
0 NULL NULL NULL NULL structural changes were promoted by 
0 NULL NULL NULL structural changes were promoted by toxicity 
17 NULL structural changes were promoted by toxicity of glucose 
0 by toxicity of glucose degradation products ( gdps ) 
0 NULL NULL besides their direct toxicity gdps promote formation 
17 their direct toxicity gdps promote formation of advanced glycation 
8 direct toxicity gdps promote formation of advanced glycation endproducts 
9 for ages and is expressed on mesothelial cells . 
0 NULL NULL NULL the effects of pdfs with different 
7 gdps were compared on morphological changes in the peritoneal 
7 were compared on morphological changes in the peritoneal membrane 
16 be demonstrated that rage plays a pivotal role in 
16 that rage plays a pivotal role in structural damage 
16 rage plays a pivotal role in structural damage ( 
6 a pivotal role in structural damage ( e.g. inflammation 
6 pivotal role in structural damage ( e.g. inflammation , 
3 ( e.g. inflammation , angiogenesis and fibrosis ) of 
0 pathway with regard to preventing peritoneal fibrosis should be 
19 blood endothelial progenitor cell therapy in patients with peripheral 
0 NULL NULL NULL no effective medical therapies have been 
0 NULL no effective medical therapies have been developed sofar 
0 medical therapies have been developed sofar to enhance blood 
0 been developed sofar to enhance blood flow in the 
0 of patients with peripheral arterial disease ( pad ) 
0 evidence in experimental and clinical studies that adult bone 
0 studies that adult bone derived stem cells and endothelial 
0 and endothelial progenitor cells participate in the development of 
2 cells participate in the development of new blood vessels 
3 blood vessels , called angiogenesis or neovascularization . NULL 
3 , called neoangiogenesis or neovascularization . NULL NULL NULL 
0 NULL NULL NULL NULL clinical results induced by autologous 
0 NULL NULL NULL clinical results induced by autologous bone 
0 NULL NULL clinical results induced by autologous bone marrow 
3 marrow stem cells or angiogenic growth/differentiation factors in end-stage 
0 stem cells or angiogenic growth factors in end-stage patients 
0 stem cells or angiogenic differentiation factors in end-stage patients 
19 few number of patients treated by angiogenic therapy , 
3 of patients treated by angiogenic therapy , the interpretation 
0 patients treated by angiogenic therapy , the interpretation of 
0 , the interpretation of clinical results needs cautiousness . 
0 the interpretation of clinical results needs cautiousness . NULL 
2 NULL NULL NULL NULL formation of new bone during 
19 of new bone during vertical distraction osteogenesis of the 
19 new bone during vertical distraction osteogenesis of the human 
19 bone during vertical distraction osteogenesis of the human mandible 
0 is related to the presence of blood vessels . 
0 NULL we examined the effect of distraction rate on 
0 examined the effect of distraction rate on blood vessel 
4 rate on blood vessel growth in intramembraneous ossification after 
19 in intramembraneous ossification after vertical distraction osteogenesis in the 
19 intramembraneous ossification after vertical distraction osteogenesis in the human 
19 ossification after vertical distraction osteogenesis in the human mandible 
0 a severely atrophic mandible underwent bone augmentation with distraction 
0 underwent bone augmentation with distraction osteogenesis . NULL NULL 
0 bone augmentation with distraction osteogenesis . NULL NULL NULL 
0 NULL NULL NULL two distraction rates ( 0.5 and 
0 different areas in the distraction gap : ( 1 
2 amount of new bone formed during distraction . NULL 
0 new bone formed during distraction . NULL NULL NULL 
0 histological analysis demonstrated the presence of blood vessels throughout 
0 connective tissue in the distraction gap . NULL NULL 
18 groups , suggesting a delay in angiogenesis in this 
3 suggesting a delay in angiogenesis in this group of 
0 NULL NULL NULL a positive correlation between blood vessel 
0 patients with 1 mm/day distraction rate may be related 
18 may be related to disruption of angiogenesis in the 
3 related to disruption of angiogenesis in the soft connective 
17 a less optimal mechanical stimulation of cells involved in 
0 mechanical stimulation of cells involved in angiogenesis . NULL 
3 of cells involved in angiogenesis . NULL NULL NULL 
0 NULL NULL this probably results in the slower rate 
0 the slower rate of osteogenesis seen at the 1 
0 at the 1 mm/day distraction rate compared with the 
0 with the 0.5 mm/day distraction rate . NULL NULL 
0 NULL NULL the data support the concept that a 
0 the concept that a positive relationship exists between the 
2 blood vessels and the formation of bone . NULL 
19 NULL NULL NULL for distraction of the human mandible 
0 elderly patients , a distraction rate of 0.5 mm/day 
0 of 0.5 mm/day seems beneficial . NULL NULL NULL 
0 '' cyclophosphamide is an effective and safe therapy in 
19 an effective and safe therapy in patients with relapsed 
3 NULL NULL purpose : angiogenesis is increased in aggressive 
17 purpose : angiogenesis is increased in aggressive histology non-hodgkin 
0 and may be a target with selective cyclooxygenase-2 inhibition 
18 target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy . 
19 cyclooxygenase-2 inhibition and metronomic chemotherapy . NULL NULL NULL 
0 design : we assessed response , toxicity , and 
3 , and biomarkers of angiogenesis to low-dose cyclophosphamide ( 
0 NULL NULL NULL NULL results : thirty-two of 35 
0 ) are evaluable for response . NULL NULL NULL 
19 % ) were heavily pretreated ( median of three 
19 after autologous stem cell transplant . NULL NULL NULL 
0 , the overall best response rate is 37 % 
0 % ( 2 complete clinical response/complete clinical response unconfirmed 
0 ( 2 complete clinical response clinical response unconfirmed and 
0 2 complete clinical response/complete clinical response unconfirmed and 9 
0 complete clinical response/complete clinical response unconfirmed and 9 partial 
0 unconfirmed and 9 partial response ) , with 22 
0 NULL median overall and progression survivals are 14.4 and 
0 NULL median overall and free survivals are 14.4 and 
0 NULL NULL the median response duration was 8.2 months 
0 myelosuppression and gastrointestinal side effects were uncommon . NULL 
0 NULL NULL three patients developed deep vein thromboses and 
19 thromboses and two heavily pretreated patients developed treatment-related acute 
0 two heavily pretreated patients developed treatment-related acute myelogenous leukemia 
19 heavily pretreated patients developed treatment acute myelogenous leukemia or 
19 and 12 months of therapy . NULL NULL NULL 
0 NULL NULL NULL NULL circulating endothelial cells and their 
0 cells and their precursors declined and remained low in 
0 whereas plasma vascular endothelial growth factor trended to decline 
18 growth factor trended to decline in responding patients but 
17 in responding patients but increase in nonresponders . NULL 
0 NULL NULL trough celecoxib levels achieved targeted `` antiangiogenic 
18 trough celecoxib levels achieved targeted `` antiangiogenic '' levels 
3 levels achieved targeted `` angiogenic '' levels . NULL 
0 targeted `` antiangiogenic '' levels . NULL NULL NULL 
0 is well tolerated and active in pretreated aggressive non-hodgkin 
19 tolerated and active in pretreated aggressive non-hodgkin 's lymphoma 
0 NULL close surveillance for arterial and venous thrombotic events 
18 NULL NULL NULL the decline in circulating endothelial cells 
0 NULL the decline in circulating endothelial cells and their 
18 may be working by inhibiting angiogenesis but should be 
3 be working by inhibiting angiogenesis but should be validated 
19 NULL NULL NULL NULL photodynamic therapy with verteporfin for 
19 NULL NULL NULL photodynamic therapy with verteporfin for subfoveal 
3 verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia 
0 assess the safety and effectiveness of photodynamic therapy ( 
19 safety and effectiveness of photodynamic therapy ( pdt ) 
19 and effectiveness of photodynamic therapy ( pdt ) with 
0 of photodynamic therapy ( pdt ) with verteporfin for 
3 verteporfin for subfoveal choroidal neovascularization ( cnv ) secondary 
3 subfoveal choroidal neovascularization ( cnv ) secondary to pathologic 
0 eyes ) with pm underwent pdt according to the 
19 ) with pm underwent pdt according to the guidelines 
19 of the verteporfin in photodynamic therapy study . NULL 
19 the verteporfin in photodynamic therapy study . NULL NULL 
0 NULL NULL NULL NULL clinical evaluations performed at all 
19 , and fundus fluorescein angiography . NULL NULL NULL 
19 and 3 months after treatment and thereafter at 3-month 
0 NULL NULL NULL NULL results : the final visual 
0 of 31 months , improved by greater than or=1 
3 NULL NULL NULL NULL cnv size did not affect 
0 cnv size did not affect visual outcomes . NULL 
19 NULL NULL conclusion : pdt preserves vision in patients 
3 vision in patients with cnv associated with pm . 
0 in patients with cnv associated with pm . NULL 
19 likely to benefit from pdt with verteporfin . NULL 
0 NULL NULL NULL imaging tumor angiogenesis . NULL NULL 
3 NULL NULL imaging tumor angiogenesis . NULL NULL NULL 
0 the discovery of vascular-specific growth factors with angiogenic activity 
0 vascular-specific growth factors with angiogenic activity , there has 
0 growth factors with angiogenic activity , there has been 
0 there has been a significant effort to develop cancer 
0 develop cancer drugs that restrict tumorigenesis by targeting the 
0 that restrict tumorigenesis by targeting the blood supply . 
0 , mancuso et al. use mouse models to better 
0 the plasticity of the tumor vasculature in the face 
3 in the face of angiogenic therapy ( see the 
0 the face of antiangiogenic therapy ( see the related 
4 they describe a rapid regrowth of the tumor vasculature 
0 rapid regrowth of the tumor vasculature following withdrawal of 
0 of fully understanding the function of these and similar 
0 of these and similar treatments used in the clinic 
0 these and similar treatments used in the clinic at 
0 collagen-poly glycolic acid hybrid matrix with basic fibroblast growth 
0 matrix with basic fibroblast growth factor accelerated angiogenesis and 
17 basic fibroblast growth factor accelerated angiogenesis and granulation tissue 
3 fibroblast growth factor accelerated angiogenesis and granulation tissue formation 
2 angiogenesis and granulation tissue formation in diabetic mice . 
0 poor skin wound healing associated with diabetes is thought 
18 partly a result from impaired angiogenesis , treatments that 
3 a result from impaired angiogenesis , treatments that improve 
0 from impaired angiogenesis , treatments that improve angiogenesis could 
17 angiogenesis , treatments that improve angiogenesis could have important 
3 , treatments that improve angiogenesis could have important clinical 
0 improve angiogenesis could have important clinical applications . NULL 
0 angiogenesis could have important clinical applications . NULL NULL 
0 we herein report the effects of novel developed material 
0 the effects of novel developed material , collagen-poly glycolic 
0 glycolic acid fiber hybrid matrix , being used together 
0 hybrid matrix , being used together with basic fibroblast 
0 together with basic fibroblast growth factor to promote wound 
0 fibroblast growth factor to promote wound healing of full-thickness 
0 healing of full-thickness skin defects on the back of 
17 this therapeutic approach markedly promotes angiogenesis and granulation tissue 
3 therapeutic approach markedly promotes angiogenesis and granulation tissue formation 
2 angiogenesis and granulation tissue formation in comparison with other 
0 pomegranate ) and its potential for prevention and treatment 
0 and its potential for prevention and treatment of inflammation 
0 potential for prevention and treatment of inflammation and cancer 
0 which has interesting pharmacologic activity . NULL NULL NULL 
0 , possess potent antioxidant properties , while juice , 
0 of interest for the treatment of menopausal symptoms and 
0 NULL NULL NULL the use of juice , peel 
0 shown to possess anticancer activities , including interference with 
0 anticancer activities , including interference with tumor cell proliferation 
0 , including interference with tumor cell proliferation , cell 
1 interference with tumor cell proliferation , cell cycle , 
14 , cell cycle , invasion and angiogenesis . NULL 
3 cycle , invasion and angiogenesis . NULL NULL NULL 
0 NULL these may be associated with plant based anti-inflammatory 
0 with plant based anti-inflammatory effects , the phytochemistry and 
0 a wide range of clinical applications for the treatment 
0 clinical applications for the treatment and prevention of cancer 
0 for the treatment and prevention of cancer , as 
0 inflammation is believed to play an essential etiologic role 
0 believed to play an essential etiologic role . NULL 
0 play an essential etiologic role . NULL NULL NULL 
17 NULL NULL angiotensin ii induces soluble fms-like tyrosine kinase-1 
16 NULL NULL angiotensin ii induces soluble fms-like tyrosine kinase-1 
14 soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway 
6 NULL NULL maternal endothelial dysfunction in preeclampsia is associated 
0 dysfunction in preeclampsia is associated with increased soluble fms-like 
17 preeclampsia is associated with increased soluble fms-like tyrosine kinase-1 
14 sflt-1 ) , a circulating antagonist of vascular endothelial 
0 antagonist of vascular endothelial growth factor and placental growth 
0 growth factor and placental growth factor . NULL NULL 
17 a potent vasoconstrictor that increases concomitant with sflt-1 during 
17 that ang ii may promote the expression of sflt-1 
9 ii may promote the expression of sflt-1 in pregnancy 
19 here we report that infusion of ang ii significantly 
17 of ang ii significantly increases circulating levels of sflt-1 
14 ang ii significantly increases circulating levels of sflt-1 in 
0 ii significantly increases circulating levels of sflt-1 in pregnant 
0 ang ii is a regulator of sflt-1 secretion in 
14 a regulator of sflt-1 secretion in vivo . NULL 
17 furthermore , ang ii stimulated sflt-1 production in a 
9 ang ii stimulated sflt-1 production in a dose- and 
0 in a dose- and dependent manner from human villous 
0 human villous explants and cultured trophoblasts but not from 
17 as expected , ang induced sflt-1 secretion resulted in 
14 , ang ii-induced sflt-1 secretion resulted in the inhibition 
0 ang ii-induced sflt-1 secretion resulted in the inhibition of 
17 secretion resulted in the inhibition of endothelial cell migration 
14 inhibition of endothelial cell migration and in vitro tube 
2 and in vitro tube formation . NULL NULL NULL 
17 fk506 demonstrated that ang mediated sflt-1 release was via 
16 fk506 demonstrated that ang mediated sflt-1 release was via 
14 that ang ii-mediated sflt-1 release was via ang ii 
17 ii type 1 receptor activation and calcineurin signaling , 
16 reveal a previously unrecognized regulatory role for ang ii 
16 a previously unrecognized regulatory role for ang ii on 
9 ang ii on sflt-1 expression in murine and human 
17 pregnancy and suggest that elevated sflt-1 levels in preeclampsia 
0 suggest that elevated sflt-1 levels in preeclampsia may be 
17 in preeclampsia may be caused by a dysregulation of 
18 be caused by a dysregulation of the local renin/angiotensin 
17 NULL NULL NULL NULL activation of vascular endothelial growth 
0 activation of vascular endothelial growth factor through reactive oxygen 
16 through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell 
17 oxygen species mediates 20-hydroxyeicosatetraenoic induced endothelial cell proliferation . 
1 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation . NULL NULL NULL 
8 ( 20-hete ) is formed by the omega-hydroxylation of 
17 enzymes , and it induces angiogenic responses in vivo 
3 , and it induces angiogenic responses in vivo . 
17 the hypothesis that 20-hete increases endothelial cell ( ec 
1 cell ( ec ) proliferation via vascular endothelial growth 
0 proliferation via vascular endothelial growth factor ( vegf ) 
16 , we studied the effects of wit003 [ 20-hydroxyeicosa-5 
17 as pure 20-hete , stimulated ec proliferation by approximately 
1 20-hete , stimulated ec proliferation by approximately 40 % 
0 NULL NULL NULL these proliferative effects were accompanied by 
0 NULL NULL these proliferative effects were accompanied by increased 
17 effects were accompanied by increased vegf expression and release 
9 accompanied by increased vegf expression and release that were 
14 increased vegf expression and release that were observed as 
0 and release that were observed as early as 4 
0 h after 20-hete agonist addition . NULL NULL NULL 
17 this was accompanied by increased phosphorylation of the vegf 
12 was accompanied by increased phosphorylation of the vegf receptor 
0 NULL NULL NULL the proliferative effects of 20-hete were 
0 NULL NULL the proliferative effects of 20-hete were markedly 
18 of 20-hete were markedly inhibited by a vegf-neutralizing antibody 
18 ( peg-sod ) markedly inhibited both the increases in 
17 markedly inhibited both the increases in vegf expression and 
9 the increases in vegf expression and the proliferative effects 
0 vegf expression and the proliferative effects of 20-hete . 
0 expression and the proliferative effects of 20-hete . NULL 
19 NULL in contrast , administration of the nad ( 
0 p ) h oxidase inhibitor apocynin had no effect 
16 inhibitor apocynin had no effect to the proliferative response 
0 no effect to the proliferative response to 20-hete . 
0 effect to the proliferative response to 20-hete . NULL 
17 the 20-hete agonist markedly increased superoxide formation as reflected 
8 agonist markedly increased superoxide formation as reflected by an 
0 as reflected by an increase in dihydroethidium staining of 
19 an increase in dihydroethidium staining of ec , and 
0 ec , and this increase was inhibited by peg-sod 
18 and this increase was inhibited by peg-sod but not 
17 NULL NULL 20-hete also increased the phosphorylation of p42/p44 
12 20-hete also increased the phosphorylation of p42/p44 mitogen-activated protein 
0 the phosphorylation of p42/p44 activated protein kinase ( mapk 
0 phosphorylation of p42/p44 mitogen-activated protein kinase ( mapk ) 
0 ec , whereas an inhibitor of mapk [ u0126 
18 2-aminophenylthio ) butadiene ] suppressed the proliferative and the 
0 butadiene ] suppressed the proliferative and the vegf changes 
16 proliferative and the vegf changes but not the pro-oxidant 
0 but not the pro-oxidant effects of 20-hete . NULL 
17 data suggest that 20-hete stimulates superoxide formation by pathways 
8 that 20-hete stimulates superoxide formation by pathways other than 
0 stimulates superoxide formation by pathways other than apocynin-sensitive nad 
0 by pathways other than sensitive nad ( p ) 
17 h oxidase , thereby activating mapk and then enhancing 
17 activating mapk and then enhancing vegf synthesis that drives 
9 and then enhancing vegf synthesis that drives ec proliferation 
16 enhancing vegf synthesis that drives ec proliferation . NULL 
1 synthesis that drives ec proliferation . NULL NULL NULL 
16 , 20-hete may be involved in the regulation of 
16 be involved in the regulation of ec functions , 
0 the regulation of ec functions , such as angiogenesis 
3 functions , such as angiogenesis . NULL NULL NULL 
18 NULL NULL NULL hyperforin blocks neutrophil activation of matrix 
17 NULL hyperforin blocks neutrophil activation of matrix metalloproteinase-9 , 
0 blocks neutrophil activation of matrix metalloproteinase-9 , motility and 
14 of matrix metalloproteinase-9 , motility and recruitment , and 
14 metalloproteinase-9 , motility and recruitment , and restrains inflammation-triggered 
17 recruitment , and restrains triggered angiogenesis and lung fibrosis 
3 , and restrains inflammation-triggered angiogenesis and lung fibrosis . 
0 , has emerged as key player not only in 
0 only in the antidepressant activity of the plant but 
0 but also as an inhibitor of bacteria lymphocyte and 
0 of bacteria lymphocyte and tumor cell proliferation , and 
1 lymphocyte and tumor cell proliferation , and matrix proteinases 
0 cell proliferation , and matrix proteinases . NULL NULL 
18 whether as well as inhibiting leukocyte elastase ( le 
0 elastase ( le ) activity , hyp might be 
16 , hyp might be effective in containing both polymorphonuclear 
14 ( pmn ) leukocyte recruitment and unfavorable eventual tissue 
0 NULL NULL NULL the results show that , without 
0 show that , without affecting in vitro human pmn 
0 pmn viability and chemokine-receptor expression , hyp ( as 
18 ) was able to inhibit in a dose-dependent manner 
0 to inhibit in a dependent manner their chemotaxis and 
14 a dose-dependent manner their chemotaxis and chemoinvasion ( ic50=1 
14 manner their chemotaxis and chemoinvasion ( ic50=1 microm for 
0 both ) ; this effect was associated with a 
0 ; this effect was associated with a reduced expression 
18 was associated with a reduced expression of the adhesion 
9 associated with a reduced expression of the adhesion molecule 
0 reduced expression of the adhesion molecule cd11b by formyl-met-leu-phe-stimulated 
17 adhesion molecule cd11b by stimulated neutrophils and block of 
18 by formyl-met-leu-phe-stimulated neutrophils and block of le-triggered activation of 
17 neutrophils and block of triggered activation of the gelatinase 
17 and block of le-triggered activation of the gelatinase matrix 
0 activation of the gelatinase matrix metalloproteinase-9 . NULL NULL 
17 NULL NULL NULL NULL triggered angiogenesis is also blocked 
3 NULL NULL NULL pmn-triggered angiogenesis is also blocked by 
18 pmn-triggered angiogenesis is also blocked by both local injection 
19 blocked by both local injection and daily i.p . 
19 NULL NULL NULL NULL administration of the hyp salt 
17 hyp salt in an induced murine model . NULL 
19 NULL NULL NULL NULL treatment with hyp reduces acute 
18 NULL treatment with hyp reduces acute pmn recruitment and 
14 hyp reduces acute pmn recruitment and enhances resolution in 
0 acute pmn recruitment and enhances resolution in a pulmonary 
0 resolution in a pulmonary induced inflammation model , significantly 
0 inflammation model , significantly reducing consequent fibrosis . NULL 
0 NULL NULL NULL these results indicate that hyp is 
0 anti-inflammatory compound with therapeutic potential , and they elucidate 
0 strategies for cardiovascular gene therapy . NULL NULL NULL 
0 cardiovascular diseases are the major cause of morbidity and 
0 and women in industrially developed countries . NULL NULL 
18 disorders may result from impaired angiogenesis , particularly in 
3 may result from impaired angiogenesis , particularly in response 
0 angiogenesis , particularly in response to hypoxia . NULL 
0 many limitations , gene therapy is still emerging as 
0 still emerging as a potential alternative for patients who 
3 not candidates for traditional revascularization procedures , like angioplasty 
0 recent approaches in the development of new gene delivery 
0 development of new gene delivery vectors , with great 
0 some new cardiovascular gene therapy strategies have been highlighted 
3 as combination of different angiogenic growth factors or simultaneous 
0 combination of different angiogenic growth factors or simultaneous application 
0 growth factors or simultaneous application of genes and progenitor 
2 cells in order to obtain stable and functional blood 
0 NULL NULL NULL NULL impaired apoptosis of pulmonary endothelial 
5 NULL NULL NULL impaired apoptosis of pulmonary endothelial cells 
0 pulmonary endothelial cells is associated with intimal proliferation and 
4 is associated with intimal proliferation and irreversibility of pulmonary 
0 pht ) in the clinical setting of congenital heart 
0 is reversible after complete repair in some cases but 
5 failure of endothelial cell apoptosis might lead to intimal 
0 endothelial cell apoptosis might lead to intimal proliferation and 
4 might lead to intimal proliferation and lack of reversibility 
0 investigated this and other key markers of vasoactivity and 
3 markers of vasoactivity and angiogenesis in subjects with pht 
0 pht , and 6 control patients . NULL NULL 
0 synthase , vascular endothelial growth factor , and cd34 
3 markers of vasoactivity and angiogenesis ) was also performed 
0 NULL NULL NULL NULL results : the antiapoptotic protein 
0 results : the antiapoptotic protein bcl-2 was highly expressed 
9 protein bcl-2 was highly expressed by pulmonary endothelial cells 
0 pht , nor in control patients ( p less 
4 NULL NULL NULL intimal proliferation was present in 10 
0 NULL intimal proliferation was present in 10 of 11 
0 cases , but never observed in reversible pht ( 
0 , perivascular inflammatory t-cells expressed more antiapoptotic proteins in 
17 likely to show compensatory upregulation of vascular endothelial growth 
0 upregulation of vascular endothelial growth factor and new small 
2 and new small vessel formation at the sites of 
0 irreversible pht is strongly associated with impaired endothelial cell 
18 is strongly associated with impaired endothelial cell apoptosis and 
5 with impaired endothelial cell apoptosis and antiapoptotic signaling from 
0 NULL NULL NULL these changes are associated with intimal 
0 NULL these changes are associated with intimal proliferation and 
4 are associated with intimal proliferation and vessel narrowing , 
0 , and thereby may contribute to clinical outcomes associated 
0 thereby may contribute to clinical outcomes associated with pulmonary 
0 contribute to clinical outcomes associated with pulmonary hypertension . 
18 NULL NULL NULL NULL inhibition of dll4-mediated signaling induces 
17 NULL NULL inhibition of mediated signaling induces proliferation of 
17 inhibition of dll4-mediated signaling induces proliferation of immature vessels 
4 of dll4-mediated signaling induces proliferation of immature vessels and 
0 of immature vessels and results in poor tissue perfusion 
0 results in poor tissue perfusion . NULL NULL NULL 
2 NULL NULL NULL vascular development is dependent on various 
17 NULL vascular development is dependent on various growth factors 
0 is dependent on various growth factors and certain modifiers 
0 factors and certain modifiers critical for providing arterial or 
0 modifiers critical for providing arterial or venous identity , 
15 or venous identity , interaction with the surrounding stroma 
2 tissues , hierarchic network formation , and recruitment of 
14 network formation , and recruitment of pericytes . NULL 
16 jagged and delta-like ) play a critical role in 
16 delta-like ) play a critical role in this process 
16 ) play a critical role in this process in 
0 in this process in addition to vegf . NULL 
16 the notch ligands that regulates arterial specification and maturation 
0 notch ligands that regulates arterial specification and maturation events 
2 ligands that regulates arterial specification and maturation events . 
2 regulates arterial specification and maturation events . NULL NULL 
0 we have shown that loss of function by either 
0 shown that loss of function by either targeted allele 
0 of function by either targeted allele deletion or use 
0 by either targeted allele deletion or use of a 
0 targeted allele deletion or use of a soluble form 
0 use of a soluble form of dll4 extracellular domain 
17 of dll4 extracellular domain leads to inhibition of notch 
18 extracellular domain leads to inhibition of notch signaling , 
0 of notch signaling , resulting in increased vascular proliferation 
17 signaling , resulting in increased vascular proliferation but defective 
4 resulting in increased vascular proliferation but defective maturation . 
18 increased vascular proliferation but defective maturation . NULL NULL 
2 vascular proliferation but defective maturation . NULL NULL NULL 
2 NULL NULL NULL newly forming vessels have thin caliber 
18 caliber , a markedly reduced vessel lumen , markedly 
18 vessel lumen , markedly reduced pericyte recruitment , and 
14 , markedly reduced pericyte recruitment , and deficient vascular 
0 pericyte recruitment , and deficient vascular perfusion . NULL 
0 , and deficient vascular perfusion . NULL NULL NULL 
17 NULL NULL sdll4 similarly induced defective vascular response in 
18 NULL sdll4 similarly induced defective vascular response in tumor 
2 similarly induced defective vascular response in tumor implants leading 
0 defective vascular response in tumor implants leading to reduced 
17 response in tumor implants leading to reduced tumor growth 
18 tumor implants leading to reduced tumor growth . NULL 
0 implants leading to reduced tumor growth . NULL NULL 
4 leading to reduced tumor growth . NULL NULL NULL 
0 NULL NULL NULL NULL interference with dll4-notch signaling may 
17 tumors that have highly induced dll4-notch pathway . NULL 
17 against pdgf receptor beta enhances the antitumor and the 
3 the antitumor and the angiogenic activities of an anti-vegf 
18 antitumor and the anti-angiogenic activities of an anti-vegf receptor 
0 NULL NULL NULL NULL derived growth factor ( pdgf 
0 NULL NULL NULL platelet-derived growth factor ( pdgf ) 
0 receptors ( pdgfr ) play important roles in tumorigenesis 
0 ( pdgfr ) play important roles in tumorigenesis through 
0 pdgfr ) play important roles in tumorigenesis through stimulating 
17 roles in tumorigenesis through stimulating tumor growth and promoting 
0 in tumorigenesis through stimulating tumor growth and promoting angiogenesis 
4 tumorigenesis through stimulating tumor growth and promoting angiogenesis via 
17 stimulating tumor growth and promoting angiogenesis via enhancing pericyte 
3 tumor growth and promoting angiogenesis via enhancing pericyte recruitment 
17 and promoting angiogenesis via enhancing pericyte recruitment and vessel 
14 angiogenesis via enhancing pericyte recruitment and vessel maturation . 
2 pericyte recruitment and vessel maturation . NULL NULL NULL 
0 NULL NULL here we produced a neutralizing antibody , 
15 NULL NULL NULL 1b3 binds to pdgfrbeta with high 
0 to pdgfrbeta with high affinity ( 9x10 ( -11 
18 ) m ) and blocks pdgf-bb from binding to 
15 and blocks pdgf-bb from binding to the receptor with 
18 NULL the antibody also blocks ligand-stimulated activation of pdgfrbeta 
0 the antibody also blocks stimulated activation of pdgfrbeta and 
17 antibody also blocks ligand-stimulated activation of pdgfrbeta and downstream 
0 activation of pdgfrbeta and downstream signaling molecules , including 
0 mapk p42/44 , in tumor cells . NULL NULL 
17 studies , 1b3 significantly enhanced the antitumor and the 
3 the antitumor and the angiogenic activities of dc101 , 
18 antitumor and the anti-angiogenic activities of dc101 , an 
0 against mouse vascular endothelial growth factor receptor 2 , 
0 lung ( nci-h460 ) tumor xenograft models . NULL 
19 NULL NULL NULL NULL treatment with the combination of 
17 in bxpc-3 xenograft-bearing mice resulted in tumor regression in 
0 xenograft-bearing mice resulted in tumor regression in 58 % 
18 mice resulted in tumor regression in 58 % of 
19 18 % of mice treated with dc101 alone . 
0 taken together , these results lend great support to 
0 these results lend great support to use pdgfrbeta antagonists 
0 lend great support to use pdgfrbeta antagonists in combinations 
3 with other antitumor and/or angiogenic agents in the treatment 
19 anti-angiogenic agents in the treatment of a variety of 
18 NULL NULL NULL caffeine inhibits adenosine-induced accumulation of hypoxia-inducible 
0 NULL NULL caffeine inhibits induced accumulation of hypoxia-inducible factor-1alpha 
17 NULL caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha , 
0 inhibits adenosine-induced accumulation of inducible factor-1alpha , vascular endothelial 
0 factor-1alpha , vascular endothelial growth factor , and interleukin-8 
9 factor , and interleukin-8 expression in hypoxic human colon 
0 coffee consumption has been associated with a reduced risk 
0 been associated with a reduced risk of colorectal cancer 
0 in a number of control studies . NULL NULL 
0 NULL coffee is a leading source of methylxanthines , 
17 NULL NULL NULL the induction of vascular endothelial growth 
0 induction of vascular endothelial growth factor ( vegf ) 
17 il-8 ) is an essential feature of tumor angiogenesis 
0 an essential feature of tumor angiogenesis , and the 
3 essential feature of tumor angiogenesis , and the hypoxia-inducible 
0 angiogenesis , and the inducible factor-1 ( hif-1 ) 
0 factor-1 ( hif-1 ) transcription factor is known to 
0 known to be a key regulator of this process 
0 to be a key regulator of this process . 
16 , we investigated the effects of caffeine on hif-1 
0 of caffeine on hif-1 protein accumulation and on vegf 
17 caffeine on hif-1 protein accumulation and on vegf and 
9 on vegf and il-8 expression in the human colon 
0 NULL NULL NULL our results show that caffeine significantly 
18 show that caffeine significantly inhibits adenosine-induced hif-1alpha protein accumulation 
17 that caffeine significantly inhibits induced hif-1alpha protein accumulation in 
0 significantly inhibits adenosine-induced hif-1alpha protein accumulation in cancer cells 
17 inhibits adenosine-induced hif-1alpha protein accumulation in cancer cells . 
17 hif-1alpha and vegf are increased through a3 adenosine receptor 
17 through a3 adenosine receptor stimulation , whereas the effects 
16 stimulation , whereas the effects on il-8 are mediated 
16 effects on il-8 are mediated via the a2b subtype 
19 NULL NULL NULL NULL pretreatment of cells with caffeine 
18 cells with caffeine significantly reduces adenosine-induced vegf promoter activity 
17 with caffeine significantly reduces induced vegf promoter activity and 
0 reduces adenosine-induced vegf promoter activity and vegf and il-8 
9 and vegf and il-8 expression . NULL NULL NULL 
0 NULL NULL NULL the mechanism of caffeine seems to 
16 of caffeine seems to involve the inhibition of the 
18 seems to involve the inhibition of the extracellular signal-regulated 
0 inhibition of the extracellular regulated kinase 1/2 ( erk1/2 
17 , and akt , leading to a marked decrease 
18 leading to a marked decrease in adenosine-induced hif-1alpha accumulation 
17 a marked decrease in induced hif-1alpha accumulation , vegf 
17 decrease in adenosine-induced hif-1alpha accumulation , vegf transcriptional activation 
10 hif-1alpha accumulation , vegf transcriptional activation , and vegf 
17 accumulation , vegf transcriptional activation , and vegf and 
0 and vegf and il-8 protein accumulation . NULL NULL 
17 vegf and il-8 protein accumulation . NULL NULL NULL 
18 that caffeine also significantly inhibits the a3 receptor-stimulated cell 
17 significantly inhibits the a3 stimulated cell migration of colon 
14 the a3 receptor-stimulated cell migration of colon cancer cells 
19 prepared from colon cells treated with an adenosine analog 
17 with an adenosine analog increased human umbilical vein endothelial 
14 umbilical vein endothelial cell migration . NULL NULL NULL 
16 evidence that adenosine could modulate the migration of colon 
14 adenosine could modulate the migration of colon cancer cells 
17 cancer cells by an dependent mechanism and that caffeine 
0 cells by an hif-1alpha/vegf/il-8-dependent mechanism and that caffeine has 
0 that caffeine has the potential to inhibit colon cancer 
18 has the potential to inhibit colon cancer cell growth 
1 inhibit colon cancer cell growth . NULL NULL NULL 
0 NULL NULL NULL medical therapy for intermittent claudication . 
0 NULL NULL NULL medical therapy to improve symptoms , 
0 NULL medical therapy to improve symptoms , stabilise the 
0 underlying vascular disease and improve lower limb outcomes is 
0 limb outcomes is an important and effective adjunct to 
0 is an important and effective adjunct to lifestyle modification 
0 to lifestyle modification and surgical or endovascular interventions in 
0 and surgical or endovascular interventions in patients with ic 
0 NULL NULL NULL NULL randomised placebo controlled trials have 
0 NULL NULL randomised placebo controlled trials have shown that 
0 NULL randomised placebo controlled trials have shown that the 
0 that the phosphodiesterase iii inhibitor cilostazol 100mg bid improves 
0 inhibitor cilostazol 100mg bid improves pain-free and maximum walking 
0 cilostazol 100mg bid improves free and maximum walking distance 
5 no evidence of tissue necrosis or rest pain . 
0 the evidence from 8 pivotal trials of cilostazol involving 
0 evidence from 8 pivotal trials of cilostazol involving over 
0 pivotal trials of cilostazol involving over 2000 patients with 
19 patients with intermittent claudication treated for up to 6 
0 comparatively less evidence to support the use of other 
0 evidence to support the use of other treatment modalities 
0 the use of other treatment modalities for relief of 
3 considerable interest in therapeutic angiogenesis to promote new vessel 
17 in therapeutic angiogenesis to promote new vessel formation and 
2 to promote new vessel formation and enhance collateralisation of 
17 new vessel formation and enhance collateralisation of the lower 
3 vessel formation and enhance collateralisation of the lower limb 
0 lower limb using recombinant growth factor proteins or gene 
3 the rationale for therapeutic angiogenesis is discussed , together 
0 with the most recent results from randomised trials in 
19 most recent results from randomised trials in patients with 
19 recent results from randomised trials in patients with peripheral 
0 in patients with peripheral arterial disease . NULL NULL 
3 an assay to measure angiogenesis in human fat tissue 
18 NULL NULL background : inhibition of angiogenesis reverses rodent 
3 background : inhibition of angiogenesis reverses rodent obesity . 
16 needed to study the role of angiogenesis in human 
3 study the role of angiogenesis in human obesity . 
19 fat tissue fragments from surgery were placed in 96-well 
19 fragments from surgery were placed in 96-well plates , 
19 in 96-well plates , embedded in fibrin thrombin clot 
19 fibrin thrombin clot and overlaid with cell culture media 
19 and overlaid with cell culture media containing 20 % 
0 NULL NULL NULL the effect of taxol , cobalt 
3 validated human placental vein angiogenesis model ( hpvam ) 
0 NULL NULL NULL NULL results : blood vessels initiated 
17 results : blood vessels initiated growth and elongated from 
4 : blood vessels initiated growth and elongated from the 
4 vessels initiated growth and elongated from the fat tissue 
0 NULL NULL NULL NULL presence of blood vessels was 
18 -7 ) m completely inhibited angiogenesis , while taxol 
3 ) m completely inhibited angiogenesis , while taxol 10 
18 and the heparin-steroid partially inhibited angiogenesis . NULL NULL 
3 the heparin-steroid partially inhibited angiogenesis . NULL NULL NULL 
0 NULL NULL NULL the response to taxol and heparin-steroid 
3 hpvam , a validated angiogenesis assay . NULL NULL 
0 stimulator of vascular endothelial growth factor ( vegf ) 
17 factor ( vegf ) stimulated angiogenesis initiation at 10 
3 ( vegf ) stimulated angiogenesis initiation at 10 ( 
17 vegf ) stimulated angiogenesis initiation at 10 ( -9 
4 ) m blood vessel growth was stimulated only in 
17 blood vessel growth was stimulated only in the fat 
3 NULL conclusion : this angiogenesis assay based on human 
0 NULL the vessels are derived from quiescient vessels within 
0 NULL NULL NULL these properties allow the angiogenic switch 
3 these properties allow the angiogenic switch to be evaluated 
3 NULL NULL NULL the angiogenic response of fat tissue 
0 NULL NULL the angiogenic response of fat tissue is 
17 NULL this assay allows exploration of angiogenesis in fat 
3 assay allows exploration of angiogenesis in fat tissue . 
9 NULL NULL ovarian cancers overexpress the antimicrobial protein hcap-18 
0 cancers overexpress the antimicrobial protein hcap-18 and its derivative 
17 and its derivative ll-37 increases ovarian cancer cell proliferation 
1 increases ovarian cancer cell proliferation and invasion . NULL 
14 cancer cell proliferation and invasion . NULL NULL NULL 
16 NULL NULL NULL the role of the pro-inflammatory peptide 
0 ll-37 , and its form , human cationic antimicrobial 
0 , human cationic antimicrobial protein 18 ( hcap-18 ) 
2 ) , in cancer development and progression is poorly 
2 in cancer development and progression is poorly understood . 
6 NULL NULL NULL in damaged and inflamed tissue , 
0 inflamed tissue , ll-37 functions as a chemoattractant , 
3 chemoattractant , mitogen and angiogenic factor suggesting that the 
0 the peptide may potentiate tumor progression . NULL NULL 
2 peptide may potentiate tumor progression . NULL NULL NULL 
0 was to characterize the distribution of hcap-18/ll-37 in normal 
16 and to examine the effects of ll-37 on ovarian 
9 NULL NULL NULL NULL expression of hcap-18/ll-37 was localized 
14 expression of hcap-18/ll-37 was localized to immune and granulosa 
0 tumors displayed significantly higher levels of hcap-18/ll-37 where expression 
9 levels of hcap-18/ll-37 where expression was observed in tumor 
0 hcap-18/ll-37 where expression was observed in tumor and stromal 
0 expression was observed in tumor and stromal cells . 
0 NULL NULL NULL NULL protein expression was statistically compared 
0 NULL NULL NULL protein expression was statistically compared to 
14 degree of immune cell infiltration and microvessel density in 
0 and microvessel density in derived ovarian tumors and a 
0 ovarian tumors and a significant correlation was observed for 
0 a significant correlation was observed for both . NULL 
0 was demonstrated that ovarian tumor tissue lysates and ovarian 
9 ovarian cancer cell lines express hcap-18/ll-37 . NULL NULL 
19 NULL NULL NULL NULL treatment of ovarian cancer cell 
17 lines with recombinant ll-37 stimulated proliferation , chemotaxis , 
1 with recombinant ll-37 stimulated proliferation , chemotaxis , invasion 
14 ll-37 stimulated proliferation , chemotaxis , invasion and matrix 
14 proliferation , chemotaxis , invasion and matrix metalloproteinase expression 
0 chemotaxis , invasion and matrix metalloproteinase expression . NULL 
9 invasion and matrix metalloproteinase expression . NULL NULL NULL 
9 that hcap-18/ll-37 is significantly overexpressed in ovarian tumors and 
16 and suggest ll-37 may contribute to ovarian tumorigenesis through 
0 to ovarian tumorigenesis through direct stimulation of tumor cells 
17 ovarian tumorigenesis through direct stimulation of tumor cells , 
0 through direct stimulation of tumor cells , initiation of 
17 of tumor cells , initiation of angiogenesis and recruitment 
3 cells , initiation of angiogenesis and recruitment of immune 
14 initiation of angiogenesis and recruitment of immune cells . 
2 molecules and ovarian cancer progression . NULL NULL NULL 
0 NULL NULL NULL NULL role of telomeres in vascular 
0 with the telomeres and form non-nucleosomal dna-protein complexes that 
0 telomeres and form non-nucleosomal protein complexes that serve as 
0 atherosclerotic lesions and this change is associated with telomere 
0 and this change is associated with telomere shortening . 
6 telomere integrity causes vascular dysfunction , which is prevented 
18 dysfunction , which is prevented by the activation of 
17 is prevented by the activation of telomerase . NULL 
0 develop hypertension and exhibit impaired neovascularization . NULL NULL 
3 hypertension and exhibit impaired neovascularization . NULL NULL NULL 
0 cause cardiovascular disease , manipulation of telomere function is 
0 , manipulation of telomere function is potentially an attractive 
0 attractive strategy for the treatment of vascular senescence . 
9 NULL NULL ectopic decorin expression up-regulates vegf expression in 
17 NULL ectopic decorin expression up-regulates vegf expression in mouse 
9 decorin expression up-regulates vegf expression in mouse cerebral endothelial 
17 cerebral endothelial cells via activation of the transcription factors 
0 via activation of the transcription factors sp1 , hif1alpha 
17 decorin ( dcn ) up-regulates the vascular endothelial growth 
16 decorin ( dcn ) up-regulates the vascular endothelial growth 
0 up-regulates the vascular endothelial growth factor ( vegf ) 
9 factor ( vegf ) expression with activation of vegf 
17 vegf ) expression with activation of vegf regulating transcription 
16 vegf ) expression with activation of vegf regulating transcription 
16 with activation of vegf regulating transcription factors sp1 , 
0 activation of vegf regulating transcription factors sp1 , hypoxia-inducible 
0 transcription factors sp1 , inducible factor 1alpha ( hif1alpha 
0 and signal transducer and activator of transcription 3 ( 
0 transducer and activator of transcription 3 ( stat3 ) 
0 stat3 ) via epidermal growth factor receptor ( egfr 
0 ( egfr ) , activated protein kinase extracellular signal-regulated 
0 egfr ) , mitogen-activated protein kinase extracellular signal-regulated kinase 
0 mitogen-activated protein kinase extracellular regulated kinase 1/2 ( erk1/2 
0 erk1/2 ) , and protein kinase b ( akt 
0 b ( akt ) pathways in dcn transfected mouse 
19 ) pathways in dcn transfected mouse cerebral endothelial ( 
0 NULL NULL NULL NULL treatment with pharmacological inhibitors and 
17 interfering rnas reveal that induction and activation of sp1 
17 reveal that induction and activation of sp1 , hif1alpha 
14 stat3 facilitate their nuclear localization and binding to their 
15 their nuclear localization and binding to their specific motifs 
17 the vegf promoter and induce vegf expression via two 
9 promoter and induce vegf expression via two independent pathways 
0 vegf expression via two independent pathways , dcn/egfr/phosphoinositide-3 kinase/akt 
0 expression via two independent pathways , dcn/egfr/phosphoinositide-3 kinase/akt and 
9 respectively , in dcn synthesizing mce cells . NULL 
18 cell type specific glycosylation protects sp1 and hif1alpha from 
11 and hif1alpha from proteosome degradation and plays an important 
0 from proteosome degradation and plays an important and novel 
0 degradation and plays an important and novel role in 
0 an important and novel role in the regulation of 
16 novel role in the regulation of vegf in dcn 
19 of vegf in dcn transfected mce cells . NULL 
17 NULL NULL NULL NULL induction of gelatinases ( matrix 
0 induction of gelatinases ( matrix metalloproteinase 2 and 9 
0 serine protease tissue plasminogen activator and plasmin by dcn 
19 and plasmin by dcn transfection in mce cells leads 
17 transfection in mce cells leads to extracellular proteolysis and 
0 cells leads to extracellular proteolysis and to release of 
0 extracellular proteolysis and to release of matrix-bound vegf and 
15 and to release of matrix vegf and activation of 
15 and to release of bound vegf and activation of 
17 of matrix-bound vegf and activation of angiogenesis . NULL 
3 vegf and activation of angiogenesis . NULL NULL NULL 
0 we demonstrate that two independent downstream signal pathways , 
0 demonstrate that two independent downstream signal pathways , dcn/egfr/erk1/2 
0 two independent downstream signal pathways , dcn/egfr/erk1/2 and dcn/egfr/phosphoinositide-3 
17 and dcn/egfr/phosphoinositide-3 kinase/akt , mediate up-regulation and activation of 
17 dcn/egfr/phosphoinositide-3 kinase/akt , mediate up-regulation and activation of transcription 
17 , mediate up-regulation and activation of transcription factors of 
0 up-regulation and activation of transcription factors of vegf such 
17 , and sp1 and increase vegf transcription and angiogenesis 
10 sp1 and increase vegf transcription and angiogenesis in mce 
3 increase vegf transcription and angiogenesis in mce cells . 
0 NULL NULL NULL NULL tumor microenvironment , a dangerous 
0 , a dangerous society leading to cancer metastasis . 
14 society leading to cancer metastasis . NULL NULL NULL 
0 NULL from mechanisms to therapy and prevention . NULL 
0 mechanisms to therapy and prevention . NULL NULL NULL 
4 NULL NULL NULL to grow , invade and metastasize 
14 NULL to grow , invade and metastasize , a 
14 grow , invade and metastasize , a treacherous society 
0 host cells must be formed , and this association 
0 formed , and this association provides novel and effective 
0 association provides novel and effective clinical targets for cancer 
0 provides novel and effective clinical targets for cancer control 
0 novel and effective clinical targets for cancer control and 
16 clinical targets for cancer control and prevention . NULL 
18 for cancer control and prevention . NULL NULL NULL 
0 scientific knowledge focuses on tumor cell interactions , the 
15 focuses on host-tumor cell interactions , the disastrous consequences 
0 disastrous consequences they can produce and approaches the ways 
0 , to leave the tumor cells unattended and vulnerable 
16 NULL NULL NULL NULL effects of spironolactone on corneal 
5 spironolactone on corneal allograft survival in the rat . 
0 shown to have suppressive effects on several immunoactive and 
16 , we investigated the effects of spironolactone on the 
18 of spironolactone on the prevention of corneal allograft rejection 
5 prevention of corneal allograft rejection in a mhc class 
19 i/ii mismatch rat corneal transplant model . NULL NULL 
0 NULL NULL methods : grafted animals for corneal survival 
5 grafted animals for corneal survival analysis were assigned to 
0 9 ) or remained untreated ( n = 16 
19 NULL NULL NULL additional grafted rats treated with spironolactone 
19 NULL additional grafted rats treated with spironolactone ( n 
19 = 8 ) were sacrificed on day 12 for 
0 NULL NULL NULL NULL results : mean ( +/-sem 
5 ( +/-sem ) graft survival was significantly prolonged in 
17 graft survival was significantly prolonged in animals receiving spironolactone 
19 significantly prolonged in animals receiving spironolactone ( 14.9 +/- 
19 ) compared with both treated ( 12.3 +/- 1.2 
19 = 0.007 ) and untreated controls ( 13.0 +/- 
0 0.007 ) and untreated controls ( 13.0 +/- 1.0 
18 NULL we found a decrease in corneal neovascularization in 
3 a decrease in corneal neovascularization in spironolactone-treated rats compared 
19 in corneal neovascularization in treated rats compared with the 
19 rats compared with the treated group , although the 
0 difference was not statistically significant . NULL NULL NULL 
16 NULL NULL NULL spironolactone affected both systemic ( down-regulation 
18 affected both systemic ( down-regulation of cd25+ cells in 
0 ) and local immune response ( up-regulation of il-10 
17 local immune response ( up-regulation of il-10 in cornea 
0 NULL conclusion : we present initial results demonstrating anti-inflammatory 
0 : we present initial results demonstrating anti-inflammatory effects of 
0 initial results demonstrating anti-inflammatory effects of spironolactone . NULL 
0 NULL NULL NULL [ photodynamic therapy in severe chronic 
0 NULL NULL [ photodynamic therapy in severe chronic central 
0 therapy in severe chronic central serous chorioretinopaty ] NULL 
0 : to determine the efficacy of photodynamic therapy ( 
0 determine the efficacy of photodynamic therapy ( pdt ) 
0 the efficacy of photodynamic therapy ( pdt ) in 
0 of photodynamic therapy ( pdt ) in chronic central 
0 pdt ) in chronic central serous chorioretinopathy ( csc 
0 chronic csc , with clinical evidence of activity and 
0 with clinical evidence of activity and treated with photodynamic 
19 evidence of activity and treated with photodynamic therapy , 
0 activity and treated with photodynamic therapy , are included 
0 and treated with photodynamic therapy , are included in 
0 , fluorescein and indocyanine angiography and optical coherence tomography 
0 the mean visual acuity change . NULL NULL NULL 
0 NULL NULL NULL NULL results : 11 eyes of 
0 NULL the mean bcva increased from 20/76 to 20/64 
17 35 % of eyes improved their bcva by 2 
0 NULL choroidal hyperpermeability was reduced in every case . 
0 NULL NULL neurosensorial retinal detachment decreased in 80 % 
0 NULL neurosensorial retinal detachment decreased in 80 % of 
0 NULL only one eye received a second pdt treatment 
19 eye received a second pdt treatment due to choroidal 
19 received a second pdt treatment due to choroidal neovascularization 
3 treatment due to choroidal neovascularization . NULL NULL NULL 
17 NULL NULL NULL an increase of atrophy over the 
0 ( rpe ) was observed in another patient . 
0 NULL NULL conclusions : pdt can reduce the clinical 
0 conclusions : pdt can reduce the clinical signs of 
0 pdt can reduce the clinical signs of activity , 
0 the clinical signs of activity , such as choroidal 
0 hyperpermeability or neurosensorial retinal detachment , in patients affected 
0 detachment , in patients affected by chronic csc . 
0 NULL however , the increase in visual acuity is 
0 the extent of rpe damage . NULL NULL NULL 
18 NULL NULL NULL angiopoietin-1 prevents vegf-induced endothelial permeability by 
17 NULL NULL angiopoietin-1 prevents induced endothelial permeability by sequestering 
18 vegf-induced endothelial permeability by sequestering src through mdia . 
16 vegf-induced endothelial permeability by sequestering src through mdia . 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
3 ) are both potent angiogenic factors , but , 
16 vascular permeability , ang1 stabilizes blood vessels and protects 
18 stabilizes blood vessels and protects them from vegf-induced plasma 
17 and protects them from induced plasma leakage . NULL 
14 them from vegf-induced plasma leakage . NULL NULL NULL 
18 we demonstrate that ang1 halts the ability of vegf 
0 that ang1 halts the ability of vegf to induce 
17 ability of vegf to induce the phosphorylation-dependent redistribution of 
12 vegf to induce the phosphorylation redistribution of the adhesion 
17 vegf to induce the dependent redistribution of the adhesion 
14 to induce the phosphorylation-dependent redistribution of the adhesion molecule 
0 phosphorylation-dependent redistribution of the adhesion molecule ve-cadherin , thereby 
0 rescuing the endothelial barrier function . NULL NULL NULL 
18 NULL NULL NULL ang1 inhibits the activation of src 
17 NULL ang1 inhibits the activation of src by vegf 
14 vegf receptors to ve-cadherin internalization . NULL NULL NULL 
17 NULL indeed , ang1 promotes the activation of mdia 
16 NULL indeed , ang1 promotes the activation of mdia 
17 , ang1 promotes the activation of mdia through rhoa 
17 mdia through rhoa , resulting in the association of 
15 , resulting in the association of mdia with src 
0 vegf receptors of an essential molecule required for promoting 
17 of an essential molecule required for promoting the disruption 
17 essential molecule required for promoting the disruption of endothelial 
18 required for promoting the disruption of endothelial cell-cell contacts 
15 the disruption of endothelial cell-cell contacts and paracellular permeability 
15 disruption of endothelial cell-cell contacts and paracellular permeability . 
0 the retinopathy is often associated with migraine , raynaud 
0 's phenomenon and mental changes , mainly forgetfulness , 
0 define this syndrome we collected medical data on 110 
19 ophthalmological examination and fluorescein angiography were performed in 61 
0 , is characterized by central and peripheral microangiopathy , 
0 , areas of capillary perfusion , haemorrhages , cotton 
17 vessels , which can induce a neovascular response . 
3 which can induce a neovascular response . NULL NULL 
3 can induce a neovascular response . NULL NULL NULL 
18 NULL NULL NULL NULL suppression of lung tumor growth 
0 NULL suppression of lung tumor growth and metastasis in 
4 suppression of lung tumor growth and metastasis in mice 
14 lung tumor growth and metastasis in mice by adeno-associated 
0 metastasis in mice by associated virus-mediated expression of vasostatin 
17 in mice by adeno-associated mediated expression of vasostatin . 
9 mice by adeno-associated virus-mediated expression of vasostatin . NULL 
3 NULL NULL purpose : angiogenesis inhibitors have strong therapeutic 
0 inhibitors have strong therapeutic potential as antitumor agents in 
18 as antitumor agents in suppressing tumor growth and metastatic 
0 antitumor agents in suppressing tumor growth and metastatic progression 
4 agents in suppressing tumor growth and metastatic progression . 
2 suppressing tumor growth and metastatic progression . NULL NULL 
2 tumor growth and metastatic progression . NULL NULL NULL 
3 , is a potent angiogenesis inhibitor . NULL NULL 
0 is a potent angiogenesis inhibitor . NULL NULL NULL 
16 , we determined the effectiveness of vasostatin delivered by 
19 the effectiveness of vasostatin delivered by recombinant pseudotype adeno-associated 
0 delivered by recombinant pseudotype associated virus 2/5 ( raav2/5-vas 
19 ) as a gene therapy approach for lung cancer 
0 approach for lung cancer treatment . NULL NULL NULL 
0 experimental design : we used raav2/5 to deliver vasostatin 
19 we used raav2/5 to deliver vasostatin intratumorally or systemically 
0 in different mouse lung tumor models -- subcutaneous , 
0 xenograft , and spontaneous metastasis lung tumor models . 
0 and spontaneous metastasis lung tumor models . NULL NULL 
0 NULL NULL the therapeutic efficacy of raav2/5-vas was determined 
0 was determined by monitoring tumor volume , survival rate 
0 monitoring tumor volume , survival rate , and degree 
3 , and degree of neovascularization after treatment in these 
0 degree of neovascularization after treatment in these models . 
0 NULL NULL NULL NULL results : mice bearing subcutaneous 
0 : mice bearing subcutaneous tumor of raav2/5-vas pretreated lewis 
19 subcutaneous tumor of raav2/5-vas pretreated lewis lung carcinoma cells 
0 lewis lung carcinoma cells showed > 50 % reduction 
18 showed > 50 % reduction in primary tumor volume 
0 % reduction in primary tumor volume and reduced spontaneous 
18 primary tumor volume and reduced spontaneous pulmonary metastases . 
14 and reduced spontaneous pulmonary metastases . NULL NULL NULL 
18 NULL NULL NULL the tumor-suppressive action of raav2/5-vas in 
18 NULL NULL the tumor-suppressive action of raav2/5-vas in subcutaneous 
0 in subcutaneous human lung tumor a549 xenograft correlated with 
18 xenograft correlated with a reduced number of capillary vessels 
18 xenograft model , raav2/5-vas suppressed metastasis of a549 tumors 
14 model , raav2/5-vas suppressed metastasis of a549 tumors to 
19 NULL NULL furthermore , treatment of immunocompetent mice in 
0 in the spontaneous lung metastases model with raav2/5-vas after 
0 with raav2/5-vas after primary tumor excision prolonged their median 
19 raav2/5-vas after primary tumor excision prolonged their median survival 
0 after primary tumor excision prolonged their median survival from 
0 excision prolonged their median survival from 21 to 51.5 
0 NULL conclusion : our results show the effectiveness of 
18 our results show the effectiveness of raav2/5-vas as an 
3 of raav2/5-vas as an angiogenesis inhibitor in suppressing tumor 
0 raav2/5-vas as an angiogenesis inhibitor in suppressing tumor growth 
18 an angiogenesis inhibitor in suppressing tumor growth during different 
0 angiogenesis inhibitor in suppressing tumor growth during different stages 
4 inhibitor in suppressing tumor growth during different stages of 
0 during different stages of tumor progression , validating the 
2 different stages of tumor progression , validating the application 
0 progression , validating the application of raav2/5-vas gene therapy 
19 application of raav2/5-vas gene therapy in treatment against lung 
0 raav2/5-vas gene therapy in treatment against lung cancer . 
0 NULL NULL NULL NULL radiation retinopathy is treatable with 
0 treatable with anti-vascular endothelial growth factor bevacizumab ( avastin 
19 to report on bevacizumab treatment for radiation retinopathy affecting 
0 on bevacizumab treatment for radiation retinopathy affecting the macula 
16 treatment for radiation retinopathy affecting the macula . NULL 
0 : twenty-one patients with radiation retinopathy ( edema , 
3 capillary dropout , and neovascularization ) and a subjective 
0 a subjective or objective loss of vision were treated 
0 loss of vision were treated . NULL NULL NULL 
0 NULL NULL NULL NULL treatment involved intravitreal injection of 
0 NULL NULL NULL treatment involved intravitreal injection of bevacizumab 
19 NULL NULL treatment involved intravitreal injection of bevacizumab ( 
19 NULL treatment involved intravitreal injection of bevacizumab ( 1.25 
0 NULL NULL NULL NULL treatment was discontinued at patient 
0 NULL NULL treatment was discontinued at patient request or 
0 there was no measurable response to therapy . NULL 
0 no measurable response to therapy . NULL NULL NULL 
0 retinal photography , and angiography . NULL NULL NULL 
0 NULL NULL NULL NULL results : bevacizumab treatment was 
19 NULL results : bevacizumab treatment was followed by reductions 
0 acuities were stable or improved in 86 % ( 
0 NULL NULL three patients discontinued therapy . NULL NULL 
0 NULL three patients discontinued therapy . NULL NULL NULL 
0 was legally blind before treatment ( n=1 ) , 
0 or systemic bevacizumab-related side effects were observed . NULL 
0 bevacizumab-related side effects were observed . NULL NULL NULL 
0 NULL NULL conclusions : intravitreal bevacizumab can be used 
0 intravitreal bevacizumab can be used to treat radiation retinopathy 
0 can be used to treat radiation retinopathy . NULL 
0 be used to treat radiation retinopathy . NULL NULL 
0 NULL in most cases treatment was associated with decreased 
0 most cases treatment was associated with decreased vascular leakage 
0 treatment was associated with decreased vascular leakage , stabilization 
0 associated with decreased vascular leakage , stabilization , or 
0 decreased vascular leakage , stabilization , or improved vision 
0 , stabilization , or improved vision . NULL NULL 
0 NULL an anti-vascular endothelial growth factor strategy may reduce 
18 growth factor strategy may reduce tissue damage associated with 
6 strategy may reduce tissue damage associated with radiation vasculopathy 
0 may reduce tissue damage associated with radiation vasculopathy and 
0 tissue damage associated with radiation vasculopathy and neuropathy . 
0 NULL NULL NULL NULL activated protein kinase kinase signaling 
0 NULL NULL NULL mitogen-activated protein kinase kinase signaling promotes 
17 protein kinase kinase signaling promotes growth and vascularization of 
4 kinase kinase signaling promotes growth and vascularization of fibrosarcoma 
3 signaling promotes growth and vascularization of fibrosarcoma . NULL 
0 that signaling through multiple activated protein kinase ( mapk 
0 signaling through multiple mitogen-activated protein kinase ( mapk ) 
0 kinase ( mkk ) pathways is essential for the 
17 mkk ) pathways is essential for the growth and 
4 is essential for the growth and vascularization of soft-tissue 
3 for the growth and vascularization of soft-tissue sarcomas , 
0 sarcomas , which are malignant tumors derived from mesenchymal 
0 which are malignant tumors derived from mesenchymal tissues . 
0 nci , and shac derived cell lines and anthrax 
18 a bacterial toxin that inactivates mkks . NULL NULL 
19 blots confirmed that letx treatment reduced the levels of 
18 confirmed that letx treatment reduced the levels of phosphorylated 
0 letx treatment reduced the levels of phosphorylated extracellular signal-regulated 
12 reduced the levels of phosphorylated extracellular signal-regulated kinase and 
0 levels of phosphorylated extracellular regulated kinase and p38 mapk 
19 NULL NULL although short treatments with letx only modestly 
16 with letx only modestly affected cell proliferation , sustained 
1 only modestly affected cell proliferation , sustained treatment markedly 
0 cell proliferation , sustained treatment markedly reduced cell numbers 
0 , sustained treatment markedly reduced cell numbers . NULL 
18 NULL letx also substantially inhibited the extracellular release of 
14 substantially inhibited the extracellular release of angioproliferative factors including 
3 the extracellular release of angioproliferative factors including vascular endothelial 
0 factors including vascular endothelial growth factor , interleukin-8 , 
0 , and basic fibroblast growth factor . NULL NULL 
0 NULL NULL NULL similar results were obtained with cell 
0 NULL similar results were obtained with cell lines derived 
0 obtained with cell lines derived from malignant fibrous histiocytomas 
0 cell lines derived from malignant fibrous histiocytomas , leiomyosarcomas 
18 in vivo , letx decreased mapk activity and blocked 
0 , letx decreased mapk activity and blocked fibrosarcoma growth 
18 decreased mapk activity and blocked fibrosarcoma growth . NULL 
4 activity and blocked fibrosarcoma growth . NULL NULL NULL 
4 NULL NULL NULL NULL growth inhibition correlated with decreased 
18 NULL NULL NULL growth inhibition correlated with decreased cellular 
0 growth inhibition correlated with decreased cellular proliferation and extensive 
1 correlated with decreased cellular proliferation and extensive necrosis , 
0 cellular proliferation and extensive necrosis , and it was 
18 was accompanied by a decrease in tumor mean vessel 
0 by a decrease in tumor mean vessel density as 
18 as well as a reduction in serum expression of 
0 a reduction in serum expression of angioproliferative cytokines . 
3 in serum expression of angioproliferative cytokines . NULL NULL 
0 imaging using high-resolution ultrasound enhanced with contrast microbubbles revealed 
16 microbubbles revealed that the effects of letx on tumor 
0 effects of letx on tumor perfusion were remarkably rapid 
2 of letx on tumor perfusion were remarkably rapid ( 
17 24 h ) and resulted in a marked reduction 
18 resulted in a marked reduction of perfusion within the 
2 a marked reduction of perfusion within the tumor but 
0 of perfusion within the tumor but not in nontumor 
0 NULL NULL NULL these results are consistent with our 
0 our initial hypothesis and lead us to propose that 
18 to propose that mkk inhibition by letx is a 
0 letx is a broadly effective strategy for targeting neovascularization 
16 broadly effective strategy for targeting neovascularization in fibrosarcomas and 
3 effective strategy for targeting neovascularization in fibrosarcomas and other 
0 fibrosarcomas and other similar proliferative lesions . NULL NULL 
19 NULL NULL acute ethanol exposure disrupts vegf receptor cell 
18 NULL acute ethanol exposure disrupts vegf receptor cell signaling 
3 NULL NULL NULL physiological angiogenesis is regulated by various 
16 NULL physiological angiogenesis is regulated by various factors , 
0 signaling through vascular endothelial growth factor ( vegf ) 
18 100 mg/dl , significantly impairs angiogenesis in murine wounds 
3 mg/dl , significantly impairs angiogenesis in murine wounds , 
0 wounds , despite adequate levels of vegf , suggesting 
0 of vegf , suggesting direct effects of ethanol on 
16 vegf , suggesting direct effects of ethanol on endothelial 
0 NULL to examine the mechanism by which ethanol influences 
16 mechanism by which ethanol influences angiogenesis in wounds , 
3 by which ethanol influences angiogenesis in wounds , we 
3 two different in vitro angiogenesis assays to determine whether 
19 determine whether acute ethanol exposure ( 100 mg/dl ) 
16 ) would have long-lasting effects on vegf-induced capillary network 
17 have long-lasting effects on induced capillary network formation . 
2 on vegf-induced capillary network formation . NULL NULL NULL 
19 NULL NULL NULL ethanol exposure resulted in reduced vegf-induced 
17 NULL NULL ethanol exposure resulted in reduced vegf-induced cord 
18 ethanol exposure resulted in reduced vegf-induced cord formation on 
17 exposure resulted in reduced induced cord formation on collagen 
2 in reduced vegf-induced cord formation on collagen and reduced 
18 formation on collagen and reduced capillary network structure on 
0 NULL NULL NULL in addition , ethanol exposure decreased 
19 in addition , ethanol exposure decreased expression of endothelial 
18 addition , ethanol exposure decreased expression of endothelial vegf 
9 , ethanol exposure decreased expression of endothelial vegf receptor-2 
12 well as vegf receptor-2 phosphorylation in vitro . NULL 
18 NULL NULL NULL NULL inhibition of ethanol metabolism by 
18 metabolism by 4-methylpyrazole partially abrogated the effect of ethanol 
16 4-methylpyrazole partially abrogated the effect of ethanol on endothelial 
2 on endothelial cell cord formation . NULL NULL NULL 
19 NULL however , mice treated with t-butanol , an 
17 , an alcohol not metabolized by alcohol dehydrogenase , 
0 by alcohol dehydrogenase , exhibited no change in wound 
0 dehydrogenase , exhibited no change in wound vascularity . 
0 NULL NULL NULL these results suggest that products of 
16 of ethanol metabolism are important factors in the development 
0 important factors in the development of ethanol-induced changes in 
17 in the development of induced changes in endothelial cell 
16 the development of ethanol-induced changes in endothelial cell responsiveness 
16 changes in endothelial cell responsiveness to vegf . NULL 
19 in vivo , ethanol exposure caused both decreased angiogenesis 
0 vivo , ethanol exposure caused both decreased angiogenesis and 
18 ethanol exposure caused both decreased angiogenesis and increased hypoxia 
3 exposure caused both decreased angiogenesis and increased hypoxia in 
0 both decreased angiogenesis and increased hypoxia in wounds . 
0 vitro experiments demonstrated a direct effect of ethanol on 
0 experiments demonstrated a direct effect of ethanol on the 
0 of ethanol on the response to hypoxia in endothelial 
18 cells , as ethanol diminished nuclear hypoxia-inducible factor-1alpha protein 
0 as ethanol diminished nuclear inducible factor-1alpha protein levels . 
0 diminished nuclear hypoxia-inducible factor-1alpha protein levels . NULL NULL 
0 nuclear hypoxia-inducible factor-1alpha protein levels . NULL NULL NULL 
19 establish that acute ethanol exposure significantly impairs angiogenesis and 
18 acute ethanol exposure significantly impairs angiogenesis and suggest that 
3 ethanol exposure significantly impairs angiogenesis and suggest that this 
0 and suggest that this effect is mediated by changes 
16 that this effect is mediated by changes in endothelial 
16 effect is mediated by changes in endothelial cell responsiveness 
16 changes in endothelial cell responsiveness to both vegf and 
19 NULL NULL NULL NULL hepatectomy was performed , and 
0 patient is alive and free of disease 1 year 
0 grossly , the tumour showed a haemorrhagic cut surface 
3 examination revealed cystic or angiomatoid spaces of various sizes 
19 , low-columnar , or flattened epithelioid cells with vacuolated 
0 epithelioid cells were entirely supported by proliferated capillaries and 
4 were entirely supported by proliferated capillaries and arteries together 
0 NULL NULL NULL NULL immunohistochemical studies showed that the 
0 NULL NULL immunohistochemical studies showed that the epithelioid cells 
0 epithelioid cells were strongly positive for a broad spectrum 
0 NULL these cells were negative for hep par-1 , 
0 antigen , neural cell adhesion molecule , cd34 , 
0 NULL NULL atypically , abundant capillaries were observed ; 
0 , abundant capillaries were observed ; however , the 
1 however , the cystic proliferation of epithelioid cells with 
0 cells with vacuoles and immunohistochemical profile of the epithelioid 
3 , is a potent angiogenesis inhibitor . NULL NULL 
0 is a potent angiogenesis inhibitor . NULL NULL NULL 
0 NULL NULL NULL at present , there are a 
0 NULL however , the action mechanism of endostatin is 
0 however , the action mechanism of endostatin is still 
0 its structure basis of activity and action mechanisms based 
0 basis of activity and action mechanisms based on the 
3 published studies reporting the angiogenic effects of endostatin-derived peptides 
18 studies reporting the antiangiogenic effects of endostatin-derived peptides were 
0 the antiangiogenic effects of derived peptides were also reviewed 
3 of endostatin contains both angiosuppressive and angiostimulatory domains . 
3 contains both angiosuppressive and angiostimulatory domains . NULL NULL 
3 exploited as a new angiogenesis inhibitor for therapeutic applications 
0 as a new angiogenesis inhibitor for therapeutic applications , 
0 understanding of the molecular action mechanisms of endostatin . 
0 NULL the tyrosine kinase inhibitor cediranib blocks ligand-induced vascular 
18 tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth 
17 kinase inhibitor cediranib blocks induced vascular endothelial growth factor 
0 blocks ligand-induced vascular endothelial growth factor receptor-3 activity and 
0 endothelial growth factor receptor-3 activity and lymphangiogenesis . NULL 
0 factor receptor-3 activity and angiogenesis . NULL NULL NULL 
0 NULL NULL solid tumors express a range of factors 
0 a range of factors required to sustain their growth 
0 required to sustain their growth and promote their dissemination 
0 sustain their growth and promote their dissemination . NULL 
0 growth and promote their dissemination . NULL NULL NULL 
0 these are vascular endothelial growth factor-a ( vegf-a ) 
0 vegf-a ) , the key angiogenic stimulant , and 
3 ) , the key angiogenic stimulant , and vegf-c 
0 vegf-c , a primary mediator of lymphangiogenesis . NULL 
0 a primary mediator of angiogenesis . NULL NULL NULL 
0 kinase inhibitors offer the potential to inhibit more than 
0 offer the potential to inhibit more than one kinase 
18 than one kinase and impede tumor growth by multiple 
0 one kinase and impede tumor growth by multiple mechanisms 
4 kinase and impede tumor growth by multiple mechanisms . 
0 their potency toward individual targets can vary . NULL 
0 azd2171 ) is an inhibitor of vegf signaling that 
18 in experimental models to prevent vegf-a-induced angiogenesis and primary 
17 experimental models to prevent induced angiogenesis and primary tumor 
3 models to prevent vegf-a-induced angiogenesis and primary tumor growth 
0 vegf-a-induced angiogenesis and primary tumor growth , yet the 
4 angiogenesis and primary tumor growth , yet the effects 
16 growth , yet the effects of cediranib on vegf 
16 receptor ( vegfr ) mediated endothelial cell function and 
0 ) -3-mediated endothelial cell function and lymphangiogenesis are unknown 
0 endothelial cell function and angiogenesis are unknown . NULL 
0 to better understand the activity of cediranib against vegfr-3 
0 against vegfr-3 and its associated signaling events compared with 
0 events compared with its activity against vegfr-2 , we 
0 against vegfr-2 , we used the receptor-specific ligands vegf-e 
18 endothelial cells , cediranib inhibited vegf-e-induced phosphorylation of vegfr-2 
17 cells , cediranib inhibited induced phosphorylation of vegfr-2 and 
12 , cediranib inhibited vegf-e-induced phosphorylation of vegfr-2 and vegf-c156s-induced 
17 phosphorylation of vegfr-2 and induced phosphorylation of vegfr-3 at 
12 of vegfr-2 and vegf-c156s-induced phosphorylation of vegfr-3 at concentrations 
0 less than /=1nmol/l and inhibited activation of downstream signaling 
0 than /=1nmol/l and inhibited activation of downstream signaling molecules 
0 and inhibited activation of downstream signaling molecules . NULL 
18 NULL additionally , cediranib blocked vegf-c156s-induced and vegf-e-induced proliferation 
17 additionally , cediranib blocked induced and vegf-e-induced proliferation , 
17 cediranib blocked vegf-c156s-induced and induced proliferation , survival , 
1 blocked vegf-c156s-induced and vegf-e-induced proliferation , survival , and 
5 and vegf-e-induced proliferation , survival , and migration of 
14 , survival , and migration of lymphatic and blood 
18 ( 6 mg/kg/d ) prevented angiogenesis and lymphangiogenesis induced 
3 6 mg/kg/d ) prevented angiogenesis and lymphangiogenesis induced by 
0 ) prevented angiogenesis and angiogenesis induced by vegf-e-expressing and 
17 prevented angiogenesis and lymphangiogenesis induced by vegf-e-expressing and vegf-c156s-expressing 
9 and lymphangiogenesis induced by expressing and vegf-c156s-expressing adenoviruses , 
9 induced by vegf-e-expressing and expressing adenoviruses , respectively . 
18 6 mg/kg/day ) also blocked angiogenesis and lymphangiogenesis induced 
3 mg/kg/day ) also blocked angiogenesis and lymphangiogenesis induced by 
0 also blocked angiogenesis and angiogenesis induced by adenoviruses expressing 
0 blocked angiogenesis and lymphangiogenesis induced by adenoviruses expressing vegf-a 
9 lymphangiogenesis induced by adenoviruses expressing vegf-a or vegf-c and 
9 and lymphatic vasculatures of expressing tumors . NULL NULL 
0 therefore , be an effective means of preventing tumor 
18 an effective means of preventing tumor progression , not 
0 effective means of preventing tumor progression , not only 
2 means of preventing tumor progression , not only by 
18 , not only by inhibiting vegfr-2 activity and angiogenesis 
0 only by inhibiting vegfr-2 activity and angiogenesis , but 
3 inhibiting vegfr-2 activity and angiogenesis , but also by 
18 but also by concomitantly inhibiting vegfr-3 activity and lymphangiogenesis 
0 by concomitantly inhibiting vegfr-3 activity and lymphangiogenesis . NULL 
0 inhibiting vegfr-3 activity and angiogenesis . NULL NULL NULL 
19 perspectives on vital pulp therapy : views from the 
19 endodontists at a pulp therapy symposium conjointly sponsored by 
0 sponsored by the american association of endodontists ( aae 
0 and postsymposium tests were administered , and respondent answers 
19 were sought : pulp therapy for cariously involved primary 
0 pulp therapy for cariously involved primary teeth ; indirect 
19 teeth ; indirect pulp treatment ( ipt ) for 
0 ipt ) for cariously involved immature permanent teeth ; 
0 teeth ; and innovative treatment options including pulpal revascularization 
3 treatment options including pulpal revascularization and regeneration . NULL 
2 including pulpal revascularization and regeneration . NULL NULL NULL 
0 NULL NULL NULL NULL results were analyzed with chi2 
19 is an acceptable pulp therapy technique for cariously involved 
0 therapy technique for cariously involved young permanent teeth . 
3 groups believe that pulp revascularization and regeneration will be 
2 that pulp revascularization and regeneration will be viable treatment 
0 regeneration will be viable treatment modalities in the future 
0 share common language and treatment recommendations for pulp therapies 
19 treatment recommendations for pulp therapies performed by both specialties 
16 NULL NULL NULL the role of platelet-derived endothelial cell 
0 NULL the role of derived endothelial cell growth factor/thymidine 
0 of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor 
0 growth factor/thymidine phosphorylase in tumor behavior . NULL NULL 
0 NULL NULL NULL NULL derived endothelial cell growth-factor ( 
0 NULL platelet-derived endothelial cell growth ( pd-ecgf ) is 
9 NULL a high tp expression at tumor sites is 
0 high tp expression at tumor sites is correlated with 
0 sites is correlated with tumor growth , induction of 
4 is correlated with tumor growth , induction of angiogenesis 
17 with tumor growth , induction of angiogenesis , and 
3 growth , induction of angiogenesis , and metastasis . 
0 of angiogenesis , and metastasis . NULL NULL NULL 
0 tp is most likely associated with a poor prognosis 
9 tp is not only expressed in tumor cells but 
0 not only expressed in tumor cells but also in 
0 cells but also in tumor surrounding tissues , such 
0 tissues , such as tumor infiltrating macrophages . NULL 
0 , such as tumor infiltrating macrophages . NULL NULL 
16 NULL NULL NULL tp catalyzes the conversion of thymidine 
0 latter in its parent form or in its sugar 
0 or in its sugar form , deoxyribose ( dr 
16 ( dr ) may play a role in the 
16 ) may play a role in the induction of 
17 a role in the induction of angiogenesis . NULL 
3 in the induction of angiogenesis . NULL NULL NULL 
0 NULL NULL it may modulate cellular energy metabolism or 
0 in a chemical reaction generating reactive oxygen species . 
0 ) and thymidine phosphorylase inhibitor ( tpi ) can 
0 ) can reverse these effects . NULL NULL NULL 
0 NULL NULL NULL the mechanism of tp induction is 
17 the mechanism of tp induction is not yet completely 
17 been clearly shown to induce its expression . NULL 
9 shown to induce its expression . NULL NULL NULL 
0 NULL the various complex interactions of tp give it 
0 tp give it an essential role in cellular functioning 
0 give it an essential role in cellular functioning and 
0 it is an ideal target in cancer therapy . 
0 ideal target in cancer therapy . NULL NULL NULL 
19 NULL NULL NULL allogeneic injection of fetal membrane-derived mesenchymal 
0 allogeneic injection of fetal derived mesenchymal stem cells induces 
17 membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a 
3 stem cells induces therapeutic angiogenesis in a rat model 
0 NULL NULL NULL bone derived mesenchymal stem cells ( 
2 cell source for tissue regeneration and repair . NULL 
2 for tissue regeneration and repair . NULL NULL NULL 
19 whether or not allogeneic transplantation of mesenchymal stem cells 
0 cells ( msc ) derived from fetal membranes ( 
0 as medical waste after delivery , has therapeutic potential 
0 delivery , has therapeutic potential . NULL NULL NULL 
19 NULL NULL fm-msc were obtained from lewis rats and 
0 and had surface antigen expression and multipotent potential partly 
0 antigen expression and multipotent potential partly similar to those 
14 with bm-msc , fm-msc secreted a comparable amount of 
0 comparable amount of hepatocyte growth factor despite a small 
0 amount of vascular endothelial growth factor . NULL NULL 
0 fm-msc and bm-msc both expressed major histocompatibility complex ( 
0 and bm-msc both expressed major histocompatibility complex ( mhc 
0 antigens and did not elicit allogeneic lymphocyte proliferation in 
1 not elicit allogeneic lymphocyte proliferation in mixed lymphocyte culture 
0 proliferation in mixed lymphocyte culture . NULL NULL NULL 
19 NULL fm-msc or bm-msc obtained from lewis rats were 
19 from lewis rats were injected into a mhc-mismatched august-copenhagen-irish 
0 NULL three weeks after injection , blood perfusion and 
0 after injection , blood perfusion and capillary density were 
19 and bm-msc were still observed . NULL NULL NULL 
19 allogeneic fm-msc and bm-msc injection were associated with a 
0 and bm-msc injection were associated with a comparatively small 
14 amount of t lymphocyte infiltration , compared with the 
19 , compared with the injection of allogeneic splenic lymphocytes 
19 conclusion , allogeneic fm-msc injection did not elicit a 
17 fm-msc injection did not elicit a lymphocyte proliferative response 
1 not elicit a lymphocyte proliferative response and provided significant 
1 elicit a lymphocyte proliferative response and provided significant improvement 
0 proliferative response and provided significant improvement in a rat 
0 , comparable to the response to bm-msc . NULL 
19 NULL thus , allogeneic injection of fm-msc may be 
0 therapeutic strategy for the treatment of severe peripheral vascular 
0 NULL NULL disclosure of potential conflicts of interest is 
19 NULL bevacizumab and irinotecan therapy in glioblastoma multiforme : 
1 NULL object : endothelial proliferation has been recognized as 
0 antibody to vascular endothelial growth factor that has been 
16 been shown to have activity in malignant gliomas when 
0 to have activity in malignant gliomas when combined with 
19 patients with recurrent heavily pretreated malignant glioma that was 
0 with recurrent heavily pretreated malignant glioma that was treated 
19 malignant glioma that was treated with the combination of 
0 NULL methods : standard therapy with primary resection followed 
0 standard therapy with primary resection followed by adjuvant chemotherapy 
19 resection followed by adjuvant chemotherapy and radiation had failed 
19 by adjuvant chemotherapy and radiation had failed in all 
0 the median number of therapies applied , including initial 
0 applied , including initial surgery , was 5 ( 
0 5 ( range 3-7 therapies ) . NULL NULL 
19 NULL nine patients were started on bevacizumab at a 
19 NULL NULL four patients received bevacizumab at a dose 
19 mg/m2 ; irinotecan was given at a dose of 
0 NULL NULL NULL NULL results : of the 13 
19 : of the 13 treated patients , 10 ( 
0 a radiologically demonstrated partial response and 3 ( 23 
0 % ) had a clinical response . NULL NULL 
0 ) had a clinical response . NULL NULL NULL 
0 median time to disease progression while on treatment was 
0 disease progression while on treatment was 24 weeks . 
0 NULL the median overall survival was 27 weeks . 
0 NULL NULL the disease progressed in 8 patients , 
0 , despite an initial response . NULL NULL NULL 
0 are still responding to therapy . NULL NULL NULL 
0 8 patients whose disease progressed have died . NULL 
5 whose disease progressed have died . NULL NULL NULL 
19 NULL NULL bevacizumab was discontinued in 2 patients because 
0 safe and has excellent activity even in this relapsed 
19 this relapsed , heavily pretreated population of patients with 
0 of patients with high-grade malignant glioma , most of 
0 not be candidates for clinical trials . NULL NULL 
0 be candidates for clinical trials . NULL NULL NULL 
19 NULL NULL NULL NULL intracerebral grafting of cultured autologous 
19 NULL NULL NULL intracerebral grafting of cultured autologous skin 
0 NULL intracerebral grafting of cultured autologous skin fibroblasts into 
0 cell population for gene therapy applications to the central 
0 therapy applications to the central nervous system , primary 
19 system , primary fibroblasts isolated from skin biopsies and 
0 from skin biopsies and maintained in culture are employed 
0 biopsies and maintained in culture are employed as autologous 
19 as autologous cells for intracerebral grafting within the adult 
19 autologous cells for intracerebral grafting within the adult rat 
0 NULL NULL NULL NULL results from the present investigation 
0 NULL results from the present investigation reveal that cultured 
19 present investigation reveal that cultured primary skin fibroblasts cease 
1 skin fibroblasts cease to proliferate once they reach confluence 
0 to proliferate once they reach confluence ; these cells 
15 these cells are thus contact inhibited in vitro . 
18 cells are thus contact inhibited in vitro . NULL 
19 NULL NULL NULL following implantation within the striatum , 
0 the graft size is dependent on the density of 
0 suspension , but not dependent on either the number 
19 either the number of passages the cells are taken 
19 are taken through in culture prior to grafting or 
19 in culture prior to grafting or on the postoperative 
0 or on the postoperative survival period . NULL NULL 
0 NULL NULL reactive astrocytic processes and phagocytic cells are 
0 phagocytic cells are also present in the grafts . 
0 the grafts are extensively vascularized with capillaries composed of 
5 fibroblasts are able to survive for at least 8 
0 least 8 weeks following intracerebral implantation and continue to 
0 8 weeks following intracerebral implantation and continue to synthesize 
9 implantation and continue to synthesize collagen and fibronectin in 
2 skin fibroblasts do not produce tumors . NULL NULL 
0 finally , dynamic host-to-graft interactions -- including phagocytic migration 
0 interactions -- including phagocytic migration , astrocytic hypertrophy and 
0 , astrocytic hypertrophy and infiltration within the grafts , 
3 the grafts , and angiogenesis -- are features that 
0 features that constitute the structural integration of primary skin 
19 of primary skin fibroblasts grafted within the adult rat 
0 within the adult rat central nervous system . NULL 
0 marker of embryonic and tumor neovascularization . NULL NULL 
3 of embryonic and tumor neovascularization . NULL NULL NULL 
2 NULL NULL NULL the formation of functional , mature 
17 , mature blood vessels depends on the interaction between 
15 vessels depends on the interaction between endothelial cells and 
0 commonality exists in the processes involved in vasculature development 
0 exists in the processes involved in vasculature development between 
2 processes involved in vasculature development between tissues whether healthy 
0 is a cell membrane protein that is expressed in 
9 membrane protein that is expressed in blood vessels during 
0 NULL NULL NULL antibodies developed to human endosialin were 
0 to human endosialin were used to investigate endosialin expression 
9 used to investigate endosialin expression and function in human 
0 investigate endosialin expression and function in human prenatal brain 
18 anti-endosialin was capable of preventing pericyte tube formation in 
2 of preventing pericyte tube formation in culture and inhibited 
0 pericyte tube formation in culture and inhibited migration . 
0 formation in culture and inhibited migration . NULL NULL 
0 in culture and inhibited migration . NULL NULL NULL 
0 NULL brain pericytes in culture had higher levels of 
0 in culture had higher levels of endosialin/tem 1 than 
14 revealed that endosialin was present in the cytoplasmic body 
0 body and in the elongated extensions essential to pericyte 
0 in the elongated extensions essential to pericyte function . 
0 extensions essential to pericyte function . NULL NULL NULL 
19 NULL NULL NULL NULL transgenic mice engineered to express 
9 transgenic mice engineered to express human endosialin bred on 
4 immunocompromised background allowed the growth of human tumor xenografts 
0 the growth of human tumor xenografts . NULL NULL 
4 colo205 and ht29 xenografts grown in human endosialin-transgenic mice 
19 xenografts grown in human transgenic mice , endosialin expression 
9 endosialin-transgenic mice , endosialin expression was largely confined to 
9 was largely confined to expressing perivascular cells and not 
9 perivascular cells and not positive endothelial cells . NULL 
9 colon tumors confirmed endosialin expression by pericytes . NULL 
9 that endosialin is strongly expressed by pericytes during periods 
0 pericytes during periods of active angiogenesis during embryonic and 
3 during periods of active angiogenesis during embryonic and tumor 
0 angiogenesis during embryonic and tumor development . NULL NULL 
2 during embryonic and tumor development . NULL NULL NULL 
0 in identifying vasculature in malignant tissues . NULL NULL 
19 the appropriate agent , targeting endosialin may interfere with 
18 , targeting endosialin may interfere with blood vessel growth 
4 interfere with blood vessel growth during tumor development . 
0 blood vessel growth during tumor development . NULL NULL 
2 vessel growth during tumor development . NULL NULL NULL 
18 NULL NULL NULL efficient inhibition of ovarian cancer growth 
4 inhibition of ovarian cancer growth and prolonged survival by 
0 ovarian cancer growth and prolonged survival by transfection with 
5 cancer growth and prolonged survival by transfection with a 
19 and prolonged survival by transfection with a novel pro-apoptotic 
0 vivo and in vitro results . NULL NULL NULL 
19 NULL objective : we transfected ovarian cancer cells and 
19 ovarian cancer cells and administered recombinant plasmid encoding hpnas-4 
16 aiming to evaluate the effect of hpnas-4 against ovarian 
19 cancer skov3 cells were transfected with hpnas-4-plasmid , and 
1 hpnas-4-plasmid , and cell proliferation was evaluated by mtt 
5 by mtt assay ; apoptosis was examined by dna 
0 dna ladder , hoechst33258 staining and flow-cytometric assays . 
19 bearing ovarian cancers were treated with hpnas-4-p/liposome . NULL 
0 NULL NULL NULL NULL tumor growth was determined and 
4 NULL NULL NULL tumor growth was determined and survival 
0 growth was determined and survival was recorded . NULL 
0 was assessed to evaluate apoptosis and angiogenesis . NULL 
3 to evaluate apoptosis and angiogenesis . NULL NULL NULL 
0 NULL NULL NULL NULL results : both inhibition of 
18 NULL results : both inhibition of proliferation ( p 
1 : both inhibition of proliferation ( p < 0.05 
17 < 0.05 ) and induction of apoptosis ( p 
5 ) and induction of apoptosis ( p < 0.05 
0 < 0.05 ) were observed in skov3 cells transfected 
19 observed in skov3 cells transfected with hpnas-4-p in vitro 
19 NULL NULL NULL in treated tumor cells in vivo 
0 NULL NULL in hpnas-4-p-treated tumor cells in vivo , 
0 cells in vivo , tumor growth significantly decreased , 
4 in vivo , tumor growth significantly decreased , while 
18 , tumor growth significantly decreased , while the survival 
5 decreased , while the survival time of tumor-bearing mice 
17 of tumor-bearing mice was prolonged compared with control groups 
0 was prolonged compared with control groups ( p < 
17 NULL NULL NULL NULL increased apoptosis of tumor cells 
5 NULL NULL NULL increased apoptosis of tumor cells and 
0 NULL increased apoptosis of tumor cells and decreased angiogenesis 
18 of tumor cells and decreased angiogenesis in tumor tissue 
3 tumor cells and decreased angiogenesis in tumor tissue were 
0 and decreased angiogenesis in tumor tissue were also observed 
0 tumor tissue were also observed . NULL NULL NULL 
0 conclusions : our promising results on the potential antitumor 
0 promising results on the potential antitumor effects of hpnas-4 
18 on the potential antitumor effects of hpnas-4 on ovarian 
17 part , by the induction of apoptosis and inhibition 
5 by the induction of apoptosis and inhibition of angiogenesis 
18 induction of apoptosis and inhibition of angiogenesis . NULL 
3 apoptosis and inhibition of angiogenesis . NULL NULL NULL 
0 consequently , hpnas-4 has potential as a new gene 
19 as a new gene therapy for human ovarian cancer 
3 NULL NULL NULL NULL angiogenesis associated with visceral and 
0 NULL NULL NULL angiogenesis associated with visceral and subcutaneous 
2 NULL objective : the expansion of adipose tissue is 
16 of adipose tissue is linked to the development of 
2 is linked to the development of its vasculature . 
16 NULL however , the regulation of adipose tissue angiogenesis 
3 regulation of adipose tissue angiogenesis in humans has not 
3 was to compare the angiogenesis associated with subcutaneous adipose 
0 to compare the angiogenesis associated with subcutaneous adipose tissue 
19 sat ) sites , obtained from 36 obese patients 
0 ) ) during bariatric surgery , were layered on 
19 bariatric surgery , were layered on chick chorioallantoic membrane 
0 NULL NULL NULL NULL results : both sat and 
0 both sat and vat expressed angiogenic factors without significant 
3 sat and vat expressed angiogenic factors without significant difference 
0 expressed angiogenic factors without significant difference for vascular endothelial 
0 difference for vascular endothelial growth factor ( vegf ) 
9 factor ( vegf ) expression . NULL NULL NULL 
19 NULL NULL adipose tissue layered on cam stimulated angiogenesis 
17 tissue layered on cam stimulated angiogenesis . NULL NULL 
3 layered on cam stimulated angiogenesis . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenic stimulation was macroscopically detectable 
17 NULL NULL NULL angiogenic stimulation was macroscopically detectable , 
0 angiogenic stimulation was macroscopically detectable , with engulfment of 
0 and was evidenced by angiography in 59 % of 
15 NULL NULL NULL a connection between cam and adipose 
14 by immunohistochemistry , with recruitment of both avian and 
3 NULL NULL NULL the angiogenic potency of adipose tissue 
14 not related to its localization ( with an angiogenic 
3 localization ( with an angiogenic stimulation in 60 % 
17 ( with an angiogenic stimulation in 60 % of 
17 NULL NULL NULL NULL stimulation of angiogenesis by adipose 
3 NULL NULL stimulation of angiogenesis by adipose tissue was 
18 adipose tissue was nearly abolished by bevacizumab , which 
16 bevacizumab , which specifically targets human vegf . NULL 
0 conclusions : we have established a model to study 
16 model to study the regulation of angiogenesis by human 
3 study the regulation of angiogenesis by human adipose tissue 
16 this model highlighted the role of vegf in angiogenesis 
3 role of vegf in angiogenesis in both sat and 
0 NULL the in vivo properties of stx243 : a 
3 stx243 : a potent angiogenesis inhibitor in breast cancer 
0 : a potent angiogenesis inhibitor in breast cancer . 
0 stx243 ) has been developed as a potent antiangiogenic 
3 developed as a potent angiogenic and antitumour compound . 
0 whether stx243 is more active in vivo than the 
4 NULL NULL the tumour growth inhibition efficacy , antiangiogenic 
18 NULL the tumour growth inhibition efficacy , antiangiogenic potential 
0 the tumour growth inhibition efficacy , antiangiogenic potential and 
3 growth inhibition efficacy , angiogenic potential and pharmacokinetics of 
18 inhibition efficacy , antiangiogenic potential and pharmacokinetics of stx243 
18 stx140 were capable of retarding the growth of mda-mb-231 
4 capable of retarding the growth of mda-mb-231 xenograft tumours 
0 ) , whereas no inhibition was observed for animals 
0 whereas no inhibition was observed for animals treated with 
19 was observed for animals treated with 2-meoe2 . NULL 
18 NULL NULL further tumour inhibition studies showed that stx243 
0 further tumour inhibition studies showed that stx243 was also 
16 that stx243 was also active against mcf-7 paclitaxel-resistant tumours 
3 model , in vivo angiogenesis was restricted with stx243 
18 in vivo angiogenesis was restricted with stx243 and stx140 
3 , thereby showing the angiogenic activity of both compounds 
18 thereby showing the antiangiogenic activity of both compounds . 
0 NULL NULL NULL these results show that stx243 is 
0 and could be clinically effective at treating a number 
0 be clinically effective at treating a number of oncological 
16 NULL NULL NULL m-csf signals through the mapk/erk pathway 
17 pathway via sp1 to induce vegf production and induces 
9 sp1 to induce vegf production and induces angiogenesis in 
0 induce vegf production and induces angiogenesis in vivo . 
3 vegf production and induces angiogenesis in vivo . NULL 
16 NULL background : m-csf recruits mononuclear phagocytes which regulate 
16 recruits mononuclear phagocytes which regulate processes such as angiogenesis 
0 mononuclear phagocytes which regulate processes such as angiogenesis and 
3 regulate processes such as angiogenesis and metastases in tumors 
14 such as angiogenesis and metastases in tumors . NULL 
17 vegf is a potent activator of angiogenesis as it 
3 a potent activator of angiogenesis as it promotes endothelial 
17 of angiogenesis as it promotes endothelial cell proliferation and 
1 it promotes endothelial cell proliferation and new blood vessel 
2 and new blood vessel formation . NULL NULL NULL 
17 that in vitro m-csf induces the expression of biologically-active 
9 vitro m-csf induces the expression of biologically-active vegf from 
0 induces the expression of active vegf from human monocytes 
0 NULL NULL methodology and results : in this study 
0 we demonstrate the molecular mechanism of m-csf-induced vegf production 
17 the molecular mechanism of induced vegf production . NULL 
9 mechanism of m-csf-induced vegf production . NULL NULL NULL 
19 containing the vegf promoter linked to a luciferase reporter 
18 found that a mutation reducing hif binding to the 
15 a mutation reducing hif binding to the vegf promoter 
0 vegf promoter had no significant effect on luciferase production 
16 promoter had no significant effect on luciferase production induced 
9 significant effect on luciferase production induced by m-csf stimulation 
17 effect on luciferase production induced by m-csf stimulation . 
17 production induced by m-csf stimulation . NULL NULL NULL 
17 analysis revealed that m-csf induced vegf through the mapk/erk 
16 analysis revealed that m-csf induced vegf through the mapk/erk 
0 signaling pathway via the transcription factor , sp1 . 
18 NULL NULL thus , inhibition of either erk or 
18 either erk or sp1 suppressed m-csf-induced vegf at the 
17 erk or sp1 suppressed induced vegf at the mrna 
0 m-csf-induced vegf at the mrna and protein level . 
0 at the mrna and protein level . NULL NULL 
17 NULL NULL m-csf also induced the nuclear localization of 
14 also induced the nuclear localization of sp1 , which 
18 sp1 , which was blocked by erk inhibition . 
18 was blocked by erk inhibition . NULL NULL NULL 
19 NULL NULL finally , mutating the sp1 binding sites 
0 , mutating the sp1 binding sites within the vegf 
18 the vegf promoter or inhibiting erk decreased vegf promoter 
18 promoter or inhibiting erk decreased vegf promoter activity in 
0 erk decreased vegf promoter activity in m-csf-treated human monocytes 
19 vegf promoter activity in treated human monocytes . NULL 
17 biological significance of m-csf induced vegf production , we 
9 of m-csf induced vegf production , we used an 
0 vegf production , we used an in vivo angiogenesis 
3 used an in vivo angiogenesis model to illustrate the 
16 model to illustrate the ability of m-csf to recruit 
14 ability of m-csf to recruit mononuclear phagocytes , increase 
17 recruit mononuclear phagocytes , increase vegf levels , and 
0 phagocytes , increase vegf levels , and enhance angiogenesis 
17 vegf levels , and enhance angiogenesis . NULL NULL 
3 levels , and enhance angiogenesis . NULL NULL NULL 
0 NULL importantly , the addition of a neutralizing vegf 
18 a neutralizing vegf antibody abolished m-csf-induced blood vessel formation 
17 neutralizing vegf antibody abolished induced blood vessel formation . 
2 abolished m-csf-induced blood vessel formation . NULL NULL NULL 
17 delineate an erk- and dependent mechanism of m-csf induced 
0 an erk- and sp1-dependent mechanism of m-csf induced vegf 
17 sp1-dependent mechanism of m-csf induced vegf production and demonstrate 
9 of m-csf induced vegf production and demonstrate for the 
0 the first time the ability of m-csf to induce 
17 ability of m-csf to induce angiogenesis via vegf in 
16 ability of m-csf to induce angiogenesis via vegf in 
3 of m-csf to induce angiogenesis via vegf in vivo 
0 a5-1 , screened by protein chip system as a 
3 system as a potent angiogenesis inhibitor . NULL NULL 
0 as a potent angiogenesis inhibitor . NULL NULL NULL 
0 on a proteochip was used to screen new antagonistic 
15 NULL the integrin alpha5beta1-fibronectin interaction was demonstrated on the 
0 ) , with high affinity to integrin alpha5beta1 was 
0 basis of a competitive inhibition assay . NULL NULL 
18 NULL NULL NULL a5-1 inhibits the integrin-fibronectin interaction in 
15 a5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner 
0 integrin-fibronectin interaction in a dependent manner ( ic ( 
0 NULL NULL NULL in addition , it inhibits human 
18 in addition , it inhibits human umbilical vein endothelial 
1 umbilical vein endothelial cell proliferation , migration , adhesion 
14 endothelial cell proliferation , migration , adhesion , tubular 
15 proliferation , migration , adhesion , tubular network formation 
2 adhesion , tubular network formation , and bfgf-induced neovascularization 
17 network formation , and induced neovascularization in a chick 
3 formation , and bfgf-induced neovascularization in a chick chorioallantoic 
0 NULL NULL NULL these results suggest that a5-1 will 
0 will be a potent inhibitor of neovascularization . NULL 
3 a potent inhibitor of neovascularization . NULL NULL NULL 
0 NULL evaluation of electrical stimulation for ischemic wound therapy 
0 stimulation for ischemic wound therapy : a feasibility study 
0 chronic wounds are a major secondary complication for many 
0 for many people with impaired mobility . NULL NULL 
0 many people with impaired mobility . NULL NULL NULL 
0 NULL NULL NULL electrical stimulation ( es ) has 
0 recommended as a adjunctive therapy , however optimal treatment 
0 therapy , however optimal treatment paradigms have not been 
0 paradigms have not been established . NULL NULL NULL 
0 mechanisms underlying es wound therapy , an area where 
0 where understanding is currently limited . NULL NULL NULL 
0 systematic investigation of the effects of electrical stimulation on 
0 the effects of electrical stimulation on ischemic wound therapy 
0 stimulation on ischemic wound therapy . NULL NULL NULL 
0 NULL NULL a standardized surgical procedure incorporated a hybrid 
0 procedure incorporated a hybrid stimulation system comprising an implantable 
0 employed to evaluate the effects of two empirically selected 
0 of two empirically selected stimulation paradigms applied continuously for 
0 animal as its own control . NULL NULL NULL 
0 included transcutaneous blood gas levels , histology , total 
0 , and vascular endothelial growth factor ( vegf ) 
9 factor ( vegf ) expression using real-time quantitative pcr 
0 NULL all markers for stimulated wounds showed increased activity 
0 markers for stimulated wounds showed increased activity relative to 
0 for stimulated wounds showed increased activity relative to non-stimulated 
0 stimulated wounds showed increased activity relative to non-stimulated control 
0 increased activity relative to stimulated control wounds between 7 
0 activity relative to non-stimulated control wounds between 7 and 
0 injury , with peak activity at 14 days . 
0 days post-injury , all activity had returned to near 
0 NULL vegf and col-iv levels were found to be 
0 a may be more effective at promoting angiogenesis . 
17 be more effective at promoting angiogenesis . NULL NULL 
3 more effective at promoting angiogenesis . NULL NULL NULL 
0 both col-i and col-v showed statistically significant ( p 
0 and col-v showed statistically significant ( p less than 
0 less than 0.05 ) increased activity between day 7 
17 than 0.05 ) increased activity between day 7 and 
16 potentially indicating a continued effect on matrix remodeling . 
0 a continued effect on matrix remodeling . NULL NULL 
7 continued effect on matrix remodeling . NULL NULL NULL 
0 NULL NULL the early closure of all wounds implies 
0 asthma : new molecular targets in airway angiogenesis and 
3 molecular targets in airway angiogenesis and microvascular remodeling . 
7 airway angiogenesis and microvascular remodeling . NULL NULL NULL 
3 NULL NULL NULL airway angiogenesis and microvascular remodeling are 
7 airway angiogenesis and microvascular remodeling are known features of 
0 the mechanisms of these structural alterations are just beginning 
0 mechanisms of these structural alterations are just beginning to 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
3 of the most potent angiogenic factors , stimulates endothelial 
17 potent angiogenic factors , stimulates endothelial cell proliferation and 
1 , stimulates endothelial cell proliferation and induces the angiogenesis 
17 endothelial cell proliferation and induces the angiogenesis . NULL 
3 proliferation and induces the angiogenesis . NULL NULL NULL 
0 devoted to the physiological roles of angiopoietin ( ang 
0 -1 and -2 as regulatory factors of vegf . 
17 has been shown to induce the migration and sprouting 
14 shown to induce the migration and sprouting of endothelial 
2 induce the migration and sprouting of endothelial cells , 
9 endothelial cells , and coexpression of ang-1 and vegf 
17 of ang-1 and vegf enhanced angiogenesis . NULL NULL 
3 ang-1 and vegf enhanced angiogenesis . NULL NULL NULL 
14 NULL NULL in the presence of high levels of 
0 the presence of high levels of vegf , ang-2 
17 vegf , ang-2 also promotes rapid increase in capillary 
0 ang-2 also promotes rapid increase in capillary diameter , 
7 in capillary diameter , remodeling of the basal lamina 
1 the basal lamina , proliferation and migration of endothelial 
14 lamina , proliferation and migration of endothelial cells , 
17 endothelial cells , and stimulates sprouting of new blood 
2 cells , and stimulates sprouting of new blood vessels 
16 ang-1 and -2 may play complementary and coordinated roles 
16 and -2 may play complementary and coordinated roles in 
16 may play complementary and coordinated roles in airway angiogenesis 
16 play complementary and coordinated roles in airway angiogenesis and 
3 coordinated roles in airway angiogenesis and microvascular remodeling , 
7 airway angiogenesis and microvascular remodeling , and these structural 
0 remodeling , and these structural changes are potentially reversible 
0 , and these structural changes are potentially reversible by 
0 the scope of the present review is to discuss 
0 to discuss from a clinical point of view the 
0 point of view the potential interactions between vegf and 
15 of view the potential interactions between vegf and angiopoietins 
0 on the therapeutic implications targeting for these angiogenic factors 
3 implications targeting for these angiogenic factors . NULL NULL 
0 , there is an increasing number of patents which 
0 the inhibitors of vegf action . NULL NULL NULL 
0 regarding inhibitors of vegf action in the present review 
0 vegf action in the present review . NULL NULL 
0 NULL NULL NULL NULL effect of transplanted mesenchymal stem 
19 NULL NULL effect of transplanted mesenchymal stem cells from 
0 the improvement of heart function after acute myocardial infarction 
19 cells ( mscs ) transplantation is of therapeutic potential 
0 transplantation is of therapeutic potential after ischemic injury in 
0 in both experimental and clinical studies . NULL NULL 
0 the characteristics of young derived mscs transplanted to old 
19 of young donor-derived mscs transplanted to old patients with 
0 NULL NULL NULL the present study was designed to 
0 designed to investigate the effect of transplanted mscs from 
19 investigate the effect of transplanted mscs from rats of 
0 the improvement of heart function after ami . NULL 
19 sd ) rats were isolated and cultured in vitro 
19 rats were isolated and cultured in vitro . NULL 
5 NULL NULL NULL the apoptosis characteristics of mscs were 
0 characteristics of mscs were observed under conditions of ischemia 
0 NULL NULL sd rats underwent mi received intramyocardial injection 
0 sd rats underwent mi received intramyocardial injection of mscs 
19 underwent mi received intramyocardial injection of mscs from young 
0 NULL NULL NULL ami control group received equal volume 
0 NULL ami control group received equal volume physiological saline 
0 NULL NULL immunofluorescence was used to observe the differentiation 
2 used to observe the differentiation of the grafted cells 
19 the differentiation of the grafted cells into cardiomyocytes . 
19 four weeks after cell transplantation , reverse transcriptase-polymerase chain 
0 immunohistochemistry for vascular endothelial growth factor ( vegf ) 
5 , caspase-3 for cardiomyocyte apoptosis , echocardiography and hemodynamic 
0 hemodynamic detection for heart function were performed . NULL 
0 NULL NULL NULL NULL results : the apoptosis rate 
5 NULL results : the apoptosis rate of the old 
0 rate of the old derived mscs group was significantly 
0 that of the young derived mscs group under conditions 
19 NULL NULL NULL NULL engrafted mscs survived , proliferated 
5 NULL NULL engrafted mscs survived , proliferated and differentiated 
1 engrafted mscs survived , proliferated and differentiated into myocardium-like 
2 survived , proliferated and differentiated into myocardium-like cells . 
9 NULL NULL vegf gene expression and capillary density in 
0 density in the old derived group were lower than 
0 those in the young derived group but higher than 
0 than those in the control group ( p less 
19 NULL NULL NULL the transplantation of old donor-derived mscs 
0 the transplantation of old derived mscs attenuated apoptosis of 
18 of old donor-derived mscs attenuated apoptosis of cardiomyocytes in 
5 old donor-derived mscs attenuated apoptosis of cardiomyocytes in the 
0 region compared with the control group and the effect 
16 control group and the effect was elevated in young 
17 and the effect was elevated in young donor-derived mscs 
0 was elevated in young derived mscs ( p less 
0 NULL NULL the heart functions ( left ventricle ejection 
0 lvfs ) ) were improved more significantly in the 
0 significantly in the old derived mscs group than in 
0 group than in the control group and the heart 
0 group and the heart function in the young donor-derived 
0 function in the young derived mscs group further improved 
17 donor-derived mscs group further improved ( p less than 
0 NULL conclusions : young derived mscs can improve heart 
17 young donor-derived mscs can improve heart function significantly through 
16 young donor-derived mscs can improve heart function significantly through 
0 mscs can improve heart function significantly through angiogenesis and 
3 heart function significantly through angiogenesis and decreasing cardiomyocyte apoptosis 
18 significantly through angiogenesis and decreasing cardiomyocyte apoptosis when transplanted 
5 angiogenesis and decreasing cardiomyocyte apoptosis when transplanted to the 
19 decreasing cardiomyocyte apoptosis when transplanted to the infarcted area 
0 NULL NULL NULL NULL clinical significance of chicken ovalbumin 
0 of chicken ovalbumin upstream transcription factor ii expression in 
9 upstream promoter-transcription factor ii expression in human colorectal cancer 
0 NULL chicken ovalbumin upstream transcription factor ii ( coup-tfii 
16 ii ( coup-tfii ) plays an essential role in 
16 coup-tfii ) plays an essential role in angiogenesis and 
16 ) plays an essential role in angiogenesis and development 
3 an essential role in angiogenesis and development . NULL 
0 role in angiogenesis and development . NULL NULL NULL 
0 NULL a previous study showed that the expression of 
9 study showed that the expression of coup-tfii enhanced invasiveness 
17 the expression of coup-tfii enhanced invasiveness of human lung 
14 expression of coup-tfii enhanced invasiveness of human lung carcinoma 
0 concerning the biological and clinical significance of coup-tfii expression 
9 clinical significance of coup-tfii expression in colorectal cancer . 
9 was to explore the expression of coup-tfii in colorectal 
0 as well as its association with clinicopathological features , 
16 and to evaluate the role of coup-tfii as a 
14 NULL we investigated the presence of coup-tfii in human 
9 the correlation between the expression of coup-tfii and clinicopathologic 
0 NULL NULL the 3-year free survival ( dfs ) 
0 NULL the 3-year disease-free survival ( dfs ) and 
0 dfs ) and overall survival ( os ) of 
9 of patients with tumors expressing different levels of coup-tfii 
0 with tumors expressing different levels of coup-tfii were evaluated 
0 NULL NULL NULL no significant correlation was found between 
9 was found between coup-tfii expression and age at surgery 
0 expression and age at surgery , gender , histopathologic 
0 , gender , histopathologic differentiation , vessel invasion , 
14 histopathologic differentiation , vessel invasion , carcinoembryonic antigen ( 
0 ) , or nodal involvement . NULL NULL NULL 
0 NULL NULL however , survival analysis showed that the 
0 however , survival analysis showed that the coup-tfii-positive group 
9 analysis showed that the positive group had a significantly 
9 better os compared to negative group ( 80.4 % 
0 NULL based on our results , coup-tfii may represent 
0 NULL NULL NULL NULL involvement of pten promoter methylation 
0 prevalent cerebral vascular lesions involving aberrant angiogenesis . NULL 
0 cerebral vascular lesions involving aberrant angiogenesis . NULL NULL 
3 vascular lesions involving aberrant angiogenesis . NULL NULL NULL 
0 however , the underlying mechanism is poorly understood . 
0 pten ) , a tumor suppressor , is frequently 
0 ) , a tumor suppressor , is frequently deficient 
9 suppressor , is frequently deficient in various pathologies due 
0 to mutation or epigenetic alterations . NULL NULL NULL 
0 promoter hypermethylation is a major epigenetic silencing mechanism leading 
0 a major epigenetic silencing mechanism leading to activation of 
17 major epigenetic silencing mechanism leading to activation of angiogenesis 
17 silencing mechanism leading to activation of angiogenesis in tumors 
3 leading to activation of angiogenesis in tumors . NULL 
0 NULL NULL NULL the present study aimed to investigate 
0 pten promoter methylation was involved in ccms . NULL 
0 pten promoter methylation was detected in surgical specimens of 
0 methylation was detected in surgical specimens of ccms ( 
0 was correlated to the clinical manifestations and to pten 
9 manifestations and to pten expression , which was analyzed 
1 to investigate the endothelial proliferation and the potential signaling 
0 endothelial proliferation and the potential signaling pathways affected by 
0 and the potential signaling pathways affected by pten methylation 
16 the potential signaling pathways affected by pten methylation , 
0 by pten methylation , proliferating cell nuclear antigen as 
0 phosphor-erk1 , 2 were detected by immunofluorescence and western 
0 NULL NULL NULL NULL results : methylation-specific polymerase chain 
0 of 6 familial ccms showed pten promoter methylation ( 
0 NULL NULL NULL in addition , pten promoter methylation 
0 blot revealed a more significant pten downregulation in pten-methylated 
18 a more significant pten downregulation in pten-methylated ccms in 
18 NULL NULL NULL NULL reduced pten expression was inversely 
9 NULL NULL reduced pten expression was inversely correlated to 
9 inversely correlated to the expression of proliferating cell nuclear 
0 to the expression of proliferating cell nuclear antigen and 
17 antigen and to the activation of erk1 , 2 
0 the first time the involvement of pten promoter methylation 
0 epigenetic alteration as a potential pathomechanism of ccms . 
0 erk1 , 2 as triggered signaling in the lesions 
0 be valuable for the development of effective therapy for 
0 for the development of effective therapy for this disease 
0 the development of effective therapy for this disease . 
18 NULL grape seed extract inhibits angiogenesis via suppression of 
3 grape seed extract inhibits angiogenesis via suppression of the 
18 extract inhibits angiogenesis via suppression of the vascular endothelial 
0 of the vascular endothelial growth factor receptor signaling pathway 
18 NULL NULL NULL NULL blockade of angiogenesis is an 
3 NULL NULL blockade of angiogenesis is an important approach 
0 of angiogenesis is an important approach for cancer treatment 
19 important approach for cancer treatment and prevention . NULL 
18 for cancer treatment and prevention . NULL NULL NULL 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
0 one of the most critical factors that induce angiogenesis 
17 most critical factors that induce angiogenesis and has thus 
3 critical factors that induce angiogenesis and has thus become 
0 thus become an attractive target for antiangiogenesis treatment . 
3 an attractive target for angiogenesis treatment . NULL NULL 
18 attractive target for antiangiogenesis treatment . NULL NULL NULL 
0 often cause some side effects when given chronically . 
0 some side effects when given chronically . NULL NULL 
0 naturally occurring vegf inhibitors derived from diet would be 
0 ) , a widely used dietary supplement , is 
18 known to have antitumor activity . NULL NULL NULL 
0 we have explored the activity of gse on vegf 
3 on vegf receptor and angiogenesis . NULL NULL NULL 
18 that gse could directly inhibit the kinase activity of 
0 directly inhibit the kinase activity of purified vegf receptor 
0 the kinase activity of purified vegf receptor 2 , 
0 2 , a novel activity of gse that has 
18 NULL gse could also inhibit the vegf receptor/mitogen-activated protein 
0 also inhibit the vegf activated protein kinase-mediated signaling pathway 
0 inhibit the vegf receptor/mitogen-activated protein kinase-mediated signaling pathway in 
17 the vegf receptor/mitogen-activated protein mediated signaling pathway in endothelial 
18 result , gse could inhibit vegf-induced endothelial cell proliferation 
17 , gse could inhibit induced endothelial cell proliferation and 
1 inhibit vegf-induced endothelial cell proliferation and migration as well 
14 endothelial cell proliferation and migration as well as sprout 
2 as well as sprout formation from aorta ring . 
0 in vivo assay further showed that gse could inhibit 
18 showed that gse could inhibit tumor growth and tumor 
0 that gse could inhibit tumor growth and tumor angiogenesis 
4 gse could inhibit tumor growth and tumor angiogenesis of 
0 inhibit tumor growth and tumor angiogenesis of mda-mb-231 breast 
3 tumor growth and tumor angiogenesis of mda-mb-231 breast cancer 
19 vitro data , gse treatment of tumor-bearing mice led 
17 treatment of tumor-bearing mice led to concomitant reduction of 
18 mice led to concomitant reduction of blood vessel density 
12 blood vessel density and phosphorylation of mitogen-activated protein kinase 
0 density and phosphorylation of activated protein kinase . NULL 
0 and phosphorylation of mitogen-activated protein kinase . NULL NULL 
18 NULL NULL NULL NULL depletion of polyphenol with polyvinylpyrrolidone 
18 of polyphenol with polyvinylpyrrolidone abolished the antiangiogenic activity of 
3 with polyvinylpyrrolidone abolished the angiogenic activity of gse , 
18 polyvinylpyrrolidone abolished the antiangiogenic activity of gse , suggesting 
17 polyphenol in gse is responsible for the antiangiogenic activity 
3 is responsible for the angiogenic activity . NULL NULL 
18 responsible for the antiangiogenic activity . NULL NULL NULL 
0 and inexpensive natural vegf inhibitor and could potentially be 
18 be useful in cancer prevention or treatment . NULL 
19 in cancer prevention or treatment . NULL NULL NULL 
18 an alternative strategy for inhibiting tumour angiogenesis by vascular 
3 strategy for inhibiting tumour angiogenesis by vascular endothelial growth 
0 angiogenesis by vascular endothelial growth factors . NULL NULL 
16 NULL NULL background : aberrant angiogenesis is a landmark 
3 NULL background : aberrant angiogenesis is a landmark feature 
0 cancer , which is important for proliferation , growth 
0 which is important for proliferation , growth and metastasis 
0 important for proliferation , growth and metastasis , and 
0 proliferation , growth and metastasis , and is mediated 
16 metastasis , and is mediated by various pro-angiogenic factors 
3 is mediated by various angiogenic factors . NULL NULL 
0 one of the most important and best-studied angiogenic pathways 
3 most important and best-studied angiogenic pathways . NULL NULL 
0 important and best-studied angiogenic pathways . NULL NULL NULL 
18 NULL NULL NULL NULL inhibition of this pathway may 
0 this pathway may provide clinical benefits to cancer patients 
18 objectives : strategies to inhibit the vegf pathway , 
0 and compares the latest development of these strategies , 
0 , a novel decoy fusion protein of domain 2 
0 a novel decoy fusion protein of domain 2 of 
0 NULL NULL NULL NULL results : aflibercept was shown 
0 shown to have early clinical activity . NULL NULL 
0 to have early clinical activity . NULL NULL NULL 
0 ongoing to determine the clinical benefits of aflibercept in 
16 NULL NULL NULL the effect of perfluorocarbon-based artificial oxygen 
16 NULL NULL the biological effect of the perfluorocarbon-based artificial 
0 NULL NULL NULL media supplemented with and without 10 
0 NULL chondrocyte-degrapol constructs were cultured for 1 month with 
0 NULL NULL NULL oxygent perfusion medium increased the tet 
0 NULL oxygent perfusion medium increased the tet epithelial pto 
0 than 0.01 ) and decreased the lactate concentration ( 
0 ) ; histology slides showed poor acid mucopolysaccharides formation 
8 showed poor acid mucopolysaccharides formation . NULL NULL NULL 
0 orthogonal polarization spectral imaging showed no difference in functional 
19 density between the scaffolds cultured on chorioallantoic membranes . 
17 we conclude that oxygent increases tet epithelial pto ( 
0 ( 2 ) , improves epithelial metabolism , does 
18 metabolism , does not impair angiogenesis , and tends 
3 , does not impair angiogenesis , and tends to 
18 , and tends to slow cartilage tissue formation . 
2 to slow cartilage tissue formation . NULL NULL NULL 
14 is lost during melanoma metastasis . NULL NULL NULL 
2 NULL NULL NULL the transformation of normal melanocytes , 
0 is a complex process involving multiple mechanisms . NULL 
0 NULL NULL NULL NULL loss of tumor suppressor proteins 
0 NULL NULL loss of tumor suppressor proteins , which 
0 NULL loss of tumor suppressor proteins , which function 
0 suppressor proteins , which function as brakes on cell 
18 , which function as brakes on cell growth , 
1 as brakes on cell growth , migration , or 
14 on cell growth , migration , or cell survival 
5 migration , or cell survival , was recognized early 
0 early on as an important mechanism for initiation and 
0 on as an important mechanism for initiation and progression 
0 an important mechanism for initiation and progression of melanoma 
0 mechanism for initiation and progression of melanoma . NULL 
0 and neuropilins , are involved in neuronal pathfinding , 
0 neuronal pathfinding , immune function , and tumor progression 
0 immune function , and tumor progression through effects on 
2 function , and tumor progression through effects on blood 
16 and tumor progression through effects on blood vessel growth 
4 effects on blood vessel growth and cell migration . 
14 vessel growth and cell migration . NULL NULL NULL 
15 sema7a ) is a linked semaphorin that is expressed 
9 membrane-linked semaphorin that is expressed by human keratinocytes , 
15 have shown that sema7a binds to human melanocytes through 
0 NULL NULL functional studies showed that sema7a stimulates cytoskeletal 
17 studies showed that sema7a stimulates cytoskeletal reorganization in human 
0 showed that sema7a stimulates cytoskeletal reorganization in human melanocytes 
16 that sema7a stimulates cytoskeletal reorganization in human melanocytes , 
17 in human melanocytes , resulting in adhesion and dendrite 
15 melanocytes , resulting in adhesion and dendrite formation . 
2 resulting in adhesion and dendrite formation . NULL NULL 
2 in adhesion and dendrite formation . NULL NULL NULL 
0 NULL NULL NULL NULL downstream targets of plexin c1 
16 NULL NULL NULL downstream targets of plexin c1 signaling 
0 both of which are critical mediators of cell adhesion 
15 critical mediators of cell adhesion and migration . NULL 
14 of cell adhesion and migration . NULL NULL NULL 
9 , we analyzed the expression of plexin c1 using 
0 of primary and matched metastatic lesions from 19 subjects 
0 in a large melanoma tumor microarray . NULL NULL 
0 our data show a significant loss of plexin c1 
0 data show a significant loss of plexin c1 in 
0 of plexin c1 in metastatic melanoma compared with primary 
0 c1 receptor is a tumor suppressor protein for melanoma 
0 receptor is a tumor suppressor protein for melanoma . 
0 is a tumor suppressor protein for melanoma . NULL 
16 NULL NULL NULL NULL role of the interferon-inducible ifi16 
17 NULL role of the inducible ifi16 gene in the 
17 ifi16 gene in the induction of icam-1 by tnf-alpha 
17 NULL NULL NULL the inducible gene ifi16 , a 
17 hin200 family , is activated by oxidative stress and 
0 cell density , in addition to interferons , and 
0 , and it is implicated in the regulation of 
16 is implicated in the regulation of endothelial cell proliferation 
1 regulation of endothelial cell proliferation and vessel formation in 
2 cell proliferation and vessel formation in vitro . NULL 
0 shown that ifi16 is required for proinflammatory gene stimulation 
0 required for proinflammatory gene stimulation by ifn-gamma through the 
17 to examine whether ifi16 induction might be extended to 
17 ifi16 induction might be extended to other proinflammatory cytokines 
0 proinflammatory cytokines such as tumor necrosis factor ( tnf 
0 cytokines such as tumor necrosis factor ( tnf ) 
0 ) -alpha , we used the strategy of the 
0 strategy of the rna interference to knock down ifi16 
19 the rna interference to knock down ifi16 expression , 
9 to knock down ifi16 expression , and analyze the 
17 capability of tnf-alpha to stimulate intercellular adhesion molecule-1 ( 
0 tnf-alpha to stimulate intercellular adhesion molecule-1 ( icam-1 or 
9 icam-1 or cd54 ) expression in the absence of 
16 studies demonstrate that ifi16 mediates icam-1 stimulation by tnf-alpha 
17 that ifi16 mediates icam-1 stimulation by tnf-alpha through the 
0 , thus reinforcing the role of the ifi16 molecule 
0 characterization of the metabolic changes underlying growth factor angiogenic 
0 the metabolic changes underlying growth factor angiogenic activation : 
3 changes underlying growth factor angiogenic activation : identification of 
17 underlying growth factor angiogenic activation : identification of new 
0 : identification of new potential therapeutic targets . NULL 
0 of new potential therapeutic targets . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenesis is a fundamental process 
4 normal and abnormal tissue growth and repair , which 
2 abnormal tissue growth and repair , which consists of 
14 , which consists of recruiting endothelial cells toward an 
3 endothelial cells toward an angiogenic stimulus . NULL NULL 
1 NULL the cells subsequently proliferate and differentiate to form 
2 cells subsequently proliferate and differentiate to form endothelial tubes 
2 proliferate and differentiate to form endothelial tubes and capillary-like 
2 cells through such a transformation . NULL NULL NULL 
16 we studied the metabolic changes of endothelial cell activation 
17 changes of endothelial cell activation by growth factors using 
0 endothelial cell activation by growth factors using human umbilical 
0 -glucose and mass isotopomer distribution analysis . NULL NULL 
0 the main glucose metabolic pathways , including glycogen synthesis 
8 pathways , including glycogen synthesis , the pentose cycle 
0 cycle and the glycolytic pathways . NULL NULL NULL 
0 NULL NULL so we established that these pathways were 
0 we established that these pathways were crucial to endothelial 
0 that these pathways were crucial to endothelial cell proliferation 
1 crucial to endothelial cell proliferation under vascular endothelial growth 
0 proliferation under vascular endothelial growth factor ( vegf ) 
0 vegf ) and fibroblast growth factor ( fgf ) 
17 factor ( fgf ) stimulation . NULL NULL NULL 
0 a specific vegf receptor-2 inhibitor demonstrated the importance of 
0 NULL furthermore , we showed that glycogen was depleted 
11 showed that glycogen was depleted in a low glucose 
0 , we demonstrated that direct inhibition of key enzymes 
0 we demonstrated that direct inhibition of key enzymes to 
0 that direct inhibition of key enzymes to glycogen metabolism 
0 metabolism and pentose phosphate pathways reduced huvec viability and 
18 and pentose phosphate pathways reduced huvec viability and migration 
14 reduced huvec viability and migration . NULL NULL NULL 
0 , inhibitors of these pathways have been shown to 
0 been shown to be effective antitumoral agents . NULL 
0 data suggest that the inhibition of metabolic pathways offers 
0 the inhibition of metabolic pathways offers a novel and 
18 approach , which simultaneously inhibits tumor cell proliferation and 
0 , which simultaneously inhibits tumor cell proliferation and tumor-induced 
1 simultaneously inhibits tumor cell proliferation and tumor-induced angiogenesis . 
17 tumor cell proliferation and induced angiogenesis . NULL NULL 
3 cell proliferation and tumor-induced angiogenesis . NULL NULL NULL 
16 NULL NULL rab gtpase regulation of vegfr2 trafficking and 
14 gtpase regulation of vegfr2 trafficking and signaling in endothelial 
0 objective : vascular endothelial growth factor receptor 2 ( 
16 receptor tyrosine kinase that regulates vascular physiology . NULL 
0 NULL NULL however , mechanism ( s ) by 
14 which vegfr2 signaling and trafficking is coordinated are not 
0 signaling and trafficking is coordinated are not clear . 
16 endocytic rab gtpases for regulation of vegfr2 trafficking and 
14 for regulation of vegfr2 trafficking and signaling linked to 
16 vegfr2 trafficking and signaling linked to endothelial cell migration 
14 linked to endothelial cell migration . NULL NULL NULL 
0 NULL NULL methods and results : quiescent vegfr2 displays 
14 quiescent vegfr2 displays endosomal localization and colocalization with the 
14 displays endosomal localization and colocalization with the rab5a gtpase 
0 , an early endosome fusion regulator . NULL NULL 
0 an early endosome fusion regulator . NULL NULL NULL 
9 NULL NULL NULL NULL expression of gtp or gdp-bound 
15 expression of gtp or bound rab5a mutants block activated 
18 or gdp-bound rab5a mutants block activated vegfr2 trafficking and 
17 gdp-bound rab5a mutants block activated vegfr2 trafficking and degradation 
14 mutants block activated vegfr2 trafficking and degradation . NULL 
11 activated vegfr2 trafficking and degradation . NULL NULL NULL 
16 NULL NULL NULL NULL manipulation of rab7a gtpase activity 
0 manipulation of rab7a gtpase activity associated with late endosomes 
0 of rab7a gtpase activity associated with late endosomes using 
9 with late endosomes using overexpression of wild-type or mutant 
18 wild-type or mutant proteins blocks activated vegfr2 trafficking and 
17 or mutant proteins blocks activated vegfr2 trafficking and degradation 
14 proteins blocks activated vegfr2 trafficking and degradation . NULL 
11 activated vegfr2 trafficking and degradation . NULL NULL NULL 
18 NULL NULL NULL NULL depletion of rab7a decreased vegfr2 
18 NULL depletion of rab7a decreased vegfr2 y1175 phosphorylation but 
12 rab7a decreased vegfr2 y1175 phosphorylation but increased p42/44 ( 
17 vegfr2 y1175 phosphorylation but increased p42/44 ( perk1/2 ) 
12 ( perk1/2 ) mapk phosphorylation . NULL NULL NULL 
14 NULL NULL endothelial cell migration was increased by rab5a 
17 endothelial cell migration was increased by rab5a depletion but 
18 was increased by rab5a depletion but decreased by rab7a 
18 by rab5a depletion but decreased by rab7a depletion . 
18 but decreased by rab7a depletion . NULL NULL NULL 
16 : rab5a and rab7a regulate vegfr2 trafficking toward early 
14 and rab7a regulate vegfr2 trafficking toward early and late 
16 our data suggest that mediated regulation of endothelial function 
16 data suggest that vegfr2-mediated regulation of endothelial function is 
0 vegfr2-mediated regulation of endothelial function is dependent on different 
17 of endothelial function is dependent on different but specific 
16 on different but specific mediated gtp hydrolysis activity required 
11 but specific rab-mediated gtp hydrolysis activity required for endosomal 
0 specific rab-mediated gtp hydrolysis activity required for endosomal trafficking 
0 rab-mediated gtp hydrolysis activity required for endosomal trafficking . 
0 activity required for endosomal trafficking . NULL NULL NULL 
0 NULL NULL angiomirs -- key regulators of angiogenesis . 
3 -- key regulators of angiogenesis . NULL NULL NULL 
2 NULL NULL NULL the formation of new blood vessels 
3 through the process of angiogenesis is critical in vascular 
17 process of angiogenesis is critical in vascular development and 
2 is critical in vascular development and homeostasis . NULL 
16 NULL NULL NULL NULL aberrant angiogenesis leads to a 
3 NULL NULL NULL aberrant angiogenesis leads to a variety 
17 NULL NULL aberrant angiogenesis leads to a variety of 
0 recent studies have revealed important roles for mirnas in 
0 studies have revealed important roles for mirnas in regulating 
16 roles for mirnas in regulating endothelial cell ( ec 
0 cell ( ec ) function , especially angiogenesis . 
3 ) function , especially angiogenesis . NULL NULL NULL 
18 NULL mice with ec-specific deletion of dicer , a 
0 of dicer , a key enzyme for generating mirnas 
0 a key enzyme for generating mirnas , display defective 
0 generating mirnas , display defective postnatal angiogenesis . NULL 
3 , display defective postnatal angiogenesis . NULL NULL NULL 
16 recently been shown to regulate angiogenesis in vivo . 
3 been shown to regulate angiogenesis in vivo . NULL 
0 NULL mirna-126 , an restricted mirna , regulates vascular 
16 an ec-restricted mirna , regulates vascular integrity and developmental 
3 vascular integrity and developmental angiogenesis . NULL NULL NULL 
16 and the mir-17-92 cluster contribute to tumor angiogenesis . 
0 mir-17-92 cluster contribute to tumor angiogenesis . NULL NULL 
3 cluster contribute to tumor angiogenesis . NULL NULL NULL 
3 the settings of pathological vascularization represents a new therapeutic 
17 NULL NULL NULL NULL promoting angiogenesis via manipulation of 
3 NULL NULL NULL promoting angiogenesis via manipulation of vegf 
16 NULL promoting angiogenesis via manipulation of vegf responsiveness with 
0 via manipulation of vegf responsiveness with notch signaling . 
17 NULL NULL NULL NULL promoting angiogenesis via delivery of 
3 NULL NULL NULL promoting angiogenesis via delivery of vascular 
14 NULL promoting angiogenesis via delivery of vascular endothelial growth 
0 delivery of vascular endothelial growth factor ( vegf ) 
3 vegf ) and other angiogenic factors is both a 
0 factors is both a potential therapy for cardiovascular diseases 
0 is both a potential therapy for cardiovascular diseases and 
0 cardiovascular diseases and a critical aspect for tissue regeneration 
2 critical aspect for tissue regeneration . NULL NULL NULL 
16 that vegf signaling is modulated by the notch signaling 
18 however , suggests that inhibiting notch signaling may enhance 
17 inhibiting notch signaling may enhance regional neovascularization , by 
3 signaling may enhance regional neovascularization , by altering the 
16 , by altering the responsiveness of local endothelial cells 
3 local endothelial cells to angiogenic stimuli . NULL NULL 
19 NULL NULL NULL NULL treatment of cultured human endothelial 
19 NULL NULL treatment of cultured human endothelial cells with 
0 , a gamma secretase inhibitor , increased cell migration 
17 gamma secretase inhibitor , increased cell migration and sprout 
14 inhibitor , increased cell migration and sprout formation in 
2 cell migration and sprout formation in response to vegf 
0 and sprout formation in response to vegf stimulation with 
17 in response to vegf stimulation with a biphasic dependence 
0 NULL NULL further , delivery of an appropriate combination 
0 system into ischemic hindlimbs led to a faster recovery 
0 or dapt alone ; perfusion levels reached 80 % 
0 dapt alone ; perfusion levels reached 80 % of 
14 combined dapt and vegf delivery . NULL NULL NULL 
0 NULL NULL NULL NULL direct intramuscular or intraperitoneal injection 
19 direct intramuscular or intraperitoneal injection of dapt did not 
0 of dapt ( gel delivery ) is important for 
0 gel delivery ) is important for its activity . 
0 is important for its activity . NULL NULL NULL 
14 NULL NULL NULL dapt delivery from the hydrogels also 
0 hydrogels also did not lead to any adverse side 
0 to any adverse side effects , in contrast to 
17 in contrast to systemic introduction of dapt . NULL 
0 NULL altogether , these results suggest a new approach 
17 a new approach to promote angiogenesis by controlling notch 
3 new approach to promote angiogenesis by controlling notch signaling 
16 to promote angiogenesis by controlling notch signaling , and 
19 provide new options to treat patients with diseases that 
18 patients with diseases that diminish angiogenic responsiveness . NULL 
3 with diseases that diminish angiogenic responsiveness . NULL NULL 
0 diseases that diminish angiogenic responsiveness . NULL NULL NULL 
17 NULL NULL NULL [ activation of sterol regulatory element 
0 [ activation of sterol regulatory element binding protein and 
0 of sterol regulatory element binding protein and its involvement 
0 sterol regulatory element binding protein and its involvement in 
16 binding protein and its involvement in endothelial cell migration 
14 involvement in endothelial cell migration ] NULL NULL NULL 
17 : to study the activation of sterol regulatory element 
0 the activation of sterol regulatory element binding protein ( 
0 of sterol regulatory element binding protein ( srebp ) 
0 sterol regulatory element binding protein ( srebp ) and 
16 srebp ) and its critical role in endothelial cell 
16 ) and its critical role in endothelial cell migration 
14 role in endothelial cell migration . NULL NULL NULL 
19 ( ecs ) were cultured . NULL NULL NULL 
9 NULL NULL NULL the expression of srebp and cdc42 
0 NULL moreover , outward growth migration model and transwell 
0 moreover , outward growth migration model and transwell chamber 
0 transwell chamber assay were used to detect ecs migration 
14 used to detect ecs migration . NULL NULL NULL 
0 NULL NULL NULL NULL results : ( 1 ) 
17 1 ) srebp was activated during ecs migration . 
14 was activated during ecs migration . NULL NULL NULL 
17 western blot analysis demonstrated increased active form srebp in 
0 blot analysis demonstrated increased active form srebp in migrating 
0 analysis demonstrated increased active form srebp in migrating as 
14 active form srebp in migrating as compared to non-migrating 
14 migrating as compared to non-migrating ecs population . NULL 
17 NULL NULL NULL srebp activation decreased as ecs migration 
18 NULL NULL srebp activation decreased as ecs migration slowed 
14 activation decreased as ecs migration slowed ; ( 2 
18 decreased as ecs migration slowed ; ( 2 ) 
17 ) coincidental with srebp activation , mrna expression of 
10 with srebp activation , mrna expression of its target 
10 srebp activation , mrna expression of its target genes 
0 mrna expression of its target genes such as low 
17 fatty acid synthase also increased in migrating ecs population 
14 synthase also increased in migrating ecs population as detected 
0 migrating ecs population as detected by real-time pcr ; 
14 ; ( 3 ) migration induced srebp activation in 
17 ( 3 ) migration induced srebp activation in ecs 
17 ) migration induced srebp activation in ecs was inhibited 
18 activation in ecs was inhibited by srebp-acting protein rnai 
0 was inhibited by srebp-acting protein rnai and pharmacologically by 
18 ; ( 4 ) inhibition of srebp led to 
17 ) inhibition of srebp led to decreased ecs migration 
18 of srebp led to decreased ecs migration in various 
14 led to decreased ecs migration in various models ; 
9 5 ) cells genetically deficient in srebp-acting protein , 
0 genetically deficient in srebp-acting protein , s1p , or 
0 or s2p , phenotypically exhibited impaired migration ; ( 
0 s2p , phenotypically exhibited impaired migration ; ( 6 
0 , phenotypically exhibited impaired migration ; ( 6 ) 
18 ( 6 ) srebp inhibition in ecs suppressed the 
18 srebp inhibition in ecs suppressed the activity of small 
0 in ecs suppressed the activity of small gtpase cdc42 
0 gtpase cdc42 , a key molecule for ecs motility 
14 key molecule for ecs motility . NULL NULL NULL 
17 conclusions : srebp is activated during and plays a 
16 is activated during and plays a critical role in 
16 during and plays a critical role in ecs migration 
16 and plays a critical role in ecs migration . 
14 critical role in ecs migration . NULL NULL NULL 
19 NULL NULL NULL NULL targeting srebp could become a 
0 approach in fighting diseases involving abnormal ecs migration . 
14 diseases involving abnormal ecs migration . NULL NULL NULL 
0 NULL NULL NULL fibroblast growth factor receptor 2-positive fibroblasts 
0 fibroblast growth factor receptor positive fibroblasts provide a suitable 
0 a suitable microenvironment for tumor development and progression in 
2 suitable microenvironment for tumor development and progression in esophageal 
2 for tumor development and progression in esophageal carcinoma . 
0 NULL NULL purpose : tumor fibroblasts ( tf ) 
16 have been suggested to play an essential role in 
16 suggested to play an essential role in the complex 
16 to play an essential role in the complex process 
0 the complex process of tumor interactions and tumorigenesis . 
15 complex process of tumor-stroma interactions and tumorigenesis . NULL 
0 the aim of the present study was to investigate 
0 to investigate the specific role of tf in the 
0 design : an affymetrix expression microarray was used to 
0 affymetrix expression microarray was used to compare gene expression 
0 used to compare gene expression profiles between six pairs 
0 NULL NULL NULL differentially expressed genes were identified , 
0 NULL NULL NULL NULL results : about 43 % 
0 genes in tfs were associated with cell proliferation , 
1 were associated with cell proliferation , extracellular matrix remodeling 
0 cell proliferation , extracellular matrix remodeling , and immune 
7 proliferation , extracellular matrix remodeling , and immune response 
0 remodeling , and immune response . NULL NULL NULL 
17 NULL NULL NULL NULL up-regulation of fibroblast growth factor 
0 NULL up-regulation of fibroblast growth factor receptor 2 ( 
0 fgfr2 ) , which showed the most significant change 
0 which showed the most significant change , was detected 
0 showed the most significant change , was detected in 
0 significant change , was detected in all six tested 
0 further study found that positive fibroblasts were only observed 
0 fgfr2-positive fibroblasts were only observed inside the tumor tissues 
0 only observed inside the tumor tissues and not in 
0 tissues and not in tumor stromal tissues , suggesting 
0 that fgfr2 could be used as a tf-specific marker 
0 to be able to promote escc tumor cell growth 
0 able to promote escc tumor cell growth , migration 
1 promote escc tumor cell growth , migration , and 
14 tumor cell growth , migration , and invasion in 
14 , migration , and invasion in vitro . NULL 
0 NULL based on our results , we hypothesize that 
0 a suitable microenvironment via secretion of proteins that could 
0 of proteins that could promote cancer development and progression 
0 that could promote cancer development and progression through stimulation 
0 promote cancer development and progression through stimulation of cancer 
17 development and progression through stimulation of cancer cell proliferation 
1 stimulation of cancer cell proliferation , induction of angiogenesis 
17 cancer cell proliferation , induction of angiogenesis , inhibition 
3 proliferation , induction of angiogenesis , inhibition of cell 
18 induction of angiogenesis , inhibition of cell adhesion , 
15 , inhibition of cell adhesion , enhancement of cell 
17 of cell adhesion , enhancement of cell mobility , 
14 , enhancement of cell mobility , and promotion of 
17 cell mobility , and promotion of the epithelial-mesenchymal transition 
2 promotion of the epithelial-mesenchymal transition . NULL NULL NULL 
0 NULL NULL NULL [ role of the tumor suppressor 
0 [ role of the tumor suppressor arf in oncogenesis 
0 role of the tumor suppressor arf in oncogenesis ] 
0 the literature on a role of the tumor suppressor 
0 a role of the tumor suppressor arf in oncogenesis 
0 role of the tumor suppressor arf in oncogenesis and 
0 a gene encoding arf protein . NULL NULL NULL 
17 NULL NULL NULL the dependent and p-53-independent functions of 
16 NULL the p53-dependent and independent functions of this protein 
0 the p53-dependent and p-53-independent functions of this protein are 
0 p-53-independent functions of this protein are under many studies 
16 is evidence for the implication of arf in angiogenesis 
3 implication of arf in angiogenesis . NULL NULL NULL 
0 more information on the role of arf in the 
16 of arf in the regulation of a cell cycle 
5 a cell cycle , apoptosis , and autophagy . 
0 the importance of this tumor suppressor in the mechanisms 
0 importance of this tumor suppressor in the mechanisms of 
0 in the mechanisms of carcinogenesis is beyond question as 
18 beyond question as the inactivation of arf suppressor activity 
0 the inactivation of arf suppressor activity leads to the 
0 inactivation of arf suppressor activity leads to the rapid 
17 of arf suppressor activity leads to the rapid growth 
4 leads to the rapid growth of neoplasia . NULL 
0 exact mechanisms of arf action yet remain unclear and 
0 yet remain unclear and require further studies by different 
0 molecular genetic and other levels of investigation . NULL 
0 NULL NULL NULL NULL impact of tumor cell vegf 
0 NULL NULL impact of tumor cell vegf expression on 
9 of tumor cell vegf expression on the in vivo 
0 on the in vivo efficacy of vandetanib ( zactima 
0 NULL vegf is the key player in tumor angiogenesis 
0 the key player in tumor angiogenesis . NULL NULL 
3 key player in tumor angiogenesis . NULL NULL NULL 
0 current study , the impact of vegf expression on 
9 the impact of vegf expression on the response of 
16 vegf expression on the response of tumors to the 
15 tumors to the vegfr2 associated tyrosine kinase inhibitor vandetanib 
0 vegfr2 associated tyrosine kinase inhibitor vandetanib was evaluated . 
9 ) clonal cell lines expressing varying levels of vegf 
0 cell lines expressing varying levels of vegf were established 
0 levels of vegf were established and their response to 
16 were established and their response to vandetanib was assessed 
0 was assessed in tissue culture and as solid tumors 
0 NULL NULL NULL NULL results : vandetanib treatment had 
19 NULL results : vandetanib treatment had no effect on 
16 vandetanib treatment had no effect on tumor cell clonogenic 
0 had no effect on tumor cell clonogenic cell survival 
5 tumor cell clonogenic cell survival in vitro but doses 
18 > or=10 nm significantly reduced endothelial cell migration . 
14 significantly reduced endothelial cell migration . NULL NULL NULL 
0 in vivo , tumors derived from cell clones expressing 
9 derived from cell clones expressing high levels of vegf 
0 cell clones expressing high levels of vegf displayed significantly 
17 of vegf displayed significantly enhanced angiogenesis and more aggressive 
3 vegf displayed significantly enhanced angiogenesis and more aggressive growth 
4 angiogenesis and more aggressive growth . NULL NULL NULL 
3 NULL NULL an intradermal angiogenesis assay was used to 
0 intradermal angiogenesis assay was used to demonstrate that a 
19 demonstrate that a 4-day treatment with vandetanib ( 50 
18 was able to significantly inhibit blood vessel growth induced 
4 significantly inhibit blood vessel growth induced by both parental 
17 inhibit blood vessel growth induced by both parental and 
9 both parental and high expressing tumor cell clones . 
0 parental and high vegf-expressing tumor cell clones . NULL 
0 NULL in the ht29 tumor model , treatment response 
19 ht29 tumor model , treatment response to vandetanib ( 
16 tumor model , treatment response to vandetanib ( 50 
0 was greatest in xenografts derived from the highest vegf-expressing 
9 derived from the highest expressing cell clones . NULL 
0 noted in the sccvii tumor model . NULL NULL 
0 NULL NULL NULL the present findings indicate that vandetanib 
19 findings indicate that vandetanib therapy effectively counteracted the aggressive 
18 that vandetanib therapy effectively counteracted the aggressive feature of 
0 the aggressive feature of tumor growth resulting from vegf 
4 aggressive feature of tumor growth resulting from vegf over-expressing 
0 feature of tumor growth resulting from vegf over-expressing tumor 
9 growth resulting from vegf over-expressing tumor cells and suggest 
0 resulting from vegf over-expressing tumor cells and suggest that 
18 well suited for anti-vegf interventions . NULL NULL NULL 
16 NULL NULL NULL mechanical regulation of the proangiogenic factor 
3 mechanical regulation of the angiogenic factor ccn1/cyr61 gene requires 
17 proangiogenic factor ccn1/cyr61 gene requires the combined activities of 
0 gene requires the combined activities of mrtf-a and creb-binding 
0 activities of mrtf-a and binding protein histone acetyltransferase . 
0 of mrtf-a and creb-binding protein histone acetyltransferase . NULL 
16 NULL smooth muscle-rich tissues respond to mechanical overload by 
0 by an adaptive hypertrophic growth combined with activation of 
17 hypertrophic growth combined with activation of angiogenesis , which 
3 combined with activation of angiogenesis , which potentiates their 
0 of angiogenesis , which potentiates their mechanical overload-bearing capabilities 
3 NULL NULL NULL NULL neovascularization is associated with mechanical 
0 NULL NULL neovascularization is associated with mechanical strain-dependent induction 
0 is associated with mechanical dependent induction of angiogenic factors 
17 associated with mechanical strain-dependent induction of angiogenic factors such 
3 mechanical strain-dependent induction of angiogenic factors such as ccn1 
17 immediate-early gene-encoded matricellular molecule critical for vascular development and 
2 molecule critical for vascular development and repair . NULL 
2 for vascular development and repair . NULL NULL NULL 
0 have demonstrated that mechanical dependent induction of the ccn1 
17 demonstrated that mechanical strain-dependent induction of the ccn1 gene 
0 of the ccn1 gene involves signaling cascades through rhoa-mediated 
16 involves signaling cascades through mediated actin remodeling and the 
0 cascades through rhoa-mediated actin remodeling and the p38 stress-activated 
0 remodeling and the p38 activated protein kinase ( sapk 
0 and the p38 stress-activated protein kinase ( sapk ) 
16 NULL NULL actin signaling controls serum response factor ( 
0 actin signaling controls serum response factor ( srf ) 
0 factor ( srf ) activity via srf interaction with 
15 ) activity via srf interaction with the myocardin-related transcriptional 
0 interaction with the myocardin-related transcriptional activator ( mrtf ) 
0 with the myocardin-related transcriptional activator ( mrtf ) -a 
0 NULL NULL NULL such activity was abolished in mechanically 
0 NULL such activity was abolished in mechanically stimulated mouse 
17 was abolished in mechanically stimulated mouse mrtf-a ( -/- 
18 ) cells or upon inhibition of creb-binding protein ( 
0 or upon inhibition of binding protein ( cbp ) 
0 upon inhibition of creb-binding protein ( cbp ) histone 
17 NULL NULL mechanical strain induced cbp-mediated acetylation of histones 
17 NULL mechanical strain induced mediated acetylation of histones 3 
0 and 4 at the binding site and within the 
18 NULL NULL NULL NULL inhibition of p38 sapk reduced 
18 inhibition of p38 sapk reduced cbp hat activity and 
0 sapk reduced cbp hat activity and its recruitment to 
15 hat activity and its recruitment to the srf.mrtf-a complex 
0 srf.mrtf-a complex , whereas enforced induction of p38 by 
17 complex , whereas enforced induction of p38 by upstream 
17 mkk3 and mkk6 ) enhanced both cbp hat and 
0 hat and ccn1 promoter activities . NULL NULL NULL 
17 NULL similarly , mechanical induced ccn1 gene expression in 
9 mechanical overload-induced ccn1 gene expression in vivo was associated 
16 expression in vivo was associated with nuclear localization of 
14 was associated with nuclear localization of mrtf-a and enrichment 
16 these data suggest that controlled activation of srf , 
17 data suggest that signal-controlled activation of srf , mrtf-a 
0 cbp provides a novel connection between mechanical stimuli and 
3 between mechanical stimuli and angiogenic gene expression . NULL 
0 stimuli and angiogenic gene expression . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenesis in platelet endothelial cell 
0 in platelet endothelial cell adhesion molecule-1-null mice . NULL 
9 platelet endothelial cell adhesion null mice . NULL NULL 
0 NULL platelet endothelial cell adhesion molecule ( pecam ) 
0 -1 has been previously implicated in endothelial cell migration 
14 implicated in endothelial cell migration ; additionally , anti-pecam-1 
18 have been shown to inhibit in vivo angiogenesis . 
3 to inhibit in vivo angiogenesis . NULL NULL NULL 
9 were therefore performed with null mice to further define 
16 to further define the involvement of pecam-1 in blood 
2 pecam-1 in blood vessel formation . NULL NULL NULL 
3 NULL NULL NULL NULL vascularization of subcutaneous matrigel implants 
0 implants as well as tumor angiogenesis were both inhibited 
3 as well as tumor angiogenesis were both inhibited in 
18 tumor angiogenesis were both inhibited in pecam-1-null mice . 
9 were both inhibited in null mice . NULL NULL 
19 NULL reciprocal bone marrow transplants that involved both wild-type 
0 bone marrow transplants that involved both wild-type and pecam-1-deficient 
9 involved both wild-type and deficient mice revealed that the 
18 mice revealed that the impaired angiogenic response resulted from 
3 revealed that the impaired angiogenic response resulted from a 
0 that the impaired angiogenic response resulted from a loss 
0 the impaired angiogenic response resulted from a loss of 
14 response resulted from a loss of endothelial , but 
0 NULL in vitro wound migration and single-cell motility by 
14 wound migration and single-cell motility by pecam-1-null endothelial cells 
0 and single-cell motility by null endothelial cells were also 
0 NULL NULL NULL in addition , filopodia formation , 
2 in addition , filopodia formation , a feature of 
18 motile cells , was inhibited in pecam-1-null endothelial cells 
0 , was inhibited in null endothelial cells as well 
19 in human endothelial cells treated with either anti-pecam-1 antibody 
9 NULL furthermore , the expression of pecam-1 promoted filopodia 
17 the expression of pecam-1 promoted filopodia formation and increased 
2 of pecam-1 promoted filopodia formation and increased the protein 
17 promoted filopodia formation and increased the protein expression levels 
0 formation and increased the protein expression levels of cdc42 
9 and increased the protein expression levels of cdc42 , 
0 increased the protein expression levels of cdc42 , a 
17 that is known to promote the formation of filopodia 
2 known to promote the formation of filopodia . NULL 
2 NULL NULL in the developing retinal vasculature , numerous 
3 at the tips of angiogenic sprouts , were observed 
0 angiogenic sprouts , were observed in wild-type animals , 
9 lesser extent in the null mice . NULL NULL 
16 data further establish the involvement of endothelial pecam-1 in 
3 of endothelial pecam-1 in angiogenesis and suggest that , 
17 vivo , pecam-1 may stimulate endothelial cell motility by 
14 may stimulate endothelial cell motility by promoting the formation 
17 endothelial cell motility by promoting the formation of filopodia 
2 motility by promoting the formation of filopodia . NULL 
16 NULL NULL mek5/erk5 signaling modulates endothelial cell migration and 
14 signaling modulates endothelial cell migration and focal contact turnover 
0 cell migration and focal contact turnover . NULL NULL 
0 migration and focal contact turnover . NULL NULL NULL 
2 NULL NULL NULL the formation of new blood vessels 
17 vessels from pre-existing ones requires highly coordinated restructuring of 
0 pre-existing ones requires highly coordinated restructuring of endothelial cells 
7 ones requires highly coordinated restructuring of endothelial cells ( 
0 and the surrounding extracellular matrix . NULL NULL NULL 
14 NULL NULL directed ec migration is a central step 
0 ec migration is a central step in this process 
0 in this process and depends on cellular signaling cascades 
0 cellular signaling cascades that initiate and control the structural 
0 cascades that initiate and control the structural rearrangements . 
0 initiate and control the structural rearrangements . NULL NULL 
9 earlier findings that erk5 deficiency in mouse ec results 
17 deficiency in mouse ec results in massive defects in 
18 ec results in massive defects in vessel architecture , 
16 we focused on the impact of the mek5/erk5 signaling 
14 signaling pathway on ec migration . NULL NULL NULL 
17 we found that constitutive activation of mek5/erk5 signaling strongly 
18 of mek5/erk5 signaling strongly inhibits ec migration and results 
14 signaling strongly inhibits ec migration and results in massive 
0 inhibits ec migration and results in massive morphological changes 
0 and results in massive morphological changes . NULL NULL 
0 results in massive morphological changes . NULL NULL NULL 
14 the area covered by spread ec was dramatically enlarged 
0 , accompanied by an increase in focal contacts and 
0 an increase in focal contacts and altered organization of 
0 in focal contacts and altered organization of actin filaments 
7 focal contacts and altered organization of actin filaments . 
18 more rigid and show reduced motility . NULL NULL 
14 rigid and show reduced motility . NULL NULL NULL 
0 most likely based on decreased focal contact turnover caused 
0 based on decreased focal contact turnover caused by reduced 
0 on decreased focal contact turnover caused by reduced expression 
0 decreased focal contact turnover caused by reduced expression of 
18 contact turnover caused by reduced expression of p130cas , 
9 turnover caused by reduced expression of p130cas , a 
0 of p130cas , a key player in directed cell 
14 player in directed cell migration . NULL NULL NULL 
16 signaling not only is involved in ec survival and 
5 is involved in ec survival and stress response but 
0 ec survival and stress response but also controls migration 
16 stress response but also controls migration and morphology of 
14 response but also controls migration and morphology of ec 
0 NULL the down syndrome critical region gene 1 short 
0 1 short variant promoters direct vascular bed-specific gene expression 
0 direct vascular bed-specific gene expression during inflammation in mice 
0 NULL NULL down syndrome critical region gene 1 ( 
0 dscr-1s ) is an inhibitor of calcineurin/nfat signaling encoded 
17 previously reported that vegf induces dscr-1s expression in endothelial 
9 that vegf induces dscr-1s expression in endothelial cells , 
0 , which in turn negatively feeds back to attenuate 
18 negatively feeds back to attenuate endothelial cell activation . 
17 to attenuate endothelial cell activation . NULL NULL NULL 
0 order to characterize the role of the promoter that 
0 of the promoter that drives dscr-1s expression in mediating 
9 promoter that drives dscr-1s expression in mediating inducible expression 
0 drives dscr-1s expression in mediating inducible expression in vivo 
0 dscr-1s expression in mediating inducible expression in vivo and 
0 expression in mediating inducible expression in vivo and to 
19 in inflammation , we targeted a dna construct containing 
19 the human dscr1s promoter coupled to the lacz reporter 
9 that lacz was uniformly expressed in the endothelium of 
0 in the endothelium of transgenic embryos but was markedly 
18 embryos but was markedly downregulated postnatally . NULL NULL 
19 NULL NULL NULL systemic administration of vegf or lps 
17 lps in adult mice resulted in cyclosporine a-sensitive reactivation 
16 mice resulted in cyclosporine sensitive reactivation of the dscr1s 
17 resulted in cyclosporine a-sensitive reactivation of the dscr1s promoter 
0 promoter and endogenous gene expression in a subset of 
17 dscr1s promoter was similarly induced in the endothelium of 
0 in the endothelium of tumor xenografts . NULL NULL 
9 model of endotoxemia , deficient mice demonstrated increased sepsis 
0 , dscr-1s-deficient mice demonstrated increased sepsis mortality , whereas 
17 sepsis mortality , whereas mediated dscr-1s overexpression protected against 
9 , whereas adenovirus-mediated dscr-1s overexpression protected against lps-induced lethality 
0 dscr-1s overexpression protected against induced lethality . NULL NULL 
9 promoter directs vascular bed-specific expression in activated endothelium and 
17 vascular bed-specific expression in activated endothelium and that dscr-1s 
0 to dampen the host response to infection . NULL 
0 the host response to infection . NULL NULL NULL 
18 NULL NULL NULL epox inhibits angiogenesis by degradation of 
3 NULL NULL epox inhibits angiogenesis by degradation of mcl-1 
11 epox inhibits angiogenesis by degradation of mcl-1 through erk 
18 of mcl-1 through erk inactivation . NULL NULL NULL 
3 NULL NULL purpose : angiogenic therapy is considered as 
18 NULL purpose : antiangiogenic therapy is considered as an 
0 is considered as an effective strategy for controlling the 
16 an effective strategy for controlling the growth and metastasis 
4 strategy for controlling the growth and metastasis of tumors 
14 controlling the growth and metastasis of tumors . NULL 
0 a myriad of biological activities described for xanthone derivatives 
18 derivatives , the anticancer activity is quite remarkable , 
0 , but the molecular mechanism is not clearly resolved 
0 NULL NULL in the present study , we investigated 
3 , we investigated the angiogenic mechanism of 3 , 
18 we investigated the antiangiogenic mechanism of 3 , 6-di 
16 , a novel mcl-1 targeting drug . NULL NULL 
3 : to evaluate the angiogenic activity of epox , 
18 to evaluate the antiangiogenic activity of epox , we 
2 cell cycle , tube formation assay in vitro , 
16 NULL to evaluate the effect of epox on the 
0 NULL NULL intracellular glutathione levels were determined with the 
0 were determined with the use of monochlorobimane , a 
0 NULL NULL NULL NULL results : epox induced endothelial 
17 NULL results : epox induced endothelial cell apoptosis in 
5 epox induced endothelial cell apoptosis in association with proteasome-dependent 
16 endothelial cell apoptosis in association with proteasome-dependent mcl-1 degradation 
17 apoptosis in association with dependent mcl-1 degradation . NULL 
11 association with proteasome-dependent mcl-1 degradation . NULL NULL NULL 
18 NULL NULL NULL NULL down-regulation of mcl-1 resulted in 
17 NULL down-regulation of mcl-1 resulted in an increase in 
17 mcl-1 resulted in an increase in mcl-1-free bim , 
16 in an increase in free bim , activation of 
17 in mcl-1-free bim , activation of bax , and 
0 and then signaling of mediated apoptosis . NULL NULL 
0 then signaling of mitochondria-mediated apoptosis . NULL NULL NULL 
18 NULL additionally , glutathione depletion and extracellular signal-regulated kinase 
0 glutathione depletion and extracellular regulated kinase ( erk ) 
18 kinase ( erk ) inactivation was observed in epox-treated 
0 erk ) inactivation was observed in epox-treated cells . 
19 inactivation was observed in treated cells . NULL NULL 
19 NULL NULL NULL glutathione supplementation reversed the inhibitory effects 
18 NULL NULL glutathione supplementation reversed the inhibitory effects of 
18 glutathione supplementation reversed the inhibitory effects of epox on 
18 supplementation reversed the inhibitory effects of epox on erk 
17 on erk , which increases the phosphorylation of mcl-1 
12 , which increases the phosphorylation of mcl-1 at t 
9 t ( 163. ) overexpression of mitogen-activated protein/erk kinase 
0 163. ) overexpression of activated protein/erk kinase ( mek 
0 ) overexpression of mitogen-activated protein kinase ( mek ) 
18 ( mek ) partially reversed the effect of epox 
16 ) partially reversed the effect of epox on mcl-1 
13 of epox on mcl-1 dephosphorylation , ubiquitination , and 
11 , ubiquitination , and degradation , further implicating erk 
16 implicating erk in the regulation of mcl-1 stability . 
17 provides evidence that epox induces glutathione depletion , erk 
18 that epox induces glutathione depletion , erk inactivation , 
18 glutathione depletion , erk inactivation , and mcl-1 degradation 
11 inactivation , and mcl-1 degradation on endothelial cells , 
17 endothelial cells , which leads to inhibition of angiogenesis 
18 , which leads to inhibition of angiogenesis . NULL 
3 leads to inhibition of angiogenesis . NULL NULL NULL 
0 NULL NULL NULL our results suggest that epox is 
3 epox is a novel angiogenic agent , making it 
0 making it a promising lead compound for further development 
0 lead compound for further development in the treatment of 
0 further development in the treatment of angiogenesis-related pathologies . 
3 in the treatment of angiogenesis pathologies . NULL NULL 
15 beta } 2-glycoprotein i binds angiostatin 4.5 ( plasminogen 
18 kringle 1-5 ) and attenuates its antiangiogenic property . 
3 ) and attenuates its angiogenic property . NULL NULL 
18 and attenuates its antiangiogenic property . NULL NULL NULL 
18 plasminogen fragment with antitumor/antiangiogenic property . NULL NULL NULL 
0 kringle 5 , is produced by autoproteolysis and present 
0 produced by autoproteolysis and present in human plasma . 
17 beta2gpi ) is proteolytically cleaved by plasmin in its 
17 nicked beta2gpi ) , resulting in binding to plasminogen 
15 ) , resulting in binding to plasminogen . NULL 
3 NULL NULL NULL NULL angiogenic properties have been recently 
18 NULL NULL NULL antiangiogenic properties have been recently reported 
0 NULL NULL in the present study , we found 
0 study , we found significant binding of nicked beta2gpi 
15 , we found significant binding of nicked beta2gpi to 
15 NULL NULL via this binding , nicked beta2gpi attenuates 
18 binding , nicked beta2gpi attenuates the antiangiogenic functions of 
3 nicked beta2gpi attenuates the angiogenic functions of as4.5 in 
18 beta2gpi attenuates the antiangiogenic functions of as4.5 in the 
1 of as4.5 in the proliferation of arterial/venous endothelial cells 
0 , in the extracellular matrix invasion and the tube 
14 in the extracellular matrix invasion and the tube formation 
2 invasion and the tube formation of venous endothelial cells 
3 , and in vivo angiogenesis . NULL NULL NULL 
15 intact beta2gpi does not bind to as4.5 or inhibit 
18 bind to as4.5 or inhibit its antiangiogenic activity . 
3 as4.5 or inhibit its angiogenic activity . NULL NULL 
18 or inhibit its antiangiogenic activity . NULL NULL NULL 
0 nicked beta2gpi exerts dual effects on angiogenesis , that 
3 exerts dual effects on angiogenesis , that is , 
17 is , nicked beta2gpi promotes angiogenesis in the presence 
3 , nicked beta2gpi promotes angiogenesis in the presence of 
0 promotes angiogenesis in the presence of as4.5 , whereas 
18 , whereas nicked beta2gpi inhibits angiogenesis at concentrations high 
3 whereas nicked beta2gpi inhibits angiogenesis at concentrations high enough 
0 concentrations high enough to neutralize as4.5 . NULL NULL 
16 suggest that plasmin-nicked beta2gpi promotes angiogenesis by interacting with 
3 that plasmin-nicked beta2gpi promotes angiogenesis by interacting with plasmin-generated 
15 beta2gpi promotes angiogenesis by interacting with plasmin-generated as4.5 in 
0 as4.5 in sites of increased fibrinolysis such as thrombus 
0 NULL NULL NULL NULL targeting angiogenesis : progress with 
3 NULL NULL NULL targeting angiogenesis : progress with anti-vegf 
0 : progress with anti-vegf treatment with large molecules . 
3 NULL NULL NULL NULL angiogenesis -- one of the 
0 as a valid therapeutic target in oncology . NULL 
0 vegf system represents a key mediator of tumor-initiated angiogenesis 
0 system represents a key mediator of tumor-initiated angiogenesis and 
17 a key mediator of initiated angiogenesis and the first 
3 key mediator of tumor-initiated angiogenesis and the first target 
0 angiogenesis and the first target of antiangiogenesis agents introduced 
3 the first target of angiogenesis agents introduced in clinical 
0 antiangiogenesis agents introduced in clinical practice . NULL NULL 
19 NULL NULL although anti-vegf therapies have clearly demonstrated antitumor 
18 have clearly demonstrated antitumor efficacy in various malignancies , 
0 combined with conventional cytotoxic chemotherapy , their mechanism of 
0 cytotoxic chemotherapy , their mechanism of action is not 
0 , their mechanism of action is not fully understood 
3 the rationale for using angiogenic compounds and will focus 
0 as antibodies , that target the vegf system . 
0 NULL NULL NULL NULL clinical data on bevacizumab is 
0 well as its continued use beyond progression remain unanswered 
0 its continued use beyond progression remain unanswered , in 
0 , in spite of negative data on bevacizumab in 
19 data on bevacizumab in treating patients with adjuvant colon 
0 NULL nonetheless , anti-vegf therapy has enhanced the arsenal 
0 , anti-vegf therapy has enhanced the arsenal of anticancer 
0 the arsenal of anticancer therapies and has provided new 
3 an experimental study on angiogenesis of non-vascularized autogenous bone 
3 study on angiogenesis of vascularized autogenous bone graft with 
19 graft with vascular bundle implantation ] NULL NULL NULL 
16 : to investigate the effect of vascular bundle implantation 
19 effect of vascular bundle implantation in autogenous bone graft 
3 autogenous bone graft on angiogenesis . NULL NULL NULL 
19 of a rabbit were removed as free bone grafts 
0 rabbit were removed as free bone grafts , whose 
19 , whose periostea were peeled off . NULL NULL 
0 NULL NULL NULL in control group , there was 
19 was no vascular bundle implantation . NULL NULL NULL 
19 NULL each bone was placed in masseter muscle separately 
19 NULL the rabbits were sacrificed and the specimens were 
0 and 6 weeks after surgery for histological observation , 
0 observation , chinese ink perfusion and cd34 immunohistochemistry . 
3 in order to evaluate angiogenesis of autogenous bone grafts 
0 NULL NULL NULL NULL results : the bone grafts 
3 bone grafts were found revascularization in 3 days after 
0 in 3 days after surgery in the test group 
0 2 weeks in the control group . NULL NULL 
0 and 4 weeks after surgery , the mvd of 
0 higher than that of control group . NULL NULL 
0 in 4 weeks after surgery , angiogenesis of test 
3 weeks after surgery , angiogenesis of test group reached 
19 conclusion : vascular bundle implantation improved angiogenesis in non-vascularized 
17 : vascular bundle implantation improved angiogenesis in non-vascularized autogenous 
3 vascular bundle implantation improved angiogenesis in non-vascularized autogenous bone 
3 implantation improved angiogenesis in vascularized autogenous bone graft in 
0 NULL NULL [ ambiguity role of neutrophils in oncogenesis 
2 ( neutrophils ) in development and spreading of a 
14 ) in development and spreading of a tumor . 
0 and spreading of a tumor . NULL NULL NULL 
0 both the well known functions of neutrophils ( degranulation 
8 neutrophils ( degranulation , production of reactive oxygen species 
0 ambiguity of the neutrophil role in oncogenesis . NULL 
18 neutrophils display exclusively antitumor properties . NULL NULL NULL 
0 information testifies about protumoral activity of neutrophils : they 
14 of neutrophils : they migrate to a tumor and 
0 they migrate to a tumor and promote angiogenesis and 
17 to a tumor and promote angiogenesis and metastasis at 
3 a tumor and promote angiogenesis and metastasis at late 
14 and promote angiogenesis and metastasis at late stages of 
0 late stages of the tumor . NULL NULL NULL 
0 , specific enzymes ) participate both in antitumoral defenses 
0 an organism and protumoral activity . NULL NULL NULL 
14 NULL NULL endothelial cell migration and vascular endothelial growth 
0 migration and vascular endothelial growth factor expression are the 
9 vascular endothelial growth factor expression are the result of 
0 are the result of loss of breast tissue polarity 
14 NULL NULL NULL NULL recruiting a new blood supply 
0 blood supply is a limiting step in tumor progression 
0 a rate-limiting step in tumor progression . NULL NULL 
2 rate-limiting step in tumor progression . NULL NULL NULL 
0 three-dimensional model of breast carcinogenesis , disorganized , proliferative 
0 carcinogenesis , disorganized , proliferative transformed breast epithelial cells 
2 , disorganized , proliferative transformed breast epithelial cells express 
0 transformed breast epithelial cells express significantly higher expression of 
0 cells express significantly higher expression of angiogenic genes compared 
0 significantly higher expression of angiogenic genes compared with their 
0 with their polarized , growth nonmalignant counterparts . NULL 
17 NULL NULL NULL NULL elevated vascular endothelial growth factor 
0 NULL elevated vascular endothelial growth factor ( vegf ) 
14 factor ( vegf ) secretion by malignant cells enhanced 
0 vegf ) secretion by malignant cells enhanced recruitment of 
17 secretion by malignant cells enhanced recruitment of endothelial cells 
14 by malignant cells enhanced recruitment of endothelial cells ( 
2 NULL NULL significantly , phenotypic reversion of malignant cells 
2 NULL significantly , phenotypic reversion of malignant cells via 
0 , phenotypic reversion of malignant cells via reexpression of 
9 of malignant cells via reexpression of hoxd10 , which 
0 which is lost in malignant progression , significantly attenuated 
0 is lost in malignant progression , significantly attenuated vegf 
18 malignant progression , significantly attenuated vegf expression in a 
9 , significantly attenuated vegf expression in a hypoxia-inducible factor 
0 vegf expression in a inducible factor 1alpha-independent fashion and 
16 in a hypoxia-inducible factor independent fashion and reduced ec 
18 factor 1alpha-independent fashion and reduced ec migration . NULL 
14 fashion and reduced ec migration . NULL NULL NULL 
17 to restoring polarity : forced proliferation of polarized , 
1 restoring polarity : forced proliferation of polarized , nonmalignant 
17 nonmalignant cells did not induce vegf expression and ec 
9 did not induce vegf expression and ec recruitment , 
14 vegf expression and ec recruitment , whereas disrupting the 
0 ec recruitment , whereas disrupting the architecture of growth-arrested 
0 disrupting the architecture of growth , reverted cells did 
18 these data show that disrupting cytostructure activates the angiogenic 
17 show that disrupting cytostructure activates the angiogenic switch even 
3 disrupting cytostructure activates the angiogenic switch even in the 
0 in the absence of proliferation and/or hypoxia and restoring 
0 and/or hypoxia and restoring organization of malignant clusters reduces 
0 and restoring organization of malignant clusters reduces vegf expression 
18 organization of malignant clusters reduces vegf expression and ec 
9 malignant clusters reduces vegf expression and ec activation to 
17 vegf expression and ec activation to levels found in 
0 and ec activation to levels found in quiescent nonmalignant 
0 architecture and polarity in malignant progression . NULL NULL 
2 and polarity in malignant progression . NULL NULL NULL 
0 NULL NULL NULL metronomic chemotherapy ( the frequent , 
0 term , low dose administration of chemotherapeutic drugs ) 
0 ) is a promising therapy because it enhances the 
17 promising therapy because it enhances the anti-endothelial activity of 
18 it enhances the anti-endothelial activity of conventional chemotherapeutics , 
0 lower or no toxic effects compared to maximum tolerated 
0 to maximum tolerated dose administration . NULL NULL NULL 
0 the aims of the present study were to compare 
3 in vivo , the angiogenic and antitumor activities of 
18 the antiangiogenic and antitumor activities of metronomic irinotecan ( 
1 NULL in vitro cell proliferation , combination studies and 
0 studies and vascular endothelial growth factor ( vegf ) 
14 factor ( vegf ) secretion analyses were performed on 
19 ( ht-29 ) cells exposed for 144 h to 
0 of sn-38 , the active metabolite of cpt-11 , 
0 cancer xenograft model was used and tumour growth , 
4 was used and tumour growth , microvessel density and 
0 in tumours after the administration of metronomic cpt-11 , 
18 and l-ohp , preferentially inhibited endothelial cell proliferation . 
1 preferentially inhibited endothelial cell proliferation . NULL NULL NULL 
19 NULL simultaneous and continuous exposure of ht-29 and hmvec-d 
0 sn-38+l-ohp+5-fu for 144 h showed a strong antagonism and 
0 h showed a strong antagonism and an unfavorable dose-reduction 
0 antagonism and an unfavorable reduction index . NULL NULL 
0 , the ternary combination resulted in a significant increase 
0 combination resulted in a significant increase of vegf secretion 
17 resulted in a significant increase of vegf secretion in 
14 significant increase of vegf secretion in ht-29 cancer cells 
18 and l-ohp , significantly inhibits ht-29 tumor growth and 
4 , significantly inhibits ht-29 tumor growth and microvessel density 
4 significantly inhibits ht-29 tumor growth and microvessel density in 
19 contrary , metronomic 5-fu+l-ohp+cpt-11 therapy did not affect the 
16 5-fu+l-ohp+cpt-11 therapy did not affect the microvascular count . 
0 combination regimens should be used with caution . NULL 
0 NULL NULL NULL a key role for the integrin 
0 NULL NULL a key role for the integrin alpha2beta1 
3 in experimental and developmental angiogenesis . NULL NULL NULL 
16 the alpha2beta1 integrin receptor plays a key role in 
16 integrin receptor plays a key role in angiogenesis . 
16 receptor plays a key role in angiogenesis . NULL 
3 a key role in angiogenesis . NULL NULL NULL 
0 here we investigated the effects of small molecule inhibitors 
0 smis ) designed to disrupt integrin alpha2 i or 
0 or beta1 i-like domain function on angiogenesis . NULL 
3 i-like domain function on angiogenesis . NULL NULL NULL 
19 NULL NULL NULL in unchallenged endothelial cells , fibrillar 
17 cells , fibrillar collagen induced robust capillary morphogenesis . 
2 collagen induced robust capillary morphogenesis . NULL NULL NULL 
2 in contrast , tube formation was significantly reduced by 
18 tube formation was significantly reduced by smi496 , a 
0 a beta1 i-like domain inhibitor and by function-blocking anti-alpha2beta1 
0 domain inhibitor and by function anti-alpha2beta1 but not -alpha1beta1 
0 domain inhibitor and by blocking anti-alpha2beta1 but not -alpha1beta1 
15 NULL NULL endothelial cells bound fluorescein-labeled collagen i fibrils 
19 NULL endothelial cells bound labeled collagen i fibrils , 
0 i fibrils , an interaction specifically inhibited by smi496 
18 , an interaction specifically inhibited by smi496 . NULL 
17 NULL moreover , smi496 caused cell retraction and cytoskeletal 
5 caused cell retraction and cytoskeletal collapse of endothelial cells 
5 cell retraction and cytoskeletal collapse of endothelial cells as 
18 cells as well as delayed endothelial cell wound healing 
0 NULL NULL NULL smi activities were examined in vivo 
0 vivo by supplementing the growth medium of zebrafish embryos 
9 medium of zebrafish embryos expressing green fluorescent protein under 
0 embryos expressing green fluorescent protein under the control of 
16 fluorescent protein under the control of the vascular endothelial 
0 of the vascular endothelial growth factor receptor-2 promoter . 
0 , but not a control compound , interfered with 
18 a control compound , interfered with angiogenesis in vivo 
3 compound , interfered with angiogenesis in vivo by reversibly 
18 in vivo by reversibly inhibiting sprouting from the axial 
2 vivo by reversibly inhibiting sprouting from the axial vessels 
0 similar vascular phenotype was induced by morpholino-mediated knockdown of 
0 phenotype was induced by mediated knockdown of the integrin 
19 was induced by morpholino-mediated knockdown of the integrin alpha2 
0 NULL collectively , our results provide strong biochemical and 
16 genetic evidence of a central role for alpha2beta1 integrin 
16 evidence of a central role for alpha2beta1 integrin in 
3 in experimental and developmental angiogenesis . NULL NULL NULL 
16 NULL NULL NULL dopamine regulates phosphorylation of vegf receptor 
12 NULL NULL dopamine regulates phosphorylation of vegf receptor 2 
16 vegf receptor 2 by engaging src-homology-2-domain-containing protein tyrosine phosphatase 
0 2 by engaging src-homology-2-domain-containing protein tyrosine phosphatase 2 . 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
0 factor ( vegf ) induced receptor phosphorylation is the 
0 vegf ) -induced receptor phosphorylation is the crucial step 
0 receptor phosphorylation is the crucial step for initiating downstream 
0 crucial step for initiating downstream signaling pathways that lead 
0 for initiating downstream signaling pathways that lead to angiogenesis 
17 downstream signaling pathways that lead to angiogenesis or related 
3 pathways that lead to angiogenesis or related pathophysiological outcomes 
18 the neurotransmitter dopamine could inhibit vegf-induced phosphorylation of vegf 
17 neurotransmitter dopamine could inhibit induced phosphorylation of vegf receptor 
12 dopamine could inhibit vegf-induced phosphorylation of vegf receptor 2 
1 ) , endothelial cell proliferation , migration , microvascular 
14 endothelial cell proliferation , migration , microvascular permeability , 
3 , and thus , angiogenesis . NULL NULL NULL 
0 , we address the mechanism by which vegfr-2 phosphorylation 
12 mechanism by which vegfr-2 phosphorylation is regulated by dopamine 
16 which vegfr-2 phosphorylation is regulated by dopamine . NULL 
14 receptor ( d2dr ) colocalizes with vegfr-2 at the 
19 NULL NULL NULL dopamine pretreatment increases the translocation and 
17 NULL NULL dopamine pretreatment increases the translocation and colocalization 
14 dopamine pretreatment increases the translocation and colocalization of src-homology-2-domain-containing 
14 increases the translocation and colocalization of src-homology-2-domain-containing protein tyrosine 
0 and colocalization of src-homology-2-domain-containing protein tyrosine phosphatase ( shp-2 
19 NULL NULL NULL dopamine administration leads to increased vegf-induced 
17 NULL NULL dopamine administration leads to increased vegf-induced phosphorylation 
17 dopamine administration leads to increased vegf-induced phosphorylation of shp-2 
17 administration leads to increased induced phosphorylation of shp-2 and 
12 leads to increased vegf-induced phosphorylation of shp-2 and this 
17 of shp-2 and this increased phosphorylation parallels the increased 
12 shp-2 and this increased phosphorylation parallels the increased phosphatase 
17 increased phosphorylation parallels the increased phosphatase activity of shp-2 
0 parallels the increased phosphatase activity of shp-2 . NULL 
0 NULL NULL NULL NULL active shp-2 then dephosphorylates vegfr-2 
13 NULL active shp-2 then dephosphorylates vegfr-2 at y951 , 
17 NULL active shp-2 then dephosphorylates vegfr-2 at y951 , 
19 also observe that shp-2 knockdown impairs the dopamine-regulated inhibition 
18 observe that shp-2 knockdown impairs the dopamine-regulated inhibition of 
0 shp-2 knockdown impairs the regulated inhibition of vegf-induced phosphorylation 
18 knockdown impairs the dopamine-regulated inhibition of vegf-induced phosphorylation of 
17 the dopamine-regulated inhibition of induced phosphorylation of vegfr-2 and 
12 dopamine-regulated inhibition of vegf-induced phosphorylation of vegfr-2 and , 
12 , subsequently , src phosphorylation and migration . NULL 
14 , src phosphorylation and migration . NULL NULL NULL 
16 data establish a novel role for shp-2 phosphatase in 
0 shp-2 phosphatase in the mediated regulation of vegfr-2 phosphorylation 
16 phosphatase in the dopamine-mediated regulation of vegfr-2 phosphorylation . 
12 dopamine-mediated regulation of vegfr-2 phosphorylation . NULL NULL NULL 
0 NULL NULL NULL glioma tumor stem-like cells promote tumor 
17 glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis 
16 glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis 
0 tumor stem-like cells promote tumor angiogenesis and vasculogenesis via 
3 stem-like cells promote tumor angiogenesis and vasculogenesis via vascular 
3 promote tumor angiogenesis and vasculogenesis via vascular endothelial growth 
0 vasculogenesis via vascular endothelial growth factor and stromal-derived factor 
0 endothelial growth factor and derived factor 1 . NULL 
0 are predicted to be critical drivers of tumor progression 
0 be critical drivers of tumor progression due to their 
2 critical drivers of tumor progression due to their self-renewal 
1 self-renewal capacity and limitless proliferative potential . NULL NULL 
0 capacity and limitless proliferative potential . NULL NULL NULL 
17 that csc may also support tumor progression by promoting 
0 csc may also support tumor progression by promoting tumor 
2 may also support tumor progression by promoting tumor angiogenesis 
17 support tumor progression by promoting tumor angiogenesis . NULL 
0 tumor progression by promoting tumor angiogenesis . NULL NULL 
3 progression by promoting tumor angiogenesis . NULL NULL NULL 
16 to investigate how csc contribute to tumor vascular development 
0 how csc contribute to tumor vascular development , we 
2 contribute to tumor vascular development , we used an 
0 vascular development , we used an approach comparing tumor 
0 used an approach comparing tumor xenografts of the c6 
0 tumors , csc-high tumors exhibited increased microvessel density and 
17 , csc-high tumors exhibited increased microvessel density and blood 
0 microvessel density and blood perfusion and induced increased mobilization 
17 and blood perfusion and induced increased mobilization and tumor 
0 blood perfusion and induced increased mobilization and tumor recruitment 
14 perfusion and induced increased mobilization and tumor recruitment of 
0 induced increased mobilization and tumor recruitment of bone marrow-derived 
14 increased mobilization and tumor recruitment of bone marrow-derived endothelial 
0 tumor recruitment of bone derived endothelial progenitor cells ( 
17 c6 cell cultures also induced higher levels of endothelial 
0 cultures also induced higher levels of endothelial cell proliferation 
1 levels of endothelial cell proliferation and tubule organization in 
2 cell proliferation and tubule organization in vitro compared with 
9 csc-high cultures and tumors expressed increased levels of the 
17 cultures and tumors expressed increased levels of the proangiogenic 
0 and tumors expressed increased levels of the proangiogenic factors 
3 increased levels of the angiogenic factors vascular endothelial growth 
0 proangiogenic factors vascular endothelial growth factor and stromal-derived factor 
0 endothelial growth factor and derived factor 1 , and 
18 by either factor was blocked , all aspects of 
3 , all aspects of angiogenesis observed in csc-high cultures 
0 all aspects of angiogenesis observed in csc-high cultures and 
0 including microvessel density , perfusion , epc mobilization/recruitment , 
14 , perfusion , epc mobilization/recruitment , and stimulation of 
17 epc mobilization/recruitment , and stimulation of endothelial cell activity 
0 stimulation of endothelial cell activity , were reduced to 
18 cell activity , were reduced to levels comparable with 
0 , were reduced to levels comparable with those observed 
0 levels comparable with those observed in csc-low cultures/tumors . 
0 NULL NULL NULL these results suggest that csc contribute 
16 results suggest that csc contribute to tumor angiogenesis by 
0 that csc contribute to tumor angiogenesis by promoting both 
3 csc contribute to tumor angiogenesis by promoting both local 
17 to tumor angiogenesis by promoting both local endothelial cell 
0 both local endothelial cell activity and systemic angiogenic processes 
3 cell activity and systemic angiogenic processes involving bone marrow-derived 
0 activity and systemic angiogenic processes involving bone marrow-derived epc 
0 and systemic angiogenic processes involving bone marrow-derived epc in 
0 angiogenic processes involving bone derived epc in a vascular 
0 in a vascular endothelial growth factor-dependent and stromal-derived factor 
17 a vascular endothelial growth dependent and stromal-derived factor 1-dependent 
0 endothelial growth factor-dependent and derived factor 1-dependent manner . 
17 factor-dependent and stromal-derived factor dependent manner . NULL NULL 
17 NULL NULL islet endothelial activation and oxidative stress gene 
0 and oxidative stress gene expression is reduced by il-1ra 
18 stress gene expression is reduced by il-1ra treatment in 
19 is reduced by il-1ra treatment in the type 2 
6 a component of islet dysfunction in both rodent and 
0 because islet inflammation may originate from endothelial cells , 
0 , we assessed the expression of selected genes involved 
0 expression of selected genes involved in endothelial cell activation 
17 involved in endothelial cell activation in islets from a 
0 os ) /inflammation-related gene expression , islet vascularization and 
3 gene expression , islet vascularization and fibrosis after treatment 
19 vascularization and fibrosis after treatment with the interleukin-1 ( 
0 methodology/principal findings : gene expression was analyzed by quantitative 
19 quantitative rt-pcr on islets isolated from 10-week-old diabetic gk 
0 10-week-old diabetic gk and control wistar rats . NULL 
19 , gk rats were treated s.c twice daily with 
0 were selected encoding molecules involved in endothelial cell activation 
17 involved in endothelial cell activation , particularly fibrinolysis , 
3 tone , os , angiogenesis and also inflammation . 
18 hydrolase ( that were decreased ) , and 12-lipoxygenase 
0 12-lipoxygenase and vascular endothelial growth factor ( that showed 
16 growth factor ( that showed no change ) , 
16 ( that showed no change ) , were significantly 
17 ) , were significantly up-regulated in gk islets . 
19 NULL NULL after il-1ra treatment of gk rats in 
0 endothelium/os/immune cells/fibrosis were significantly down-regulated . NULL NULL NULL 
17 NULL NULL il-1ra also improved islet vascularization , reduced 
3 il-1ra also improved islet vascularization , reduced fibrosis and 
0 improved islet vascularization , reduced fibrosis and ameliorated glycemia 
0 gk rat islets have increased mrna expression of markers 
0 rat islets have increased mrna expression of markers of 
0 islets have increased mrna expression of markers of early 
17 early islet endothelial cell activation , possibly triggered by 
0 cell activation , possibly triggered by several metabolic factors 
0 , and also some defense mechanisms . NULL NULL 
17 NULL NULL NULL the beneficial effect of il-1ra on 
17 NULL NULL the beneficial effect of il-1ra on most 
0 parameters analyzed highlights a major endothelial-related role for il-1 
16 highlights a major endothelial-related role for il-1 in gk 
2 il-1 in gk islet alterations . NULL NULL NULL 
16 NULL NULL thus , altered islet endothelium might affect 
16 metabolically-altered islet endothelium might affect the beta-cell microenvironment and 
0 the beta-cell microenvironment and contribute to progressive type 2 
0 type 2 diabetic beta-cell dysfunction in gk rats . 
0 be one way to prevent beta-cell dysfunction in type 
0 way to ameliorate/prevent beta-cell dysfunction in type 2 diabetes 
6 new combretastatin derivative vascular disrupting agent . NULL NULL 
3 NULL NULL NULL NULL angiogenesis has an essential role 
16 NULL angiogenesis has an essential role in promoting and 
16 angiogenesis has an essential role in promoting and supporting 
17 an essential role in promoting and supporting tumor growth 
17 role in promoting and supporting tumor growth and it 
0 in promoting and supporting tumor growth and it is 
4 promoting and supporting tumor growth and it is an 
0 and it is an important therapeutic target . NULL 
0 is an important therapeutic target . NULL NULL NULL 
0 NULL NULL NULL the tumor vascular network is the 
3 is the result of angiogenic and inhibitory factors as 
0 result of pro-angiogenic and inhibitory factors as well as 
15 well as of the interaction between endothelial cells and 
0 endothelial cells and extracellular matrix . NULL NULL NULL 
3 NULL NULL NULL different angiogenic therapeutics have been developed 
0 antiangiogenic therapeutics have been developed to improve tumor control 
17 have been developed to improve tumor control through vascular-targeting 
0 been developed to improve tumor control through vascular-targeting agents 
16 developed to improve tumor control through vascular-targeting agents ( 
0 improve tumor control through targeting agents ( vta ) 
3 into two groups : angiogenic agents and vascular-disrupting agents 
0 : antiangiogenic agents and disrupting agents ( vdas ) 
0 NULL NULL NULL vtas inhibit specific factors required to 
0 vtas inhibit specific factors required to induce and direct 
0 specific factors required to induce and direct the angiogenic 
0 required to induce and direct the angiogenic process , 
3 induce and direct the angiogenic process , with major 
0 angiogenic process , with major activity against small tumor 
0 process , with major activity against small tumor masses 
0 major activity against small tumor masses and at the 
0 masses and at the tumor periphery , encompassing monoclonal 
16 NULL NULL vdas specifically target and destroy well-established tumor 
18 vdas specifically target and destroy well-established tumor vessels with 
2 specifically target and destroy established tumor vessels with ischemia 
0 target and destroy well-established tumor vessels with ischemia and 
6 vessels with ischemia and destruction of large masses with 
0 of large masses with central hemorrhagic necrosis and survival 
5 masses with central hemorrhagic necrosis and survival of a 
5 central hemorrhagic necrosis and survival of a thin peripheral 
0 of a thin peripheral tumor layer . NULL NULL 
0 we will discuss the mechanism of action , as 
0 discuss the mechanism of action , as well as 
0 as the preclinical and clinical results , of one 
0 the preclinical and clinical results , of one of 
0 NULL NULL NULL NULL targeting tnf for treatment of 
19 NULL targeting tnf for treatment of cancer and autoimmunity 
0 NULL NULL NULL NULL tumor necrosis factor-alpha ( tnf-alpha 
0 NULL NULL NULL tumor necrosis factor-alpha ( tnf-alpha ) 
0 tnf-alpha ) was first isolated two decades ago as 
0 ago as a macrophageproduced protein that can effectively kill 
5 protein that can effectively kill tumor cells . NULL 
17 protein that can effectively kill tumor cells . NULL 
0 that can effectively kill tumor cells . NULL NULL 
0 tnf-alpha is also an essential component of the immune 
0 immune system and is required for hematopoiesis , for 
0 for hematopoiesis , for protection from bacterial infection and 
0 for protection from bacterial infection and for immune cell-mediated 
0 infection and for immune mediated cytotoxicity . NULL NULL 
16 is one of the major players in tumor initiation 
16 one of the major players in tumor initiation , 
0 the major players in tumor initiation , proliferation , 
17 major players in tumor initiation , proliferation , invasion 
4 in tumor initiation , proliferation , invasion , angiogenesis 
14 initiation , proliferation , invasion , angiogenesis and metastasis 
3 proliferation , invasion , angiogenesis and metastasis . NULL 
14 invasion , angiogenesis and metastasis . NULL NULL NULL 
0 NULL NULL the proinflammatory activities link tnf-alpha with a 
19 been approved for the treatment inflammatory bowel disease , 
0 , exhibit severe side effects and are expensive . 
0 NULL NULL hence orally active blockers of tnf-alpha that 
18 been described which can suppress tnf expression and tnf 
9 which can suppress tnf expression and tnf signaling but 
0 tnf signaling but their clinical potential is yet uncertain 
0 signaling but their clinical potential is yet uncertain . 
0 NULL NULL NULL NULL inducible nitric oxide synthase modulates 
16 inducible nitric oxide synthase modulates angiogenesis in ischemic hindlimb 
3 nitric oxide synthase modulates angiogenesis in ischemic hindlimb of 
3 NULL NULL background : angiogenesis plays an important role 
16 NULL background : angiogenesis plays an important role in 
16 : angiogenesis plays an important role in maintaining adequate 
16 angiogenesis plays an important role in maintaining adequate oxygen 
16 an important role in maintaining adequate oxygen delivery , 
14 in maintaining adequate oxygen delivery , and nitric oxide 
0 no ) is a potential regulator of angiogenesis . 
0 ) is a potential regulator of angiogenesis . NULL 
3 a potential regulator of angiogenesis . NULL NULL NULL 
8 NULL NULL no is synthesized through three isoforms of 
0 hypothesized that the no derived from inducible nos ( 
0 the no derived from inducible nos ( inos ) 
17 ( inos ) may promote survival of ischemic tissue 
16 ( inos ) may promote survival of ischemic tissue 
5 inos ) may promote survival of ischemic tissue through 
3 of ischemic tissue through angiogenesis . NULL NULL NULL 
0 , we investigated the effect of inos deficiency ( 
0 the effect of inos deficiency ( by l-nil ) 
3 by l-nil ) on angiogenesis in a hindlimb ischemia 
0 , hindlimb ischemia was induced by ligation of femoral 
19 ischemia was induced by ligation of femoral artery and 
19 femoral artery and they received l-nil and saline respectively 
19 3 and 4 also received l-nil and saline respectively 
0 and saline respectively without surgical procedure . NULL NULL 
9 , capillary density and expression of hif1alpha were determined 
0 NULL NULL NULL NULL results : serum nitrite levels 
0 results : serum nitrite levels were significantly lower in 
0 < 0.05 ) .in addition , expression of hif1alpha 
9 ) .in addition , expression of hif1alpha was significantly 
17 of hif1alpha was significantly increased in ischemic groups ( 
18 NULL conclusion : selective inhibition of inos by l-nil 
18 of inos by l-nil inhibits angiogenesis in a hindlimb 
3 inos by l-nil inhibits angiogenesis in a hindlimb ischemic 
0 NULL NULL NULL in addition , ischemia induces expression 
17 in addition , ischemia induces expression of hif1alpha in 
9 addition , ischemia induces expression of hif1alpha in hypoxic 
9 NULL NULL NULL NULL expression of basic fibroblast growth 
0 expression of basic fibroblast growth factor in normal human 
14 NULL NULL NULL the distribution of basic fibroblast growth 
0 distribution of basic fibroblast growth factor ( bfgf ) 
19 NULL NULL NULL NULL immunodetection was performed with a 
18 , and to specifically neutralize the mitogenic activity of 
0 specifically neutralize the mitogenic activity of bfgf on bovine 
9 NULL NULL NULL NULL expression of bfgf on normal 
14 normal human tissues was ubiquitously detected in the basement 
14 human tissues was ubiquitously detected in the basement membranes 
14 intensity and patterns of localization in blood vessels was 
0 and intense immunoreactivity were observed in large and intermediate 
9 vessels , heterogeneity of expression was found in capillaries 
0 most intense immunoreactivity was observed in branching capillaries . 
2 immunoreactivity was observed in branching capillaries . NULL NULL 
0 NULL NULL endothelial cell staining was heterogeneous and varied 
0 NULL NULL NULL strong staining for bfgf was also 
0 the myometrium , in central nervous system neurons and 
14 NULL NULL NULL the presence of bfgf in the 
16 variety of organs may play a role in angiogenesis 
16 organs may play a role in angiogenesis . NULL 
3 play a role in angiogenesis . NULL NULL NULL 
0 NULL however , the function of bfgf in parenchymal 
3 NULL NULL NULL retinal revascularisation in diabetic retinopathy . 
0 1975 he had bilateral proliferative retinopathy with new vessels 
0 large areas of capillary perfusion lateral to the macula 
0 in the right eye associated with the new vessels 
0 , after extensive repeated photocoagulation , revascularisation of large 
3 extensive repeated photocoagulation , revascularisation of large areas previously 
2 do not have the appearance of new vessels . 
3 the uterine cervix and angiogenesis : morphologic study ] 
19 cervix specimens sampled following conization or total hysterectomy were 
19 following conization or total hysterectomy were studied using histology 
0 ( vessel phosphatase alkaline activity ) , and immunohistochemistry 
0 NULL NULL NULL NULL results were compared to findings 
0 to findings in a control group . NULL NULL 
0 is consistent with colposcopic results . NULL NULL NULL 
3 NULL NULL NULL anarchic angiogenesis with large , moniliform 
0 seem to precede the development of histologic lesions in 
2 NULL NULL NULL NULL histogenesis of the abnormal vessels 
0 the abnormal vessels may involve production of an angiogenic 
0 abnormal vessels may involve production of an angiogenic factor 
3 involve production of an angiogenic factor by the cancerized 
0 cited theory for the pathogenesis of neovascularization in diabetic 
3 for the pathogenesis of neovascularization in diabetic retinopathy is 
0 retinal hypoxia and/or ischemia release a factor which stimulates 
17 release a factor which stimulates neovascularization . NULL NULL 
3 a factor which stimulates neovascularization . NULL NULL NULL 
0 , there is no direct in vivo evidence in 
0 whether worsening retinopathy was associated with changes in conjunctival 
16 retinopathy was associated with changes in conjunctival oxygen tension 
0 NULL NULL diabetics with proliferative retinopathy showed a conjunctival 
0 diabetics with proliferative retinopathy showed a conjunctival po2 that 
0 NULL NULL these findings support the hypoxic theory of 
3 hypoxic theory of diabetic neovascular retinopathy . NULL NULL 
0 NULL NULL NULL new functions of epidermal growth factor 
0 new functions of epidermal growth factor : stimulation of 
17 epidermal growth factor : stimulation of capillary endothelial cell 
14 of capillary endothelial cell migration and matrix dependent proliferation 
0 endothelial cell migration and matrix dependent proliferation . NULL 
17 cell migration and matrix dependent proliferation . NULL NULL 
1 migration and matrix dependent proliferation . NULL NULL NULL 
1 NULL NULL NULL the proliferative response of bovine retinal 
16 NULL NULL the proliferative response of bovine retinal capillary 
17 cells to egf is dependent upon attaching the cells 
15 egf is dependent upon attaching the cells to a 
0 the cells to a matrix of fibronectin . NULL 
17 endothelial cells are also stimulated to actively migrate when 
14 also stimulated to actively migrate when exposed to egf 
19 to actively migrate when exposed to egf in vitro 
0 NULL NULL NULL these activities provide an explanation for 
3 an explanation for the angiogenic properties of egf in 
0 explanation for the angiogenic properties of egf in vivo 
14 NULL NULL capillary cell migration and proliferation are proposed 
1 capillary cell migration and proliferation are proposed as sensitive 
0 proliferation are proposed as sensitive quantifiable bioassays to explore 
18 NULL studies on the inactivation of these properties of 
0 the inactivation of these properties of egf by specific 
11 of egf by specific cleavage of the molecule with 
17 of egf by specific cleavage of the molecule with 
0 20 to 31 is essential for at least some 
0 for at least some functions . NULL NULL NULL 
17 NULL NULL the specific enhancement of tumor proliferation in 
0 the specific enhancement of tumor proliferation in vitro . 
4 specific enhancement of tumor proliferation in vitro . NULL 
17 of their capacity to enhance profoundly the proliferation of 
4 to enhance profoundly the proliferation of a variety of 
0 mast cell/tumor ratios which reflect the stoichiometry of host 
0 NULL NULL NULL the growth factor was found to 
0 sequential purification and enzymatic degradation . NULL NULL NULL 
0 NULL NULL this cellular interaction was tumor-specific , although 
0 was tumor-specific , although isolated granules could enhance fibroblast 
17 although isolated granules could enhance fibroblast proliferation . NULL 
1 granules could enhance fibroblast proliferation . NULL NULL NULL 
16 reports of in vitro mediated tumor cytotoxicity , and 
0 of in vitro mast-cell-mediated tumor cytotoxicity , and the 
16 cytotoxicity , and the role of mast cells in 
3 of mast cells in angiogenesis and connective tissue proliferation 
4 angiogenesis and connective tissue proliferation . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenesis : initiation and control 
17 NULL NULL angiogenesis : initiation and control . NULL 
16 angiogenesis : initiation and control . NULL NULL NULL 
4 becoming clear that the growth of a capillary involves 
16 growth of a capillary involves an ordered sequence of 
6 of events that includes lysis of the basement membrane 
14 parent venule , directional migration of capillary endothelial cells 
3 endothelial cells toward the angiogenic stimulus , lumen formation 
2 angiogenic stimulus , lumen formation , development of branches 
2 , lumen formation , development of branches , and 
2 of branches , and anastomosis of the tip of 
0 tube with another to form a loop . NULL 
3 also clear that diffusible angiogenic stimuli can be released 
0 angiogenic stimuli can be released not only from most 
17 NULL NULL these include activated macrophages , sensitized lymphocytes 
17 normal tissues can also stimulate angiogenesis , but the 
3 tissues can also stimulate angiogenesis , but the type 
3 giving rise to the angiogenic stimulus is unknown , 
3 and the period of angiogenic stimulation is brief . 
17 the period of angiogenic stimulation is brief . NULL 
0 NULL with the recent ability to clone capillary endothelial 
19 the recent ability to clone capillary endothelial cells and 
19 carry them in long-term culture , it has been 
0 to further delineate the mechanism of capillary growth . 
4 the mechanism of capillary growth . NULL NULL NULL 
17 , in some way speeding up their rate of 
14 their rate of directional migration . NULL NULL NULL 
0 principal mast cell factor responsible for this effect on 
16 factor responsible for this effect on capillary endothelial cells 
2 that mast cells may prepare the matrix , perhaps 
0 cells may prepare the matrix , perhaps by slow 
0 matrix , perhaps by slow release of heparin , 
14 , perhaps by slow release of heparin , so 
3 through it toward their angiogenic target . NULL NULL 
0 it toward their angiogenic target . NULL NULL NULL 
3 while the study of angiogenesis as a phenomenon is 
17 more thoroughly understand the initiation and control of capillary 
16 understand the initiation and control of capillary growth . 
4 and control of capillary growth . NULL NULL NULL 
0 NULL NULL NULL NULL protection from experimental ocular herpetic 
0 zealand white rabbits were given limbal inoculations of a 
19 rabbits were given limbal inoculations of a heat-killed suspension 
19 were challenged by intrastromal inoculation with 10 , 000 
0 with 10 , 000 forming units of viable hsv 
3 and necrotizing keratitis with neovascularization of the cornea developed 
2 neovascularization of the cornea developed in control animals . 
0 the cornea developed in control animals . NULL NULL 
2 and corneal edema also developed in the immunized animals 
3 absence of iritis , neovascularization , and necrotizing keratitis 
3 NULL NULL NULL subretinal neovascularization following rubella retinopathy . 
0 with rubella retinopathy had decreased vision in one eye 
3 eye secondary to subretinal neovascularization and hemorrhage . NULL 
0 disciform scar with permanent decrease in central vision resulted 
0 with permanent decrease in central vision resulted . NULL 
0 decrease in central vision resulted . NULL NULL NULL 
15 NULL molecular mediators of interactions with extracellular matrix components 
0 of interactions with extracellular matrix components in metastasis and 
0 extracellular matrix components in metastasis and angiogenesis . NULL 
3 components in metastasis and angiogenesis . NULL NULL NULL 
0 NULL NULL NULL NULL metastasis and tumor angiogenesis are 
0 NULL NULL metastasis and tumor angiogenesis are invasive phenomena 
3 NULL metastasis and tumor angiogenesis are invasive phenomena and 
0 and share many common properties at the physiological level 
15 of repetitive cycles of interaction with adjacent extracellular matrix 
0 interaction with adjacent extracellular matrix components by mediating cellular 
16 extracellular matrix components by mediating cellular adhesion , matrix 
15 components by mediating cellular adhesion , matrix dissolution , 
6 mediating cellular adhesion , matrix dissolution , and cellular 
6 cellular adhesion , matrix dissolution , and cellular motility 
14 dissolution , and cellular motility to achieve metastasis of 
14 cellular motility to achieve metastasis of cancer cells or 
3 of cancer cells or neovascularization of tumors . NULL 
0 transduction components which may regulate them . NULL NULL 
0 and therapeutic modalities for tumor angiogenesis and metastatic disease 
3 therapeutic modalities for tumor angiogenesis and metastatic disease are 
0 for tumor angiogenesis and metastatic disease are also discussed 
9 NULL NULL NULL vegf165 expressed by a replication-deficient recombinant 
0 vegf165 expressed by a deficient recombinant adenovirus vector induces 
17 replication-deficient recombinant adenovirus vector induces angiogenesis in vivo . 
3 recombinant adenovirus vector induces angiogenesis in vivo . NULL 
0 evaluate the concept that localized delivery of angiogenic factors 
0 the concept that localized delivery of angiogenic factors via 
3 that localized delivery of angiogenic factors via virus-mediated gene 
0 of angiogenic factors via mediated gene transfer may be 
0 be useful in the treatment of ischemic disorders , 
0 ischemic disorders , the deficient adenovirus ( ad ) 
0 vegf is vascular endothelial growth factor ) containing the 
0 human vegf165 , a secreted endothelial cell-specific angiogenic growth 
3 a secreted endothelial cell-specific angiogenic growth factor , was 
0 secreted endothelial cell-specific angiogenic growth factor , was constructed 
0 growth factor , was constructed . NULL NULL NULL 
19 cells ( rasmcs ) infected with adcmv.vegf165 ( 5 
0 ( 5 and 20 forming units [ pfu ] 
0 cell ) demonstrated vegf mrna expression and protein secretion 
10 ) demonstrated vegf mrna expression and protein secretion into 
0 vegf mrna expression and protein secretion into the supernatant 
14 mrna expression and protein secretion into the supernatant . 
17 medium from these cells enhanced vascular permeability in vivo 
0 contrast , neither vegf mrna nor secreted protein was 
14 neither vegf mrna nor secreted protein was found in 
0 vegf mrna nor secreted protein was found in uninfected 
19 protein was found in uninfected huvecs or rasmcs or 
19 rasmcs or in cells infected with the control vector 
0 cells infected with the control vector adcmv.beta gal ( 
19 sixfold more cells for infected huvecs ( 20 pfu 
19 ) than for either infected or uninfected control cells 
19 for either infected or uninfected control cells . NULL 
0 either infected or uninfected control cells . NULL NULL 
1 NULL NULL NULL rasmc proliferation was unaffected by infection 
16 NULL rasmc proliferation was unaffected by infection with adcmv.vegf165 
19 proliferation was unaffected by infection with adcmv.vegf165 . NULL 
19 NULL NULL NULL when plated in 2 % serum 
0 on dishes precoated with reconstituted basement membrane ( matrigel 
19 matrigel ) , huvecs infected with adcmv.vegf165 ( 20 
2 pfu per cell ) differentiated into capillary-like structures . 
19 similar conditions , both uninfected huvecs and huvecs infected 
19 uninfected huvecs and huvecs infected with adcmv.beta gal did 
2 adcmv.beta gal did not differentiate . NULL NULL NULL 
0 NULL to evaluate the ability of adcmv.vegf165 to function 
0 ability of adcmv.vegf165 to function in vivo , either 
19 ) pfu ) was resuspended in 0.5 ml matrigel 
19 0.5 ml matrigel and injected subcutaneously into mice . 
19 NULL NULL NULL NULL immunohistochemical staining demonstrated vegf in 
19 NULL NULL NULL immunohistochemical staining demonstrated vegf in the 
19 to 3 weeks after injection , whereas no vegf 
0 was found in the control plugs with adcmv.beta gal 
0 NULL two weeks after injection , there was histological 
3 was histological evidence of neovascularization in the tissues surrounding 
0 adcmv.vegf165 , whereas no significant angiogenesis was observed in 
3 , whereas no significant angiogenesis was observed in response 
0 no significant angiogenesis was observed in response to adcmv.beta 
16 angiogenesis was observed in response to adcmv.beta gal . 
0 strategy for efficient local delivery of vegf165 in the 
0 of vegf165 in the treatment of ischemic diseases . 
16 NULL NULL NULL NULL effects of doxycycline on in 
1 doxycycline on in vitro growth , migration , and 
14 in vitro growth , migration , and gelatinase activity 
0 migration , and gelatinase activity of breast carcinoma cells 
0 NULL NULL NULL NULL metastatic disease is one of 
0 is one of the major causes of death from 
5 the major causes of death from cancer in human 
0 enzyme systems have been implicated in the metastatic process 
0 been implicated in the metastatic process , but the 
0 appear to be the major group involved in most 
0 be the major group involved in most instances of 
0 most instances of neoplastic invasion . NULL NULL NULL 
17 NULL NULL NULL NULL increased mp activity has been 
0 NULL NULL increased mp activity has been correlated with 
0 been correlated with the metastatic potential of many cancers 
0 correlated with the metastatic potential of many cancers , 
16 NULL NULL mps also play a role in tumor 
16 mps also play a role in tumor angiogenesis . 
0 play a role in tumor angiogenesis . NULL NULL 
3 a role in tumor angiogenesis . NULL NULL NULL 
18 antimicrobial agents that can suppress mp activity in a 
0 that can suppress mp activity in a variety of 
18 indicated that tetracyclines can suppress tumor mps as well 
0 that tetracyclines can suppress tumor mps as well . 
18 tetracycline , doxycycline , inhibits migration of human mda-mb-435 
14 , doxycycline , inhibits migration of human mda-mb-435 breast 
7 adenocarcinoma cells through a reconstituted basement membrane ( matrigel 
0 ) , an assay used as an in vitro 
0 in vivo process of tumor invasion through basement membranes 
14 vivo process of tumor invasion through basement membranes . 
18 NULL additionally , doxycycline diminishes the proliferation of this 
1 , doxycycline diminishes the proliferation of this breast cancer 
0 cell line and also decreases its gelatinolytic activity , 
0 also decreases its gelatinolytic activity , as determined by 
16 human cancer tissue : role in tumor-host interaction ? 
15 : role in tumor-host interaction ? NULL NULL NULL 
14 NULL somatostatin receptors were detected in peritumoral veins of 
0 renal-cell carcinomas and 7 malignant lymphomas were analyzed for 
0 for somatostatin receptors by use of quantitative receptor autoradiography 
9 , the peritumoral vessels expressed a high density of 
9 neoplastic tissue itself was negative in many cases . 
2 vessels was low in differentiated gastrointestinal and bronchial carcinoids 
0 receptors in the carcinoid tumor tissue . NULL NULL 
0 as renal-cell carcinomas or malignant lymphomas also frequently expressed 
9 malignant lymphomas also frequently expressed somatostatin receptors . NULL 
14 the somatostatin receptors were localized in veins , particularly 
0 NULL NULL NULL they exhibited specific and high-affinity binding 
0 they exhibited specific and affinity binding of somatostatin-14 , 
15 exhibited specific and high-affinity binding of somatostatin-14 , somatostatin-28 
9 , suggesting a preferential expression of the sstr2 receptor 
17 somatostatin receptors , the increased somatostatin receptor expression in 
9 the increased somatostatin receptor expression in peritumoral vessels observed 
0 expression in peritumoral vessels observed in this study may 
0 this study may be linked to the neoplastic process 
0 NULL NULL NULL the results suggest that somatostatin and 
16 and somatostatin receptors may play a regulatory role for 
16 receptors may play a regulatory role for hemodynamic tumor-host 
16 may play a regulatory role for hemodynamic tumor-host interactions 
15 role for hemodynamic tumor-host interactions , possibly involving tumor 
16 tumor-host interactions , possibly involving tumor stroma generation , 
0 interactions , possibly involving tumor stroma generation , tumor 
2 possibly involving tumor stroma generation , tumor environment , 
0 tumor stroma generation , tumor environment , angiogenesis and 
3 , tumor environment , angiogenesis and , particularly , 
2 vascular drainage of poorly differentiated neoplasms . NULL NULL 
17 NULL NULL NULL NULL stimulation of endothelial cell migration 
14 stimulation of endothelial cell migration by vascular permeability factor/vascular 
0 vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms 
0 factor through cooperative mechanisms involving the alphavbeta3 integrin , 
3 mechanisms by which the angiogenic cytokine vascular permeability factor/vascular 
0 vascular permeability factor/vascular endothelial growth factor ( vpf/vegf ) 
16 ( vpf/vegf ) likely regulates endothelial cells ( ec 
14 cells ( ec ) migration . NULL NULL NULL 
17 NULL NULL NULL vpf/vegf induced dermal microvascular ec expression 
10 induced dermal microvascular ec expression of mrnas encoding the 
0 and beta3 integrin subunits resulting in increased levels of 
17 integrin subunits resulting in increased levels of the alphavbeta3 
0 subunits resulting in increased levels of the alphavbeta3 heterodimer 
17 , and vpf/vegf also induced mrna encoding osteopontin ( 
0 and vpf/vegf also induced mrna encoding osteopontin ( opn 
17 NULL NULL NULL opn promoted ec migration in vitro 
14 NULL opn promoted ec migration in vitro ; and 
17 vitro ; and vpf/vegf induction of alphavbeta3 was accompanied 
17 alphavbeta3 was accompanied by increased ec migration toward opn 
14 accompanied by increased ec migration toward opn . NULL 
11 NULL NULL because thrombin cleavage of opn results in 
17 NULL NULL because thrombin cleavage of opn results in 
0 thrombin cleavage of opn results in substantial enhancement of 
17 opn results in substantial enhancement of opn 's adhesive 
0 enhancement of opn 's adhesive properties , and because 
0 of opn 's adhesive properties , and because vpf/vegf 
17 , and because vpf/vegf promotes increased microvascular permeability leading 
17 and because vpf/vegf promotes increased microvascular permeability leading to 
0 promotes increased microvascular permeability leading to activation of the 
17 microvascular permeability leading to activation of the extrinsic coagulation 
16 also investigated whether vpf/vegf facilitates thrombin cleavage of opn 
11 whether vpf/vegf facilitates thrombin cleavage of opn in vivo 
17 whether vpf/vegf facilitates thrombin cleavage of opn in vivo 
19 with this hypothesis , co-injection of vpf/vegf together with 
0 vpf/vegf together with opn resulted in rapid cleavage of 
11 opn resulted in rapid cleavage of opn by endogenous 
17 opn resulted in rapid cleavage of opn by endogenous 
11 with native opn , cleaved opn stimulated a greater 
17 with native opn , cleaved opn stimulated a greater 
17 opn , thrombin-cleaved opn stimulated a greater rate of 
14 greater rate of ec migration in vitro , which 
0 was additive to the increased migration associated with induction 
0 additive to the increased migration associated with induction of 
0 to the increased migration associated with induction of alpha 
17 increased migration associated with induction of alpha v beta 
16 cooperative mechanisms for vpf/vegf regulation of ec migration involving 
14 vpf/vegf regulation of ec migration involving the alphavbeta3 integrin 
0 regulation of ec migration involving the alphavbeta3 integrin , 
11 opn , and thrombin cleavage of opn . NULL 
17 opn , and thrombin cleavage of opn . NULL 
0 operational link between vpf/vegf induction of ec gene expression 
0 induction of ec gene expression and vpf/vegf enhancement of 
17 gene expression and vpf/vegf enhancement of microvascular permeability , 
0 that these distinct biological activities may act accordingly to 
0 distinct biological activities may act accordingly to stimulate ec 
17 may act accordingly to stimulate ec migration during angiogenesis 
14 accordingly to stimulate ec migration during angiogenesis . NULL 
3 stimulate ec migration during angiogenesis . NULL NULL NULL 
0 isoforms of vascular endothelial growth factor stimulates collateral development 
17 vascular endothelial growth factor stimulates collateral development in vivo 
2 growth factor stimulates collateral development in vivo . NULL 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
14 ) is a naturally secreted endothelial cell-specific mitogen . 
0 for vegf could be used in a strategy of 
19 in a strategy of arterial gene therapy to stimulate 
19 strategy of arterial gene therapy to stimulate collateral artery 
17 arterial gene therapy to stimulate collateral artery development . 
2 to stimulate collateral artery development . NULL NULL NULL 
0 an angioplasty balloon and delivered percutaneously to one iliac 
0 of rabbits with operatively induced hindlimb ischemia . NULL 
0 NULL NULL compared with control animals transfected with lacz 
19 compared with control animals transfected with lacz , site-specific 
19 transfected with lacz , site-specific transfection of phvegf resulted 
19 with lacz , site-specific transfection of phvegf resulted in 
17 site-specific transfection of phvegf resulted in augmented collateral vessel 
2 in augmented collateral vessel development documented by serial angiography 
0 development documented by serial angiography , and improvement in 
0 normal limb ) , resting and maximum blood flow 
0 NULL NULL NULL similar results were obtained with phvegf121 
0 NULL similar results were obtained with phvegf121 , phvegf165 
3 respect to in vivo angiogenesis . NULL NULL NULL 
0 adjunctive vectors were not required further suggests that secreted 
0 required further suggests that secreted gene products may have 
0 gene products may have potential therapeutic utility even when 
0 the number of successfully transfected cells remains low . 
0 NULL NULL NULL NULL arterial gene transfer of naked 
0 dna encoding for a secreted angiogenic cytokine , thus 
3 encoding for a secreted angiogenic cytokine , thus , 
0 thus , represents a potential alternative to recombinant protein 
0 potential alternative to recombinant protein administration for stimulating collateral 
0 alternative to recombinant protein administration for stimulating collateral vessel 
17 recombinant protein administration for stimulating collateral vessel development . 
2 for stimulating collateral vessel development . NULL NULL NULL 
17 NULL NULL NULL NULL induction of ets-1 in endothelial 
3 in endothelial cells during reendothelialization after denuding injury . 
0 NULL ets-1 , a transcription factor , is induced 
17 transcription factor , is induced in endothelial cells ( 
3 ( ecs ) during angiogenesis . NULL NULL NULL 
9 , we investigated the expression of ets-1 during reendothelialization 
3 expression of ets-1 during reendothelialization . NULL NULL NULL 
19 , ecv304 , was denuded , ecv304 at the 
9 at the wound edge expressed ets-1 . NULL NULL 
0 NULL NULL NULL an immunohistochemical analysis revealed that ets-1 
17 analysis revealed that ets-1 accumulated in migrating cells at 
0 that ets-1 accumulated in migrating cells at the wound 
3 to basal level when reendothelialization was accomplished . NULL 
17 NULL NULL NULL this induction of ets-1 could be 
17 of ets-1 could be reproduced in in vivo denudation 
19 reproduced in in vivo denudation of rat aortic endothelium 
17 NULL NULL NULL the induction of ets-1 in ecs 
19 ets-1 in ecs after denudation was regulated transcriptionally , 
16 ecs after denudation was regulated transcriptionally , and humeral 
14 , and humeral factors released from injured ecs might 
0 ecs might not be responsible . NULL NULL NULL 
0 NULL NULL NULL NULL activated protein kinase ( mapk 
0 NULL NULL NULL mitogen-activated protein kinase ( mapk ) 
0 kinase ( mapk ) activities were investigated to explore 
0 investigated to explore the mechanism of this induction . 
17 the mechanism of this induction . NULL NULL NULL 
0 NULL NULL although extracellular regulated protein kinase 1/2 ( 
0 NULL although extracellular signal-regulated protein kinase 1/2 ( erk1/2 
17 , and p38 were activated after denudation , the 
0 p38 were activated after denudation , the activation of 
17 after denudation , the activation of erk1 and p38 
0 ( mek ) 1 inhibitor , did not affect 
16 inhibitor , did not affect the induction of ets-1 
17 did not affect the induction of ets-1 mrna , 
0 the induction of ets-1 mrna , whereas sb203580 , 
0 , a specific p38 inhibitor , almost completely abrogated 
18 inhibitor , almost completely abrogated its induction . NULL 
17 almost completely abrogated its induction . NULL NULL NULL 
0 NULL NULL NULL these results indicate that ets-1 is 
17 indicate that ets-1 is induced in ecs after denudation 
19 induced in ecs after denudation through activation of p38 
17 ecs after denudation through activation of p38 . NULL 
17 NULL NULL NULL this induction of ets-1 may be 
3 may be relevant for reendothelialization by regulating the expression 
0 relevant for reendothelialization by regulating the expression of certain 
0 reendothelialization by regulating the expression of certain genes . 
14 NULL NULL store-operated calcium entry promotes shape change in 
17 NULL store-operated calcium entry promotes shape change in pulmonary 
2 store-operated calcium entry promotes shape change in pulmonary endothelial 
2 calcium entry promotes shape change in pulmonary endothelial cells 
9 in pulmonary endothelial cells expressing trp1 . NULL NULL 
17 NULL NULL NULL NULL activation of ca2+ entry is 
14 NULL activation of ca2+ entry is known to produce 
16 entry is known to produce endothelial cell shape change 
2 to produce endothelial cell shape change , leading to 
2 produce endothelial cell shape change , leading to increased 
0 cell shape change , leading to increased permeability , 
0 change , leading to increased permeability , leukocyte migration 
14 increased permeability , leukocyte migration , and initiation of 
17 leukocyte migration , and initiation of angiogenesis in conduit-vessel 
3 , and initiation of angiogenesis in conduit-vessel endothelial cells 
14 the mode of ca2+ entry regulating cell shape is 
0 mode of ca2+ entry regulating cell shape is unknown 
0 ca2+ entry regulating cell shape is unknown . NULL 
0 NULL we hypothesized that activation of store-operated ca2+ channels 
0 ( socs ) is sufficient to promote cell shape 
0 ) is sufficient to promote cell shape change necessary 
2 sufficient to promote cell shape change necessary for these 
2 to promote cell shape change necessary for these processes 
0 change necessary for these processes . NULL NULL NULL 
0 NULL NULL NULL soc activation in rat pulmonary arterial 
0 activation in rat pulmonary arterial endothelial cells increased free 
17 pulmonary arterial endothelial cells increased free cytosolic ca2+ that 
0 arterial endothelial cells increased free cytosolic ca2+ that was 
17 cytosolic ca2+ that was dependent on a membrane current 
2 NULL NULL NULL NULL changes in endothelial cell shape 
0 changes in endothelial cell shape accompanied soc activation and 
0 cell shape accompanied soc activation and were dependent on 
17 soc activation and were dependent on ca2+ entry-induced reconfiguration 
14 were dependent on ca2+ entry reconfiguration of peripheral ( 
17 were dependent on ca2+ induced reconfiguration of peripheral ( 
16 dependent on ca2+ entry-induced reconfiguration of peripheral ( cortical 
0 drosophila melanogaster transient receptor potential ( trp ) gene 
0 have been proposed to form ca2+ entry channels in 
14 proposed to form ca2+ entry channels in nonexcitable cells 
0 rat and human pulmonary arterial endothelial cells . NULL 
9 types were found to express trp1 , but neither 
9 trp1 , but neither expressed trp3 nor trp6 . 
14 that 1 ) ca2+ entry in pulmonary endothelial cells 
16 endothelial cells through socs produces cell shape change that 
2 through socs produces cell shape change that is dependent 
2 socs produces cell shape change that is dependent on 
0 shape change that is dependent on site-specific rearrangement of 
0 that is dependent on site-specific rearrangement of the microfilamentous 
0 NULL NULL NULL NULL effect of u-995 , a 
0 , a potent shark derived angiogenesis inhibitor , on 
3 a potent shark cartilage-derived angiogenesis inhibitor , on anti-angiogenesis 
0 potent shark cartilage-derived angiogenesis inhibitor , on anti-angiogenesis and 
3 angiogenesis inhibitor , on angiogenesis and anti-tumor activities . 
18 on anti-angiogenesis and anti-tumor activities . NULL NULL NULL 
3 background : a potent angiogenesis inhibitor , u-995 , 
0 : a potent angiogenesis inhibitor , u-995 , has 
19 u-995 , has been purified from the cartilage of 
14 cell ( huvec ) migration and proliferation in vitro 
1 huvec ) migration and proliferation in vitro and angiogenesis 
3 proliferation in vitro and angiogenesis induced by tnf alpha 
17 in vitro and angiogenesis induced by tnf alpha in 
0 , we determined the ability of u-995 to inhibiting 
18 ability of u-995 to inhibiting tumor cell growth and 
0 of u-995 to inhibiting tumor cell growth and metastasis 
1 to inhibiting tumor cell growth and metastasis . NULL 
14 tumor cell growth and metastasis . NULL NULL NULL 
0 NULL NULL NULL NULL results : u-995 ( 15 
18 30 micrograms/ml ) markedly inhibited huvec migration and , 
14 ) markedly inhibited huvec migration and , at 15-50 
0 , at 15-50 micrograms/ml produced a dose-dependent decline in 
0 15-50 micrograms/ml produced a dependent decline in [ 3h 
0 micrograms/ml produced a dose-dependent decline in [ 3h ] 
0 [ 3h ] -thymidine incorporation . NULL NULL NULL 
19 of u-995 , when added to tnf alpha-induced angiogenesis 
17 when added to tnf induced angiogenesis caused discontinuous and 
3 added to tnf alpha-induced angiogenesis caused discontinuous and disrupted 
17 to tnf alpha-induced angiogenesis caused discontinuous and disrupted blood 
6 angiogenesis caused discontinuous and disrupted blood vessels . NULL 
18 30 micrograms/ml ) markedly prevented collagenase-induced collagenolysis . NULL 
17 micrograms/ml ) markedly prevented induced collagenolysis . NULL NULL 
3 ) markedly prevented collagenase-induced collagenolysis . NULL NULL NULL 
0 NULL NULL NULL in addition , when 200 micrograms 
19 200 micrograms u-995 was injected i.p . NULL NULL 
18 NULL into mice it suppressed sarcoma-180 cell growth and 
1 it suppressed sarcoma-180 cell growth and b16-f10 mouse melanoma 
14 b16-f10 mouse melanoma cell metastasis in vivo . NULL 
0 NULL conclusions : these results suggest that the anti-angiogenic 
3 results suggest that the angiogenic effects of u-995 may 
18 suggest that the anti-angiogenic effects of u-995 may be 
18 be be due to interference with the proliferation and 
1 to interference with the proliferation and migration of huvecs 
14 with the proliferation and migration of huvecs as well 
18 huvecs as well as inhibition of collagenolysis , thereby 
0 well as inhibition of collagenolysis , thereby leading to 
0 of collagenolysis , thereby leading to inhibition of both 
18 , thereby leading to inhibition of both angiogenesis and 
3 to inhibition of both angiogenesis and tumor cell growth 
0 of both angiogenesis and tumor cell growth . NULL 
1 angiogenesis and tumor cell growth . NULL NULL NULL 
